xoma-10q_20180331.htm

0001564590-18-012453.txt : 20180509 0001564590-18-012453.hdr.sgml : 20180509 20180509163117 ACCESSION NUMBER: 0001564590-18-012453 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 75 CONFORMED PERIOD OF REPORT: 20180331 FILED AS OF DATE: 20180509 DATE AS OF CHANGE: 20180509 FILER: COMPANY DATA: COMPANY CONFORMED NAME: XOMA Corp CENTRAL INDEX KEY: 0000791908 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 522154066 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-14710 FILM NUMBER: 18818774 BUSINESS ADDRESS: STREET 1: 2200 POWELL STREET STREET 2: SUITE 310 CITY: EMERYVILLE STATE: CA ZIP: 94608 BUSINESS PHONE: 510-204-7239 MAIL ADDRESS: STREET 1: 2200 POWELL STREET STREET 2: SUITE 310 CITY: EMERYVILLE STATE: CA ZIP: 94608 FORMER COMPANY: FORMER CONFORMED NAME: XOMA LTD /DE/ DATE OF NAME CHANGE: 19990107 FORMER COMPANY: FORMER CONFORMED NAME: XOMA CORP /DE/ DATE OF NAME CHANGE: 19920703 10-Q 1 xoma-10q_20180331.htm 10-Q xoma-10q_20180331.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2018

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________to__________

Commission File No. 0-14710

XOMA Corporation

(Exact name of registrant as specified in its charter)

Delaware		52-2154066
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

2200 Powell Street, Suite 310 Emeryville, California 94608		(510) 204-7200
(Address of principal executive offices, including zip code)		(Telephone Number)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐		Accelerated filer	☐
Non-accelerated filer	☐	(Do not check if a smaller reporting company)	Smaller reporting company	☒
Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act of 1934). Yes ☐ No ☒

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

Class	Outstanding at May 7, 2018
Common Stock, $0.0075 par value	8,367,118

XOMA CORPORATION

FORM 10-Q

TABLE OF CONTENTS

		Page
PART I	FINANCIAL INFORMATION

Item 1.	Condensed Consolidated Financial Statements	1

	Condensed Consolidated Balance Sheets as of March 31, 2018 and December 31, 2017	1

	Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three Months Ended March 31, 2018 and 2017	2

	Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2018 and 2017	3

	Notes to Condensed Consolidated Financial Statements	4

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	21

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	26

Item 4.	Controls and Procedures	26

PART II	OTHER INFORMATION	27

Item 1.	Legal Proceedings	27

Item 1A.	Risk Factors	27

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	45

Item 3.	Defaults Upon Senior Securities	45

Item 4.	Mine Safety Disclosure	45

Item 5.	Other Information	45

Item 6.	Exhibits	46

Signatures		48

PART I - FINANCIAL INFORMATION

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

XOMA CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share amounts)

	March 31,			December 31,
	2018			2017
	(unaudited)			(Note 1)
ASSETS
Current assets:
Cash and cash equivalents	$	41,968		$	43,471
Trade and other receivables		436			397
Prepaid expenses and other current assets		273			327
Total current assets		42,677			44,195
Property and equipment, net		75			83
Other assets		559			657
Total assets	$	43,311		$	44,935

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	1,420		$	1,679
Accrued and other liabilities		1,338			2,675
Income taxes payable		1,666			1,637
Unearned revenue recognized under units-of-revenue method – current		658			615
Contract liabilities		798			798
Accrued interest on long-term debt – current		—			18
Total current liabilities		5,880			7,422
Unearned revenue recognized under units-of-revenue method – non-current		17,019			17,123
Long-term debt		14,572			14,572
Other liabilities – non-current		203			32
Total liabilities		37,674			39,149

Commitments and Contingencies (Note 10)

Stockholders’ equity:
Convertible preferred stock, $0.05 par value, 1,000,000 shares authorized, 5,003 shares issued and outstanding at March 31, 2018 and December 31, 2017		—			—
Common stock, $0.0075 par value, 277,333,332 shares authorized, 8,332,118 and 8,249,158 shares issued and outstanding at March 31, 2018 and December 31, 2017, respectively		62			62
Additional paid-in capital		1,188,440			1,184,783
Accumulated deficit		(1,182,865	)		(1,179,059	)
Total stockholders’ equity		5,637			5,786
Total liabilities and stockholders’ equity	$	43,311		$	44,935

The accompanying notes are an integral part of these condensed consolidated financial statements.

(Note 1) The condensed consolidated balance sheet as of December 31, 2017 has been derived from the audited consolidated financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017.

XOMA CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(unaudited)

(in thousands, except per share amounts)

	Three Months Ended March 31,
	2018			2017
Revenues:
Revenue from contracts with customers	$	401		$	150
Revenue recognized under units-of-revenue method		62			110
Total revenues		463			260

Operating expenses:
Research and development		432			3,993
General and administrative		5,168			5,167
Restructuring		—			2,020
Total operating expenses		5,600			11,180

Loss from operations		(5,137	)		(10,920	)

Other income (expense):
Interest expense		(170	)		(609	)
Loss on extinguishment of debt		—			(515	)
Other income, net		1,501			1,329
Net loss and comprehensive loss		(3,806	)		(10,715	)
Deemed dividend on convertible preferred stock		—			(5,603	)
Net loss and comprehensive loss available to common stockholders, basic and diluted	$	(3,806	)	$	(16,318	)
Basic and diluted net loss per share available to common stockholders	$	(0.46	)	$	(2.37	)
Weighted average shares used in computing basic and diluted net loss per share available to common stockholders		8,313			6,887

The accompanying notes are an integral part of these condensed consolidated financial statements.

XOMA CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

(in thousands)

	Three Months Ended March 31,
	2018			2017
Cash flows used in operating activities:
Net loss	$	(3,806	)	$	(10,715	)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense		1,416			1,000
Common stock contribution to 401(k)		20			506
Depreciation and amortization		8			147
Amortization of debt issuance costs, debt discount and final payment on debt		—			286
Loss on extinguishment of debt		—			515
Unrealized loss on foreign currency exchange		—			261
Gain on sale of equipment		—			(1,314	)
Other		(21	)		55
Changes in assets and liabilities:
Trade and other receivables		(39	)		33
Prepaid expenses and other current assets		53			345
Accounts payable and accrued liabilities		(1,593	)		(5,281	)
Accrued interest on long-term debt		138			(76	)
Unearned revenue recognized under units-of-revenue method		(62	)		(110	)
Income tax payable		29			—
Other liabilities		18			—
Net cash used in operating activities		(3,839	)		(14,348	)

Cash flows from investing activities:
Proceeds from sale of property and equipment		—			813
Net cash provided by investing activities		—			813

Cash flows from financing activities:
Proceeds from issuance of convertible preferred stock, net of issuance costs		—			20,072
Proceeds from issuance of common stock, net of issuance costs		2,309			5,380
Proceeds from exercise of options		14			—
Principal payments – debt		—			(16,380	)
Payment of final fee related to loan extinguishment		—			(1,150	)
Principal payments – capital lease		(4	)		(51	)
Taxes paid related to net share settlement of equity awards		(3	)		—
Net cash provided by financing activities		2,316			7,871

Effect of exchange rate changes on cash		20			(33	)

Net decrease in cash and cash equivalents		(1,503	)		(5,697	)
Cash and cash equivalents at the beginning of the period		43,471			25,742
Cash and cash equivalents at the end of the period	$	41,968		$	20,045

Supplemental Cash Flow Information:
Cash paid for interest	$	—		$	396
Non-cash investing and financing activities:
Prepaid financing cost related to issuance of common stock	$	100		$	—
Other receivable related to sale of equipment	$	—		$	811

The accompanying notes are an integral part of these consolidated financial statements.

XOMA CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

1. Description of Business

XOMA Corporation (referred to as “XOMA” or the “Company”), a Delaware corporation, has a long history of discovering and developing innovative therapeutics derived from its unique platform of antibody technologies. Over the Company’s 37-year history, it built an extensive portfolio of fully-funded programs by advancing product candidates into the earlier stages of development and then licensing them to licensees who assumed the responsibilities of later stage development, approval and commercialization. Fully-funded programs are those for which the Company’s partners pay all of the development and commercialization costs. As licensees advance these programs, the Company is eligible for potential milestone and royalty payments. As part of the Company’s royalty aggregator business model, the Company intends to expand its portfolio of fully-funded programs by acquiring potential milestone and royalty revenue streams on additional product candidates.

Liquidity and Financial Condition

With the exception of the year ended December 31, 2017, the Company has typically incurred significant operating losses and negative cash flows from operations since its inception. As of March 31, 2018, the Company had cash and cash equivalents of $42.0 million. The Company has evaluated and concluded there are no conditions or events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern for a period of one year following the date that these financial statements are issued.

2. Basis of Presentation and Significant Accounting Policies

Basis of Presentation

The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions among consolidated entities were eliminated upon consolidation. The unaudited consolidated financial statements were prepared in accordance with generally accepted accounting principles (“GAAP”) in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. As permitted under those rules certain footnotes or other financial information can be condensed or omitted. These financial statements and related disclosures have been prepared with the assumption that users of the interim financial information have read or have access to the audited consolidated financial statements for the preceding fiscal year. Accordingly, these statements should be read in conjunction with the audited consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, filed with the U.S. Securities and Exchange Commission (“SEC”) on March 7, 2018.

These financial statements have been prepared on the same basis as the Company’s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments that are necessary for a fair statement of the Company’s consolidated financial information. The interim results of operations are not necessarily indicative of the results that may be expected for the full year.

Use of Estimates

The preparation of financial statements in conformity with GAAP in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to, those related to revenue recognition, debt amendments, long-lived assets, restructuring liabilities, legal contingencies, and stock-based compensation. The Company bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ significantly from these estimates, such as the Company’s billing under government contracts. Under the Company’s contracts with the National Institute of Allergy and Infectious Diseases (“NIAID”), a part of the National Institutes of Health (“NIH”), the Company billed using NIH’s provisional rates and thus is subject to future audits at the discretion of NIAID’s contracting office. These audits can result in an adjustment to revenue previously reported which potentially could be significant.

Revenue Recognition

Effective January 1, 2018, the Company adopted Accounting Standards Codification Topic 606, Revenue from Contracts with Customers ("ASC 606") using the modified retrospective transition method and applied the standard only to contracts that are still active or in place at that date. Also, as permitted, the Company applied the practical expedient under ASC 606 which permits the Company to treat all contract modifications that occurred prior to the adoption in aggregate when determining the performance obligations, transaction price and its allocation. Except for the Company’s license agreement with Rezolute, Inc. (formerly AntriaBio, Inc.) (“Rezolute”), the Company did not have any other contracts with customers for which the Company had not completed its performance obligations as of the adoption date January 1, 2018. The license agreement with Rezolute was not considered a contract under ASC 606 as it is not probable that the Company will collect substantially all of the consideration to which it will be entitled in exchange for the goods or services that will be transferred to Rezolute and there was no consideration exchanged upon execution of the arrangement or as of January 1, 2018 (see Note 4). Thus, the Company determined that the adoption of ASC 606 did not have a financial impact on the Company's consolidated financial statements and related disclosures. In addition, the adoption of ASC 606 has no material impact for tax purposes. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services.

To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation based on relative fair values, when (or as) the performance obligation is satisfied.

The Company recognizes revenue from its license and collaboration arrangements and royalties. The terms of the arrangements generally include payment to the Company of one or more of the following: non-refundable, upfront license fees, development, regulatory and commercial milestone payments, and royalties on net sales of licensed products.

Licenses of intellectual property: If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, such as transfer of related materials, process and know-how, the Company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. Under the Company’s license agreements, the nature of the combined performance obligation is the granting of licenses to the customers as the other promises are not separately identifiable in the context of the arrangement. Since the Company grants the license to a customer as it exists at the point of transfer, and is not involved in any future development or commercialization of the products related to the license, the nature of the license is a right to use the Company’s intellectual property as transferred. As such, the Company recognizes revenue related to the combined performance obligation upon completion of the delivery of the related materials, process and know-how (i.e., at a point in time).

Milestone payments: At the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. ASC 606 suggests two alternatives to use when estimating the amount of variable consideration: the expected value method and the most likely amount method. Under the expected value method, an entity considers the sum of probability-weighted amounts in a range of possible consideration amounts. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. The Company expects to use the most likely amount method for development and regulatory milestone payments. If it is probable that a significant cumulative revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability or achievement of each such milestone and any related constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and earnings in the period of adjustment.

Royalties: For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).

Upfront payments and fees are recorded as deferred revenue upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company’s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one year or less.

Sale of Future Revenue Streams

The Company has sold its rights to receive certain milestones and royalties on product sales. In the circumstance where the Company has sold its rights to future milestones and royalties under a license agreement and also maintains limited continuing involvement in the arrangement (but not significant continuing involvement in the generation of the cash flows that are due to the purchaser), the Company defers recognition of the proceeds it receives for the sale of milestone or royalty streams and recognizes such unearned revenue as revenue under units-of-revenue method over the life of the underlying license agreement.. Under the units-of-revenue method, amortization for a reporting period is calculated by computing a ratio of the proceeds received from the purchaser to the total payments expected to be made to the purchaser over the term of the agreement, and then applying that ratio to the period’s cash payment.

Estimating the total payments expected to be received by the purchaser over the term of such arrangements requires management to use subjective estimates and assumptions. Changes to the Company’s estimate of the payments expected to be made to the purchaser over the term of such arrangements could have a material effect on the amount of revenues recognized in any particular period.

Stock-Based Compensation

The Company recognizes compensation expense for all stock-based payment awards made to the Company’s employees, consultants and directors that are expected to vest based on estimated fair values. The valuation of stock option awards is determined at the date of grant using the Black-Scholes Option Pricing Model (the “Black-Scholes Model”). The Black-Scholes Model requires inputs such as the expected term of the option, expected volatility and risk-free interest rate. To establish an estimate of expected term, the Company considers the vesting period and contractual period of the award and its historical experience of stock option exercises, post-vesting cancellations and volatility. The estimate of expected volatility is based on the Company’s historical volatility. The risk-free rate is based on the yield available on United States Treasury zero-coupon issues corresponding to the expected term of the award. The Company records forfeitures when they occur.

The Company records compensation expense for service-based awards over the vesting period of the award on a straight-line basis. For awards with performance-based conditions, the Company records the expense over the remaining service period when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based condition is probable based on the expected satisfaction of the performance conditions as of the reporting date. The amount of stock-based compensation expense recognized during a period is based on the value of the portion of the awards that are ultimately expected to vest.

The valuation of restricted stock units (“RSUs”) is determined at the date of grant using the Company’s closing stock price.

Net Loss per Share Available to Common Stockholders

Basic net loss per share available to common stockholders is based on the weighted average number of shares of common stock outstanding during the period. Net loss available to common stockholders consists of net loss, as adjusted for the convertible preferred stock deemed dividends related to the beneficial conversion feature on this instrument at issuance. For the three months ended March 31, 2017, the convertible preferred stock had a deemed dividend which represented the accretion of a beneficial conversion feature. As such, the net loss for the three months ended March 31, 2017 was adjusted for the convertible preferred stock deemed dividend related to the beneficial conversion feature on these shares at issuance. During periods of loss, the Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company. Diluted net loss per share available to common stockholders is based on the weighted average number of shares outstanding during the period, adjusted to include the assumed conversion of preferred stock, and the exercise of certain stock options, RSUs, and warrants for common stock. The calculation of diluted loss per share available to common stockholders requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of any outstanding options, RSUs or warrants and the presumed exercise of such securities are dilutive to earnings (loss) per share available to common stockholders for the period. Adjustments to the denominator are required to reflect the related dilutive shares.

Concentration of Risk

Cash equivalents and receivables are financial instruments which potentially subject the Company to concentrations of credit risk, as well as liquidity risk for certain cash equivalents, such as money market funds. The Company has not encountered any such liquidity issues during 2018.

The Company has not experienced any significant credit losses and does not generally require collateral on receivables. For the three months ended March 31, 2018, two partners represented 86% and 13% of total revenues, respectively. For the three months ended March 31, 2017, two partners represented 58% and 42% of total revenues, respectively. As of March 31, 2018, two partners represented 50% of the trade receivables balance, respectively. As of December 31, 2017, one partner represented 95% of the trade receivables balance.

Recent Accounting Pronouncements

In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-02, Leases (Topic 842). ASU 2016-2 is aimed at making leasing activities more transparent and comparable, and requires substantially all leases be recognized by lessees on their balance sheet as a right-of-use asset and corresponding lease liability, including leases currently accounted for as operating leases. ASU 2016-2 is effective for the Company’s interim and annual reporting periods during the year ending December 31, 2019, and all annual and interim reporting periods thereafter. Early adoption is permitted. The Company is evaluating the impact of the adoption of the standard on its consolidated financial statements.

3. Condensed Consolidated Financial Statements Detail

Cash and Cash Equivalents

As of March 31, 2018, cash and cash equivalents consisted of demand deposits of $7.0 million and money market funds of $35.0 million with maturities of less than 90 days at the date of purchase. As of December 31, 2017, cash and cash equivalents consisted of demand deposits of $34.9 million and money market funds of $8.6 million with maturities of less than 90 days at the date of purchase.

Property and Equipment, net

During the three months ended March 31, 2017, the Company completed the sale of equipment located in one of its leased facilities for total proceeds of $1.6 million. The carrying value of the equipment sold was $0.3 million. Accordingly, the Company recorded a gain of $1.3 million on the sale of equipment in the other income (expense), net line of the condensed consolidated statement of operations and comprehensive loss.

Accrued and Other Liabilities

Accrued and other liabilities consisted of the following (in thousands):

	March 31,		December 31,
	2018		2017
Accrued payroll and other benefits	$	83	$	141
Accrued restructuring		—		130
Accrued incentive compensation		90		229
Accrued legal and accounting fees		237		431
Deferred rent		754		765
Liability related to sublease		—		800
Other		174		179
Total	$	1,338	$	2,675

Net Loss Per Share Available to Common Stockholders

The following is a reconciliation of the numerator (net loss) and the denominator (number of shares) used in the calculation of basic and diluted net loss per share available to common stockholders (in thousands):

	Three Months Ended March 31,
	2018			2017
Numerator
Net loss	$	(3,806	)	$	(10,715	)
Less: Deemed dividend on convertible preferred stock		—			(5,603	)
Net loss available to common stockholders, basic and diluted	$	(3,806	)	$	(16,318	)

Denominator
Weighted average shares outstanding used for basic and diluted net loss per share available to common stockholders		8,313			6,887

Potentially dilutive securities are excluded from the calculation of diluted net loss per share available to common stockholders if their inclusion is anti-dilutive. The following table shows the weighted-average outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per share available to common stockholders (in thousands):

	Three Months Ended March 31,
	2018		2017
Common stock options and RSUs		1,645		653
Warrants for common stock		17		381
Convertible preferred stock		5,003		2,446
Total		6,665		3,480

4. Licensing and Other Arrangements

Novartis – Gevokizumab and IL-1 Beta

On August 24, 2017, the Company and Novartis Pharma AG (“Novartis”) entered into a license agreement (the “XOMA-052 License Agreement”) under which the Company granted to Novartis an exclusive, worldwide, royalty-bearing license to gevokizumab, a novel anti-Interleukin-1 (“IL-1”) beta allosteric monoclonal antibody (the “Antibody”) and related know-how and patents (altogether, the “XOMA IP”). Under the terms of the XOMA-052 License Agreement, Novartis will be solely responsible for the development and commercialization of the Antibody and products containing the Antibody.

On August 24, 2017, pursuant to a separate agreement (the “IL-1 Target License Agreement”), the Company granted to Novartis non-exclusive licenses to its intellectual property covering the use of IL-1 beta targeting antibodies in the treatment and prevention of cardiovascular disease and other diseases and conditions, and an option to obtain an exclusive license (the “Exclusivity Option”) to such intellectual property for the treatment and prevention of cardiovascular disease.

Under the XOMA-052 License Agreement, the Company received total consideration of $30.0 million for the license and rights granted to Novartis. Of the total consideration, $15.7 million was paid in cash and $14.3 million (equal to €12.0 million) was paid by Novartis Institutes for BioMedical Research, Inc. (“NIBR”), on behalf of the Company, to settle the Company’s outstanding debt with Les Laboratories Servier (“Servier”) (the “Servier Loan”). In addition, NIBR extended the maturity date on the Company’s debt to Novartis. The Company also received $5.0 million cash related to the sale of 539,131 shares of the Company’s common stock, at a purchase price of $9.2742 per share. The fair market value of the common stock issued to Novartis was $4.8 million, based on the closing stock price of $8.93 per share on August 24, 2017, resulting in a $0.2 million premium paid to the Company.

Based on the achievement of pre-specified criteria, the Company is eligible to receive up to $438.0 million in development, regulatory and commercial milestones under the XOMA-052 License Agreement. The Company is also eligible to receive royalties on sales of licensed products, which are tiered based on sales levels and range from the high single digits to mid-teens. Under the IL-1 Target License Agreement, the Company received an upfront cash payment of $10.0 million and is eligible to receive low single-digit royalties on canakinumab sales in cardiovascular indications covered by the Company’s patents. Should Novartis exercise the Exclusivity Option, the royalties on canakinumab sales will increase to the mid-single digits.

Unless terminated earlier, the XOMA-052 License Agreement and IL-1 Target License Agreement will remain in effect, on a country-by-country and product-by-product basis, until Novartis’ royalty obligations end. The two agreements contain customary termination rights relating to material breach by either party. Novartis also has a unilateral right to terminate the XOMA-052 License Agreement on a product-by-product and country-by-country basis or in its entirety on six months’ prior written notice to the Company. Under the IL-1 Target License Agreement, Novartis has a unilateral right to terminate the agreement on a product-by-product and country-by-country basis or in its entirety upon a prior written notice.

The XOMA-052 License Agreement and IL-1 Target License Agreement were accounted for as one arrangement because they were entered into at the same time in contemplation of each other. The Company concluded that there are multiple promised goods and services under the combined arrangement, including the transfer of license to IL-1 beta targeting antibodies, and the transfer of license, know-how, process, materials and inventory related the gevokizumab antibody, which were determined to represent two distinct performance obligations. The Company determined that the Exclusivity Option is not an option with material right because the upfront payments to the Company were not negotiated to provide an incremental discount for the future additional royalties upon exercise of the Exclusivity Option. Therefore, the Company concluded that the Exclusivity Option is not a performance obligation. The additional royalties will be recognized as revenue when, and if, Novartis exercises its option because the Company has no further performance obligations at that point.

At the inception of the arrangement, the Company determined that the transaction price under the arrangement was $40.2 million, which consisted of the $25.7 million upfront cash payments, the $14.3 million Servier Loan payoff and the $0.2 million premium on the sale of the common stock. The transaction price was allocated to the two performance obligations based on their standalone selling prices. The Company determined that the nature of the two performance obligations is the right to use the licenses as they exist at the point of transfer, which occurred when the transfer of materials, process and know-how, and filings to regulatory authority were completed. During the year ended December 31, 2017, the Company recognized the entire transaction price of $40.2 million as revenue upon completion of the delivery of the licenses and related materials, process and know-how and filings to regulatory authority.

The Company concluded that the development and regulatory milestone payments are solely dependent on Novartis’ performance and achievement of specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the development and regulatory milestones are fully constrained and excluded from the transaction price as of March 31, 2018. Any consideration related to commercial milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the licenses granted to Novartis and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.

As of March 31, 2018, and December 31, 2017, there are no contract assets or contract liabilities related to this arrangement. In addition, the Company did not recognize any revenue related to this arrangement during the three months ended March 31, 2018. None of the costs to obtain or fulfill the contract were capitalized.

Novartis International – Anti-TGFβ Antibody

On September 30, 2015, the Company and Novartis International Pharmaceutical Ltd. (“Novartis International”) entered into a license agreement (the “License Agreement”) under which the Company granted Novartis International an exclusive, world-wide, royalty-bearing license to the Company’s anti-transforming growth factor beta (TGFβ) antibody program (now “NIS793”). Under the terms of the License Agreement, Novartis International has worldwide rights to NIS793 and is responsible for the development and commercialization of antibodies and products containing antibodies arising from NIS793. Unless terminated earlier, the License Agreement will remain in effect, on a country-by-country and product-by-product basis, until Novartis International’s royalty obligations end. The License Agreement contains customary termination rights relating to material breach by either party. Novartis International also has a unilateral right to terminate the License Agreement on an antibody-by-antibody and country-by-country basis or in its entirety on one hundred eighty days’ notice.

The Company concluded that there are multiple promised goods and services under the License Agreement, including the transfer of license, regulatory services and transfer of materials, process and know-how, which were determined to represent one combined performance obligation. The Company recognized the entire upfront payment of $37.0 million as revenue in the consolidated statement of comprehensive loss in 2015 as it had completed its performance obligations as of December 31, 2015.

During the three months ended June 30, 2017, Novartis International achieved a clinical development milestone pursuant to the License Agreement and, as a result, the Company earned a $10.0 million milestone payment which was recognized as license fees in the consolidated statement of comprehensive income. As of March 31, 2018, the Company is eligible to receive up to a total of $470.0 million in development, regulatory and commercial milestones.

The Company concluded that the development and regulatory milestone payments are solely dependent on Novartis’ performance and achievement of the specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the development and regulatory milestones are fully constrained and excluded from the transaction price as of March 31, 2018. Any consideration related to commercial milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the licenses granted to Novartis and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.

The Company is also eligible to receive royalties on sales of licensed products, which are tiered based on sales levels and range from a mid-single digit percentage rate to up to a low double-digit percentage rate. Novartis International’s obligation to pay royalties with respect to a particular product and country will continue for the longer of the date of expiration of the last valid patent claim covering the product in that country, or ten years from the date of the first commercial sale of the product in that country.

Rezolute

On December 6, 2017, the Company entered into a license agreement with Rezolute pursuant to which the Company granted an exclusive global license to Rezolute to develop and commercialize X358 (now “RZ358”) for all indications. The Company and Rezolute also entered into a common stock purchase agreement pursuant to which Rezolute agreed to issue to the Company, as consideration for receiving the license for RZ358, a certain number of its common stock related to its future financing activities.

Under the terms of the license agreement, Rezolute is responsible for all development, regulatory, manufacturing and commercialization activities associated with RZ358 and is required to make certain development, regulatory and commercial milestone payments to the Company of up to $232.0 million in the aggregate based on the achievement of pre-specified criteria. Under the license agreement, the Company is also eligible to receive royalties ranging from the high single digits to the mid-teens based upon annual net sales of any commercial product incorporating RZ358. Rezolute is obligated to take customary steps to advance RZ358, including using diligent efforts to commence the next clinical study for RZ358 by a certain deadline and to meet certain spending requirements on an annual basis for the program until a marketing approval application for RZ358 is accepted by the Food and Drug Administration. Rezolute’s obligation to pay royalties with respect to a particular RZ358 product and country will continue for the longer of the date of expiration of the last valid patent claim covering the product in that country, or twelve years from the date of the first commercial sale of the product in that country. Rezolute has an option through June 1, 2019 to obtain an exclusive license for their choice of one of the Company’s preclinical monoclonal antibody fragments, including X129, in exchange for a $1.0 million upfront option fee and additional clinical, regulatory and commercial milestone payments to the Company of up to $237.0 million in the aggregate based on the achievement of pre-specified criteria as well as royalties ranging from the high single digits to the mid-teens based on annual net sales.

Pursuant to the license agreement and common stock purchase agreement, the Company is eligible to receive $6.0 million in cash and $12.0 million of Rezolute’s common stock contingent on the completion of Rezolute’s financing activities. Further, in the event that Rezolute does not complete a financing that raises at least $20.0 million in aggregate gross proceeds (“Qualified Financing”) by March 31, 2019 (the “2019 Closing”), the Company will receive an additional number of shares of Rezolute’s common stock equal to $7.0 million divided by the weighted average of the closing bid and ask prices or the average closing prices of Rezolute’s common stock on the ten-day trading period prior to March 31, 2019. Finally, in the event that Rezolute is unable to complete a Qualified Financing by March 31, 2020, the Company is eligible to receive $15.0 million in cash in order to maintain the license. Under the common stock purchase agreement, Rezolute granted the Company the right and option to sell the greater of (i) 5,000,000 shares of common stock or (ii) one third of the aggregate shares held by the Company upon failure by Rezolute to list its shares of its common stock on the Nasdaq Stock Market or a similar national exchange on or prior to December 31, 2018.

In addition, under the terms of the license agreement, the Company is eligible to receive a low single digit royalty on sales of Rezolute’s other products from its current programs. Rezolute’s obligation to pay royalties with respect to a particular Rezolute product and country will continue for the longer of twelve years from the date of the first commercial sale of the product in that country or for so long as Rezolute or its licensee is selling such product in such country, provided that such royalty will terminate upon the termination of the licensee’s obligation to make payments to Rezolute based on sales of such product in such country.

The license agreement contains customary termination rights relating to material breach by either party. Rezolute also has a unilateral right to terminate the license agreement in its entirety on ninety days’ notice at any time. The Company has the right to terminate the license agreement if Rezolute challenges the licensed patents.

On March 30, 2018, the Company and Rezolute amended the license agreement and common stock purchase agreement. The license agreement was amended to add terms specifying the financial responsibility for certain tasks related to the technology transfer. The common stock purchase agreement was amended as follows: (1) adjusted the total shares due upon the Initial Closing (as defined in the common stock purchase agreement) from $5.0 million in value to 7,000,000 shares; (2) increase the shares due upon a Qualified Financing from $7.0 million in value to $8.5 million in value; and (3) increase the shares due upon the 2019 Closing from $7.0 million in value to $8.5 million in value. All other terms of the license agreement and common stock purchase agreement remain unchanged.

Under the license agreement and common stock purchase agreement, no consideration was exchanged upon execution of the arrangement. In consideration for receiving the license for RZ358, Rezolute agreed to issue shares of its common stock and pay cash to the Company upon the occurrence of Rezolute’s financing activities and the amounts to be paid will be based on the timing of those activities. Upon execution of the arrangement, the Company determined that it is not probable that the Company will collect substantially all of the consideration to which it will be entitled in exchange for the goods or services that will be transferred to Rezolute. Therefore, the Company determined that there is no contract on December 6, 2017 under ASC 606.

During the three months ended March 31, 2018, Rezolute completed an Interim Financing Closing as defined in the common stock purchase agreement resulting in consideration due to XOMA consisting of 69,252 shares of Rezolute’s common stock and cash of $50,000. In addition, during the three months ended March 31, 2018, the Company completed the delivery of the license and related materials, product data/filing, process and know-how to Rezolute. However, the Company determined that the achievement of the Interim Financing Closing and related consideration as well as the amendment in March 2018 were not substantive to overcome the collectability criterion required to establish a contract under ASC 606. Thus, there is no contract as of March 31, 2018 and no revenue was recognized during the three months ended March 31, 2018 under the arrangement. (See Note 14).

NIAID

Prior to the sale of the Company’s biodefense business discussed in Note 6, the Company performed services under a $64.8 million multiple-year contract funded with federal funds from NIAID (Contract No. HHSN272200800028C), for development of anti-botulinum antibody product candidates. The contract work was being performed on a cost plus fixed fee basis over a three-year period. The Company recognized revenue under the arrangement as the services were performed on a proportional performance basis. Consistent with the Company’s other contracts with the U.S. government, invoices were provisional until finalized. The Company operated under provisional rates from 2010 through 2014, subject to adjustment based on actual rates upon agreement with the government. In 2014, upon completion of NIAID’s review of hours and external expenses, XOMA agreed to exclude certain hours and external expenses resulting in a $0.4 million receivable and $0.8 million deferred revenue balances. As of December 31, 2017, the Company wrote off the $0.4 million receivable from NIAID as the likelihood of collection is remote. The Company classified $0.8 million as contract liabilities on the consolidated balance sheets as of March 31, 2018 and December 31, 2017, respectively.

Sale of Future Revenue Streams

On December 21, 2016, the Company entered into two Royalty Interest Acquisition Agreements (together, the “Acquisition Agreements”) with HealthCare Royalty Partners II, L.P. (“HCRP”). Under the first Acquisition Agreement, the Company sold its right to receive milestone payments and royalties on future sales of products subject to a License Agreement, dated August 18, 2005, between XOMA and Wyeth Pharmaceuticals (subsequently acquired by Pfizer, Inc. (“Pfizer”)) for an upfront cash payment of $6.5 million, plus potential additional payments totaling $4.0 million in the event three specified net sales milestones are met in 2017, 2018 and 2019. The 2017 sales milestone was not achieved. The Company remains eligible to receive up to $3.0 million if specified net sales milestones are achieved in 2018 and 2019. Under the second Acquisition Agreement, the Company sold all rights to royalties under an Amended and Restated License Agreement dated October 27, 2006 between XOMA and Dyax Corp. for a cash payment of $11.5 million.

The Company classified the proceeds received from HCRP as unearned revenue, to be recognized as revenue under units-of-revenue method over the life of the license agreements because of the Company's limited continuing involvement in the Acquisition Agreements. Such limited continuing involvement is related to the Company’s undertaking to cooperate with HCRP in the event of litigation or a dispute related to the license agreements. Because the transaction was structured as a non-cancellable sale, the Company does not have significant continuing involvement in the generation of the cash flows due to HCRP and there are no guaranteed rates of return to HCRP, the Company recorded the total proceeds of $18.0 million as unearned revenue recognized under units-of-revenue method. The Company allocated the total proceeds between the two Acquisition Agreements based on the relative fair value of expected payments to be made to HCRP under the license agreements. The unearned revenue is being recognized as revenue over the life of the underlying license agreements under the "units-of-revenue" method. Under this method, amortization for a reporting period is calculated by computing a ratio of the allocated proceeds received from HCRP to the payments expected to be made by the licensees to HCRP over the term of the Acquisition Agreements, and then applying that ratio to the period’s cash payment. The Company recognized $0.1 million as revenue recognized under units-of-revenue method under these arrangements during the three months ended March 31, 2018 and 2017. As of March 31, 2018, the current and non-current portion of the remaining unearned revenue recognized under units-of-revenue method was $0.7 million and $17.0 million, respectively. As of December 31, 2017, the Company classified $0.6 million and $17.1 million as current and non-current unearned revenue recognized under units-of-revenue method, respectively.

5. Fair Value Measurements

The Company records its financial assets and liabilities at fair value. The carrying amounts of certain of the Company’s financial instruments, including cash and cash equivalents, trade receivables and accounts payable, approximate their fair value due to their short maturities. Fair value is defined as the exchange price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting guidance for fair value establishes a framework for measuring fair value and a fair value hierarchy that prioritizes the inputs used in valuation techniques. The accounting standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value, which are the following:

Level 1 – Observable inputs, such as quoted prices in active markets for identical assets or liabilities.

Level 2 – Observable inputs, either directly or indirectly, other than quoted prices in active markets for identical assets or liabilities, such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities; therefore, requiring an entity to develop its own valuation techniques and assumptions.

The following tables set forth the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as follows (in thousands):

	Fair Value Measurements at March 31, 2018 Using
	Quoted Prices in Active Markets for Identical Assets		Significant Other Observable Inputs		Significant Unobservable Inputs
	(Level 1)		(Level 2)		(Level 3)		Total
Assets:
Money market funds ⁽¹⁾	$	35,021	$	—	$	—	$	35,021

	Fair Value Measurements at December 31, 2017 Using
	Quoted Prices in Active Markets for Identical Assets		Significant Other Observable Inputs		Significant Unobservable Inputs
	(Level 1)		(Level 2)		(Level 3)		Total
Assets:
Money market funds ⁽¹⁾	$	34,907	$	—	$	—	$	34,907

(1)Included in cash and cash equivalents

During the three-month period ended March 31, 2018, there were no transfers between Level 1, Level 2, or Level 3 assets reported at fair value on a recurring basis and the valuation techniques used did not change compared to the Company’s established practice.

The estimated fair value of the Company’s outstanding long-term debt is estimated using the net present value of the payments, discounted at an interest rate that is consistent with market interest rates, which is a Level 2 input. The carrying amount and the estimated fair value of the Company’s outstanding long-term debt at March 31, 2018, and December 31, 2017, are as follows (in thousands):

	March 31, 2018				December 31, 2017
	Carrying Amount		Fair Value		Carrying Amount		Fair Value
Novartis note	$	14,572	$	13,873	$	14,572	$	14,178

6. Dispositions

On November 4, 2015, XOMA and Ology Bioservices entered into an asset purchase agreement under which Ology Bioservices agreed to acquire XOMA’s biodefense business and related assets (including certain contracts with the U.S. government), and to assume certain liabilities of XOMA. As part of the transaction, the parties entered into an intellectual property license agreement (the “Ology Bioservices License Agreement”), under which XOMA agreed to license to Ology Bioservices certain intellectual property rights related to the purchased assets. Under the Ology Bioservices License Agreement, the Company was eligible to receive contingent consideration up to a maximum of $4.5 million in cash and 23,008 shares of common stock of Ology Bioservices, based upon Ology Bioservices achieving certain specified future operational objectives. In addition, the Company is eligible to receive 15% royalties on net sales of any future Ology Bioservices products covered by or involving the related patents or know-how.

In February 2017, the Company executed an Amendment and Restatement to both the asset purchase agreement and Ology Bioservices License Agreement primarily to (i) remove the obligation to issue 23,008 shares of Ology Bioservices under the asset purchase agreement, and (ii) revise the payment schedule related to the timing of the $4.5 million cash payments due to the Company under the Ology Bioservices License Agreement. Of the $4.5 million, $3.0 million was contingent upon Ology Bioservices achieving certain specified future operating objectives. In the first quarter of 2017, the Company became entitled to receive $1.6 million under the agreement that will be received in quarterly payments through September 2018. In the third quarter of 2017, Ology Bioservices achieved the specified operating objectives and the Company earned the $3.0 million milestone fee that will be received in monthly payments through July 2018. The Company received $1.0 million and $0.2 million during the three months ended March 31, 2018 and 2017, respectively, which was recognized as other income in the condensed consolidated statements of operations and comprehensive loss.

7. Restructuring Charges

On December 19, 2016, the Board of Directors approved a restructuring of the Company’s business based on its decision to focus the Company’s efforts on clinical development, with an initial focus on the X358 clinical programs. The restructuring included a reduction-in-force in which the Company terminated 57 employees. In early 2017, the Company further revised its strategy to prioritize out-licensing activities and further curtail research and development spending and terminated five additional employees.

The following table summarizes the accrued restructuring costs on the condensed consolidated balance sheet as of March 31, 2018 (in thousands):

	Employee Severance
	and Other Benefits
Balance at December 31, 2016	$	3,594
Restructuring charges		3,447
Cash payments		(6,911	)
Balance at December 31, 2017		130
Cash payments		(130	)
Balance at March 31, 2018	$	—

8. Long-Term Debt

Novartis Note

In May 2005, the Company executed a secured note agreement (the “Note Agreement”) with Novartis, which was due and payable in full in June 2015. Under the Note Agreement, the Company borrowed semi-annually to fund up to 75% of the Company’s research and development and commercialization costs under its collaboration arrangement with Novartis, not to exceed $50.0 million in aggregate principal amount. Interest on the principal amount of the loan accrued at six-month LIBOR plus 2%, which was equal to 3.81% at March 31, 2018 is payable semi-annually in June and December of each year. Additionally, the interest rate resets in June and December of each year. At the Company’s election, the semi-annual interest payments could be added to the outstanding principal amount, in lieu of a cash payment, as long as the aggregate principal amount did not exceed $50.0 million. The Company made this election for all interest payments. Loans under the Note Agreement were secured by the Company’s interest in its collaboration with Novartis, including any payments owed to it thereunder.

On September 30, 2015, concurrent with the execution of a license agreement with Novartis International as discussed in Note 4, XOMA and NIBR, who assumed the rights to the note from Novartis Vaccines Diagnostics, Inc. executed an amendment to the Note Agreement (the “Secured Note Amendment”) under which the parties extended the maturity date of the note from September 30, 2015 to September 30, 2020, and eliminated the mandatory prepayment previously required to be made with certain proceeds of pre-tax profits and royalties. In addition, upon achievement of a specified development and regulatory milestone, the then-outstanding principal amount of the note will be reduced by $7.3 million rather than the Company receiving such amount as a cash payment.

On September 22, 2017, in connection with the XOMA-052 License Agreement with Novartis, the Company and NIBR executed an amendment to the Secured Note Amendment under which the parties further extended the maturity date of the Secured Note Amendment from September 30, 2020 to September 30, 2022.

As of March 31, 2018 and December 31, 2017, the outstanding principal balance under the Secured Note Amendment was $14.6 million, and was included in long-term debt in the accompanying consolidated balance sheets.

Servier Loan Agreement

In December 2010, in connection with the collaboration agreement entered into with Servier, the Company executed a loan agreement with Servier (the “Servier Loan Agreement”), which provided for an advance of up to €15.0 million. The loan was secured by an interest in XOMA’s intellectual property rights to gevokizumab and its use in indications worldwide, excluding certain rights in the U.S. and Japan. Interest was calculated at a floating rate based on a Euro Inter-Bank Offered Rate (“EURIBOR”) and subjected to a cap.

The Company and Servier executed multiple amendments to the Servier Loan Agreement in 2015 and 2017 primarily to revise the timing of the payments and the maturity date of the loan. On August 25, 2017, NIBR settled the Servier Loan in cash by paying directly to Servier $14.3 million which represented the outstanding balance of the loan based on a euro to dollar exchange rate of 1.1932. The funds that NIBR paid directly to Servier were a portion of the upfront payment due to XOMA under the XOMA-052 License Agreement (see Note 4). As a result of the debt being fully paid, the intellectual property securing the Servier Loan Agreement was released. A loss on extinguishment of $0.1 million from the payoff of the loan was recognized in the condensed consolidated statement of operations and comprehensive income during the three months ended September 30, 2017.

Hercules Term Loan

On February 27, 2015, the Company entered into a loan and security agreement with Hercules Technology Growth Capital, Inc. (the “Hercules Term Loan”). The Hercules Term Loan had a variable interest rate that was the greater of either (i) 9.40% plus the prime rate as reported from time to time in The Wall Street Journal minus 7.25%, or (ii) 9.40%. As security for its obligations under the Hercules Term Loan, the Company granted a security interest in substantially all of its existing and after-acquired assets, excluding its intellectual property assets.

On March 21, 2017, the Hercules Term Loan was paid in full and the Company was not required to pay the 1% prepayment charge due pursuant to the terms of the loan. A loss on extinguishment of $0.5 million from the payoff of the Hercules Term Loan was recognized in the condensed consolidated statement of operations and comprehensive loss during the three months ended March 31, 2017.

In connection with the Hercules Term Loan, the Company issued unregistered warrants that entitle Hercules to purchase up to an aggregate of 9,063 unregistered shares of XOMA common stock at an exercise price equal to $66.20 per share. These warrants were exercisable immediately and have a five-year term expiring in February 2020. The warrants are classified in stockholders’ equity on the condensed consolidated balance sheets. As of March 31, 2018, all of these warrants were outstanding.

Interest Expense

Amortization of debt issuance costs and discounts are included in interest expense. Interest expense in the condensed consolidated statements of operations and comprehensive loss relates to the following debt instruments (in thousands):

	Three Months Ended March 31,
	2018		2017
Novartis note	$	139	$	117
Servier loan		—		177
Hercules loan		—		311
Other		31		4
Total interest expense	$	170	$	609

9. Common Stock Warrants

As of March 31, 2018 and December 31, 2017, the following common stock warrants were outstanding:

			Exercise Price		March 31,		December 31,
Issuance Date	Expiration Date	Balance Sheet Classification	per Share		2018		2017
February 2015	February 2020	Stockholders' equity	$	66.20		9,063		9,063
February 2016	February 2021	Stockholders' equity	$	15.40		8,249		8,249
						17,312		17,312

10. Commitments and Contingencies

Collaborative Agreements, Royalties and Milestone Payments

The Company has committed to make potential future milestone payments to third parties as part of licensing and development programs. Payments under these agreements become due and payable only upon the achievement of certain developmental, regulatory and commercial milestones by the Company’s licensees. Because it is uncertain if and when these milestones will be achieved, such contingencies, aggregating up to $15.5 million (assuming one product per contract meets all milestones events) have not been recorded on the accompanying consolidated balance sheets. The Company is unable to determine precisely when and if payment obligations under the agreements will become due as these obligations are based on milestone events, the achievement of which is subject to a significant number of risks and uncertainties.

Lease Agreements

The Company leases facilities and office equipment under operating leases expiring on various dates through April 2023. These leases require the Company to pay taxes, insurance, maintenance and minimum lease payments. For each facility lease, the Company has two successive renewal options to extend the lease for five years upon the expiration of the initial lease term.

On November 21, 2017, the Company entered into a non-cancellable sublease agreement for a portion of one of its three leased facilities. The term of the sublease agreement commenced on December 26, 2017. Under the term of the sublease agreement, the Company will receive $5.1 million over the term of the sublease, which ends at the same time as the original lease in April 2023. Under the sublease agreement, the Company’s future sublease income will be equal to the amount required to be paid to the Company’s landlord. In addition, the sublease provides for a tenant improvement allowance of $0.8 million to the subtenant, which was funded by the Company in January 2018. Upon execution of the sublease agreement, the Company recognized a loss on the sublease equal to the tenant improvement allowance. Under the sublease agreement, the sub-lessee executed a standby letter of credit naming the Company as the beneficiary amounting to $1.0 million as security under the sublease in the event of uncured default by the sub-lessee. As of March 31, 2018, the Company has not drawn any funds from the letter of credit as there was no default by the sub-lessee. During the three months ended March 31, 2018, the Company recognized $0.4 million of sublease income under this agreement.

11. Stock-based Compensation

The Company grants qualified and non-qualified stock options, RSUs, common stock and other stock-based awards under various plans to directors, officers, employees and other individuals. Stock options are granted at exercise prices of not less than the fair market value of the Company’s common stock on the date of grant. Additionally, the Company has an Employee Stock Purchase Plan (“ESPP”) that allows employees to purchase Company shares at a purchase price equal to 85% of the lower of the fair market value of the Company’s common stock on the first trading day of the offering period or on the last day of the offering period.

Stock Options

Stock options generally vest monthly over three to four years for employees and one year for directors. Stock options held by employees who qualify for retirement age (defined as employees that are a minimum of 55 years of age and the sum of their age plus years of full-time employment with the Company exceeds 70 years) vest on the earlier of scheduled vest date or the date of retirement.

The fair value of the stock options granted during the three months ended March 31, 2018 and 2017, was estimated based on the following weighted average assumptions:

	Three Months Ended March 31,
	2018			2017
Dividend yield		0	%		0	%
Expected volatility		101	%		100	%
Risk-free interest rate		2.72	%		1.95	%
Expected term	5.6 years			5.6 years

Stock option activity for the three months ended March 31, 2018, was as follows:

	Number of shares			Weighted Average Exercise Price Per Share		Weighted Average Contractual Term (in years)		Aggregate Intrinsic Value (in thousands)
Outstanding at beginning of year		1,622,065		$	24.54
Granted		133,000			26.90
Exercised		(400	)		33.80
Forfeited, expired or cancelled		(101,469	)		54.24
Outstanding at end of period		1,653,196		$	22.91		8.32	$	16,625
Exercisable at end of period		915,442		$	29.09		7.55	$	9,959

As of March 31, 2018, $6.7 million of total unrecognized compensation expense related to stock options is expected to be recognized over a weighted average period of 2.3 years.

Performance-Based Stock Options

As of March 31, 2018, the Company had 82,500 shares related to outstanding performance-based stock options with a grant date fair value of $0.4 million that will vest based on the achievement of corporate goals set by the Compensation Committee of the Company’s Board of Directors. Of this amount, options related to 41,250 shares were deemed probable of achievement as of March 31, 2018 and therefore, the related expense is being recognized over the service period. During the three months ended March 31, 2018, the Company recognized stock-based compensation expense of $56,000 related to these stock options. As of March 31, 2018, there was $0.4 million unrecognized compensation costs related to these outstanding performance-based stock options.

In December 2017, the Company granted 130,000 stock options to executives with corporate performance-based vesting conditions. During the three months ended March 31, 2018, the Board of Directors approved a modification of 80,000 of these options from performance-based vesting to service-based vesting. The remaining 50,000 stock options were cancelled in conjunction with an executive’s termination.

Restricted Stock Units

RSUs generally vest annually over three years for employees and one year for directors. RSUs held by employees who qualify for retirement age (defined as employees that are a minimum of 55 years of age and the sum of their age plus years of full-time employment with the Company exceeds 70 years) vest on the earlier of scheduled vest date or the date of retirement. The valuation of RSUs is determined at the date of grant using the closing stock price.

RSU activity for the three months ended March 31, 2018, is summarized below:

				Weighted-
	Number of			Average Grant-
	Shares			Date Fair Value
Unvested balance at January 1, 2018		18,480		$	18.00
Granted		—			—
Vested		(13,360	)		13.08
Forfeited		—			—
Unvested balance at March 31, 2018		5,120		$	30.86

As of March 31, 2018, $24,000 of unrecognized compensation expense related to employee RSUs is expected to be recognized over a weighted average period of 0.6 years.

Stock-based Compensation Expense

The following table shows total stock-based compensation expense for stock options, RSUs and ESPP in the condensed consolidated statements of operations and comprehensive loss (in thousands):

	Three Months Ended March 31,
	2018		2017
Research and development	$	104	$	441
General and administrative		1,312		559
Total stock-based compensation expense	$	1,416	$	1,000

12. Capital Stock

Biotechnology Value Fund Financing

In February 2017, the Company sold 1,200,000 shares of its common stock and 5,003 shares of Series X convertible preferred stock directly to Biotechnology Value Fund, L.P. and certain of its affiliates (“BVF”) in a registered direct offering, for aggregate net cash proceeds of $24.8 million.

BVF purchased the shares of common stock from the Company at a price of $4.03 per share, the closing stock price on the date of purchase. Each share of Series X convertible preferred stock has a stated value of $4,030 per share and is convertible into 1,000 shares of registered common stock based on a conversion price of $4.03 per share of common stock. The total number of shares of common stock issued upon conversion of all issued Series X convertible preferred stock will be 5,003,000 shares. Each share is convertible at the option of the holder at any time, provided that the holder will be prohibited from converting into common stock if, as a result of such conversion, the holder, together with its affiliates, would beneficially own a number of shares above a conversion blocker, which is initially set at 19.99% of the total common stock then issued and outstanding immediately following the conversion of such shares. As of March 31, 2018, BVF owned approximately 18.0% of the Company’s total outstanding shares, and if all of the Series X convertible preferred shares were converted, BVF would own 48.8% of the Company’s total outstanding common shares. As of March 31, 2018, none of the preferred stock has been converted into shares of the Company’s common stock.

The designations, preferences, rights and limitations of the convertible preferred shares are set forth in a Certificate of Designation of Preferences, Rights and Limitations of Series X convertible preferred stock filed with the Delaware Secretary of State. Shares of Series X convertible preferred stock will generally have no voting rights, except as required by law and except that the consent of the holders of the outstanding Series X convertible preferred stock will be required to amend the terms of the Series X preferred stock and to approve certain corporate actions. In the event of the Company’s liquidation, dissolution or winding up, holders of Series X convertible preferred stock will participate, on a pro-rata basis, with any distribution of proceeds to holders of common stock. Holders of Series X convertible preferred stock are entitled to receive dividends on shares of Series X convertible preferred stock equal (on an as if converted to common stock basis) to and in the same form as dividends actually paid on the Company’s common stock or other junior securities.

The Company evaluated the Series X convertible preferred stock for liability or equity classification under the applicable accounting guidance, and determined that equity treatment was appropriate because the Series X convertible preferred stock did not meet the definition of the liability instruments defined thereunder for convertible instruments. Specifically, the Series X convertible preferred shares are not mandatorily redeemable and do not embody an obligation to buy back the shares outside of the Company’s control in a manner that could require the transfer of assets. Additionally, the Company determined that the Series X convertible preferred stock would be recorded as permanent equity, not temporary equity, based on the relevant guidance given that they are not redeemable for cash or other assets (i) on a fixed or determinable date, (ii) at the option of the holder, and (iii) upon the occurrence of an event that is not solely within control of the Company.

The Company has also evaluated the embedded conversion and redemption features within the Series X convertible preferred stock in accordance with the accounting guidance for derivatives. Based on this assessment, the Company determined that the conversion option is clearly and closely related to the equity host, and thus, bifurcation is not required. The contingent redemption feature was determined to not be clearly and closely related to the equity-like host; however, it met the criteria as a scope exception for derivative accounting. Therefore, the contingent redemption feature was also not bifurcated from the Series X convertible preferred stock.

The fair value of the common stock into which the Series X convertible preferred stock is convertible exceeded the allocated purchase price of the Series X convertible preferred stock by $5.6 million on the date of issuance, as such the Company recorded a deemed dividend. The Company recognized the resulting beneficial conversion feature as a deemed dividend equal to the number of shares of Series X convertible preferred stock sold on February 16, 2017 multiplied by the difference between the fair value of the common stock and the Series X convertible preferred stock effective conversion price per share on that date. The dividend was reflected as a one-time, non-cash, deemed dividend to the holders of Series X convertible preferred stock on the date of issuance, which is the date the stock first became convertible.

ATM Agreement

On November 12, 2015, the Company entered into an At Market Issuance Sales Agreement (the “2015 ATM Agreement”) with Cowen and Company, LLC (“Cowen”), under which the Company may offer and sell from time to time at its sole discretion shares of its common stock through Cowen as its sales agent, in an aggregate amount not to exceed $75 million. Cowen may sell the shares by any method permitted by law deemed to be an “at the market” offering as defined in Rule 415 of the Securities Act, including without limitation sales made directly on The NASDAQ Global Market, and also may sell the shares in privately negotiated transactions, subject to the Company’s prior approval. The Company will pay Cowen a commission equal to 3% of the gross proceeds of the sales price of all shares sold through it as sales agent under the 2015 ATM Agreement. For the three months ended March 31, 2018, the Company sold a total of 67,658 shares of common stock under the 2015 ATM Agreement for aggregate gross proceeds of $2.4 million. Total offering costs of $0.1 million were offset against the proceeds upon the sale of common stock. For the three months ended March 31, 2017, the Company sold a total of 110,252 shares of common stock under the 2015 ATM Agreement for aggregate gross proceeds of $0.6 million. Total offering costs of $0.2 million were offset against the proceeds upon sale of common stock. The shares subject to 2015 ATM Agreement were registered on the shelf registration statement on Form S-3 that expired in February 2018.

Common Stock Purchase Agreement

In August 2017, in connection with the XOMA-052 License Agreement, the Company and Novartis entered into a Common Stock Purchase Agreement under which Novartis purchased 539,131 shares of the Company’s common stock, at a price per share of $9.2742 for the aggregate purchase price of $5.0 million in cash. The fair market value of the common stock issued to Novartis AG was $4.8 million, based on the closing stock price of $8.93 per share on the effective date of the Common Stock Purchase Agreement, or August 24, 2017. The excess of the purchase price over the fair market value of the common stock represents a premium of $0.2 million which was accounted for as additional consideration to the license agreements (See Note 4 for further discussion). The shares issued to Novartis are unregistered securities and the Company agreed to use commercially reasonable efforts to make and keep public information available and timely file all reports and other documents with the SEC as required of the Company under the Securities Exchange Act of 1934, as amended. Under the Common Stock Purchase Agreement, upon a request by Novartis, the Company will use commercially reasonable efforts to register the shares for resale under the Securities Act on a registration statement on Form S-3, to be filed within 60 days of the written request, and will use commercially reasonable efforts to keep such registration statement continuously effective under the Securities Act until the date all of the shares of common stock covered by such registration statement have been sold or can be sold publicly without restriction or limitation under Rule 144.

13. Income Taxes

No provision was made for federal income tax, since the Company has incurred net operating losses during the three months ended March 31, 2018 and 2017, respectively. As of March 31, 2018 and December 31, 2017, the Company had a total of $4.5 million of net unrecognized tax benefits, none of which would affect the effective tax rate upon realization. The Company does not expect its unrecognized tax benefits to change significantly over the next twelve months.

In accordance with SAB 118, the effects of the Tax Cuts and Jobs Act of 2017 (the “Tax Act”) may be adjusted within a one-year measurement period from the enactment date for items that were previously reported as provisional, or where a provisional estimate could not be made. The income tax provision for the three months ended March 31, 2018 did not reflect any adjustment to the previously assessed Tax Act enactment effect. The Company will continue to assess forthcoming guidance and accounting interpretations on the effects of the Tax Act and expects to complete its analysis within the measurement period in accordance with the SEC guidance.

14. Subsequent Events

Rezolute

On April 2, 2018, Rezolute completed a closing on a convertible note financing for gross proceeds of $4.0 million, which triggered the Initial Closing defined under the amended common stock purchase agreement between the Company and Rezolute (see Note 4). As such, pursuant to the terms of the amended common stock purchase agreement with Rezolute, the Company received 8,023,758 shares of Rezolute’s common stock and cash of $0.5 million. In addition, in April 2018, the Company received from Rezolute the 69,252 shares of common stock and cash of $50,000 in connection with the Interim Financing Closing that occurred during the three months ended March 31, 2018 (see Note 4).

Sublease

On April 14, 2018, the Company entered into a non-cancellable sublease agreement for a portion of one of its three leased facilities. The term of the sublease agreement commenced on May 1, 2018. Under the term of the sublease agreement, the Company will receive $1.1 million over the term of the sublease, which ends at the same time as the original lease in April 2023. In addition, the sublease provides for a tenant improvement allowance of $65,000 to the subtenant.

Silicon Valley Bank Loan Agreement

On May 7, 2018 (the “Effective Date”), the Company executed a Loan and Security Agreement (the “Loan Agreement”) with Silicon Valley Bank (“SVB”). Under the Loan Agreement, upon the Company’s request, SVB may make advances (each, a “Term Loan Advance”) available to the Company up to $20.0 million (the “Term Loan”), subject to additional funding at the bank’s discretion. The Company may borrow advances under the Term Loan from the Effective Date until the earlier of March 31, 2019 (which will be extended to March 31, 2020, if the Company receives $20.0 million in gross cash proceeds from milestone/licensing payments by March 31, 2019) or an event of default (the “Draw Period”). The interest rate will be calculated at a rate equal to the greater of (i) 4.75%, and (ii) 0.25% plus the prime rate as reported from time to time in The Wall Street Journal.

Payments under the Loan Agreement are interest only until the first anniversary of the funding date of each Term Loan Advance. The interest-only period will be followed by equal monthly payments of principal and interest over 24 months. Each Term Loan Advance will mature at the earlier of (i) the 23 months following the applicable term loan amortization date for each such Term Loan Advance (ii) March 1, 2023, or (iii) 30 days prior to the earliest maturity of any portion of the Company’s loan with Novartis (the “Loan Maturity Date”). After repayment, no Term Loan Advance (or any portion thereof) may be reborrowed.

The entire principal balance, including a final payment equal to 8.5% of the principal, will be due and payable on the Loan Maturity Date. If the Company prepays the Term Loan Advance prior to the Loan Maturity Date, it will pay SVB a prepayment premium, based on a prepayment fee equal to 3.00% of the amount prepaid, if the prepayment occurs on or before the first anniversary of the Effective Date, 2.00% of the amount prepaid, if the prepayment occurs after the first anniversary of the Effective Date but prior to the second anniversary of the Effective Date, and 1.00% of the amount prepaid if the prepayment occurs after the second anniversary of the Effective Date. Upon the occurrence of an event of default, a default interest rate of an additional 4% may be applied to the outstanding payments due to SVB, and SVB may declare all outstanding obligations immediately due and payable and take such other actions as set forth in the Loan Agreement.

Under the Loan Agreement, the Company may be obligated to pay a fee equal to 1% of the unused portion of the Term Loan upon the earlier of (i) the termination of the Loan Agreement, or (ii) the Draw Period.

The Company’s obligations under the Loan Agreement are secured by a security interest in substantially all of its assets, other than its intellectual property. The Loan Agreement includes customary affirmative and restrictive covenants, but does not include any financial maintenance covenants, and also includes standard events of default, including payment defaults.

In connection with the Loan Agreement, the Company issued a warrant to SVB which is exercisable in whole or in part for up to an aggregate of 6,332 shares of common stock with an exercise price of $23.69 per share (the “Warrant”). The Warrant may be exercised on a cashless basis and is exercisable for a term beginning on the date of issuance and ending on the earlier to occur of 10 years from the date of issuance or the consummation of certain acquisitions of the Company as set forth in the Warrant. The number of shares for which the Warrant is exercisable and the associated exercise price are subject to certain proportional adjustments as set forth in the Warrant.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Forward Looking Statements

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and the Private Securities Litigation Reform Act of 1995, which are subject to the “safe harbor” created by those sections. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to them. In some cases you can identify forward-looking statements by words such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “predicts,” “potential,” “intend” and similar expressions intended to identify forward-looking statements. Examples of these statements include, but are not limited to, statements regarding: our future operating expenses, our future losses, extent to which our issued and pending patents may protect our products and technology, the potential of our existing product candidates to lead to the development of commercial products, our ability to receive potential milestone or royalty payments under license and collaboration agreements and the timing of receipt of those payments, the timing and adequacy of cost-cutting measures, and our ability to defend against claims that have been made in litigation. These statements are based on assumptions that may not prove accurate. Actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry and for our licensees engaged in the development of new products in a regulated market. Among other things: our product candidates subject to our out-license agreements are still being developed, and our licensees may require substantial funds to continue development which may not be available; we may not realize the expected benefits of our cost-saving initiatives; we may not be successful in entering into out-license agreements for our product candidates; if our therapeutic product candidates do not receive regulatory approval, our third-party licensees will not be able to manufacture and market them; products or technologies of other companies may render some or all of our product candidates noncompetitive or obsolete; we do not know whether there will be, or will continue to be, a viable market for the products in which we have an ownership or royalty interest; even once approved, a product may be subject to additional testing or significant marketing restrictions, its approval may be withdrawn or it may be voluntarily taken off the market; we and our licensees are subject to various state and federal healthcare related laws and regulations that may impact the commercialization of our product candidates and could subject us to significant fines and penalties; and certain of our technologies are in-licensed from third parties, so our capabilities using them are restricted and subject to additional risks. These and other risks, including those related to current economic and financial market conditions, are contained principally in Part II, Item 1A of this Quarterly Report on Form 10-Q and our other filings with the SEC. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this Quarterly Report on Form 10-Q. You should read this Quarterly Report on Form 10-Q completely and with the understanding that our actual future results may be materially different from those we expect. Except as required by law, we assume no obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise.

The following discussion and analysis should be read in conjunction with the unaudited financial statements and notes thereto included in Part I, Item 1 of this Quarterly Report on Form 10-Q and with the audited consolidated financial statements and related notes thereto included as part of our Annual Report on Form 10-K for the year ended December 31, 2017.

Overview

XOMA Corporation (“XOMA”), a Delaware corporation, has a long history of discovering and developing innovative therapeutics derived from its unique platform of antibody technologies. Over our 37-year history, we built an extensive portfolio of fully-funded programs by advancing product candidates into the earlier stages of development and then licensing them to licensees who assumed the responsibilities of later stage development, approval and commercialization. Fully-funded programs are those for which our partners pay all of the development and commercialization costs. As licensees advance these programs, we are eligible for potential milestone and royalty payments.

Certain Factors Important to Understanding Our Financial Condition and Results of Operations

We have historically specialized in the discovery and development of innovative antibody-based therapeutics. In March 2017, we transformed our business model to become a royalty aggregator where we focus on expanding our portfolio of fully-funded programs by out-licensing our internally developed product candidates and acquiring potential milestone and royalty revenue streams on additional product candidates. We combined our royalty aggregator model with a significantly reduced corporate cost structure to further build value for our shareholders. Our long-term prospects depend upon the ability of our partners to successfully commercialize new therapeutics. Our financial performance is driven by many factors and is subject to the risks set forth in Part II, Item 1A - Risk Factors.

Critical Accounting Policies

Critical accounting policies are those that require significant judgment and/or estimates by management at the time that the financial statements are prepared such that materially different results might have been reported if other assumptions had been made. We consider certain accounting policies including, but not limited to, those related to revenue recognition, and stock-based compensation to be critical policies. Except for the adoption of the new revenue recognition standard on January 1, 2018, as described below and in Note 2 to the Condensed Consolidated Financial Statements, there have been no significant changes in our critical accounting policies during the three months ended March 31, 2018, as compared with those previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2017, filed with the SEC on March 7, 2018.

Revenue Recognition

Effective January 1, 2018, we adopted Accounting Standards Codification Topic 606, Revenue from Contracts with Customers ("ASC 606") using the modified retrospective transition method and applied the standard only to contracts are still active or in place at that date. Also, as permitted, we applied the practical expedient under ASC 606 which permits us to treat all contract modifications that occurred prior to the adoption in aggregate when determining the performance obligations, transaction price and its allocation. Except for the license agreement with Rezolute, Inc. (formerly AntriaBio, Inc.), we did not have any other contracts with customers for which we have not completed our performance obligations, as of the adoption date January 1, 2018. The license agreement with Rezolute was not considered a contract under ASC 606 as it is not probable that the Company will collect substantially all of the consideration to which it will be entitled in exchange for the goods or services that will be transferred to Rezolute and there was no consideration exchanged upon execution of the arrangement or as of January 1, 2018. Thus, we determined that the adoption of ASC 606 did not have a financial impact on our consolidated financial statements and related disclosures. In addition, the adoption of ASC 606 has no material impact for tax purposes.

We have certain license arrangements in the scope of ASC 606. The terms of these agreements may contain multiple performance obligations, which primarily include transfer of our licenses. Prior to recognizing revenue, we make estimates of the transaction price, including variable consideration that is subject to a constraint. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur and when the uncertainty associated with the variable consideration is subsequently resolved. Variable consideration may include payments based upon the achievement of specified milestones, and royalty payments based on product sales derived from the license agreements. If there are multiple distinct performance obligations, we allocate the transaction price to each distinct performance obligation based on its relative standalone selling price. All licenses we grant to customers are unique, as each uses a specific technology of XOMA or is geared towards a specific unique product candidate. Thus, there is no observable evidence of standalone selling price for the licenses. The standalone selling price is generally determined using a valuation approach based on discounted cash flow analysis. For licenses that are bundled with other promises, we utilize judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. Under our license agreements, the nature of the combined performance obligation is the granting of licenses to the customers. As such, we recognize revenue related to the combined performance obligation upon transfer of the license to the customers or completion of the transfer of related materials and services (i.e., point in time).

Results of Operations

Revenues

Total revenues for the three months ended March 31, 2018 and 2017, were as follows (in thousands):

	Three Months Ended March 31,				2017-2018
	2018		2017		Change
Revenue from contracts with customers	$	401	$	150	$	251
Revenue recognized under units-of-revenue method		62		110		(48	)
Total revenues	$	463	$	260	$	203

Revenue from Contracts with Customers

Revenue from contracts with customers includes upfront fees, milestone payments and royalties related to the out-licensing of our product candidates and technologies. The increase for the three months ended March 31, 2018, as compared to the same periods of 2017, was primarily due to $0.4 million in milestone payments from two of our partners for which there was no comparable payment in 2017.

Revenue recognized under units-of-revenue method

Revenues include the amortization of unearned revenue from the sale of royalty interests to HealthCare Royalty Partners II, L.P. in December 2016.

The generation of future revenues related to licenses, milestones, and royalties is dependent on our ability to attract new licensees to our antibody technologies, and the achievement of milestones or product sales by our existing licensees.

Research and Development Expenses

Research and development (“R&D”) expenses were $0.4 million for the three months ended March 31, 2018, compared with $4.0 million for the same period in 2017. The decrease of $3.6 million for the three months ended March 31, 2018, as compared to the same period of 2017, was primarily due to decreases of $1.0 million in clinical trial costs, $0.8 million in consulting costs, $0.6 million in the allocation of facilities costs, $0.3 million in salaries and related expenses, $0.3 million in stock-based compensation, and $0.3 million in costs of external manufacturing activities. The decrease in allocation of facilities costs is a result of a decreased proportion of research and development employees as a result of our restructuring activities in December 2016 (the “2016 Restructuring”) and June 2017 (the “2017 Restructuring”).

We expect our R&D spending during the remainder of 2018 will be reduced as compared with 2017 levels due to the implementation of our royalty aggregator business model and related discontinuation of clinical trial activities.

General and Administrative Expenses

General and administrative (“G&A”) expenses include salaries and related personnel costs, facilities costs and professional fees. G&A expenses were $5.2 million for the three months ended March 31, 2018 and 2017, respectively. The minimal change for the three months ended March 31, 2018 was due primarily to decreases of $0.8 million in consulting services, $0.3 million in legal and audit fees, and $0.2 million in information technology costs, partially offset by increases of $0.7 million in stock compensation cost and $0.6 million in the allocation of facilities costs due to a greater proportion of general and administrative personnel after our restructuring activities.

We expect our G&A expenses during the remainder of 2018 to decrease as compared with 2017 levels due to our restructuring activities in 2016 and 2017. To support our royalty aggregator business model, we engage third parties to assist in our evaluation of potential acquisitions of milestone and royalty streams. While we expect our G&A expenses to decrease as compared with 2017, G&A expenses may increase in response to an increase in the volume of acquisition targets evaluated.

Restructuring Charges

On December 21, 2016, we announced a restructuring of our business based on our decision to focus our efforts on clinical development, with an initial focus on the X358 clinical programs. The restructuring included a reduction-in-force in which we terminated 57 employees, which was implemented in December 2016. In early 2017, we further revised our strategy to prioritize out-licensing activities and further curtail research and development spending and we eliminated an additional five employees with an effective termination date of June 30, 2017.

During the three months ended March 31, 2017, we recorded a charge of $1.5 million, related to severance, other termination benefits and outplacement services for the 2016 Restructuring and 2017 Restructuring activities. There were no such charges during the three months ended March 31, 2018.

Other Income (Expense)

Interest Expense

Amortization of debt issuance costs and discounts are included in interest expense. Interest expense is shown below for the three and ended March 31, 2018 and 2017 (in thousands):

	Three Months Ended March 31,				2017-2018
	2018		2017		Change
Novartis note	$	139	$	117	$	22
Servier loan		—		177		(177	)
Hercules loan		—		311		(311	)
Other		31		4		27
Total interest expense	$	170	$	609	$	(439	)

The decrease in interest expense is due to the repayment of the Hercules term loan and Servier loan in 2017.

We expect interest expense during the remainder of 2018 to decrease as compared with 2017 due to the March 2017 payoff of the Hercules loan and August 2017 payoff of the Servier Loan. On May 7, 2018, we executed a loan agreement with Silicon Valley Bank and our interest expense may increase if we choose to access the funds.

Other Income, Net

The following table shows the activity in other income, net for the three months ended March 31, 2018 and 2017 (in thousands):

	Three Months Ended March 31,					2017-2018
	2018		2017			Change
Other income, net
Unrealized foreign exchange loss	$	—	$	(261	)	$	261
Sublease income		355		28			327
Gain on sale and disposal of equipment		—		1,314			(1,314	)
Income under the agreement with Ology Bioservices		1,000		150			850
Other		146		98			48
Total other income, net	$	1,501	$	1,329		$	172

The income under the agreement with Ology Bioservices was due to payments we received from Ology Bioservices during the three months ended March 31, 2018 and 2017 related to the disposition of our biodefense business in March 2016. The gain on sale of equipment of $1.3 million for the three months ended March 31, 2017 is related to the sale of equipment located in one of our leased facilities.

Loss on Extinguishment of Debt

In March 2017, we paid off our outstanding principal balance, final payment fee and accrued interest totaling $6.5 million under our loan and security agreement with Hercules, and we were not required to pay the 1% prepayment charge pursuant to the terms of the loan. We recognized a loss on extinguishment of $0.5 million from the payoff of the term loan.

Provision for Income Taxes

No provision was made for federal income tax, since we have incurred net operating losses during the three months ended March 31, 2018 and 2017, respectively. As of March 31, 2018 and December 31, 2017, we had a total of $4.5 million of net unrecognized tax benefits, none of which would affect the effective tax rate upon realization. We do not expect our unrecognized tax benefits to change significantly over the next twelve months.

In accordance with SAB 118, the effects of the Tax Cuts and Jobs Act of 2017 (the “Tax Act”) may be adjusted within a one-year measurement period from the enactment date for items that were previously reported as provisional, or where a provisional estimate could not be made. Our income tax provision for the three months ended March 31, 2018 did not reflect any adjustment to the previously assessed Tax Act enactment effect. We will continue to assess forthcoming guidance and accounting interpretations on the effects of the Tax Act and expect to complete our analysis within the measurement period in accordance with the SEC guidance.

Liquidity and Capital Resources

The following table summarizes our cash and cash equivalents, our working capital and our cash flow activities for each of the periods presented (in thousands):

	March 31,		December 31,
	2018		2017		Change
Cash and cash equivalents	$	41,968	$	43,471	$	(1,503	)
Working capital	$	36,797	$	36,773	$	24

	Three Months Ended March 31,						2017-2018
	2018			2017			Change
Net cash used in operating activities	$	(3,839	)	$	(14,348	)	$	10,509
Net cash provided by investing activities		—			813			(813	)
Net cash provided by financing activities		2,316			7,871			(5,555	)
Effect of exchange rate changes on cash		20			(33	)		53
Net decrease in cash and cash equivalents	$	(1,503	)	$	(5,697	)	$	4,194

Cash Used in Operating Activities

The change in net cash from operating activities for the three months ended March 31, 2018, as compared with the same period in 2017, was primarily due to reduced spending as a result of the implementation of our royalty aggregator business model.

The decrease in net cash used in operating activities for the three months ended March 31, 2017, as compared with the same period in 2016, was primarily due to decreased research and development spending related to manufacturing costs and clinical trial costs during the three months ended March 31, 2017 primarily due to the termination of the collaboration agreement with Servier in March 2016 and decreased clinical trial costs associated with the termination of the gevokizumab PG global Phase 3 program in March 2016.

Cash Provided by Investing Activities

Net cash provided by investing activities for the three months ended March 31, 2017 of $0.8 million was due to the proceeds from the sale of equipment.

Cash Provided by Financing Activities

Net cash provided by financing activities for the three months ended March 31, 2018 of $2.3 million was primarily related to the sale of common stock for net proceeds of $2.3 million.

Net cash provided by financing activities for the three months ended March 31, 2017 of $7.9 million was primarily related to the sale of preferred stock and common stock to BVF for total net proceeds of $24.9 million. This increase was partially offset by the payoff of our outstanding loan with Hercules of $17.5 million.

* * *

We have incurred significant operating losses since our inception and have an accumulated deficit of $1.2 billion as of March 31, 2018. As of March 31, 2018, we had cash and cash equivalents of $42.0 million, which will enable us to maintain our operations for a period of at least 12 months following the filing date of this report.

Our ability to raise additional capital in the equity and debt markets, should we choose to do so, is dependent on a number of factors, including the market demand for our common stock or debt, which itself is subject to a number of pharmaceutical development and business risks and uncertainties, as well as the uncertainty that we would be able to raise such additional capital at a price or on terms that are favorable to us.

Changes in Contractual Obligations

Our future contractual obligations were reported in our Annual Report on Form 10-K for the year ended December 31, 2017, as filed with the SEC. There have been no material changes from the contractual obligations previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2017.

Off-balance Sheet Arrangements

We have not engaged in any off-balance sheet arrangements, including the use of structured finance, special purpose entities or variable interest entities.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Interest Rate Risk

We are exposed to market risks in the ordinary course of our business. These risks primarily include risk related to interest rate sensitivities. Our market risks related to interest rate sensitivities at March 31, 2018, have not changed materially from those discussed in Item 7A of our Form 10-K for the year ended December 31, 2017 filed with the SEC.

Foreign Currency Risk

We incur expenses denominated in foreign currencies. The amount of expenses incurred will be impacted by fluctuations in these foreign currencies. When the U.S. Dollar weakens against foreign currencies, the U.S. Dollar value of the foreign-currency denominated expense increases, and when the U.S. Dollar strengthens against these currencies, the U.S. dollar value of the foreign-currency denominated expense decreases. A hypothetical 10% change in foreign exchange rates would not have had a material impact on our consolidated financial statements.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Controls and Procedures

We have established disclosure controls and procedures, as defined in Rule 13a-15(e) of the Exchange Act. Our Chief Executive Officer and our Chief Financial Officer have concluded, based on the evaluation of the effectiveness of our disclosure controls and procedures by our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, as of the end of the period covered by this report, that our disclosure controls and procedures were effective at the reasonable assurance level.

Changes in Internal Control

There have been no changes in our internal controls over financial reporting as defined in Rule 13a-15(f) under the Exchange Act during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

PART II – OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

None.

ITEM 1A. RISK FACTORS

This Quarterly Report on Form 10-Q contains forward-looking information based on our current expectations. Because our actual results may differ materially from any forward-looking statements made by or on behalf of us, this section includes a discussion of important factors that could affect our actual future results, including our revenues, expenses, operating results, cash flows, net loss and loss per share. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations. You should carefully consider these risk factors, together with all of the other information included in this Quarterly Report on Form 10-Q as well as our other publicly available filings with the U.S. Securities and Exchange Commission, or SEC.

We have marked with an asterisk (*) those risks described below that reflect substantive changes from, or additions to, the risks described in our Annual Report on Form 10-K for the year ended December 31, 2017.

Risks Related to our Recently Undertaken Royalty Aggregator Strategy

Our planned acquisition of royalties may not produce anticipated revenues, and if such transactions are secured by collateral, we may be, or may become, under-secured by the collateral or such collateral may lose value and we will not be able recuperate our capital expenditures in the acquisition.

We are engaged in a continual review of opportunities to acquire royalties and other intellectual property assets as part of our royalty aggregator strategy or to acquire companies that hold royalty assets. We currently, and generally at any time, have acquisition opportunities in various stages of active review, including, for example, our engagement of consultants and advisors to analyze particular opportunities, technical, financial and other confidential information, submission of indications of interest and involvement as a bidder in competitive auctions. Many potential acquisition targets do not meet our criteria, and for those that do, we may face significant competition for these acquisitions from other royalty buyers and enterprises. Competition for future asset acquisition opportunities in our markets could increase the price we pay for such assets and could reduce the number of potential acquisition targets. The success of our acquisitions is based on our ability to make accurate assumptions regarding the valuation, timing and amount of future royalty and milestone payments as well as the viability of the underlying technology. The failure of any of these acquisitions to produce anticipated revenues may materially and adversely affect our financial condition and results of operations.

Some of these acquisitions may expose us to credit risk in the event of default by the counterparty. To mitigate this risk, on occasion, we may obtain a security interest as collateral in the assets of such counterparty. Our credit risk in respect of such counterparty may be exacerbated when the collateral held by us cannot be realized upon or is liquidated at prices not sufficient to recover the full amount we are due pursuant to the terms of the particular assets. This could occur in circumstances where the original collateral was not sufficient to cover a complete loss (e.g., our interests were only partially secured) or may result from the deterioration in value of the collateral, so that, in either such case, we are unable to recuperate our full capital outlay. Any such losses resulting therefrom could materially and adversely affect our financial condition and results of operations.

Many of our potential royalty acquisitions are in companies or assets that have no approved or commercialized products or are dependent on the actions of unrelated third parties, which may negatively impact our investment returns.

As part of our recently launched royalty aggregator strategy, we will likely make investments in royalty assets, such as an upfront payment for a profit share or royalty stream in the healthcare industry, many of which investments are in companies that, at the time of investment, have limited or no approved or commercialized products. If the assets are not successfully developed and subsequently commercialized, the value of our investments will be negatively affected. The ultimate success of our royalty aggregator strategy will depend on the ability of the counterparty to innovate, develop and commercialize their products, in increasingly competitive and highly regulated markets. Their inability to do so would negatively affect our investment. In addition, we are dependent, to a large extent, on third parties to enforce certain rights for our benefit, such as protection of a patent estate, and their failure to do so would negatively impact our investment returns.

We depend on our licensees and royalty-agreement counterparties for the determination of royalty and milestone payments. While we typically have rights to audit our licensees and royalty-agreement counterparties, the independent auditors may have difficulty determining the correct royalty calculation, we may not be able to detect errors and payment calculations may call for retroactive adjustments. We may have to exercise legal remedies to resolve any disputes resulting from the audit.

The royalty and milestone payments we receive are determined by our licensees based on their reported development and product sales. Each licensee's calculation of the royalty payments is subject to and dependent upon the adequacy and accuracy of its sales and accounting functions, and errors may occur from time to time in the calculations made by a licensee. Our license and royalty agreements typically provide us the right to audit the calculations and sales data for the associated royalty payments; however, such audits may occur many months following our recognition of the royalty revenue, may require us to adjust our royalty revenues in later periods and may require expense on the part of the Company. Further, our licensees and royalty-agreement counterparties may be uncooperative or have insufficient records, which may complicate and delay the audit process.

Although we intend to regularly exercise our royalty audit rights, we rely in the first instance on our licensees and royalty-agreement counterparties to accurately report sales and calculate and pay applicable royalties and, upon exercise of such royalty audit rights, we rely on licensees' and royalty-agreement counterparties' cooperation in performing such audits. In the absence of such cooperation, we may be forced to exercise legal remedies to enforce our agreements.

The lack of liquidity in our acquisitions may adversely affect our business and, if we need to sell any of our acquired assets, we may not be able to do so at a favorable price. As a result, we may suffer losses.

We generally acquire patents, license agreements and royalty rights that have limited secondary resale markets. The illiquidity of most of our assets may make it difficult for us to dispose of them at a favorable price and, as a result, we may suffer losses if we are required to dispose of any or all such assets in a liquidation or otherwise. In addition, if we liquidate all or a portion of our assets quickly or relating to a liquidation, we may realize significantly less than the value at which we had previously recorded these assets.

As we continue to develop our business, our mix of assets and our sources of income may require that we register with the SEC as an “investment company” in accordance with the Investment Company Act of 1940.

We have not been and have no current intention to register as an "investment company" under the Investment Company Act of 1940, or the ‘40 Act, because we believe the nature of our assets and the sources of our income currently exclude us from the definition of an investment company pursuant to Sections (3)(a)(1)(A) and (3)(a)(1)(C) under the ‘40 Act and Rule 3a-1 thereunder. Accordingly, we are not currently subject to the provisions of the ‘40 Act, such as compliance with the ‘40 Act’s registration and reporting requirements, capital structure requirements, affiliate transaction restrictions, conflict of interest rules, requirements for disinterested directors, and other substantive provisions. Generally, to avoid being a company that is an "investment company" under the ‘40 Act, it must both: (a) not be or hold itself out as being engaged primarily in the business of investing, reinvesting or trading in securities, and (b) either (i) not be engaged or propose to engage in the business of investing in securities or own or propose to acquire investment securities having a value exceeding 40% of the value of its total assets (exclusive of U.S. government securities and cash items) on an unconsolidated basis or (ii) not have more than 45% of the value of its total assets (exclusive of government securities and cash items) consist of or more than 45% of its net income after taxes (for the last four fiscal quarters combined) be derived from certain types of securities. In addition, we would not be an “investment company” if an exception, exemption, or safe harbor under the ‘40 Act applies.

We monitor our assets and income for compliance with the tests under the ‘40 Act and seek to conduct our business activities to ensure that we do not fall within its definitions of “investment company.” If we were to become an “investment company” and be subject to the restrictions of the ‘40 Act, those restrictions would likely require changes in the way we do business and add significant administrative burdens to our operations. To ensure that we do not fall within the ‘40 Act, we may need to take various actions which we might otherwise not pursue. These actions may include restructuring the Company and/or modifying our mixture of assets and income.

Specifically, our mixture of securities vs. royalty assets will be important to our classification as an “investment company”. While we currently believe that none of the definitions of “investment company” apply to us, we may in the future rely on an exception under the ‘40 Act provided by Section 3(c)(5)(A). To qualify under Section 3(c)(5)(A), as interpreted by the staff of the SEC, we would be required to have at least 55% of our total assets in "notes, drafts, acceptances, open accounts receivable, and other obligations representing part or all of the sales price of merchandise, insurance, and services" (or Qualifying Assets). The SEC staff has stated in a no action letter that royalty interests are Qualifying Assets under this exception. If the SEC or its staff in the future adopts a contrary interpretation or otherwise restricts the conclusions in the staff's no-action letter such that our royalty interests are no longer Qualifying Assets for purposes of Section 3(c)(5)(A), or if we fail to have 55% of our total assets in Qualifying Assets, we could be required to register under the ‘40 Act.

The rules and interpretations of the SEC and the courts, relating to the definition of "investment company" are very complex. While we currently intend to conduct our operations so that we will not be an investment company under applicable SEC interpretations, we can provide no assurance that the SEC would not take the position that the Company would be required to register under the ‘40 Act.

Risks Related to our Financial Results and Capital Requirements

We have sustained losses in the past, and we expect to sustain losses in the foreseeable future.

With the exception of the year ended December 31, 2017, we have incurred significant operating losses and negative cash flows from operations since its inception. We had net losses of $3.8 million and $10.7 million for the three months ended March 31, 2018 and 2017, respectively. As of March 31, 2018, we had an accumulated deficit of $1.2 billion.

We do not know whether we will ever achieve sustained profitability or whether cash flow from future operations will be sufficient to meet our needs.

To date, we have financed our operations primarily through the sale of equity securities and debt, and collaboration and licensing arrangements. The size of our future net losses will depend, in part, on the rate of our future expenditures and our and our partner’s ability to generate revenues. If our partner’s product candidates are not successfully developed or commercialized by our licensees, or if revenues are insufficient following marketing approval, we will not achieve profitability and our business may fail. Our ability to achieve profitability is dependent in large part on the success of our ability to license our product candidates, and the success of our licensees’ development programs, both of which are uncertain. Our success is also dependent on our licensees obtaining regulatory approval to market our product candidates which may not materialize or prove to be successful.

Our new strategy may require us to raise additional funds to acquire royalty assets; we cannot be certain that funds will be available, and if they are not available, we may be unsuccessful in acquiring assets to sustain the business in the future.

We may need to commit substantial funds to continue our business, and we may not be able to obtain sufficient funds on acceptable terms, or at all. Any additional debt financing or additional equity that we raise may contain terms that are not favorable to our stockholders or us. If we raise additional funds through licensing arrangements with third parties, we may be required to relinquish some rights to our technologies or our product candidates, grant licenses on terms that are not favorable to us or enter into a license arrangement for a product candidate at an earlier stage of development or for a lesser amount than we might otherwise choose.

Additional funds may not be available when we need them on terms that are acceptable to us, or at all. If adequate funds are not available on a timely basis, we may:

•

reduce or eliminate royalty aggregation efforts; or

•

further reduce our capital or operating expenditures; or

•

curtail our spending on protecting our intellectual property.

We have significantly restructured our business and revised our business plan and there are no assurances that we will be able to successfully implement our business plan or successfully operate as a royalty aggregator.

We have historically been focused on discovering and developing innovative therapeutics derived from our unique platform of antibody technologies. Prospectively, we will become a royalty aggregator where we focus on expanding our portfolio of fully-funded programs by out-licensing our internally developed product candidates and acquiring potential milestone and royalty revenue streams on additional product candidates. Our strategy is based on a number of factors and assumptions, some of which are not within our control, such as the actions of third parties. There can be no assurance that we will be able to successfully execute all or any elements of our strategy, or that our ability to successfully execute our strategy will be unaffected by external factors. If we are unsuccessful in acquiring potential milestone and royalty revenue streams on additional product candidates, or those acquisitions do not perform to our expectations, our financial performance could be adversely affected.

We may not realize the expected benefits of our cost-saving initiatives.

Reducing costs is a key element of our current business strategy. On August 21, 2015, in connection with our efforts to lower operating expenses and preserve capital while continuing to focus on our product pipeline, we implemented a workforce reduction, which led to the termination of 52 employees during the second half of 2015. On December 19, 2016, we approved a restructuring of our business based on our decision to focus our efforts on clinical development, with an initial focus on the X358 clinical program. The restructuring included a reduction-in-force in which we terminated 57 employees. In early 2017, we implemented a royalty aggregator business model, which resulted in the termination of five additional employees effective June 30, 2017.

If we experience excessive unanticipated inefficiencies or incremental costs in connection with restructuring activities, such as unanticipated inefficiencies caused by reducing headcount, we may be unable to meaningfully realize cost savings and we may incur expenses in excess of what we anticipate. Either of these outcomes could prevent us from meeting our strategic objectives and could adversely impact our results of operations and financial condition.

Risks Related to Our Reliance on Third Parties

We rely heavily on licensee relationships, and any disputes or litigation with our partners or termination or breach of any of the related agreements could reduce the financial resources available to us, including milestone payments and future royalty revenues.

Our existing collaborations may not continue or be successful, and we may be unable to enter into future collaborative arrangements to develop and commercialize our unpartnered assets. Generally, our current collaborative partners also have the right to terminate their collaborations at will or under specified circumstances. If any of our collaborative partners breach or terminate their agreements with us or otherwise fail to conduct their collaborative activities successfully (for example, by not making required payments when due, or at all), our product development under these agreements will be delayed or terminated. Disputes or litigation may also arise with our collaborators (with us and/or with one or more third parties), including those over ownership rights to intellectual property, know-how or technologies developed with our collaborators. For example, we are asserting our rights to receive payment against one of our collaborative partners which could harm our relationship with such partner. Such disputes or litigation could adversely affect our rights to one or more of our product candidates and could delay, interrupt or terminate the collaborative research, development and commercialization of certain potential products, create uncertainty as to ownership rights of intellectual property, or could result in litigation or arbitration. In addition, a significant downturn or deterioration in the business or financial condition of our collaborators or partners could result in a loss of expected revenue and our expected returns on investment. The occurrence of any of these problems could be time-consuming and expensive and could adversely affect our business.

Our licensees rely on third parties to provide services in connection with our product candidate development and manufacturing programs. The inadequate performance by or loss of any of these service providers could affect our licensees’ product candidate development.

Third parties provide services in connection with preclinical and clinical development programs, including in vitro and in vivo studies, assay and reagent development, immunohistochemistry, toxicology, pharmacokinetics, clinical trial support, manufacturing and other outsourced activities. If these service providers do not adequately perform the services for which we or our licensees have contracted, or cease to continue operations, and we are not able to find a replacement provider quickly or we lose information or items associated with our product candidates, our development programs may be delayed.

Agreements with other third parties, many of which are significant to our business, expose us to numerous risks.

Because our licensees, suppliers and contractors are independent third parties, they may be subject to different risks than we are and have significant discretion in, and different criteria for, determining the efforts and resources they will apply related to their agreements with us. If these licensees, suppliers and contractors do not successfully perform the functions for which they are responsible, we may not have the capabilities, resources or rights to do so on our own.

We do not know whether we or our licensees will successfully develop and market any of the products that are or may become the subject of any of our licensing arrangements. In addition, third-party arrangements such as ours also increase uncertainties in the related decision-making processes and resulting progress under the arrangements, as we and our licensees may reach different conclusions, or support different paths forward, based on the same information, particularly when large amounts of technical data are involved.

Under our contract with NIAID, a part of the National Institute of Health (“NIH”), we invoiced using NIH provisional rates, and these are subject to future audits at the discretion of NIAID’s contracting office. These audits can result in an adjustment to revenue previously reported, which potentially could be significant.

Failure of our licensees’ product candidates to meet current Good Manufacturing Practices standards may subject us to delays in regulatory approval and penalties for noncompliance.

Our licensees may rely on third party manufacturers and such contract manufacturers are required to produce clinical product candidates under current Good Manufacturing Practices (“cGMP”) to meet acceptable standards for use in clinical trials and for commercial sale, as applicable. If such standards change, the ability of contract manufacturers to produce our product candidates on the schedule required for our clinical trials or to meet commercial requirements may be affected. In addition, contract manufacturers may not perform their obligations under their agreements with our licensees, may discontinue their business before the time required by us to successfully produce clinical and commercial supplies of our product candidates.

Contract manufacturers are subject to pre-approval inspections and periodic unannounced inspections by the FDA and corresponding state and foreign authorities to ensure strict compliance with cGMP and other applicable government regulations and corresponding foreign standards. We do not have control over a third-party manufacturer’s compliance with these regulations and standards. Any difficulties or delays in contractors’ manufacturing and supply of our product candidates or any failure of our licensees’ contractors to maintain compliance with the applicable regulations and standards could increase costs, cause us to reduce revenue, make us or our licensees postpone or cancel clinical trials, prevent or delay regulatory approval by the FDA and corresponding state and foreign authorities, prevent the import and/or export of our product candidates, or cause any of our product candidates that may be approved for commercial sale to be recalled or withdrawn.

Certain of our technologies are in-licensed from third parties, so our and our licensees’ capabilities using them are restricted and subject to additional risks.

We have licensed technologies from third parties. These technologies include phage display technologies licensed to us in connection with our bacterial cell expression technology licensing program and antibody products. However, our and our licensees’ use of these technologies is limited by certain contractual provisions in the licenses relating to them, and although we have obtained numerous licenses, intellectual property rights in the area of phage display are particularly complex. If we are unable to maintain our licenses, patents or other intellectual property, we could lose important protections that are material to continuing our operations and for future prospects. Our licensors also may seek to terminate our license, which could cause us and our licensees to lose the right to use the licensed intellectual property and adversely affect our ability to commercialize our technologies, products or services.

Because many of the companies with which we do business also are in the biotechnology sector, the volatility of that sector can affect us indirectly as well as directly.

The same factors that affect us directly also can adversely affect us indirectly by affecting the ability of our partners and others with whom we do business to meet their obligations to us and reduce our ability to realize the value of the consideration provided to us by these other companies.

For example, in connection with our dispositions or license arrangements, we have in the past and may in the future agree to accept equity securities of the licensee in payment of fees. The future value of these or any other shares we receive is subject both to market risks affecting our ability to realize the value of these shares and more generally to the business and other risks to which the issuer of these shares may be subject.

Risks Related to an Investment in Our Common Stock

Our share price may be volatile, and there may not be an active trading market for our common stock.

There can be no assurance the market price of our common stock will not decline below its present market price or there will be an active trading market for our common stock. The market prices of biotechnology companies have been and are likely to continue to be highly volatile. Fluctuations in our operating results and general market conditions for biotechnology stocks could have a significant impact on the volatility of our common stock price. We have experienced significant volatility in the price of our common stock. From January 1, 2018, through May 7, 2018, the share price of our common stock has ranged from a high of $36.86 to a low of $19.09. Additionally, we have two significant holders of our stock that could affect the liquidity of our stock and have a significant negative impact on our stock price if one or both of the holders were to quickly sell their ownership positions.

If we fail to meet continued listing standards of NASDAQ, our common stock may be delisted, which could have a material adverse effect on the liquidity of our common stock.

Our common stock is currently traded on the Nasdaq Global Market. The NASDAQ Stock Market LLC (“NASDAQ”) has requirements that a company must meet in order to remain listed on NASDAQ.

We have in the past temporarily fallen out of compliance with NASDAQ listing standards and there can be no assurance that we will continue to meet NASDAQ listing requirements in the future.

We received a letter from the Listing Qualifications Staff of The NASDAQ Stock Market LLC (the “Staff”) on March 22, 2017, providing notification that we no longer complied with the $50 million in total assets and total revenue standard for continued listing on The Nasdaq Global Market under NASDAQ’s Listing Rule 5450(b)(3)(A) and that we also did not comply with either of the two alternative standards of Listing Rule 5450(b), the equity standard and the market value standard.

On May 2, 2017, following ten consecutive business days where the market value of our listed securities was $50 million or greater, we regained compliance with NASDAQ Listing Rule 5450(b)(2)(A).

If future events cause our common stock to be delisted, the liquidity of our common stock would be adversely affected and the market price of our common stock could decrease.

Our results of operations and liquidity needs could be materially negatively affected by market fluctuations or an economic downturn.*

Our results of operations could be materially negatively affected by economic conditions generally, both in the United States and elsewhere around the world. Concerns over inflation, energy costs, geopolitical issues, the availability and cost of credit, and the U.S. financial markets have in the past contributed to, and may continue in the future contributed to, increased volatility and diminished expectations for the economy and the markets. Domestic and international equity markets periodically experience heightened volatility and turmoil. These events may have an adverse effect on us. In the event of a market downturn, our results of operations could be adversely affected by those factors in many ways, including making it more difficult for us to raise funds if necessary, and our stock price may decline.

We may issue additional equity securities and thereby materially and adversely affect the price of our common stock.

We expect that significant additional capital will be needed in the future to continue our planned operations. To the extent we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. We may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities in more than one transaction, investors may be materially diluted by subsequent sales. These sales may also result in material dilution to our existing stockholders, and new investors could gain rights superior to our existing stockholders.

We are authorized to issue, without stockholder approval, 1,000,000 shares of preferred stock, of which 5,003 shares of Series X preferred stock were issued and outstanding as of May 7, 2018. Each share of Series X is convertible into 1,000 shares of registered common stock based on a conversion price of $4.03 per share of common stock. The total number of shares of common stock issued upon conversion of all issued Series X convertible preferred stock will be 5,003,000 shares. Each share is convertible at the option of the holder at any time, provided that the holder will be prohibited from converting into common stock if, as a result of such conversion, the holder, together with its affiliates, would beneficially own a number of shares above a conversion blocker, which is initially set at 19.99% of our total common stock then issued and outstanding immediately following the conversion of such shares. In addition, we are authorized to issue, generally without stockholder approval, up to 277,333,332 shares of common stock, of which 8,367,118 were issued and outstanding as of May 7, 2018. If we issue additional equity securities, the price of our common stock may be materially and adversely affected.

In addition, funding from collaboration partners and others has in the past and may in the future involve issuance by us of our common stock. We cannot be certain how the purchase price of such shares, the relevant market price or premium, if any, will be determined or when such determinations will be made.

Any issuance by us of equity securities, whether through an underwritten public offering, an at the market offering, a private placement, in connection with a collaboration or otherwise could result in dilution in the value of our issued and outstanding shares, and a decrease in the trading price of our common stock.

We may sell additional equity or debt securities to fund our operations, which may result in dilution to our stockholders and impose restrictions on our business.

In order to raise additional funds to support our operations, we may sell additional equity or debt securities, which would result in dilution to our stockholders and may impose restrictive covenants that would adversely impact our business. The sale of additional equity or convertible debt securities could result in the issuance of additional shares of our capital stock and dilution to all of our stockholders. The incurrence of indebtedness would result in increased fixed payment obligations and could also result in certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. If we are unable to expand our operations or otherwise capitalize on our business opportunities, our business, financial condition and results of operations could be materially adversely affected and we may not be able to meet our debt service obligations.

Our organizational documents contain provisions that may prevent transactions that could be beneficial to our stockholders and may insulate our management from removal.

Our charter and by-laws:

•

require certain procedures to be followed and time periods to be met for any stockholder to propose matters to be considered at annual meetings of stockholders, including nominating directors for election at those meetings; and

•

authorize our Board of Directors to issue up to 1,000,000 shares of preferred stock without stockholder approval and to set the rights, preferences and other designations, including voting rights, of those shares as the Board of Directors may determine.

In addition, we are subject to the provisions of Section 203 of the Delaware General Corporation Law (the “DGCL”), that may prohibit large stockholders, in particular those owning 15% or more of our outstanding common stock, from merging or combining with us.

These provisions of our organizational documents and the DGCL, alone or in combination with each other, may discourage transactions involving actual or potential changes of control, including transactions that otherwise could involve payment of a premium over prevailing market prices to holders of common stock, could limit the ability of stockholders to approve transactions that they may deem to be in their best interests, and could make it considerably more difficult for a potential acquirer to replace management.

As a public company in the United States, we are subject to the Sarbanes-Oxley Act. We have determined our disclosure controls and procedures and our internal control over financial reporting are effective. We can provide no assurance that we will, at all times, in the future be able to report that our internal controls over financial reporting are effective.

Companies that file reports with the SEC, including us, are subject to the requirements of Section 404 of the Sarbanes-Oxley Act of 2002 (“SOX”). Section 404 requires management to establish and maintain a system of internal control over financial reporting, and annual reports on Form 10-K filed under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), must contain a report from management assessing the effectiveness of our internal control over financial reporting. Ensuring we have adequate internal financial and accounting controls and procedures in place to produce accurate financial statements on a timely basis is a time-consuming effort that needs to be re-evaluated frequently. Failure on our part to have effective internal financial and accounting controls would cause our financial reporting to be unreliable, could have a material adverse effect on our business, operating results, and financial condition, and could cause the trading price of our common stock to fall.

We incur significant costs as a result of operating as a public company, which may adversely affect our operating results and financial condition.

As a public company, we incur significant accounting, legal and other expenses, including costs associated with our public company reporting requirements. We also anticipate that we will continue to incur costs associated with corporate governance requirements, including requirements and rules under SOX and the Dodd-Frank Wall Street Reform and Consumer Protection Act ("Dodd-Frank") among other rules and regulations implemented by the SEC, as well as listing requirements of NASDAQ. Furthermore, these laws and regulations could make it difficult or costly for us to obtain certain types of insurance, including director and officer liability insurance, and we may be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these requirements could also make it difficult for us to attract and retain qualified persons to serve on our Board of Directors, our Board Committees or as executive officers.

New laws and regulations as well as changes to existing laws and regulations affecting public companies, including the provisions of SOX and Dodd-Frank and rules adopted by the SEC and NASDAQ, will likely result in increased costs to us as we respond to their requirements. We continue to invest resources to comply with evolving laws and regulations, and this investment may result in increased general and administrative expense.

Our ability to use our net operating loss carry-forwards and other tax attributes will be substantially limited by Section 382 of the U.S. Internal Revenue Code.

Under the newly enacted federal income tax law, federal net operating losses incurred in 2018 and in future years may be carried forward indefinitely, but the deductibility of such federal net operating losses is limited. It is uncertain if and to what extent various states will conform to the newly enacted federal tax law. In addition, Section 382 of the U.S. Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, generally limit the ability of a corporation that undergoes an “ownership change” to utilize its net operating loss carry-forwards (“NOLs”) and certain other tax attributes against any taxable income in taxable periods after the ownership change. The amount of taxable income in each taxable year after the ownership change that may be offset by pre-change NOLs and certain other pre-change tax attributes is generally equal to the product of (a) the fair market value of the corporation’s outstanding shares (or, in the case of a foreign corporation, the fair market value of items treated as connected with the conduct of a trade or business in the United States) immediately prior to the ownership change and (b) the long-term tax exempt rate (i.e., a rate of interest established by the U.S. Internal Revenue Service that fluctuates from month to month). In general, an “ownership change” occurs whenever the percentage of the shares of a corporation owned, directly or indirectly, by “5-percent shareholders” (within the meaning of Section 382 of the Internal Revenue Code) increases by more than 50 percentage points over the lowest percentage of the shares of such corporation owned, directly or indirectly, by such “5-percent shareholders” at any time over the preceding three years.

Based on an analysis under Section 382 of the Internal Revenue Code (which subjects the amount of pre-change NOLs and certain other pre-change tax attributes that can be utilized to an annual limitation), we experienced ownership changes in 2009 and 2012, which substantially limit the future use of our pre-change NOLs and certain other pre-change tax attributes per year. In February 16, 2017, we completed an equity financing for net proceeds of $24.8 million which triggered an additional ownership change under Section 382 that significantly impacted the availability of our tax attributes against future income. Further, due to the existence of a net unrealized built-in loss at the ownership change date, Section 382 further limits our ability to fully utilize the tax deductions associated with certain of our assets, including depreciation and amortization deductions recognized during the 60-month period following the ownership change ending in 2022. Although these deductions will occur in the post-change period, Section 382 treats the deductions as pre-change losses subject to the annual 382 limitation. As of December 31, 2017, we have excluded the NOLs and research and development credits that will expire as a result of the annual limitations. To the extent that we do not utilize our carry-forwards within the applicable statutory carry-forward periods, either because of Section 382 limitations or the lack of sufficient taxable income, the carry-forwards will also expire unused.

The recently passed comprehensive tax reform bill could adversely affect our business and financial condition.

On December 22, 2017, the Tax Cuts and Jobs Act of 2017 was signed into law that significantly revises the Internal Revenue Code of 1986, as amended. The newly enacted federal income tax law, among other things, contains significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%, limitation of the tax deduction for interest expense to 30% of adjusted earnings (except for certain small businesses), limitation of the deduction for net operating losses to 80% of current year taxable income and elimination of net operating loss carrybacks, one time taxation of offshore earnings at reduced rates regardless of whether they are repatriated, immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and credits (including reducing the business tax credit for certain clinical testing expenses incurred in the testing of certain drugs for rare diseases or conditions). Notwithstanding the reduction in the corporate income tax rate, the overall impact of the new federal tax law is uncertain and our business and financial condition could be adversely affected. In addition, it is uncertain if and to what extent various states will conform to the newly enacted federal tax law. The impact of this tax reform on holders of our common stock is also uncertain and could be adverse. We urge our stockholders to consult with their legal and tax advisors with respect to this legislation and the potential tax consequences of investing in or holding our common stock.

Risks Related to the Development and Commercialization of our Current and Future Product Candidates

We may not be able to successfully identify and acquire and/or in-license other products, product candidates, programs or companies to grow and diversify our business, and, even if we are able to do so, we may not be able to successfully manage the risks associated with integrating any such products, product candidates, programs or companies into our business or we may otherwise fail to realize the anticipated benefits of these licenses or acquisitions.

To grow and diversify our business, we plan to continue our business development efforts to identify and seek to acquire and/or in-license other products, product candidates, programs or companies. Future growth through acquisition or in-licensing will depend upon the availability of suitable products, product candidates, programs or companies for acquisition or in-licensing on acceptable prices, terms and conditions. Even if appropriate opportunities are available, we may not be able to acquire rights to them on acceptable terms, or at all. The competition to acquire or in-license rights to promising products, product candidates, programs and companies is fierce, and many of our competitors are large, multinational pharmaceutical and biotechnology companies with considerably more financial, development and commercialization resources, personnel, and experience than we have. In order to compete successfully in the current business climate, we may have to pay higher prices for assets than may have been paid historically, which may make it more difficult for us to realize an adequate return on any acquisition.

Even if we are able to successfully identify and acquire or in-license new products, product candidates, programs or companies, we may not be able to successfully manage the risks associated with integrating any products, product candidates, programs or companies into our business or the risks arising from anticipated and unanticipated problems in connection with an acquisition or in-licensing. Further, while we seek to mitigate risks and liabilities of potential acquisitions through, among other things, due diligence, there may be risks and liabilities that such due diligence efforts fail to discover, that are not disclosed to us, or that we inadequately assess. Any failure in identifying and managing these risks and uncertainties effectively would have a material adverse effect on our business. In any event, we may not be able to realize the anticipated benefits of any acquisition or in-licensing for a variety of reasons, including the possibility that a product candidate fails to advance to clinical development, proves not to be safe or effective in clinical trials, or that a product fails to reach its forecasted commercial potential or that the integration of a product, product candidate, program or company gives rise to unforeseen difficulties and expenditures. Any failure in identifying and managing these risks and uncertainties would have a material adverse effect on our business.

We may not be successful in entering into out-license agreements for our product candidates, which may adversely affect our liquidity and business.

We intend to pursue a strategy to out-license all of our product candidates in order to provide for potential payments, funding and/or royalties on future product sales. The out-license agreements may be structured to share in the proceeds received by a licensee as a result of further development or commercialization of the product candidates. We may not be successful in entering into out-licensing agreements with favorable terms as a result of factors, many of which are outside of our control. These factors include:

•

research and spending priorities of potential licensing partners;

•

willingness of, and the resources available to, pharmaceutical and biotechnology companies to in-license drug candidates to fill their clinical pipelines; or

•

our inability to generate proof-of-concept data and to agree with a potential partner on the value of our product candidates, or on the related terms.

If we are unable to enter into out-licensing agreements for our product candidates and realize license, milestone and royalty fees when anticipated, it may adversely affect our liquidity, which in turn may harm our business.

If our licensees’ therapeutic product candidates do not receive regulatory approval, our licensees will be unable to market them.

Our licensees’ product candidates cannot be manufactured and marketed in the United States or any other countries without required regulatory approvals. The U.S. government and governments of other countries extensively regulate many aspects of our product candidates, including:

•

clinical development and testing;

•

manufacturing;

•

labeling;

•

storage;

•

record keeping;

•

promotion and marketing; and

•

importing and exporting.

In the United States, the FDA regulates pharmaceutical products under the Federal Food, Drug, and Cosmetic Act and other laws, including, in the case of biologics, the Public Health Service Act. At the present time, we believe all of our product candidates will be regulated by the FDA as biologics.

Initiation of clinical trials requires approval by health authorities. Clinical trials involve the administration of the investigational new drug to healthy volunteers or to patients under the supervision of a qualified principal investigator. Clinical trials must be conducted in accordance with FDA and International Conference on Harmonization Good Clinical Practices and the European Clinical Trials Directive, as applicable, under protocols that detail the objectives of the study, the parameters to be used to monitor safety and the efficacy criteria to be evaluated. Other national, foreign and local regulations also may apply. The developer of the drug must provide information relating to the characterization and controls of the product before administration to the patients participating in the clinical trials. This requires developing approved assays of the product to test before administration to the patient and during the conduct of the trial. In addition, developers of pharmaceutical products must provide periodic data regarding clinical trials to the FDA and other health authorities, and these health authorities may issue a clinical hold upon a trial if they do not believe, or cannot confirm, that the trial can be conducted without unreasonable risk to the trial participants.

The results of the preclinical studies and clinical testing, together with chemistry, manufacturing and controls information, are submitted to the FDA and other health authorities in the form of a New Drug Application (“NDA”) for a drug, and in the form of a Biologic License Application (“BLA”) for a biological product, requesting approval to commence commercial sales. In responding to an NDA or BLA, the FDA or foreign health authorities may grant marketing approvals, request additional information or further research, or deny the application if they determine the application does not satisfy regulatory approval criteria. Regulatory approval of an NDA, BLA, or supplement is never guaranteed. The approval process can take several years, is extremely expensive and can vary substantially based upon the type, complexity, and novelty of the products involved, as well as the target indications. Our licensees ultimately may not be able to obtain approval in a timely fashion or at all.

The FDA and foreign health authorities have substantial discretion in the drug and biologics approval processes. Despite the time and expense incurred, failure can occur at any stage, and our potential development partners could encounter problems that cause abandonment of clinical trials or to repeat or perform additional preclinical, clinical or manufacturing-related studies.

Changes in the regulatory approval policy during the development period, changes in, or the enactment of additional regulations or statutes, or changes in regulatory review for each submitted product application may cause delays in the approval or rejection of an application.

The FDA and other regulatory agencies have substantial discretion in both the product approval process and manufacturing facility approval process, and as a result of this discretion and uncertainties about outcomes of testing, we cannot predict at what point, or whether, the FDA or other regulatory agencies will be satisfied with our licensees’ submissions or whether the FDA or other regulatory agencies will raise questions that may be material and delay or preclude product approval or manufacturing facility approval. In light of this discretion and the complexities of the scientific, medical and regulatory environment, our or our licensees’ interpretation or understanding of the FDA’s or other regulatory agencies’ requirements, guidelines or expectations may prove incorrect, which also could delay further or increase the cost of the approval process.

Our licensees face uncertain results of clinical trials of product candidates.

Drug development has inherent risk, and our licensees are required to demonstrate through adequate and well-controlled clinical trials that product candidates are effective, with a favorable benefit-risk profile for use in their target profiles before they can seek regulatory approvals for commercial use. It is possible we or our licensees may never receive regulatory approval for any licensed product candidates. Even if a product candidate receives regulatory approval, the resulting product may not gain market acceptance among physicians, patients, healthcare payors and the medical community.

Our licensees’ product candidates require significant additional research and development, extensive preclinical studies and clinical trials and regulatory approval prior to any commercial sales. This process is lengthy and expensive, often taking a number of years. As clinical results frequently are susceptible to varying interpretations that may delay, limit or prevent regulatory approvals, the length of time necessary to complete clinical trials and to submit an application for marketing approval for a final decision by a regulatory authority varies significantly. As a result, it is uncertain whether:

•

our licensees’ future filings will be delayed;

•

our licensees’ preclinical studies will be successful;

•

our licensees will be successful in generating viable product candidates;

•

we will be successful in finding collaboration and licensing partners to advance our product candidates on our behalf;

•

our licensees will be able to provide necessary data;

•

results of future clinical trials by our licensees will justify further development; or

•

our licensees ultimately will achieve regulatory approval for our product candidates.

The timing of the commencement, continuation and completion of clinical trials by our licensees may be subject to significant delays relating to various causes, including failure to complete preclinical testing and earlier-stage clinical trials in a timely manner, engaging contract research organizations and other service providers, scheduling conflicts with participating clinicians and clinical institutions, changes in key personnel at clinical institutions, difficulties in identifying and enrolling patients who meet trial eligibility criteria and shortages of available drug supply. In addition, since we license our product candidates to others to fund and conduct clinical trials, we have limited control over how quickly and efficiently such licensees advance those trials. Patient enrollment is a function of many factors, including the size of the patient population, the proximity of patients to clinical sites, the concentration of patients in specialist centers, the eligibility criteria for the trial, the existence of competing clinical trials and the availability of alternative or new treatments. Regardless of the initial size or relative complexity of a clinical trial, the costs of such trial may be higher than expected due to increases in duration or size of the trial, changes in the protocol under which the trial is being conducted, additional or special requirements of one or more of the healthcare centers where the trial is being conducted, or changes in the regulatory requirements applicable to the trial or in the standards or guidelines for approval of the product candidate being tested or for other unforeseen reasons.

In addition, our licensees conduct clinical trials in foreign countries, which may subject us to further delays and expenses as a result of increased drug shipment costs, additional regulatory requirements and the engagement of foreign clinical research organizations, and may expose us to risks associated with foreign currency transactions to make contract payments denominated in the foreign currency where the trial is being conducted.

All of our licensees’ product candidates are prone to the risks of failure inherent in drug development. Preclinical studies may not yield results that satisfactorily support the filing of an Investigational New Drug application (“IND”) (or a foreign equivalent) with respect to our product candidates. Even if these applications would be or have been filed with respect to our product candidates, the results of preclinical studies do not necessarily predict the results of clinical trials. Similarly, early stage clinical trials may not predict the results of later-stage clinical trials, including the safety and efficacy profiles of any particular product candidates.

In addition, there can be no assurance the design of our licensees’ clinical trials will be focused on appropriate indications, patient populations, dosing regimens or other variables that will result in obtaining the desired efficacy data to support regulatory approval to commercialize the drug. Moreover, FDA officials or foreign regulatory agency officials may question the integrity of our data or otherwise subject our licensees’ clinical trials to additional scrutiny when the clinical trials are conducted by principal investigators who serve, or previously served, as scientific advisors or consultants to us and receive cash compensation in connection with such services. Preclinical and clinical data can also be interpreted in different ways. Accordingly, FDA officials or officials from foreign regulatory authorities could interpret the data differently than we or our collaboration or development partners do, which could delay, limit or prevent regulatory approval.

Administering any of our product candidates may produce undesirable side effects, also known as adverse effects. Toxicities and adverse effects that we have observed in preclinical studies for some compounds in a particular research and development program may occur in preclinical studies or clinical trials of other compounds from the same program. Such toxicities or adverse effects could delay or prevent the filing of an IND (or a foreign equivalent) with respect to such product candidates or cause us to cease clinical trials with respect to any drug candidate. In clinical trials, administering any of our product candidates to humans may produce adverse effects. These adverse effects could interrupt, delay or halt clinical trials of our product candidates and could result in the FDA or other regulatory authorities denying approval of our product candidates for any or all targeted indications. The FDA, other regulatory authorities, our development partners or we may suspend or terminate clinical trials at any time. Even if one or more of our product candidates were approved for sale, the occurrence of even a limited number of toxicities or adverse effects when used in large populations may cause the FDA or other regulatory authorities to impose restrictions on, or stop, the further marketing of such drugs. Indications of potential adverse effects or toxicities that may occur in clinical trials and that we believe are not significant during the course of such clinical trials may actually turn out later to constitute serious adverse effects or toxicities when a drug has been used in large populations or for extended periods of time. Any failure or significant delay in completing preclinical studies or clinical trials for our product candidates, or in receiving and maintaining regulatory approval for the sale of any drugs resulting from our product candidates, may severely harm our reputation and business.

Products and technologies of other companies may render some or all of our licensees’ product candidates noncompetitive or obsolete.

Developments by others may render our licensees’ product candidates or technologies obsolete or uncompetitive. Technologies developed and utilized by the biotechnology and pharmaceutical industries are changing continuously and substantially. Competition in antibody-based technologies is intense and is expected to increase in the future as a number of established biotechnology firms and large chemical and pharmaceutical companies advance in these fields. Many of these competitors may be able to develop products and processes competitive with or superior to our own for many reasons, including that they may have:

•

significantly greater financial resources;

•

larger research and development staffs;

•

entered into arrangements with, or acquired, biotechnology companies to enhance their capabilities; or

•

extensive experience in preclinical testing and human clinical trials.

These factors may enable others to develop products and processes competitive with or superior to our own or those of our licensees. In addition, a significant amount of research in biotechnology is being carried out in universities and other non-profit research organizations. These entities are becoming increasingly interested in the commercial value of their work and may become more aggressive in seeking patent protection and licensing arrangements. Furthermore, many companies and universities tend not to announce or disclose important discoveries or development programs until their patent position is secure or, for other reasons, later. As a result, we and our licensees may not be able to track development of competitive products, particularly at the early stages.

Positive developments in connection with a potentially competing product may have an adverse impact on our revenue derived from development milestones. For example, if another product is perceived to have a competitive advantage, or another product’s failure is perceived to increase the likelihood that our licensed product will fail, our licensees may halt development of our licensed product candidates.

Our licensees may be unable to price our products effectively or obtain adequate reimbursement for sales of our products, which would prevent our products from becoming profitable.

If our third-party licensees succeed in bringing our product candidates to the market, they may not be considered cost effective, and reimbursement to the patient may not be available or may not be sufficient to allow us to sell our products on a competitive basis. In both the United States and elsewhere, sales of medical products and treatments are dependent, in part, on the availability of reimbursement to the patient from third-party payors, such as government and private insurance plans. Third-party payors are increasingly challenging the prices charged for pharmaceutical products and services. Our business is affected by the efforts of government and third-party payors to contain or reduce the cost of healthcare through various means. In the United States, there have been and will continue to be a number of federal and state proposals to implement government controls on pricing.

In addition, the emphasis on managed care in the United States has increased and will continue to increase the pressure on the pricing of pharmaceutical products. We cannot predict whether any legislative or regulatory proposals will be adopted or the effect these proposals or managed care efforts may have on our business.

We do not know whether there will be, or will continue to be, a viable market for the product candidates in which we have an ownership or royalty interest.

Even if product candidates in which we have an interest receive approval in the future, they may not be accepted in the marketplace. In addition, we or our licensees may experience difficulties in launching new products, many of which are novel and based on technologies that are unfamiliar to the healthcare community. We have no assurance healthcare providers and patients will accept such products, if developed. Similarly, physicians may not accept a product if they believe other products to be more effective or more cost effective or are more comfortable prescribing other products.

Furthermore, government agencies, as well as private organizations involved in healthcare, from time to time publish guidelines or recommendations to healthcare providers and patients. Such guidelines or recommendations can be very influential and may adversely affect product usage directly (for example, by recommending a decreased dosage of a product in conjunction with a concomitant therapy) or indirectly (for example, by recommending a competitive product over our product). Consequently, we do not know if physicians or patients will adopt or use our products for their approved indications.

Even approved and marketed products are subject to risks relating to changes in the market for such products. Introduction or increased availability of generic or biosimilar versions of products can alter the market acceptance of branded products. In addition, unforeseen safety issues may arise at any time, regardless of the length of time a product has been on the market.

We are exposed to an increased risk of product liability claims.

The testing, marketing and sales of medical products entails an inherent risk of allegations of product liability. In the past, we were party to product liability claims filed against Genentech Inc. and, even though Genentech agreed to indemnify us in connection with these matters and these matters have been settled, there can be no assurance other product liability lawsuits will not result in liability to us or that our insurance or contractual arrangements will provide us with adequate protection against such liabilities. In the event of one or more large, unforeseen awards of damages against us, our product liability insurance may not provide adequate coverage. A significant product liability claim for which we were not covered by insurance or indemnified by a third party would have to be paid from cash or other assets, which could have an adverse effect on our business and the value of our common stock. To the extent we have sufficient insurance coverage, such a claim would result in higher subsequent insurance rates. In addition, product liability claims can have various other ramifications, including loss of future sales opportunities, increased costs associated with replacing products, a negative impact on our goodwill and reputation, and divert our management’s attention from our business, each of which could also adversely affect our business and operating results.

If we and our partners are unable to protect our intellectual property, in particular our patent protection for our principal products, product candidates and processes, and prevent the use of the covered subject matter by third parties, our licensees’ ability to compete in the market will be harmed, and we may not realize our profit potential.

We rely on patent protection, as well as a combination of copyright, trade secret, and trademark laws to protect our proprietary technology and prevent others from duplicating our products or product candidates. However, these means may afford only limited protection and may not:

•

prevent our competitors from duplicating our products;

•

prevent our competitors from gaining access to our proprietary information and technology; or

•

permit us to gain or maintain a competitive advantage.

Because of the length of time and the expense associated with bringing new products to the marketplace, we and our collaboration and development partners hold and are in the process of applying for a number of patents in the United States and abroad to protect our product candidates and important processes and also have obtained or have the right to obtain exclusive licenses to certain patents and applications filed by others. However, the mere issuance of a patent is not conclusive as to its validity or its enforceability.

The U.S. Federal Courts, the U.S. Patent & Trademark Office or equivalent national courts or patent offices elsewhere may invalidate our patents or find them unenforceable. The America Invents Act introduced post-grant review procedures subjecting U.S. patents to post-grant review procedures similar to European oppositions. U.S. patents owned or licensed by us may therefore be subject to post-grant review procedures, as well as other forms of review and re-examination. A decision in such proceedings adverse to our interests could result in the loss of valuable patent rights, which would have a material adverse effect on our business. In addition, the laws of foreign countries may not protect our intellectual property rights effectively or to the same extent as the laws of the United States.

If our intellectual property rights are not protected adequately, our licensees may not be able to commercialize our technologies or products, and our competitors could commercialize our technologies or products, which could result in a decrease in our licensees’ sales and market share that would harm our business and operating results. Specifically, the patent position of biotechnology companies generally is highly uncertain and involves complex legal and factual questions. The legal standards governing the validity of biotechnology patents are in transition, and current defenses as to issued biotechnology patents may not be adequate in the future. Accordingly, there is uncertainty as to:

•

whether any pending or future patent applications held by us will result in an issued patent, or whether issued patents will provide meaningful protection against competitors or competitive technologies;

•

whether competitors will be able to design around our patents or develop and obtain patent protection for technologies, designs or methods that are more effective than those covered by our patents and patent applications; or

•

the extent to which our product candidates could infringe on the intellectual property rights of others, which may lead to costly litigation, result in the payment of substantial damages or royalties, and prevent our licensees from using our technology or product candidates.

If certain patents issued to others are upheld or if certain patent applications filed by others issue and are upheld, our licensees may require licenses from others to develop and commercialize certain potential products incorporating our technology or we may become involved in litigation to determine the proprietary rights of others. These licenses, if required, may not be available on acceptable terms, and any such litigation may be costly and may have other adverse effects on our business, such as inhibiting our licensees’ ability to compete in the marketplace and absorbing significant management time.

Due to the uncertainties regarding biotechnology patents, we also have relied and will continue to rely upon trade secrets, know-how and continuing technological advancement to develop and maintain our competitive position. Our employees and contractors are typically required to sign confidentiality agreements under which they agree not to use or disclose any of our proprietary information. Research and development contracts and relationships between us and our scientific consultants and potential licensees provide access to aspects of our know-how that are protected generally under confidentiality agreements. These confidentiality agreements may be breached or may not be enforced by a court. To the extent proprietary information is divulged to competitors or to the public generally, such disclosure may affect our licensees’ ability to develop or commercialize our products adversely by giving others a competitive advantage or by undermining our patent position.

Litigation regarding intellectual property can be costly and expose us to risks of counterclaims against us.

We may be required to engage in litigation or other proceedings to protect our intellectual property. The cost to us of this litigation, even if resolved in our favor, could be substantial. Such litigation also could divert management’s attention and resources. If this litigation is resolved against us, our patents may be declared invalid, and we could be held liable for significant damages.

In addition, we may be subject to claims that we, or our licensees, are infringing other parties’ patents. If such claims are resolved against us, we or our licensees may be enjoined from developing, manufacturing, selling or importing products, processes or services unless we obtain a license from the other party. Such license may not be available on reasonable terms, thus preventing us, or our licensees, from using these products, processes or services and adversely affecting our revenue.

Risks Related to Employees, Location, Data Integrity, and Litigation

The loss of key personnel, including our Chief Executive Officer or Chief Financial Officer, could delay or prevent achieving our objectives.

Our business efforts could be affected adversely by the loss of one or more key members of our staff, particularly our executive officers: James R. Neal, our Chief Executive Officer and Thomas Burns, our Senior Vice President, Finance and Chief Financial Officer. We currently do not have key person insurance on any of our employees.

Because we are a small biopharmaceutical company with limited resources, we may not be able to attract and retain qualified personnel.

After a series of restructuring activities during 2016 and 2017, we had 12 employees as of May 7, 2018. We may require additional experienced executive, accounting, legal, administrative and other personnel from time to time in the future. There is intense competition for the services of these personnel, especially in California. Moreover, we expect that the high cost of living in the San Francisco Bay Area, where our headquarters are located, may impair our ability to attract and retain employees in the future. If we do not succeed in attracting new personnel and retaining and motivating existing personnel, our business may suffer and we may be unable to implement our current initiatives or grow effectively.

Calamities, power shortages or power interruptions at our Emeryville headquarters could disrupt our business and adversely affect our operations.

Our principal operations are located in Northern California, including our corporate headquarters in Emeryville, California. This location is in an area of seismic activity near active earthquake faults. Any earthquake, terrorist attack, fire, power shortage or other calamity affecting our facilities may disrupt our business and could have material adverse effect on our results of operations.

Our business and operations would suffer in the event of system failures.

Despite the implementation of security measures, our internal computer systems and those of our current and any future licensees, suppliers, contractors and consultants are vulnerable to damage from cyber−attacks, computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. We could experience failures in our information systems and computer servers, which could be the result of a cyber−attack and could result in an interruption of our normal business operations and require substantial expenditure of financial and administrative resources to remedy. System failures, accidents or security breaches can cause interruptions in our operations and can result in a material disruption of our development programs and other business operations. The loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Similarly, we rely on third parties to manufacture our product candidates, and conduct clinical trials of our product candidates, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the development of any of our product candidates could be delayed or otherwise adversely affected.

Data breaches and cyber-attacks could compromise our intellectual property or other sensitive information and cause significant damage to our business and reputation.

In the ordinary course of our business, we maintain sensitive data on our networks, including our intellectual property and proprietary or confidential business information relating to our business and that of our customers and business partners. The secure maintenance of this information is critical to our business and reputation. We believe companies have been increasingly subject to a wide variety of security incidents, cyber-attacks and other attempts to gain unauthorized access. These threats can come from a variety of sources, all ranging in sophistication from an individual hacker to a state-sponsored attack. Cyber threats may be generic, or they may be custom-crafted against our information systems. Cyber-attacks have become more prevalent and much harder to detect and defend against. Our network and storage applications may be subject to unauthorized access by hackers or breached due to operator error, malfeasance or other system disruptions. It is often difficult to anticipate or immediately detect such incidents and the damage caused by such incidents. These data breaches and any unauthorized access or disclosure of our information or intellectual property could compromise our intellectual property and expose sensitive business information. A data security breach could also lead to public exposure of personal information of our clinical trial patients, customers and others which could expose us to liability under federal or state privacy laws. Cyber-attacks result in the theft of proprietary information which could be used to compete against us and could cause us to incur significant remediation costs, result in product development delays, disrupt key business operations and divert attention of management and key information technology resources. These incidents could also subject us to liability, expose us to significant expense and cause significant harm to our reputation and business.

Significant disruptions of information technology systems, including cloud-based systems, or breaches of data security could adversely affect our business.*

Our business is increasingly dependent on critical, complex and interdependent information technology systems, including cloud-based systems, to support business processes as well as internal and external communications. Our computer systems, and those of our partners and contractors, are potentially vulnerable to breakdown, malicious intrusion and computer viruses that may result in the impairment of key business processes. Such disruptions and breaches of security could have a material adverse effect on our business, financial condition and results of operations.

In addition, our data security and information technology systems, as well as those of our partners and contractors, are potentially vulnerable to data security breaches, whether by employees or others, that may expose sensitive data or personal information to unauthorized persons. Effective May 25, 2018, the European Union (“EU”) will implement the General Data Protection Regulation (“GDPR”) a broad data protection framework that expands the scope of current EU data protection law to non-European Union entities that process, or control the processing of, the personal information of EU subjects, including clinical trial data. The GDPR allows for the imposition of fines and/or corrective action on entities that improperly use or disclose the personal information of EU subjects, including through a data security breach. Accordingly, data security breaches experienced by us, our partners or contractors could lead to significant fines, required corrective action, the loss of trade secrets or other intellectual property, public disclosure of sensitive clinical or commercial data, and the exposure of personally identifiable information (including sensitive personal information) of our employees, partners, and others. A data security breach or privacy violation that leads to disclosure or modification of or prevents access to patient information, including personally identifiable information or protected health information, could result in fines, increased costs or loss of revenue as a result of:

•harm to our reputation;

•fines imposed on us by regulatory authorities;

•additional compliance obligations under federal, state or foreign laws;

•requirements for mandatory corrective action to be taken by us; and

•requirements to verify the correctness of database contents and otherwise subject us to liability under laws and regulations that protect personal data.

If we are unable to prevent such data security breaches or privacy violations or implement satisfactory remedial measures, our operations could be disrupted, and we may suffer loss of reputation, financial loss and other regulatory penalties because of lost or misappropriated information, including sensitive patient data. In addition, these breaches and other inappropriate access can be difficult to detect, and any delay in identifying them may lead to increased harm of the type described above. Moreover, the prevalent use of mobile devices that access confidential information increases the risk of data security breaches, which could lead to the loss of confidential information, trade secrets or other intellectual property. While we have implemented security measures to protect our data security and information technology systems, such measures may not prevent such events.

Shareholder lawsuits, and potential similar or related lawsuits, could result in substantial damages, divert management’s time and attention from our business, and have a material adverse effect on our results of operations.

Securities-related class action and shareholder derivative litigation has often been brought against companies, including many biotechnology companies, which experience volatility in the market price of their securities. This risk is especially relevant for us because biotechnology and biopharmaceutical companies often experience significant stock price volatility in connection with their product development programs.

It is possible that suits will be filed, or allegations received from stockholders, naming us and/or our officers and directors as defendants. These potential lawsuits are subject to inherent uncertainties, and the actual defense and disposition costs will depend upon many unknown factors. The outcome of these lawsuits are uncertain. We could be forced to expend significant resources in the defense of these suits and we may not prevail. In addition, we may incur substantial legal fees and costs in connection with these lawsuits. It is possible that we could, in the future, incur judgments or enter into settlements of claims for monetary damages. A decision adverse to our interests on these actions could result in the payment of substantial damages, or possibly fines, and could have a material adverse effect on our cash flow, results of operations and financial position.

Monitoring, initiating and defending against legal actions, including any currently pending litigation, are time-consuming for our management, are likely to be expensive and may detract from our ability to fully focus our internal resources on our business activities. The outcome of litigation is always uncertain, and in some cases could include judgments against us that require us to pay damages, enjoin us from certain activities, or otherwise affect our legal or contractual rights, which could have a significant adverse effect on our business. In addition, the inherent uncertainty of any future litigation could lead to increased volatility in our stock price and a decrease in the value of an investment in our common stock.

Risks Related to Government Regulation

Even after FDA approval, a product may be subject to additional testing or significant marketing restrictions, its approval may be withdrawn or it may be removed voluntarily from the market.

Even if we or our licensees receive regulatory approval for our product candidates, we or our licensees will be subject to ongoing regulatory oversight and review by the FDA and other regulatory entities. The FDA, the European Medicines Agency (“EMA”), or another regulatory agency may impose, as a condition of the approval, ongoing requirements for post-approval studies or post-approval obligations, including additional research and development and clinical trials, and the FDA, EMA or other regulatory agency subsequently may withdraw approval based on these additional trials.

Even for approved products, the FDA, EMA or other regulatory agency may impose significant restrictions on the indicated uses, conditions for use, labeling, advertising, promotion, marketing and production of such product. In addition, the labeling, packaging, adverse event reporting, storage, advertising, promotion and record-keeping for our products are subject to extensive regulatory requirements.

Furthermore, marketing approval of a product may be withdrawn by the FDA, the EMA or another regulatory agency or such a product may be withdrawn voluntarily by us based, for example, on subsequently arising safety concerns. The FDA, EMA and other agencies also may impose various civil or criminal sanctions for failure to comply with regulatory requirements, including withdrawal of product approval.

Healthcare reform measures and other statutory or regulatory changes could adversely affect our business.

The United States and some foreign jurisdictions have enacted or are considering a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our or our licensees’ ability to sell our products, if approved, profitably. Among policy makers and payers in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives.

An expansion in the government’s role in the U.S. healthcare industry may cause general downward pressure on the prices of prescription drug products, lower reimbursements for providers, reduced product utilization and adversely affect our business and results of operations. Moreover, certain politicians have announced plans to regulate the prices of pharmaceutical products. We cannot know what form any such legislation may take or the market’s perception of how such legislation would affect us. Any reduction in reimbursement from government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our current product candidates and those for which we may receive regulatory approval in the future. In addition, given the uncertainties related to the Trump Administration’s stated goal of letting the Affordable Care Act (the “ACA”) fail, we cannot be certain that current provisions of the ACA will continue to cover prescription drug products.

We and our licensees are subject to various state and federal healthcare-related laws and regulations that may impact the commercialization of our product candidates or could subject us to significant fines and penalties.

Our operations may be directly or indirectly subject to various state and federal healthcare laws, including the federal Anti-Kickback Statute, the federal False Claims Act and state and federal privacy and security laws. These laws may impact, among other things, the commercial operations for any of our product candidates that may be approved for commercial sale.

The federal Anti-Kickback Statute prohibits persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual, or the furnishing or arranging for a good or service for which payment may be made under a federal healthcare program, such as the Medicare and Medicaid programs. Several courts have interpreted the statute’s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the statute has been violated. The Anti-Kickback Statute is broad and prohibits many arrangements and practices that are lawful in businesses outside of the healthcare industry. Penalties for violations of the federal Anti-Kickback Statute include criminal penalties and civil sanctions such as fines, penalties, imprisonment and possible exclusion from Medicare, Medicaid and other federal healthcare programs.

The federal False Claims Act prohibits persons from knowingly filing, or causing to be filed, a false claim to, or the knowing use of false statements to obtain payment from the federal government. Suits filed under the False Claims Act, known as “qui tam” actions, can be brought by any individual on behalf of the government and such individuals, commonly known as “whistleblowers,” may share in any amounts paid by the entity to the government in fines or settlement. The filing of qui tam actions has caused a number of pharmaceutical, medical device and other healthcare companies to have to defend a False Claims Act action. When an entity is determined to have violated the False Claims Act, it may be required to pay up to three times the actual damages sustained by the government, plus civil penalties for each separate false claim. Various states also have enacted laws modeled after the federal False Claims Act.

The Federal Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), created new federal criminal statutes that prohibit executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters. The health care fraud statute prohibits knowingly and willfully executing a scheme to defraud any health care benefit program, including private payors. The statute prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for health care benefits, items or services. HIPAA, as amended by the Health Information Technology and Clinical Health Act, and its implementing regulations, also impose certain requirements relating to the privacy, security and transmission of individually identifiable health information. We take our obligation to maintain our compliance with these various laws and regulations seriously.

Many states also have adopted laws similar to each of the federal laws described above, some of which apply to healthcare items or services reimbursed by any source, not only the Medicare and Medicaid programs. In addition, some states have laws that require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the applicable compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources, and to report information related to payments and other transfers of value to physicians and other healthcare providers; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.

Because of the breadth of these laws, it is possible that some of our or our licensees’ business activities could be subject to challenge under one or more of such laws.

If we or our licensees are found to be in violation of any of the laws and regulations described above or other applicable state and federal healthcare laws, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from government healthcare reimbursement programs and the curtailment or restructuring of our operations, any of which could have a material adverse effect on our business and results of operations.

As we or our licensees do more business internationally, we will be subject to additional political, economic and regulatory uncertainties.

We or our licensees may not be able to operate successfully in any foreign market. We believe that because the pharmaceutical industry is global in nature, international activities will be a significant part of future business activities and when and if we or our licensees are able to generate income, a substantial portion of that income will be derived from product sales and other activities outside the United States. Foreign regulatory agencies often establish standards different from those in the United States, and an inability to obtain foreign regulatory approvals on a timely basis could put us at a competitive disadvantage or make it uneconomical to proceed with a product or product candidate’s development. International sales may be limited or disrupted by:

•

imposition of government controls;

•

export license requirements;

•

political or economic instability;

•

trade restrictions;

•

changes in tariffs;

•

restrictions on repatriating profits;

•

exchange rate fluctuations; and

•

withholding and other taxation.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS

Incorporation By Reference

Exhibit

Number

Exhibit Description

Form

SEC File No.

Exhibit

Filing Date

3.1

Certificate of Incorporation of XOMA Corporation

8-K

000-14710

3.1

01/03/2012

3.2

Certificate of Amendment of Certificate of Incorporation of XOMA Corporation

8-K

000-14710

3.1

05/31/2012

3.3

Certificate of Amendment of Amended Certificate of Incorporation of XOMA Corporation

8-K

000-14710

3.1

05/28/2014

3.4

Certificate of Amendment to the Amended Certificate of Incorporation of XOMA Corporation

8-K

000-14710

3.1

10/18/2016

3.5

Certificate of Designation of Preferences, Rights and Limitations of Series X Convertible Preferred Stock

8-K

000-14710

3.1

02/16/2017

3.6

By-laws of XOMA Corporation

8-K

000-14710

3.2

01/03/2012

4.1

Reference is made to Exhibits 3.1, 3.2, 3.3, 3.4, 3.5 and 3.6

4.2

Specimen of Common Stock Certificate

8-K

000-14710

4.1

01/03/2012

4.3

Form of Series X Preferred Stock Certificate

8-K

000-14710

4.1

02/16/2017

4.4

Form of Warrant (February 2015 Warrants)

10-Q

000-14710

4.10

05/07/2015

4.5

Form of Warrant (February 2016 Warrant)

10-Q

000-14710

4.9

05/04/2016

10.1^+#

Amendment No. 1, dated March 30, 2018, to the License Agreement, dated December 6, 2017, between XOMA (US) LLC and Rezolute, Inc. (formerly AntriaBio, Inc.)

10.2^+#

Amendment No.1, dated March 30, 2018 to the Common Stock Purchase Agreement, dated December 6, 2017, between XOMA Corporation and Rezolute, Inc. (formerly AntriaBio, Inc.)

10.3^#

License Agreement dated December 6, 2017, between XOMA (US) LLC and Rezolute, Inc. (formerly AntriaBio)

10-K

000-14710

10.66

03/07/2018

10.4#

Common Stock Purchase Agreement dated December 6, 2017, between XOMA Corporation and Rezolute, Inc. (formerly AntriaBio)

10-K

000-14710

10.65

03/07/2018

31.1⁺

Certification of Chief Executive Officer, as required by Rule 13a-14(a) or Rule 15d-14(a)

31.2⁺

Certification of Chief Financial Officer, as required by Rule 13a-14(a) or Rule 15d-14(a)

32.1⁺

Certification of Chief Executive Officer and Chief Financial Officer, as required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350)⁽¹⁾

101.INS⁺

XBRL Instance Document

101.SCH⁺

XBRL Taxonomy Extension Schema Document

101.CAL⁺

XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF⁺

XBRL Taxonomy Extension Definition Linkbase Document

101.LAB⁺

XBRL Taxonomy Extension Labels Linkbase Document

101.PRE⁺

XBRL Taxonomy Extension Presentation Linkbase Document

+	Filed herewith

*	Indicates a management contract or compensation plan or arrangement.

#	Confidential treatment has been requested for certain provisions omitted from this Exhibit pursuant to Rule 406 promulgated under the Securities Act. The omitted information has been filed separately with the SEC.

(1)

This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	XOMA Corporation

Date: May 9, 2018	By:	/s/ JAMES R. NEAL
		James R. Neal Chief Executive Officer (principal executive officer) and Director
Date: May 9, 2018	By:	/s/ THOMAS BURNS
		Thomas Burns Senior Vice President, Finance and Chief Financial Officer (principal financial and principal accounting officer)

EX-10.1 2 xoma-ex101_237.htm EX-10.1 xoma-ex101_237.htm

Confidential

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

Exhibit 10.1

AMENDMENT NO. 1 TO THE

LICENSE AGREEMENT

THIS AMENDMENT NO. 1 (the “Amendment”) to the LICENSE AGREEMENT dated as of December 6, 2017 (the “License Agreement”), is entered into on March 30, 2018 (the “Amendment Date”) between XOMA (US) LLC, a Delaware limited liability company, having an address of 2200 Powell Street, Suite 310, Emeryville, CA 94608 (“XOMA”), and Rezolute, Inc., a Delaware corporation, having an address of 1450 Infinite Drive, Louisville, CO 80027 (“Rezolute”). Terms used but not otherwise defined herein shall have the meanings ascribed to them in the License Agreement.

WHEREAS, the Parties desire to amend the License Agreement to specify financial responsibility for certain matters related to the technology transfer between the Parties associated with the fully human allosteric modulating monoclonal antibody formerly known as XOMA 358 (now known as RZ358);

NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, the Parties agree as follows:

The following new Section 2.3.6 shall be incorporated into and deemed a part of the License Agreement upon execution of this Amendment:

“2.3.6 The Parties shall share all Tech Transfer Expenses as follows: XOMA shall pay [*] of all Tech Transfer Expenses and Rezolute shall be solely responsible for and reimburse XOMA for all Tech Transfer Expenses above [*]. Rezolute shall pay XOMA’s invoices for such reimbursement within thirty (30) days following its receipt thereof accompanied by reasonable supporting documentation. “Tech Transfer Expenses” means (a) invoiced costs from [*] for services provided, whether prior to or after the Effective Date, relating to the clinical materials described in Exhibit F to the Agreement, including services for the production and delivery of batches, validation, analytical methods, stability studies and other miscellaneous expenses, and (b) any other invoices from Third Parties for services for work that is necessary or appropriate to realize the objectives of the matters set forth in this Section 2.3.

THE FOREGOING SETS FORTH THE ENTIRE SUBJECT MATTER OF THE AMENDMENT AND OTHER THAN AS SET FORTH HEREIN, ALL OTHER TERMS AND CONDITIONS OF THE LICENSE AGREEMENT SHALL REMAIN IN FULL FORCE AND EFFECT.

Confidential

[Signature Page Follows.]

IN WITNESS WHEREOF, the Parties have executed this Amendment as of the Amendment Date.

XOMA (US) LLC

By /s/ Jim Neal

Name Jim Neal

Title Chief Executive Officer

REZOLUTE, INC.

By /s/ Morgan Fields

Name Morgan Fields

Title Chief Accounting Officer

EX-10.2 3 xoma-ex102_238.htm EX-10.2 xoma-ex102_238.htm

Exhibit 10.2

AMENDMENT NO. 1

TO THE COMMON STOCK PURCHASE AGREEMENT

THIS AMENDMENT NO. 1 (the “Amendment”) TO THE COMMON STOCK PURCHASE AGREEMENT dated December 6, 2017 (the “Agreement”) is entered into as of March 30, 2018, by and among Rezolute, Inc., a Delaware corporation (formerly known as AntriaBio, Inc.) (the “Company ”), and XOMA Corporation, a Delaware corporation (“Purchaser”). Terms used but not otherwise defined herein shall have the meanings ascribed to them in the Agreement.

WHEREAS, the Purchaser and the Company entered into the Agreement and now desire to amend certain provisions of such Agreement;

NOW, THEREFORE, in consideration of the mutual promises, representations, warranties, covenants and conditions set forth in this Amendment, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:

Sections 1.2, 1.4 and 1.5 of the Agreement are e ach hereby amended and restated in their entirety as follows:

1.2 Initial Closing. The initial purchase and sale of the Shares shall take place remotely via the exchange of documents and signatures within five (5) business days following the earlier of (1) the closing of [*] of the Company occurring after January 1, 2018 resulting in [*], or (2) the initiation of [*] for the Company’s clinical study of [*] (which time, date and place are referred to in this Agreement as the “Initial Closing”) (the “Initial Closing”). At the Initial Closing, the Company shall deliver to the Purchaser 7,000,000 of shares of the Company’s Common Stock (the “Initial Closing Shares”). The Company shall instruct VStock Transfer, LLC (the “Transfer Agent”) to register such issuance via book entry at the time of such issuance.

1.4 Qualified Financing Closing. A subsequent purchase and sale of Shares shall take place remotely via the exchange of documents and signatures concurrently with the closing of a Qualified Financing (as defined below), or at such other time as the Company and Purchaser shall mutually agree (which time, date and place are referred to in this Agreement as the “Qualified Financing Closing”). At the Qualified Financing Closing, the Company shall deliver to Purchaser that number of Shares, and/or other securities issued in a Qualified Financing (the “Qualified Financing Shares”) equal to a quotient, the numerator of which shall be: (i) Eight Million Five Hundred Thousand Dollars ($8,500,000); minus (ii) the Interim Financing Value represented by Shares issued to Purchaser prior to the Qualified Financing; and the denominator of which shall be: (x) in the case of a Qualified Financing that is an equity financing, the price per share of the stock (or units, if additional securities are issued together with stock) sold in the Qualified Financing; or (y) in the case of a Qualified Financing that is non-dilutive to the Company, the weighted average of the closing bid and asked prices or the average closing prices of the Common Stock on the Principal Market for the ten day trading period prior to the announcement of such Qualified Financing. A “Qualified Financing” shall mean an equity or debt financing event resulting in aggregate gross cash proceeds to the Company of at least $20 million. The Company shall provide Purchaser a written notice specifying the date of the Qualified Financing Closing, which notice shall be delivered no less than ten (10) business days prior to the date of the Qualified Financing Closing. For the avoidance of doubt, in

the event that the Initial Closing has not occurred prior to the Qualified Financing Closing, the Company shall issue both the First Closing Shares and the Qualified Financing Shares at the Qualified Financing Closing.

1.5 2019 Closing. In the event that the Qualified Financing Closing has not occurred on or prior to March 31, 2019, then a purchase and sale of the Shares shall take place remotely via the exchange of documents and signatures on April 1, 2019 (which time, date and place are referred to in this Agreement as the “2019 Closing”). The Initial Closing, each Interim Closing, the Qualified Financing Closing and the 2019 Closing is each referred to herein as a “Closing” and, together the “Closings.” At the 2019 Closing, the Company shall deliver to the Purchaser that number of Shares, (the “2019 Shares”) equal to Eight Million Five Hundred Thousand Dollars ($8,500,000) divided by the weighted average of the closing bid and asked prices or the average closing prices of the Common Stock on the Principal Market for the ten day trading period prior to the 2019 Closing. For the avoidance of doubt, in the event that a Qualified Financing occurs after the 2019 Closing, the Qualified Financing Shares will be issued in accordance with the terms hereof in addition to the Initial Closing Shares and the 2019 Shares.

THE FOREGOING SETS FORTH THE ENTIRE SUBJECT MATTER OF THE AMENDMENT AND OTHER THAN AS SET FORTH HEREIN, ALL OTHER TERMS AND CONDITIONS OF THE AGREEMENT SHALL REMAIN IN FULL FORCE AND EFFECT. THE GENERAL PROVISIONS OF ARTICLE 10 OF THE AGREEMENT ARE INCORPORATED HEREIN AND ARE APPLICABLE TO THIS AMENDMENT.

IN WITNESS WHEREOF, the undersigned parties have duly executed this Amendment as of the date first above written.

COMPANY:

REZOLUTE, INC.

By:/s/ Morgan Fields

Name:Morgan Fields

Title:Chief Accounting Officer

Date:30-Mar-2018

PURCHASER:

XOMA CORPORATION

By:/s/ Jim Neal

Name:Jim Neal

Title:Chief Executive Officer

Date:30-Mar-2018

EX-31.1 4 xoma-ex311_18.htm EX-31.1 xoma-ex311_18.htm

Exhibit 31.1

CERTIFICATION

I, James R. Neal, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of XOMA Corporation;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

	/s/ JAMES R. NEAL
Date: May 9, 2018	James R. Neal
	Chief Executive Officer

EX-31.2 5 xoma-ex312_17.htm EX-31.2 xoma-ex312_17.htm

Exhibit 31.2

CERTIFICATION

I, Thomas Burns, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of XOMA Corporation;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

	/s/ THOMAS BURNS
Date: May 9, 2018	Thomas Burns
	Senior Vice President, Finance, and Chief Financial Officer

EX-32.1 6 xoma-ex321_6.htm EX-32.1 xoma-ex321_6.htm

Exhibit 32.1

CERTIFICATION

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), James R. Neal, Chief Executive Officer of XOMA Corporation (the “Company”), and Thomas Burns, Chief Financial Officer of the Company, each hereby certifies that, to the best of his or her knowledge:

1.The Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2018, to which this Certification is attached as Exhibit 32.1 (the “Periodic Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and

2.The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

IN WITNESS WHEREOF, the undersigned have set their hands hereto as of the 9^th day of May 2018.

	/s/ JAMES R. NEAL
	James R. Neal
	Chief Executive Officer

	/s/ THOMAS BURNS
	Thomas Burns
	Senior Vice President, Finance, and Chief Financial Officer

This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of XOMA Corporation under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.

EX-101.INS 7 xoma-20180331.xml XBRL INSTANCE DOCUMENT shares iso4217:USD iso4217:USD shares xoma:Customer pure iso4217:EUR xoma:Agreement xoma:Obligation xoma:Employee iso4217:EUR iso4217:USD xoma:RenewalOption xoma:Facility 0000791908 2018-01-01 2018-03-31 0000791908 2018-05-07 0000791908 2018-03-31 0000791908 2017-12-31 0000791908 2017-01-01 2017-03-31 0000791908 2016-12-31 0000791908 2017-03-31 0000791908 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueGoodsNetMember 2018-01-01 2018-03-31 0000791908 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueGoodsNetMember xoma:Partner1Member 2018-01-01 2018-03-31 0000791908 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueGoodsNetMember xoma:Partner2Member 2018-01-01 2018-03-31 0000791908 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueGoodsNetMember 2017-01-01 2017-03-31 0000791908 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueGoodsNetMember xoma:Partner1Member 2017-01-01 2017-03-31 0000791908 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueGoodsNetMember xoma:Partner2Member 2017-01-01 2017-03-31 0000791908 us-gaap:CustomerConcentrationRiskMember us-gaap:TradeAccountsReceivableMember 2018-01-01 2018-03-31 0000791908 us-gaap:CustomerConcentrationRiskMember xoma:Partner1Member us-gaap:TradeAccountsReceivableMember 2018-01-01 2018-03-31 0000791908 us-gaap:CustomerConcentrationRiskMember us-gaap:TradeAccountsReceivableMember 2017-01-01 2017-12-31 0000791908 us-gaap:CustomerConcentrationRiskMember xoma:Partner1Member us-gaap:TradeAccountsReceivableMember 2017-01-01 2017-12-31 0000791908 us-gaap:DemandDepositsMember 2018-03-31 0000791908 us-gaap:DemandDepositsMember 2017-12-31 0000791908 us-gaap:OtherNonoperatingIncomeExpenseMember 2017-01-01 2017-03-31 0000791908 xoma:CommonStockOptionsAndRestrictedStockUnitsMember 2018-01-01 2018-03-31 0000791908 xoma:CommonStockOptionsAndRestrictedStockUnitsMember 2017-01-01 2017-03-31 0000791908 us-gaap:WarrantMember 2018-01-01 2018-03-31 0000791908 us-gaap:WarrantMember 2017-01-01 2017-03-31 0000791908 us-gaap:ConvertiblePreferredStockMember 2018-01-01 2018-03-31 0000791908 us-gaap:ConvertiblePreferredStockMember 2017-01-01 2017-03-31 0000791908 xoma:NovartisPharmaAGMember xoma:XOMA052LicenseAgreementMember 2017-08-23 2017-08-24 0000791908 xoma:NovartisPharmaAGMember xoma:LesLaboratoriesServierMember 2017-08-23 2017-08-24 0000791908 xoma:NovartisPharmaAGMember us-gaap:CommonStockMember 2017-08-23 2017-08-24 0000791908 xoma:NovartisPharmaAGMember us-gaap:CommonStockMember 2017-08-24 0000791908 xoma:NovartisPharmaAGMember 2017-08-23 2017-08-24 0000791908 xoma:NovartisPharmaAGMember xoma:IL1TargetLicenseAgreementMember 2017-08-23 2017-08-24 0000791908 xoma:NovartisPharmaAGMember xoma:LicensesAndRelatedMaterialsProcessAndKnowHowAndFilingsToRegulatoryAuthorityMember 2017-01-01 2017-12-31 0000791908 xoma:NovartisPharmaAGMember 2018-03-31 0000791908 xoma:NovartisPharmaAGMember 2017-12-31 0000791908 xoma:NovartisPharmaAGMember 2018-01-01 2018-03-31 0000791908 xoma:NovartisInternationalPharmaceuticalLtdMember xoma:LicenseAgreementMember 2015-09-29 2015-09-30 0000791908 xoma:NovartisInternationalPharmaceuticalLtdMember xoma:LicenseAgreementMember 2015-01-01 2015-12-31 0000791908 xoma:LicenseAgreementMember xoma:NovartisInternationalPharmaceuticalLtdMember 2017-04-01 2017-06-30 0000791908 xoma:LicenseAgreementMember xoma:NovartisInternationalPharmaceuticalLtdMember 2018-01-01 2018-03-31 0000791908 xoma:NovartisInternationalPharmaceuticalLtdMember xoma:LicenseAgreementMember 2018-03-31 0000791908 xoma:NovartisInternationalPharmaceuticalLtdMember xoma:LicenseAgreementMember 2017-12-31 0000791908 xoma:RezoluteIncMember xoma:LicenseAgreementMember 2017-12-06 0000791908 us-gaap:ScenarioForecastMember xoma:RezoluteIncMember xoma:LicenseAgreementMember 2017-12-05 2019-06-01 0000791908 us-gaap:ScenarioForecastMember xoma:RezoluteIncMember xoma:LicenseAgreementMember 2019-06-01 0000791908 xoma:LicenseAgreementMember xoma:RezoluteIncMember 2017-12-05 2017-12-06 0000791908 xoma:LicenseAgreementMember xoma:RezoluteIncMember us-gaap:ScenarioForecastMember 2019-03-31 2019-03-31 0000791908 xoma:LicenseAgreementMember xoma:RezoluteIncMember us-gaap:ScenarioForecastMember 2020-03-31 2020-03-31 0000791908 xoma:LicenseAgreementMember xoma:RezoluteIncMember 2018-01-01 2018-03-31 0000791908 xoma:RezoluteIncMember xoma:InitialClosingMember 2018-03-30 2018-03-30 0000791908 xoma:RezoluteIncMember xoma:AmendedCommonStockPurchaseAgreementMember xoma:InitialClosingMember 2018-03-30 2018-03-30 0000791908 xoma:RezoluteIncMember xoma:QualifiedFinancingMember 2018-03-30 2018-03-30 0000791908 xoma:RezoluteIncMember xoma:AmendedCommonStockPurchaseAgreementMember xoma:QualifiedFinancingMember 2018-03-30 2018-03-30 0000791908 xoma:RezoluteIncMember xoma:TwoThousandNineteenClosingMember 2018-03-30 2018-03-30 0000791908 xoma:RezoluteIncMember xoma:AmendedCommonStockPurchaseAgreementMember xoma:TwoThousandNineteenClosingMember 2018-03-30 2018-03-30 0000791908 xoma:RezoluteIncMember xoma:CommonStockPurchaseAgreementMember xoma:InterimFinancingClosingMember 2018-01-01 2018-03-31 0000791908 xoma:DeferredRevenueArrangementNameOfParty2Member xoma:NonsoftwareLicenseArrangementWithGovernmentalAgency2Member 2008-09-30 0000791908 xoma:DeferredRevenueArrangementNameOfParty2Member xoma:NonsoftwareLicenseArrangementWithGovernmentalAgency3Member 2008-09-01 2008-09-30 0000791908 xoma:DeferredRevenueArrangementNameOfParty2Member xoma:NonsoftwareLicenseArrangementWithGovernmentalAgency3Member 2014-12-31 0000791908 xoma:DeferredRevenueArrangementNameOfParty2Member xoma:NonsoftwareLicenseArrangementWithGovernmentalAgency2Member 2017-01-01 2017-12-31 0000791908 xoma:DeferredRevenueArrangementNameOfParty2Member 2018-03-31 0000791908 xoma:DeferredRevenueArrangementNameOfParty2Member 2017-12-31 0000791908 xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember 2018-01-01 2018-03-31 0000791908 xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember xoma:FirstRoyaltyInterestAcquisitionAgreementMember 2016-12-20 2016-12-21 0000791908 xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember xoma:FirstRoyaltyInterestAcquisitionAgreementMember 2018-01-01 2018-03-31 0000791908 xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember xoma:SecondRoyaltyInterestAcquisitionAgreementMember 2016-12-20 2016-12-21 0000791908 xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember 2018-03-31 0000791908 xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember 2017-12-31 0000791908 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2018-03-31 0000791908 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2018-03-31 0000791908 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2017-12-31 0000791908 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2017-12-31 0000791908 xoma:NovartisNoteMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2018-03-31 0000791908 xoma:NovartisNoteMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2017-12-31 0000791908 xoma:NovartisNoteMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-03-31 0000791908 xoma:NovartisNoteMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2017-12-31 0000791908 xoma:BiodefenseBusinessMember us-gaap:MaximumMember 2015-11-02 2015-11-04 0000791908 xoma:BiodefenseBusinessMember 2015-11-02 2015-11-04 0000791908 xoma:AssetPurchaseAgreementAndOlogyBioservicesLicenseAgreementMember 2017-02-01 2017-02-28 0000791908 xoma:AssetPurchaseAgreementAndOlogyBioservicesLicenseAgreementMember 2017-03-31 0000791908 xoma:AssetPurchaseAgreementAndOlogyBioservicesLicenseAgreementMember 2017-07-01 2017-09-30 0000791908 xoma:AssetPurchaseAgreementAndOlogyBioservicesLicenseAgreementMember 2018-01-01 2018-03-31 0000791908 xoma:AssetPurchaseAgreementAndOlogyBioservicesLicenseAgreementMember 2017-01-01 2017-03-31 0000791908 xoma:TwoThousandSixteenRestructuringMember 2016-12-18 2016-12-19 0000791908 xoma:TwoThousandSeventeenRestructuringMember 2018-01-01 2018-03-31 0000791908 xoma:EmployeeSeveranceAndOtherBenefitsMember 2016-12-31 0000791908 xoma:EmployeeSeveranceAndOtherBenefitsMember 2017-01-01 2017-12-31 0000791908 xoma:EmployeeSeveranceAndOtherBenefitsMember 2017-12-31 0000791908 xoma:EmployeeSeveranceAndOtherBenefitsMember 2018-01-01 2018-03-31 0000791908 xoma:NovartisNoteMember 2005-05-01 2005-05-31 0000791908 xoma:NovartisNoteMember 2005-05-31 0000791908 xoma:NovartisNoteMember us-gaap:LondonInterbankOfferedRateLIBORMember 2005-05-01 2005-05-31 0000791908 xoma:NovartisNoteMember 2018-03-31 0000791908 xoma:NovartisNoteAmendmentMember 2015-09-29 2015-09-30 0000791908 xoma:NovartisNoteAmendmentMember 2017-09-22 2017-09-22 0000791908 xoma:NovartisNoteMember 2017-12-31 0000791908 xoma:ServierLoanMember 2010-12-01 2010-12-31 0000791908 xoma:ServierLoanMember 2010-12-31 0000791908 xoma:ServierLoanMember 2017-08-25 2017-08-25 0000791908 xoma:ServierLoanMember 2017-08-25 0000791908 xoma:ServierLoanMember 2017-07-01 2017-09-30 0000791908 xoma:HerculesTermLoanMember 2018-01-01 2018-03-31 0000791908 xoma:HerculesTermLoanMember us-gaap:MinimumMember 2015-02-27 0000791908 xoma:HerculesTermLoanMember us-gaap:PrimeRateMember 2015-02-26 2015-02-27 0000791908 xoma:HerculesTermLoanMember us-gaap:PrimeRateMember 2015-02-27 0000791908 xoma:HerculesTermLoanMember 2017-03-21 2017-03-21 0000791908 xoma:HerculesTermLoanMember 2017-01-01 2017-03-31 0000791908 xoma:HerculesTermLoanMember 2015-02-27 0000791908 xoma:HerculesTermLoanMember 2015-02-26 2015-02-27 0000791908 xoma:NovartisNoteMember 2018-01-01 2018-03-31 0000791908 xoma:NovartisNoteMember 2017-01-01 2017-03-31 0000791908 xoma:ServierLoanMember 2017-01-01 2017-03-31 0000791908 xoma:HerculesLoanMember 2017-01-01 2017-03-31 0000791908 xoma:OtherFinancingsMember 2018-01-01 2018-03-31 0000791908 xoma:OtherFinancingsMember 2017-01-01 2017-03-31 0000791908 xoma:FiveYearWarrantsIssuedFirstRangeMember xoma:StockholdersEquityMember 2018-01-01 2018-03-31 0000791908 xoma:FiveYearWarrantsIssuedSecondRangeMember xoma:StockholdersEquityMember 2018-01-01 2018-03-31 0000791908 xoma:FiveYearWarrantsIssuedFirstRangeMember xoma:StockholdersEquityMember 2018-03-31 0000791908 xoma:FiveYearWarrantsIssuedSecondRangeMember xoma:StockholdersEquityMember 2018-03-31 0000791908 xoma:FiveYearWarrantsIssuedFirstRangeMember xoma:StockholdersEquityMember 2017-12-31 0000791908 xoma:FiveYearWarrantsIssuedSecondRangeMember xoma:StockholdersEquityMember 2017-12-31 0000791908 2017-11-21 0000791908 2017-11-20 2017-11-21 0000791908 us-gaap:StandbyLettersOfCreditMember 2017-11-21 0000791908 us-gaap:StandbyLettersOfCreditMember 2018-03-30 2018-03-31 0000791908 xoma:TwoThousandFifteenEmployeeStockPurchasePlanMember 2018-01-01 2018-03-31 0000791908 xoma:NonExecutiveEmployeeMember us-gaap:MinimumMember 2018-01-01 2018-03-31 0000791908 xoma:NonExecutiveEmployeeMember us-gaap:MaximumMember 2018-01-01 2018-03-31 0000791908 us-gaap:DirectorMember 2018-01-01 2018-03-31 0000791908 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-03-31 0000791908 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-03-31 0000791908 us-gaap:EmployeeStockOptionMember 2017-12-31 0000791908 us-gaap:EmployeeStockOptionMember 2018-03-31 0000791908 us-gaap:PerformanceSharesMember 2018-03-31 0000791908 us-gaap:PerformanceSharesMember 2018-01-01 2018-03-31 0000791908 us-gaap:ExecutiveOfficerMember us-gaap:PerformanceSharesMember 2017-12-01 2017-12-31 0000791908 us-gaap:ExecutiveOfficerMember xoma:ServiceBasedStockOptionsMember 2018-01-01 2018-03-31 0000791908 us-gaap:ExecutiveOfficerMember us-gaap:PerformanceSharesMember 2018-01-01 2018-03-31 0000791908 xoma:NonExecutiveEmployeeMember us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-03-31 0000791908 us-gaap:DirectorMember us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-03-31 0000791908 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-03-31 0000791908 us-gaap:RestrictedStockUnitsRSUMember 2017-12-31 0000791908 us-gaap:RestrictedStockUnitsRSUMember 2018-03-31 0000791908 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-03-31 0000791908 us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-03-31 0000791908 us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-03-31 0000791908 us-gaap:GeneralAndAdministrativeExpenseMember 2017-01-01 2017-03-31 0000791908 us-gaap:CommonStockMember 2017-02-01 2017-02-28 0000791908 us-gaap:ConvertiblePreferredStockMember 2017-02-01 2017-02-28 0000791908 2017-02-01 2017-02-28 0000791908 us-gaap:CommonStockMember 2017-02-28 0000791908 us-gaap:ConvertiblePreferredStockMember 2017-02-28 0000791908 xoma:AtmAgreement4Member 2018-01-01 2018-03-31 0000791908 xoma:AtmAgreement4Member us-gaap:CommonStockMember 2018-01-01 2018-03-31 0000791908 xoma:AtmAgreement4Member us-gaap:CommonStockMember 2017-01-01 2017-03-31 0000791908 xoma:AtmAgreement4Member 2015-11-12 0000791908 xoma:AtmAgreement4Member 2017-01-01 2017-03-31 0000791908 xoma:NovartisInternationalPharmaceuticalLtdMember 2017-08-23 2017-08-24 0000791908 xoma:NovartisInternationalPharmaceuticalLtdMember 2017-08-24 0000791908 xoma:RezoluteIncMember xoma:AmendedCommonStockPurchaseAgreementMember us-gaap:SubsequentEventMember 2018-04-01 2018-04-02 0000791908 xoma:RezoluteIncMember xoma:AmendedCommonStockPurchaseAgreementMember us-gaap:SubsequentEventMember 2018-04-01 2018-04-30 0000791908 us-gaap:SubsequentEventMember 2018-04-14 0000791908 us-gaap:SubsequentEventMember 2018-04-13 2018-04-14 0000791908 us-gaap:SubsequentEventMember xoma:LoanAndSecurityAgreementMember xoma:TermLoanMember xoma:SiliconValleyBankMember 2018-05-07 0000791908 us-gaap:SubsequentEventMember xoma:LoanAndSecurityAgreementMember xoma:TermLoanMember xoma:SiliconValleyBankMember 2018-05-06 2018-05-07 0000791908 us-gaap:SubsequentEventMember xoma:LoanAndSecurityAgreementMember xoma:TermLoanMember us-gaap:PrimeRateMember xoma:SiliconValleyBankMember 2018-05-06 2018-05-07 0000791908 us-gaap:SubsequentEventMember xoma:NovartisMember xoma:LoanAndSecurityAgreementMember xoma:SiliconValleyBankMember 2018-05-06 2018-05-07 0000791908 us-gaap:SubsequentEventMember xoma:FirstAnniversaryMember xoma:LoanAndSecurityAgreementMember xoma:TermLoanMember xoma:SiliconValleyBankMember 2018-05-06 2018-05-07 0000791908 us-gaap:SubsequentEventMember xoma:SecondAnniversaryMember xoma:LoanAndSecurityAgreementMember xoma:TermLoanMember xoma:SiliconValleyBankMember 2018-05-06 2018-05-07 0000791908 us-gaap:SubsequentEventMember xoma:LoanAndSecurityAgreementMember us-gaap:WarrantMember xoma:SiliconValleyBankMember 2018-05-07 0000791908 us-gaap:SubsequentEventMember xoma:LoanAndSecurityAgreementMember us-gaap:WarrantMember xoma:SiliconValleyBankMember 2018-05-06 2018-05-07 XOMA Corp XOMA 0000791908 --12-31 Smaller Reporting Company 8367118 2018 Q1 10-Q false 2018-03-31

41968000

43471000

436000

397000

273000

327000

42677000

44195000

75000

83000

559000

657000

43311000

44935000

1420000

1679000

1338000 2675000

1666000

1637000

658000

615000

798000

18000

5880000

7422000

17019000

17123000

14572000

203000

32000

37674000

39149000

62000

1188440000

1184783000

-1182865000

-1179059000

5637000

5786000

43311000

44935000

0.05

1000000

5003

0.0075

277333332

8332118

8249158

8332118

8249158

401000

150000

62000 110000

463000

260000

432000

3993000

5168000

5167000

2020000

5600000

11180000

-5137000

-10920000

170000

609000

-515000

1501000

1329000

-3806000

-10715000

5603000 -3806000 -16318000

-0.46

-2.37

8313000

6887000

1416000

1000000

20000 506000

8000

147000

286000

-261000

1314000

21000

-55000

39000

-33000

-53000

-345000

-1593000

-5281000

138000

-76000

-62000

-110000

29000

18000

-3839000

-14348000

813000

20072000

2309000

5380000

14000

16380000

1150000

4000

51000

3000

2316000

7871000

20000

-33000

-1503000

-5697000

25742000

20045000

396000

100000 811000

<div> <p style="text-align:justify;margin-top:12pt;margin-bottom:4pt;text-indent:0%;font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2. Basis of Presentation and Significant Accounting Policies <p style="text-align:justify;margin-top:6pt;margin-bottom:4pt;text-indent:0%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Basis of Presentation <p style="text-align:justify;margin-top:6pt;margin-bottom:4pt;text-indent:4.54%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions among consolidated entities were eliminated upon consolidation. The unaudited consolidated financial statements were prepared in accordance with generally accepted accounting principles (“GAAP”) in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. As permitted under those rules certain footnotes or other financial information can be condensed or omitted. These financial statements and related disclosures have been prepared with the assumption that users of the interim financial information have read or have access to the audited consolidated financial statements for the preceding fiscal year. Accordingly, these statements should be read in conjunction with the audited consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, filed with the U.S. Securities and Exchange Commission (“SEC”) on March 7, 2018. <p style="text-align:justify;margin-top:12pt;margin-bottom:4pt;text-indent:4.54%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These financial statements have been prepared on the same basis as the Company’s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments that are necessary for a fair statement of the Company’s consolidated financial information. The interim results of operations are not necessarily indicative of the results that may be expected for the full year. <p style="text-align:justify;margin-top:18pt;margin-bottom:4pt;text-indent:0%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates <p style="text-align:justify;margin-top:6pt;margin-bottom:4pt;text-indent:4.54%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to, those related to revenue recognition, debt amendments, long-lived assets, restructuring liabilities, legal contingencies, and stock-based compensation. The Company bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ significantly from these estimates, such as the Company’s billing under government contracts. Under the Company’s contracts with the National Institute of Allergy and Infectious Diseases (“NIAID”), a part of the National Institutes of Health (“NIH”), the Company billed using NIH’s provisional rates and thus is subject to future audits at the discretion of NIAID’s contracting office. These audits can result in an adjustment to revenue previously reported which potentially could be significant. <p style="text-align:justify;margin-top:18pt;margin-bottom:4pt;text-indent:0%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Revenue Recognition <p style="text-align:justify;margin-top:6pt;margin-bottom:4pt;text-indent:4.54%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective January 1, 2018, the Company adopted Accounting Standards Codification Topic 606, Revenue from Contracts with Customers ("ASC 606") using the modified retrospective transition method and applied the standard only to contracts that are still active or in place at that date. Also, as permitted, the Company applied the practical expedient under ASC 606 which permits the Company to treat all contract modifications that occurred prior to the adoption in aggregate when determining the performance obligations, transaction price and its allocation. Except for the Company’s license agreement with Rezolute, Inc. (formerly AntriaBio, Inc.) (“Rezolute”), the Company did not have any other contracts with customers for which the Company had not completed its performance obligations as of the adoption date January 1, 2018. The license agreement with Rezolute was not considered a contract under ASC 606 as it is not probable that the Company will collect substantially all of the consideration to which it will be entitled in exchange for the goods or services that will be transferred to Rezolute and there was no consideration exchanged upon execution of the arrangement or as of January 1, 2018 (see Note 4). Thus, the Company determined that the adoption of ASC 606 did not have a financial impact on the Company's consolidated financial statements and related disclosures. In addition, the adoption of ASC 606 has no material impact for tax purposes. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments.  Under ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. <p style="text-align:justify;margin-top:6pt;margin-bottom:4pt;text-indent:4.54%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation.  The Company only applies the five-step model to contracts when it is probable that Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.  At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct.  The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation based on relative fair values, when (or as) the performance obligation is satisfied. <p style="text-align:justify;margin-top:6pt;margin-bottom:4pt;text-indent:4.54%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes revenue from its license and collaboration arrangements and royalties. The terms of the arrangements generally include payment to the Company of one or more of the following: non-refundable, upfront license fees, development, regulatory and commercial milestone payments, and royalties on net sales of licensed products. <p style="text-align:justify;margin-top:6pt;margin-bottom:4pt;text-indent:4.54%;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Licenses of intellectual property: If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, such as transfer of related materials, process and know-how, the Company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. Under the Company’s license agreements, the nature of the combined performance obligation is the granting of licenses to the customers as the other promises are not separately identifiable in the context of the arrangement. Since the Company grants the license to a customer as it exists at the point of transfer, and is not involved in any future development or commercialization of the products related to the license, the nature of the license is a right to use the Company’s intellectual property as transferred. As such, the Company recognizes revenue related to the combined performance obligation upon completion of the delivery of the related materials, process and know-how (i.e., at a point in time). <p style="text-align:justify;margin-top:6pt;margin-bottom:4pt;text-indent:4.54%;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Milestone payments: At the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. ASC 606 suggests two alternatives to use when estimating the amount of variable consideration: the expected value method and the most likely amount method. Under the expected value method, an entity considers the sum of probability-weighted amounts in a range of possible consideration amounts. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. The Company expects to use the most likely amount method for development and regulatory milestone payments. If it is probable that a significant cumulative revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability or achievement of each such milestone and any related constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and earnings in the period of adjustment. <p style="text-align:justify;margin-top:6pt;margin-bottom:4pt;text-indent:4.54%;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Royalties: For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). <p style="text-align:justify;margin-top:6pt;margin-bottom:4pt;text-indent:4.54%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upfront payments and fees are recorded as deferred revenue upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company’s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one year or less. <p style="text-align:justify;margin-top:18pt;margin-bottom:4pt;text-indent:0%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Sale of Future Revenue Streams <p style="text-align:justify;margin-top:6pt;margin-bottom:4pt;text-indent:4.54%;color:#auto;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> The Company has sold its rights to receive certain milestones and royalties on product sales. In the circumstance where the Company has sold its rights to future milestones and royalties under a license agreement and also maintains limited continuing involvement in the arrangement (but not significant continuing involvement in the generation of the cash flows that are due to the purchaser), the Company defers recognition of the proceeds it receives for the sale of milestone or royalty streams and recognizes such unearned revenue as revenue under units-of-revenue method over the life of the underlying license agreement.. Under the units-of-revenue method, amortization for a reporting period is calculated by computing a ratio of the proceeds received from the purchaser to the total payments expected to be made to the purchaser over the term of the agreement, and then applying that ratio to the period’s cash payment. <p style="text-align:justify;margin-top:18pt;margin-bottom:4pt;text-indent:4.54%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Estimating the total payments expected to be received by the purchaser over the term of such arrangements requires management to use subjective estimates and assumptions. Changes to the Company’s estimate of the payments expected to be made to the purchaser over the term of such arrangements could have a material effect on the amount of revenues recognized in any particular period. <p style="text-align:justify;margin-top:18pt;margin-bottom:4pt;text-indent:0%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock-Based Compensation <p style="text-align:justify;margin-top:6pt;margin-bottom:4pt;text-indent:4.54%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes compensation expense for all stock-based payment awards made to the Company’s employees, consultants and directors that are expected to vest based on estimated fair values. The valuation of stock option awards is determined at the date of grant using the Black-Scholes Option Pricing Model (the “Black-Scholes Model”). The Black-Scholes Model requires inputs such as the expected term of the option, expected volatility and risk-free interest rate. To establish an estimate of expected term, the Company considers the vesting period and contractual period of the award and its historical experience of stock option exercises, post-vesting cancellations and volatility. The estimate of expected volatility is based on the Company’s historical volatility. The risk-free rate is based on the yield available on United States Treasury zero-coupon issues corresponding to the expected term of the award. The Company records forfeitures when they occur. <p style="text-align:justify;margin-top:12pt;margin-bottom:4pt;text-indent:4.54%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company records compensation expense for service-based awards over the vesting period of the award on a straight-line basis. For awards with performance-based conditions, the Company records the expense over the remaining service period when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based condition is probable based on the expected satisfaction of the performance conditions as of the reporting date. The amount of stock-based compensation expense recognized during a period is based on the value of the portion of the awards that are ultimately expected to vest. <p style="text-align:justify;margin-top:12pt;margin-bottom:4pt;text-indent:4.54%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The valuation of restricted stock units (“RSUs”) is determined at the date of grant using the Company’s closing stock price. <p style="text-align:justify;margin-top:18pt;margin-bottom:4pt;text-indent:0%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Net Loss per Share Available to Common Stockholders <p style="text-align:justify;margin-top:6pt;margin-bottom:4pt;text-indent:4.54%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share available to common stockholders is based on the weighted average number of shares of common stock outstanding during the period. Net loss available to common stockholders consists of net loss, as adjusted for the convertible preferred stock deemed dividends related to the beneficial conversion feature on this instrument at issuance. For the three months ended March 31, 2017, the convertible preferred stock had a deemed dividend which represented the accretion of a beneficial conversion feature. As such, the net loss for the three months ended March 31, 2017 was adjusted for the convertible preferred stock deemed dividend related to the beneficial conversion feature on these shares at issuance. During periods of loss, the Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company. Diluted net loss per share available to common stockholders is based on the weighted average number of shares outstanding during the period, adjusted to include the assumed conversion of preferred stock, and the exercise of certain stock options, RSUs, and warrants for common stock. The calculation of diluted loss per share available to common stockholders requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of any outstanding options, RSUs or warrants and the presumed exercise of such securities are dilutive to earnings (loss) per share available to common stockholders for the period. Adjustments to the denominator are required to reflect the related dilutive shares. <p style="text-align:justify;margin-top:18pt;margin-bottom:4pt;text-indent:0%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of Risk <p style="text-align:justify;margin-top:6pt;margin-bottom:4pt;text-indent:4.54%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents and receivables are financial instruments which potentially subject the Company to concentrations of credit risk, as well as liquidity risk for certain cash equivalents, such as money market funds. The Company has not encountered any such liquidity issues during 2018. <p style="text-align:justify;margin-top:6pt;margin-bottom:4pt;text-indent:4.54%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has not experienced any significant credit losses and does not generally require collateral on receivables. For the three months ended March 31, 2018, two partners represented 86% and 13% of total revenues, respectively. For the three months ended March 31, 2017, two partners represented 58% and 42% of total revenues, respectively. As of March 31, 2018, two partners represented 50% of the trade receivables balance, respectively. As of December 31, 2017, one partner represented  95% of the trade receivables balance.   <p style="text-align:justify;margin-top:18pt;margin-bottom:4pt;text-indent:0%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements <p style="text-align:justify;margin-top:12pt;margin-bottom:4pt;text-indent:4.54%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-02, Leases (Topic 842). ASU 2016-2 is aimed at making leasing activities more transparent and comparable, and requires substantially all leases be recognized by lessees on their balance sheet as a right-of-use asset and corresponding lease liability, including leases currently accounted for as operating leases. ASU 2016-2 is effective for the Company’s interim and annual reporting periods during the year ending December 31, 2019, and all annual and interim reporting periods thereafter. Early adoption is permitted. The Company is evaluating the impact of the adoption of the standard on its consolidated financial statements.</div>

<div> <p style="text-align:justify;margin-top:18pt;margin-bottom:4pt;text-indent:0%;font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3. Condensed Consolidated Financial Statements Detail <p style="text-align:justify;margin-top:6pt;margin-bottom:4pt;text-indent:0%;font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash and Cash Equivalents <p style="text-align:justify;margin-top:6pt;margin-bottom:4pt;text-indent:4.54%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2018, cash and cash equivalents consisted of demand deposits of $7.0 million and money market funds of $35.0 million with maturities of less than 90 days at the date of purchase. As of December 31, 2017, cash and cash equivalents consisted of demand deposits of $34.9 million and money market funds of $8.6 million with maturities of less than 90 days at the date of purchase.   <p style="text-align:justify;margin-top:6pt;margin-bottom:4pt;text-indent:0%;font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Property and Equipment, net <p style="text-align:justify;margin-top:6pt;margin-bottom:4pt;text-indent:4.54%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the three months ended March 31, 2017, the Company completed the sale of equipment located in one of its leased facilities for total proceeds of $1.6 million. The carrying value of the equipment sold was $0.3 million. Accordingly, the Company recorded a gain of $1.3 million on the sale of equipment in the other income (expense), net line of the condensed consolidated statement of operations and comprehensive loss. <p style="text-align:justify;margin-top:18pt;margin-bottom:4pt;text-indent:0%;font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accrued and Other Liabilities   <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued and other liabilities consisted of the following (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.96%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.68%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.96%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.68%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.96%;"> Accrued payroll and other benefits</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-top:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-top:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">141</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.96%;"> Accrued restructuring</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.96%;"> Accrued incentive compensation</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">229</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.96%;"> Accrued legal and accounting fees</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">237</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">431</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.96%;"> Deferred rent</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">754</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">765</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.96%;"> Liability related to sublease</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">800</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.96%; border-bottom:solid 0.75pt transparent;"> Other</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">174</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">179</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.96%; border-bottom:double 2.5pt transparent;"> Total</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,338</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,675</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> </tr> </table></div>   <p style="text-align:justify;margin-top:8pt;margin-bottom:4pt;text-indent:0%;font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net Loss Per Share Available to Common Stockholders <p style="text-align:justify;margin-top:12pt;margin-bottom:4pt;text-indent:4.54%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a reconciliation of the numerator (net loss) and the denominator (number of shares) used in the calculation of basic and diluted net loss per share available to common stockholders (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"> Numerator</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"> Net loss</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,806</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,715</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> )</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;"> Less: Deemed dividend on convertible preferred stock</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,603</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> )</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"> Net loss available to common stockholders, basic and diluted</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,806</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,318</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> )</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"> Denominator</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;"> Weighted average shares outstanding used for basic and diluted net loss per share available to common stockholders</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,313</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,887</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> </tr> </table></div>   <p style="text-align:justify;margin-top:12pt;margin-bottom:4pt;text-indent:4.54%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Potentially dilutive securities are excluded from the calculation of diluted net loss per share available to common stockholders if their inclusion is anti-dilutive. The following table shows the weighted-average outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per share available to common stockholders (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"> Common stock options and RSUs</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,645</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">653</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"> Warrants for common stock</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">381</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;"> Convertible preferred stock</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,003</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,446</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;"> Total</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,665</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,480</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> </tr> </table></div>    </div>

<div> <p style="text-align:justify;margin-top:8pt;margin-bottom:4pt;text-indent:0%;font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8. Long-Term Debt <p style="text-align:justify;margin-top:6pt;margin-bottom:4pt;text-indent:0%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Novartis Note <p style="text-align:justify;margin-top:6pt;margin-bottom:4pt;text-indent:4.54%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2005, the Company executed a secured note agreement (the “Note Agreement”) with Novartis, which was due and payable in full in June 2015. Under the Note Agreement, the Company borrowed semi-annually to fund up to 75% of the Company’s research and development and commercialization costs under its collaboration arrangement with Novartis, not to exceed $50.0 million in aggregate principal amount. Interest on the principal amount of the loan accrued at six-month LIBOR plus 2%, which was equal to 3.81% at March 31, 2018 is payable semi-annually in June and December of each year. Additionally, the interest rate resets in June and December of each year. At the Company’s election, the semi-annual interest payments could be added to the outstanding principal amount, in lieu of a cash payment, as long as the aggregate principal amount did not exceed $50.0 million. The Company made this election for all interest payments. Loans under the Note Agreement were secured by the Company’s interest in its collaboration with Novartis, including any payments owed to it thereunder. <p style="text-align:justify;margin-top:12pt;margin-bottom:4pt;text-indent:4.54%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 30, 2015, concurrent with the execution of a license agreement with Novartis International as discussed in Note 4, XOMA and NIBR, who assumed the rights to the note from Novartis Vaccines Diagnostics, Inc. executed an amendment to the Note Agreement (the “Secured Note Amendment”) under which the parties extended the maturity date of the note from September 30, 2015 to September 30, 2020, and eliminated the mandatory prepayment previously required to be made with certain proceeds of pre-tax profits and royalties. In addition, upon achievement of a specified development and regulatory milestone, the then-outstanding principal amount of the note will be reduced by $7.3 million rather than the Company receiving such amount as a cash payment. <p style="text-align:justify;margin-top:12pt;margin-bottom:4pt;text-indent:4.54%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 22, 2017, in connection with the XOMA-052 License Agreement with Novartis, the Company and NIBR executed an amendment to the Secured Note Amendment under which the parties further extended the maturity date of the Secured Note Amendment from September 30, 2020 to September 30, 2022. <p style="text-align:justify;margin-top:12pt;margin-bottom:4pt;text-indent:4.54%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2018 and December 31, 2017, the outstanding principal balance under the Secured Note Amendment was $14.6 million, and was included in long-term debt in the accompanying consolidated balance sheets. <p style="text-align:justify;margin-top:18pt;margin-bottom:4pt;text-indent:0%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Servier Loan Agreement <p style="text-align:justify;margin-top:6pt;margin-bottom:4pt;text-indent:4.54%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2010, in connection with the collaboration agreement entered into with Servier, the Company executed a loan agreement with Servier (the “Servier Loan Agreement”), which provided for an advance of up to €15.0 million.  The loan was secured by an interest in XOMA’s intellectual property rights to gevokizumab and its use in indications worldwide, excluding certain rights in the U.S. and Japan. Interest was calculated at a floating rate based on a Euro Inter-Bank Offered Rate (“EURIBOR”) and subjected to a cap. <p style="text-align:justify;margin-top:12pt;margin-bottom:4pt;text-indent:4.54%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company and Servier executed multiple amendments to the Servier Loan Agreement in 2015 and 2017 primarily to revise the timing of the payments and the maturity date of the loan.  On August 25, 2017, NIBR settled the Servier Loan in cash by paying directly to Servier $14.3 million which represented the outstanding balance of the loan based on a euro to dollar exchange rate of 1.1932. The funds that NIBR paid directly to Servier were a portion of the upfront payment due to XOMA under the XOMA-052 License Agreement (see Note 4). As a result of the debt being fully paid, the intellectual property securing the Servier Loan Agreement was released. A loss on extinguishment of $0.1 million from the payoff of the loan was recognized in the condensed consolidated statement of operations and comprehensive income during the three months ended September 30, 2017.   <p style="text-align:justify;margin-top:18pt;margin-bottom:4pt;text-indent:0%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Hercules Term Loan <p style="text-align:justify;margin-top:6pt;margin-bottom:4pt;text-indent:4.54%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 27, 2015, the Company entered into a loan and security agreement with Hercules Technology Growth Capital, Inc. (the “Hercules Term Loan”). The Hercules Term Loan had a variable interest rate that was the greater of either (i) 9.40% plus the prime rate as reported from time to time in The Wall Street Journal minus 7.25%, or (ii) 9.40%. As security for its obligations under the Hercules Term Loan, the Company granted a security interest in substantially all of its existing and after-acquired assets, excluding its intellectual property assets. <p style="text-align:justify;margin-top:12pt;margin-bottom:4pt;text-indent:4.54%;color:#auto;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 21, 2017, the Hercules Term Loan was paid in full and the Company was not required to pay the 1% prepayment charge due pursuant to the terms of the loan. A loss on extinguishment of $0.5 million from the payoff of the Hercules Term Loan was recognized in the condensed consolidated statement of operations and comprehensive loss during the three months ended March 31, 2017. <p style="text-align:justify;margin-top:12pt;margin-bottom:4pt;text-indent:4.54%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> In connection with the Hercules Term Loan, the Company issued unregistered warrants that entitle Hercules to purchase up to an aggregate of 9,063 unregistered shares of XOMA common stock at an exercise price equal to $66.20 per share. These warrants were exercisable immediately and have a five-year term expiring in February 2020. The warrants are classified in stockholders’ equity on the condensed consolidated balance sheets. As of March 31, 2018, all of these warrants were outstanding. <p style="text-align:justify;margin-top:18pt;margin-bottom:4pt;text-indent:0%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Interest Expense <p style="text-align:justify;margin-top:6pt;margin-bottom:4pt;text-indent:4.54%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of debt issuance costs and discounts are included in interest expense. Interest expense in the condensed consolidated statements of operations and comprehensive loss relates to the following debt instruments (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"> Novartis note</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"> Servier loan</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">177</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"> Hercules loan</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">311</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;"> Other</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;"> Total interest expense</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">170</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">609</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> </tr> </table></div>  </div>

<div> <p style="text-align:justify;margin-bottom:4pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">11. Stock-based Compensation <p style="text-align:justify;margin-top:6pt;margin-bottom:4pt;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.8%;">The Company grants qualified and non-qualified stock options, RSUs, common stock and other stock-based awards under various plans to directors, officers, employees and other individuals. Stock options are granted at exercise prices of not less than the fair market value of the Company’s common stock on the date of grant. Additionally, the Company has an Employee Stock Purchase Plan (“ESPP”) that allows employees to purchase Company shares at a purchase price equal to 85% of the lower of the fair market value of the Company’s common stock on the first trading day of the offering period or on the last day of the offering period. <p style="text-align:justify;margin-top:18pt;margin-bottom:4pt;text-indent:0%;font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock Options <p style="text-align:justify;margin-top:12pt;margin-bottom:4pt;text-indent:4.54%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options generally vest monthly over three to four years for employees and one year for directors. Stock options held by employees who qualify for retirement age (defined as employees that are a minimum of 55 years of age and the sum of their age plus years of full-time employment with the Company exceeds 70 years) vest on the earlier of scheduled vest date or the date of retirement. <p style="text-align:justify;margin-top:12pt;margin-bottom:4pt;text-indent:4.54%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of the stock options granted during the three months ended March 31, 2018 and 2017, was estimated based on the following weighted average assumptions:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"> Dividend yield</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> %</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> %</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"> Expected volatility</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> %</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> %</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"> Risk-free interest rate</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.72</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> %</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.95</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> %</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"> Expected term</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.6 years</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.6 years</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> </table></div>   <p style="text-align:justify;margin-bottom:4pt;margin-top:0pt;text-indent:4.54%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock option activity for the three months ended March 31, 2018, was as follows: <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.78%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">shares</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Per Share</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual Term <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate Intrinsic Value <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.78%;"> Outstanding at beginning of year</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,622,065</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.54</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.78%;"> Granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">133,000</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26.90</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.78%;"> Exercised</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(400</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33.80</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.78%; border-bottom:solid 0.75pt transparent;"> Forfeited, expired or cancelled</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(101,469</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54.24</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.78%; border-bottom:double 2.5pt transparent;"> Outstanding at end of period</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,653,196</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22.91</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.32</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,625</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.78%;"> Exercisable at end of period</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">915,442</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29.09</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.55</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,959</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> </table></div>   As of March 31, 2018, $6.7 million of total unrecognized compensation expense related to stock options is expected to be recognized over a weighted average period of 2.3 years. <p style="text-align:justify;margin-top:12pt;margin-bottom:4pt;text-indent:4.54%;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Performance-Based Stock Options <p style="text-align:justify;margin-top:12pt;margin-bottom:4pt;text-indent:4.54%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2018, the Company had 82,500 shares related to outstanding performance-based stock options with a grant date fair value of $0.4 million that will vest based on the achievement of corporate goals set by the Compensation Committee of the Company’s Board of Directors. Of this amount, options related to 41,250 shares were deemed probable of achievement as of March 31, 2018 and therefore, the related expense is being recognized over the service period. During the three months ended March 31, 2018, the Company recognized stock-based compensation expense of $56,000 related to these stock options. As of March 31, 2018, there was $0.4 million unrecognized compensation costs related to these outstanding performance-based stock options. <p style="text-align:justify;margin-top:12pt;margin-bottom:4pt;text-indent:4.54%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2017, the Company granted 130,000 stock options to executives with corporate performance-based vesting conditions. During the three months ended March 31, 2018, the Board of Directors approved a modification of 80,000 of these options from performance-based vesting to service-based vesting. The remaining 50,000 stock options were cancelled in conjunction with an executive’s termination. <p style="text-align:justify;margin-top:18pt;margin-bottom:4pt;text-indent:0%;font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Restricted Stock Units <p style="text-align:justify;margin-bottom:4pt;margin-top:0pt;text-indent:4.54%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs generally vest annually over three years for employees and one year for directors. RSUs held by employees who qualify for retirement age (defined as employees that are a minimum of 55 years of age and the sum of their age plus years of full-time employment with the Company exceeds 70 years) vest on the earlier of scheduled vest date or the date of retirement. The valuation of RSUs is determined at the date of grant using the closing stock price. <p style="text-align:justify;margin-top:12pt;margin-bottom:4pt;text-indent:4.54%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSU activity for the three months ended March 31, 2018, is summarized below:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.34%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">  </td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.34%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">  </td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average Grant-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.34%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%;white-space:nowrap;">  </td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date Fair Value</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.34%;"> Unvested balance at January 1, 2018</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,480</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%; border-top:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18.00</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.34%;"> Granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">  </td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.34%;"> Vested</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,360</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;white-space:nowrap;"> )</td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.08</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.34%; border-bottom:solid 0.75pt transparent;"> Forfeited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.8%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.34%; border-bottom:double 2.5pt transparent;"> Unvested balance at March 31, 2018</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,120</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.8%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30.86</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> </tr> </table></div>   <p style="text-align:justify;margin-top:6pt;margin-bottom:4pt;text-indent:0%;font-size:10pt;color:#auto;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2018, $24,000 of unrecognized compensation expense related to employee RSUs is expected to be recognized over a weighted average period of 0.6 years. <p style="text-align:justify;margin-top:12pt;margin-bottom:4pt;text-indent:0%;font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock-based Compensation Expense   <p style="text-align:justify;margin-bottom:4pt;margin-top:0pt;text-indent:4.54%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table shows total stock-based compensation expense for stock options, RSUs and ESPP in the condensed consolidated statements of operations and comprehensive loss (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.32%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"> Research and development</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">441</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;"> General and administrative</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,312</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">559</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr style="height:6.2pt;"> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;"> Total stock-based compensation expense</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,416</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,000</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> </tr> </table></div>  </div>

<div> <p style="text-align:justify;margin-top:12pt;margin-bottom:4pt;text-indent:0%;font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">13. Income Taxes <p style="text-align:justify;margin-top:6pt;margin-bottom:4pt;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.8%;">No provision was made for federal income tax, since the Company has incurred net operating losses during the three months ended March 31, 2018 and 2017, respectively. As of March 31, 2018 and December 31, 2017, the Company had a total of $4.5 million of net unrecognized tax benefits, none of which would affect the effective tax rate upon realization.  The Company does not expect its unrecognized tax benefits to change significantly over the next twelve months. <p style="text-align:justify;margin-top:6pt;margin-bottom:4pt;text-indent:4.8%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with SAB 118, the effects of the Tax Cuts and Jobs Act of 2017 (the “Tax Act”) may be adjusted within a one-year measurement period from the enactment date for items that were previously reported as provisional, or where a provisional estimate could not be made.  The income tax provision for the three months ended March 31, 2018 did not reflect any adjustment to the previously assessed Tax Act enactment effect. The Company will continue to assess forthcoming guidance and accounting interpretations on the effects of the Tax Act and expects to complete its analysis within the measurement period in accordance with the SEC guidance.  </div>

<div>   <p style="text-align:justify;margin-top:12pt;margin-bottom:4pt;text-indent:0%;font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">14. Subsequent Events <p style="text-align:justify;margin-top:6pt;margin-bottom:4pt;text-indent:0%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Rezolute <p style="text-align:justify;margin-top:6pt;margin-bottom:4pt;text-indent:4.8%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 2, 2018, Rezolute completed a closing on a convertible note financing for gross proceeds of $4.0 million, which triggered the Initial Closing defined under the amended common stock purchase agreement between the Company and Rezolute (see Note 4). As such, pursuant to the terms of the amended common stock purchase agreement with Rezolute, the Company received 8,023,758 shares of Rezolute’s common stock and cash of $0.5 million. In addition, in April 2018, the Company received from Rezolute the 69,252 shares of common stock and cash of $50,000 in connection with the Interim Financing Closing that occurred during the three months ended March 31, 2018 (see Note 4). <p style="text-align:justify;margin-top:6pt;margin-bottom:4pt;text-indent:0%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Sublease <p style="text-align:justify;margin-top:6pt;margin-bottom:4pt;text-indent:4.8%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 14, 2018, the Company entered into a non-cancellable sublease agreement for a portion of one of its three leased facilities. The term of the sublease agreement commenced on May 1, 2018. Under the term of the sublease agreement, the Company will receive $1.1 million over the term of the sublease, which ends at the same time as the original lease in April 2023. In addition, the sublease provides for a tenant improvement allowance of $65,000 to the subtenant. <p style="text-align:justify;margin-top:6pt;margin-bottom:4pt;text-indent:0%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Silicon Valley Bank Loan Agreement <p style="text-align:justify;margin-top:6pt;margin-bottom:4pt;text-indent:4.8%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 7, 2018 (the “Effective Date”), the Company executed a Loan and Security Agreement (the “Loan Agreement”) with Silicon Valley Bank (“SVB”). Under the Loan Agreement, upon the Company’s request, SVB may make advances (each, a “Term Loan Advance”) available to the Company up to $20.0 million (the “Term Loan”), subject to additional funding at the bank’s discretion. The Company may borrow advances under the Term Loan from the Effective Date until the earlier of March 31, 2019 (which will be extended to March 31, 2020, if the Company receives $20.0 million in gross cash proceeds from milestone/licensing payments by March 31, 2019) or an event of default (the “Draw Period”). The interest rate will be calculated at a rate equal to the greater of (i) 4.75%, and (ii) 0.25% plus the prime rate as reported from time to time in The Wall Street Journal. <p style="text-align:justify;margin-top:6pt;margin-bottom:4pt;text-indent:4.8%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payments under the Loan Agreement are interest only until the first anniversary of the funding date of each Term Loan Advance. The interest-only period will be followed by equal monthly payments of principal and interest over 24 months. Each Term Loan Advance will mature at the earlier of (i) the 23 months following the applicable term loan amortization date for each such Term Loan Advance (ii) March 1, 2023, or (iii) 30 days prior to the earliest maturity of any portion of the Company’s loan with Novartis (the “Loan Maturity Date”). After repayment, no Term Loan Advance (or any portion thereof) may be reborrowed. <p style="text-align:justify;margin-top:6pt;margin-bottom:4pt;text-indent:4.8%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The entire principal balance, including a final payment equal to 8.5% of the principal, will be due and payable on the Loan Maturity Date. If the Company prepays the Term Loan Advance prior to the Loan Maturity Date, it will pay SVB a prepayment premium, based on a prepayment fee equal to 3.00% of the amount prepaid, if the prepayment occurs on or before the first anniversary of the Effective Date, 2.00% of the amount prepaid, if the prepayment occurs after the first anniversary of the Effective Date but prior to the second anniversary of the Effective Date, and 1.00% of the amount prepaid if the prepayment occurs after the second anniversary of the Effective Date. Upon the occurrence of an event of default, a default interest rate of an additional 4% may be applied to the outstanding payments due to SVB, and SVB may declare all outstanding obligations immediately due and payable and take such other actions as set forth in the Loan Agreement. <p style="text-align:justify;margin-top:6pt;margin-bottom:4pt;text-indent:4.8%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Loan Agreement, the Company may be obligated to pay a fee equal to 1% of the unused portion of the Term Loan upon the earlier of (i) the termination of the Loan Agreement, or (ii) the Draw Period.   <p style="text-align:justify;margin-top:6pt;margin-bottom:4pt;text-indent:4.8%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s obligations under the Loan Agreement are secured by a security interest in substantially all of its assets, other than its intellectual property. The Loan Agreement includes customary affirmative and restrictive covenants, but does not include any financial maintenance covenants, and also includes standard events of default, including payment defaults. <p style="text-align:justify;margin-top:6pt;margin-bottom:4pt;text-indent:4.8%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Loan Agreement, the Company issued a warrant to SVB which is exercisable in whole or in part for up to an aggregate of 6,332 shares of common stock with an exercise price of $23.69 per share (the “Warrant”). The Warrant may be exercised on a cashless basis and is exercisable for a term beginning on the date of issuance and ending on the earlier to occur of 10 years from the date of issuance or the consummation of certain acquisitions of the Company as set forth in the Warrant. The number of shares for which the Warrant is exercisable and the associated exercise price are subject to certain proportional adjustments as set forth in the Warrant.</div>

<div> <p style="text-align:justify;margin-top:6pt;margin-bottom:4pt;text-indent:0%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Basis of Presentation <p style="text-align:justify;margin-top:6pt;margin-bottom:4pt;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions among consolidated entities were eliminated upon consolidation. The unaudited consolidated financial statements were prepared in accordance with generally accepted accounting principles (“GAAP”) in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. As permitted under those rules certain footnotes or other financial information can be condensed or omitted. These financial statements and related disclosures have been prepared with the assumption that users of the interim financial information have read or have access to the audited consolidated financial statements for the preceding fiscal year. Accordingly, these statements should be read in conjunction with the audited consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, filed with the U.S. Securities and Exchange Commission (“SEC”) on March 7, 2018. <p style="text-align:justify;margin-top:12pt;margin-bottom:4pt;text-indent:4.54%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These financial statements have been prepared on the same basis as the Company’s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments that are necessary for a fair statement of the Company’s consolidated financial information. The interim results of operations are not necessarily indicative of the results that may be expected for the full year. </div>

<div> <p style="text-align:justify;margin-top:18pt;margin-bottom:4pt;text-indent:0%;font-weight:bold;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Revenue Recognition <p style="text-align:justify;margin-top:6pt;margin-bottom:4pt;text-indent:4.54%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective January 1, 2018, the Company adopted Accounting Standards Codification Topic 606, Revenue from Contracts with Customers ("ASC 606") using the modified retrospective transition method and applied the standard only to contracts that are still active or in place at that date. Also, as permitted, the Company applied the practical expedient under ASC 606 which permits the Company to treat all contract modifications that occurred prior to the adoption in aggregate when determining the performance obligations, transaction price and its allocation. Except for the Company’s license agreement with Rezolute, Inc. (formerly AntriaBio, Inc.) (“Rezolute”), the Company did not have any other contracts with customers for which the Company had not completed its performance obligations as of the adoption date January 1, 2018. The license agreement with Rezolute was not considered a contract under ASC 606 as it is not probable that the Company will collect substantially all of the consideration to which it will be entitled in exchange for the goods or services that will be transferred to Rezolute and there was no consideration exchanged upon execution of the arrangement or as of January 1, 2018 (see Note 4). Thus, the Company determined that the adoption of ASC 606 did not have a financial impact on the Company's consolidated financial statements and related disclosures. In addition, the adoption of ASC 606 has no material impact for tax purposes. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments.  Under ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. <p style="text-align:justify;margin-top:6pt;margin-bottom:4pt;text-indent:4.54%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation.  The Company only applies the five-step model to contracts when it is probable that Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.  At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct.  The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation based on relative fair values, when (or as) the performance obligation is satisfied. <p style="text-align:justify;margin-top:6pt;margin-bottom:4pt;text-indent:4.54%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes revenue from its license and collaboration arrangements and royalties. The terms of the arrangements generally include payment to the Company of one or more of the following: non-refundable, upfront license fees, development, regulatory and commercial milestone payments, and royalties on net sales of licensed products. <p style="text-align:justify;margin-top:6pt;margin-bottom:4pt;text-indent:4.54%;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Licenses of intellectual property: If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, such as transfer of related materials, process and know-how, the Company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. Under the Company’s license agreements, the nature of the combined performance obligation is the granting of licenses to the customers as the other promises are not separately identifiable in the context of the arrangement. Since the Company grants the license to a customer as it exists at the point of transfer, and is not involved in any future development or commercialization of the products related to the license, the nature of the license is a right to use the Company’s intellectual property as transferred. As such, the Company recognizes revenue related to the combined performance obligation upon completion of the delivery of the related materials, process and know-how (i.e., at a point in time). <p style="text-align:justify;margin-top:6pt;margin-bottom:4pt;text-indent:4.54%;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Milestone payments: At the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. ASC 606 suggests two alternatives to use when estimating the amount of variable consideration: the expected value method and the most likely amount method. Under the expected value method, an entity considers the sum of probability-weighted amounts in a range of possible consideration amounts. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. The Company expects to use the most likely amount method for development and regulatory milestone payments. If it is probable that a significant cumulative revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability or achievement of each such milestone and any related constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and earnings in the period of adjustment. <p style="text-align:justify;margin-top:6pt;margin-bottom:4pt;text-indent:4.54%;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Royalties: For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). <p style="text-align:justify;margin-top:6pt;margin-bottom:4pt;text-indent:4.54%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upfront payments and fees are recorded as deferred revenue upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company’s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one year or less.</div>

<div> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Accrued and other liabilities consisted of the following (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.96%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.68%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.96%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.82%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.68%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.96%;"> Accrued payroll and other benefits</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-top:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-top:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">141</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.96%;"> Accrued restructuring</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.96%;"> Accrued incentive compensation</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">229</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.96%;"> Accrued legal and accounting fees</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">237</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">431</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.96%;"> Deferred rent</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">754</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">765</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.96%;"> Liability related to sublease</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">800</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.9%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.96%; border-bottom:solid 0.75pt transparent;"> Other</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">174</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">179</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.96%; border-bottom:double 2.5pt transparent;"> Total</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,338</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,675</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> </tr> </table></div>  </div>

<div> <p style="text-align:justify;margin-top:12pt;margin-bottom:4pt;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The following tables set forth the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as follows (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.78%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.82%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements at March 31, 2018 Using</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.78%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quoted Prices in <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Active Markets for <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identical Assets</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant Other <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Observable <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inputs</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unobservable <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inputs</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.44%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.78%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 1)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 2)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 3)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.44%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.44%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.44%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.44%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.78%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds (1)</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,021</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.44%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.44%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.44%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,021</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">  </td> </tr> </table></div>   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.52%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.44%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements at December 31, 2017 Using</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.52%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quoted Prices in <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Active Markets for <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identical Assets</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant Other <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Observable <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inputs</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unobservable <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inputs</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.52%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 1)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 2)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.78%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Level 3)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.56%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#auto;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.52%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds (1)</td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.4%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,907</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.36%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.28%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,907</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> </tr> </table></div>   <p style="margin-bottom:4pt;margin-top:0pt;margin-left:4.54%;text-indent:0.46%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)Included in cash and cash equivalents</div>

<div> <p style="text-align:justify;margin-top:6pt;margin-bottom:4pt;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Amortization of debt issuance costs and discounts are included in interest expense. Interest expense in the condensed consolidated statements of operations and comprehensive loss relates to the following debt instruments (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"> Novartis note</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"> Servier loan</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">177</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"> Hercules loan</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">311</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;"> Other</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;"> Total interest expense</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">170</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">609</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> </tr> </table></div>  </div>

<div> <p style="text-align:justify;margin-bottom:4pt;margin-top:0pt;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Stock option activity for the three months ended March 31, 2018, was as follows: <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.78%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">shares</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Per Share</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual Term <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%;">  </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate Intrinsic Value <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.78%;"> Outstanding at beginning of year</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,622,065</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.54</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.78%;"> Granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">133,000</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26.90</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.78%;"> Exercised</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(400</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33.80</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.78%; border-bottom:solid 0.75pt transparent;"> Forfeited, expired or cancelled</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(101,469</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> )</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54.24</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.78%; border-bottom:double 2.5pt transparent;"> Outstanding at end of period</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,653,196</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22.91</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.32</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">  </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,625</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">  </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.78%;"> Exercisable at end of period</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">915,442</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29.09</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.55</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> $</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,959</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> </tr> </table></div>  </div>

0.86

0.13

0.58

0.42

0.50

0.95

7000000

34900000

35000000

8600000

1600000

300000

1300000

83000

141000

130000 90000 229000

237000

431000

754000

765000

800000

174000

179000

1645000

653000

17000

381000

5003000

2446000

6665000

3480000

30000000 15700000

14300000

12000000

5000000

539131

9.2742

4800000 8.93 200000 438000000 10000000 2 P6M 2 40200000 25700000

40200000

P180D 37000000 10000000 470000000

232000000 1000000 237000000 6000000 12000000 20000000 7000000 P10D 15000000

5000000

Under the common stock purchase agreement, Rezolute granted the Company the right and option to sell the greater of (i) 5,000,000 shares of common stock or (ii) one third of the aggregate shares held by the Company upon failure by Rezolute to list its shares of its common stock on the Nasdaq Stock Market or a similar national exchange on or prior to December 31, 2018. 0.3333 P90D 5000000 7000000 7000000 8500000 7000000 8500000

69252

50000

64800000 P3Y

400000

800000

400000

800000

2 6500000 4000000 3000000 11500000

18000000

100000

700000

600000

17000000

17100000

35021000

34907000

14572000

13873000

14178000

4500000 23008 0.15 23008 4500000 3000000

1600000

3000000 1000000 200000 57 5 3594000

3447000

6911000

130000

2015-06-30

0.75 50000000

0.02

0.0381

2020-09-30

7300000

2022-09-30

14600000

2010-12-30 15000000 14300000

1.1932

-100000

The Hercules Term Loan had a variable interest rate that was the greater of either (i) 9.40% plus the prime rate as reported from time to time in The Wall Street Journal minus 7.25%, or (ii) 9.40%.

0.0940

0.0725 0.01

-500000

9063

66.20

P5Y 2020-02

139000

117000

177000

311000

31000

4000

2015-02 2016-02 2020-02 2021-02

66.20

15.40

9063

8249

17312

9063

8249

17312

15500000 2023-04 2

P5Y

1 3 2017-12-26 5100000 2023-04

800000

1000000

400000

0.85

P3Y

P4Y

P1Y

P55Y P70Y

0.00

1.01

1.00

0.0272

0.0195

P5Y7M6D

1622065

133000

400

101469

1653196

915442

24.54

26.90

33.80

54.24

22.91

29.09

P8Y3M25D

P7Y6M18D

16625000

9959000

6700000

P2Y3M18D

82500

41250

56000

400000

130000

80000

50000

P3Y

P1Y

P55Y P70Y

18480

13360

5120

18.00

13.08

30.86

24000

P7M6D

104000

441000

1312000

559000

1416000

1000000

1200000

5003

24800000

4.03

4030

1000

4.03

5003000

0.1999

0.180

Shares of Series X convertible preferred stock will generally have no voting rights, except as required by law and except that the consent of the holders of the outstanding Series X convertible preferred stock will be required to amend the terms of the Series X preferred stock and to approve certain corporate actions.

0.488

5600000 0.03

67658

110252

75000000

2400000

600000

100000 200000 2018-02

539131

9.2742

5000000

4800000 8.93

2017-08-24

200000

4500000

4000000

8023758

69252

500000

50000

1 3 2018-05-01 1100000 2023-04

65000

20000000 20000000 2019-03-31 2020-03-31

0.0475

0.0025

The interest-only period will be followed by equal monthly payments of principal and interest over 24 months. Each Term Loan Advance will mature at the earlier of (i) the 23 months following the applicable term loan amortization date for each such Term Loan Advance (ii) March 1, 2023, or (iii) 30 days prior to the earliest maturity of any portion of the Company’s loan with Novartis (the “Loan Maturity Date”). After repayment, no Term Loan Advance (or any portion thereof) may be reborrowed.

P24M P30D P30D

2023-03-01

0 0

0.085

0.0300 0.0200 0.0100 0.04

0.01

6332

23.69

P10Y The condensed consolidated balance sheet as of December 31, 2017 has been derived from the audited consolidated financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017. Included in cash and cash equivalents

EX-101.SCH 8 xoma-20180331.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 100010 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) link:calculationLink link:presentationLink link:definitionLink 100020 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100030 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited) link:calculationLink link:presentationLink link:definitionLink 100040 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) link:calculationLink link:presentationLink link:definitionLink 100050 - Disclosure - Description of Business link:calculationLink link:presentationLink link:definitionLink 100060 - Disclosure - Basis of Presentation and Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 100070 - Disclosure - Condensed Consolidated Financial Statements Detail link:calculationLink link:presentationLink link:definitionLink 100080 - Disclosure - Collaborative, Licensing and Other Arrangements link:calculationLink link:presentationLink link:definitionLink 100090 - Disclosure - Fair Value Measurements link:calculationLink link:presentationLink link:definitionLink 100100 - Disclosure - Dispositions link:calculationLink link:presentationLink link:definitionLink 100110 - Disclosure - Restructuring Charges link:calculationLink link:presentationLink link:definitionLink 100120 - Disclosure - Long-Term Debt link:calculationLink link:presentationLink link:definitionLink 100130 - Disclosure - Common Stock Warrants link:calculationLink link:presentationLink link:definitionLink 100140 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 100150 - Disclosure - Stock-based Compensation link:calculationLink link:presentationLink link:definitionLink 100160 - Disclosure - Capital Stock link:calculationLink link:presentationLink link:definitionLink 100170 - Disclosure - Income Taxes link:calculationLink link:presentationLink link:definitionLink 100180 - Disclosure - Subsequent Events link:calculationLink link:presentationLink link:definitionLink 100190 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 100200 - Disclosure - Condensed Consolidated Financial Statements Detail (Tables) link:calculationLink link:presentationLink link:definitionLink 100210 - Disclosure - Fair Value Measurements (Tables) link:calculationLink link:presentationLink link:definitionLink 100220 - Disclosure - Restructuring Charges (Tables) link:calculationLink link:presentationLink link:definitionLink 100230 - Disclosure - Long-Term Debt (Tables) link:calculationLink link:presentationLink link:definitionLink 100240 - Disclosure - Common Stock Warrants (Tables) link:calculationLink link:presentationLink link:definitionLink 100250 - Disclosure - Stock-based Compensation (Tables) link:calculationLink link:presentationLink link:definitionLink 100260 - Disclosure - Description of Business - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100270 - Disclosure - Basis of Presentation and Significant Accounting Policies - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100280 - Disclosure - Condensed Consolidated Financial Statements Detail - Additional Information 1 (Details) link:calculationLink link:presentationLink link:definitionLink 100290 - Disclosure - Condensed Consolidated Financial Statements Detail - Additional Information 2 (Details) link:calculationLink link:presentationLink link:definitionLink 100300 - Disclosure - Condensed Consolidated Financial Statements Detail - Accrued and Other Liabilities (Details) link:calculationLink link:presentationLink link:definitionLink 100310 - Disclosure - Condensed Consolidated Financial Statements Detail - Reconciliation of Numerator and Denominator Used in Calculation of Basic and Diluted Net Loss per Share Available to Common Stockholders (Details) link:calculationLink link:presentationLink link:definitionLink 100320 - Disclosure - Condensed Consolidated Financial Statements Detail - Outstanding Securities Considered Anti-Dilutive (Details) link:calculationLink link:presentationLink link:definitionLink 100330 - Disclosure - Licensing and Other Arrangements - Novartis - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100340 - Disclosure - Licensing and Other Arrangements - Rezolute - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100350 - Disclosure - Licensing and Other Arrangements - NIAID - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100360 - Disclosure - Licensing and Other Arrangements - Sale of Future Revenue Streams - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100370 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value on Recurring Basis (Details) link:calculationLink link:presentationLink link:definitionLink 100380 - Disclosure - Fair Value Measurements - Outstanding Long Term Debt Carrying Amount and Estimated Fair Value (Details) link:calculationLink link:presentationLink link:definitionLink 100390 - Disclosure - Dispositions - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100400 - Disclosure - Restructuring Charges - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100410 - Disclosure - Restructuring Charges - Components of Accrued Restructuring Costs (Details) link:calculationLink link:presentationLink link:definitionLink 100420 - Disclosure - Long-Term Debt - Novartis Note - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100430 - Disclosure - Long-Term Debt - Servier Loan Agreement - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100440 - Disclosure - Long-Term Debt - Hercules Term Loan - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100450 - Disclosure - Long-Term Debt - Interest Expense and Amortization of Debt Issuance Costs (Details) link:calculationLink link:presentationLink link:definitionLink 100460 - Disclosure - Common Stock Warrants - Summary of Common Stock Warrants Outstanding (Details) link:calculationLink link:presentationLink link:definitionLink 100470 - Disclosure - Commitments and Contingencies - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100480 - Disclosure - Stock-based Compensation - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100490 - Disclosure - Stock-based Compensation - Weighted Average Assumptions (Details) link:calculationLink link:presentationLink link:definitionLink 100500 - Disclosure - Stock-based Compensation - Stock Option Activity (Details) link:calculationLink link:presentationLink link:definitionLink 100510 - Disclosure - Stock-based Compensation - RSU Activity (Details) link:calculationLink link:presentationLink link:definitionLink 100520 - Disclosure - Stock-based Compensation - Stock-based Compensation Expense (Details) link:calculationLink link:presentationLink link:definitionLink 100530 - Disclosure - Capital Stock - Biotechnology Value Fund Financing - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100540 - Disclosure - Capital Stock - ATM Agreements - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100550 - Disclosure - Capital Stock - Common Stock Purchase Agreement - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100560 - Disclosure - Income Taxes - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100570 - Disclosure - Subsequent Events - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 9 xoma-20180331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 10 xoma-20180331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 11 xoma-20180331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Deemed dividends on convertible preferred stock. Document and Entity Information [Abstract] Document And Entity Information [Abstract] Entity Registrant Name Entity Registrant Name Trading Symbol Trading Symbol Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Carrying value as of the balance sheet date of obligations incurred and payable, and liabilities classified as other, due within one year or within the normal operating cycle if longer. Statement Of Financial Position [Abstract] ASSETS Assets [Abstract] Current assets: Assets Current [Abstract] Cash and cash equivalents Cash And Cash Equivalents At Carrying Value Trade and other receivables Receivables Net Current Prepaid expenses and other current assets Prepaid Expense And Other Assets Current Total current assets Assets Current Property and equipment, net Property Plant And Equipment Net Other assets Other Assets Noncurrent Total assets Assets LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities And Stockholders Equity [Abstract] Current liabilities: Liabilities Current [Abstract] Accounts payable Accounts Payable Current Accrued and other liabilities Accrued And Other Liabilities Current Income taxes payable Accrued Income Taxes Current Unearned revenue recognized under units-of-revenue method – current Deferred Revenue Current Contract liabilities Contract With Customer Liability Current Accrued interest on long-term debt – current Interest Payable Current Total current liabilities Liabilities Current Unearned revenue recognized under units-of-revenue method – non-current Deferred Revenue Noncurrent Long-term debt Long Term Debt Noncurrent Other liabilities – non-current Other Liabilities Noncurrent Total liabilities Liabilities Commitments and Contingencies (Note 10) Commitments And Contingencies Stockholders’ equity: Stockholders Equity [Abstract] Convertible preferred stock, $0.05 par value, 1,000,000 shares authorized, 5,003 shares issued and outstanding at March 31, 2018 and December 31, 2017 Preferred Stock Value Common stock, $0.0075 par value, 277,333,332 shares authorized, 8,332,118 and 8,249,158 shares issued and outstanding at March 31, 2018 and December 31, 2017, respectively Common Stock Value Additional paid-in capital Additional Paid In Capital Common Stock Accumulated deficit Retained Earnings Accumulated Deficit Total stockholders’ equity Stockholders Equity Total liabilities and stockholders’ equity Liabilities And Stockholders Equity Convertible preferred stock, par value (in dollars per share) Preferred Stock Par Or Stated Value Per Share Convertible preferred stock, shares authorized (in shares) Preferred Stock Shares Authorized Convertible preferred stock, shares issued (in shares) Preferred Stock Shares Issued Convertible preferred stock, shares outstanding (in shares) Preferred Stock Shares Outstanding Common stock, par value (in dollars per share) Common Stock Par Or Stated Value Per Share Common stock, shares authorized (in shares) Common Stock Shares Authorized Common stock, shares issued (in shares) Common Stock Shares Issued Common stock, shares outstanding (in shares) Common Stock Shares Outstanding Revenue recognize under units of revenue method. Net income loss available to common stockholders basic and diluted. Statement Of Income And Comprehensive Income [Abstract] Revenues: Revenues [Abstract] Revenue from contracts with customers Contracts Revenue Revenue recognized under units-of-revenue method Revenue Recognize Under Units Of Revenue Method Total revenues Revenues Operating expenses: Operating Expenses [Abstract] Research and development Research And Development Expense General and administrative General And Administrative Expense Restructuring Restructuring Charges Total operating expenses Operating Expenses Loss from operations Operating Income Loss Other income (expense): Nonoperating Income Expense [Abstract] Interest expense Interest Expense Debt Loss on extinguishment of debt Gains Losses On Extinguishment Of Debt Other income, net Other Nonoperating Income Net loss and comprehensive loss Net Income Loss Deemed dividend on convertible preferred stock Deemed Dividends On Convertible Preferred Stock Net loss and comprehensive loss available to common stockholders, basic and diluted Net Income Loss Available To Common Stockholders Basic And Diluted Basic and diluted net loss per share available to common stockholders Earnings Per Share Basic And Diluted Weighted average shares used in computing basic and diluted net loss per share available to common stockholders Weighted Average Number Of Share Outstanding Basic And Diluted Defined contribution plan issuance of Common stock for services or claims. The cash outflow for end-of-term fee paid to the lender. Prepaid financing cost related to issuance of common stock. Other receivables related to the sale of property and equipment. Statement Of Cash Flows [Abstract] Cash flows used in operating activities: Net Cash Provided By Used In Operating Activities Continuing Operations [Abstract] Net loss Adjustments to reconcile net loss to net cash used in operating activities: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Stock-based compensation expense Share Based Compensation Common stock contribution to 401(k) Defined Contribution Plan Issuance Of Common Stock For Services Or Claims Depreciation and amortization Depreciation And Amortization Amortization of debt issuance costs, debt discount and final payment on debt Amortization Of Financing Costs And Discounts Loss on extinguishment of debt Unrealized loss on foreign currency exchange Foreign Currency Transaction Gain Loss Unrealized Gain on sale of equipment Gain Loss On Sale Of Property Plant Equipment Other Other Noncash Income Expense Changes in assets and liabilities: Increase Decrease In Operating Capital [Abstract] Trade and other receivables Increase Decrease In Receivables Prepaid expenses and other current assets Increase Decrease In Prepaid Deferred Expense And Other Assets Accounts payable and accrued liabilities Increase Decrease In Accounts Payable And Accrued Liabilities Accrued interest on long-term debt Increase Decrease In Interest Payable Net Unearned revenue recognized under units-of-revenue method Increase Decrease In Deferred Revenue Income tax payable Increase Decrease In Accrued Income Taxes Payable Other liabilities Increase Decrease In Other Operating Liabilities Net cash used in operating activities Net Cash Provided By Used In Operating Activities Continuing Operations Cash flows from investing activities: Net Cash Provided By Used In Investing Activities Continuing Operations [Abstract] Proceeds from sale of property and equipment Proceeds From Sale Of Property Plant And Equipment Net cash provided by investing activities Net Cash Provided By Used In Investing Activities Continuing Operations Cash flows from financing activities: Net Cash Provided By Used In Financing Activities Continuing Operations [Abstract] Proceeds from issuance of convertible preferred stock, net of issuance costs Proceeds From Issuance Of Convertible Preferred Stock Proceeds from issuance of common stock, net of issuance costs Proceeds From Issuance Of Common Stock Proceeds from exercise of options Proceeds From Stock Options Exercised Principal payments – debt Repayments Of Long Term Debt Payment of final fee related to loan extinguishment End Of Term Fee Paid To Lender Principal payments – capital lease Repayments Of Long Term Capital Lease Obligations Taxes paid related to net share settlement of equity awards Payments Related To Tax Withholding For Share Based Compensation Net cash provided by financing activities Net Cash Provided By Used In Financing Activities Continuing Operations Effect of exchange rate changes on cash Effect Of Exchange Rate On Cash Continuing Operations Net decrease in cash and cash equivalents Cash And Cash Equivalents Period Increase Decrease Cash and cash equivalents at the beginning of the period Cash and cash equivalents at the end of the period Supplemental Cash Flow Information: Supplemental Cash Flow Information [Abstract] Cash paid for interest Interest Paid Non-cash investing and financing activities: Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract] Prepaid financing cost related to issuance of common stock Prepaid Financing Cost Related To Issuance Of Common Stock Other receivable related to sale of equipment Other Receivables Related To Sale Of Property And Equipment Description of business. Description Of Business [Abstract] Description of Business Nature Of Operations Accounting Policies [Abstract] Basis of Presentation and Significant Accounting Policies Basis Of Presentation And Significant Accounting Policies [Text Block] Condensed consolidated financial statements detail. Condensed Consolidated Financial Statements Detail [Abstract] Condensed Consolidated Financial Statements Detail Additional Financial Information Disclosure [Text Block] License and collaboration agreements. Collaborative, licensing and other arrangements. Collaborative Licensing And Other Arrangements [Abstract] Licensing and Other Arrangements License And Collaboration Agreements [Text Block] Fair Value Disclosures [Abstract] Fair Value Measurements Fair Value Disclosures [Text Block] Dispositions disclosure. Dispositions. Dispositions [Abstract] Dispositions Dispositions Disclosure [Text Block] Restructuring And Related Activities [Abstract] Restructuring Charges Restructuring And Related Activities Disclosure [Text Block] Debt Disclosure [Abstract] Long-Term Debt Long Term Debt [Text Block] Common stock warrant. Warrants And Rights Note Disclosure [Abstract] Common Stock Warrants Common Stock Warrant Disclosure [Text Block] Commitments And Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments And Contingencies Disclosure [Text Block] Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Stock-based Compensation Disclosure Of Compensation Related Costs Share Based Payments [Text Block] Stockholders Equity Note [Abstract] Capital Stock Stockholders Equity Note Disclosure [Text Block] Income Tax Disclosure [Abstract] Income Taxes Income Tax Disclosure [Text Block] Subsequent Events [Abstract] Subsequent Events Subsequent Events [Text Block] Liquidity and financial condition. Liquidity and Financial Condition Liquidity And Financial Condition Policy [Text Block] Basis of Presentation Basis Of Accounting Policy Policy [Text Block] Use of Estimates Use Of Estimates Revenue Recognition Revenue Recognition Policy [Text Block] Sale of Future Revenue Streams Revenue Recognition Deferred Revenue Stock-Based Compensation Compensation Related Costs Policy [Text Block] Net Loss per Share Available to Common Stockholders Earnings Per Share Policy [Text Block] Concentration of Risk Concentration Risk Credit Risk Recent Accounting Pronouncements New Accounting Pronouncements Policy Policy [Text Block] Fair Value Measurements Fair Value Measurement Policy Policy [Text Block] Accrued and Other Liabilities Schedule Of Accrued Liabilities Table [Text Block] Reconciliation of Numerator and Denominator Used in Calculation of Basic and Diluted Net Loss per Share Available to Common Stockholders Schedule Of Earnings Per Share Basic And Diluted Table [Text Block] Outstanding Securities Considered Anti-Dilutive Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block] Financial Assets and Liabilities Carried at Fair Value on Recurring Basis Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block] Outstanding Long Term Debt Carrying Amount and Estimated Fair Value Fair Value By Balance Sheet Grouping [Text Block] Components of Accrued Restructuring Costs Schedule Of Restructuring And Related Costs [Text Block] Tabular disclosure of aggregate amount of interest expense and the amortization of debt issuance costs on all borrowings. Interest Expense and Amortization of Debt Issuance Costs Interest Expense And Amortization Of Debt Issuance Costs Table [Text Block] Summary of Common Stock Warrants Outstanding Schedule Of Stockholders Equity Note Warrants Or Rights [Text Block] Weighted Average Assumptions Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block] Stock Option Activity Schedule Of Share Based Compensation Stock Options Activity Table [Text Block] RSU Activity Schedule Of Nonvested Restricted Stock Units Activity Table [Text Block] Stock-based Compensation Expense Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block] Basis of presentation and significant accounting policies. Basis of presentation and significant accounting policies. Basis Of Presentation And Significant Accounting Policies [Table] Basis Of Presentation And Significant Accounting Policies [Table] Concentration Risk Type Concentration Risk By Type [Axis] Concentration Risk Type Concentration Risk Type [Domain] Customer Concentration Risk [Member] Customer Concentration Risk [Member] Concentration Risk Benchmark Concentration Risk By Benchmark [Axis] Concentration Risk Benchmark Concentration Risk Benchmark [Domain] Revenues [Member] Sales Revenue Goods Net [Member] Receivable Type Accounts Notes Loans And Financing Receivable By Receivable Type [Axis] Receivable Receivable Type [Domain] Trade Receivables [Member] Trade Accounts Receivable [Member] Customer Major Customers [Axis] Customer Name Of Major Customer [Domain] Name or description of a single external partner 1 that accounts for 10 percent or more of the entity's revenues. Partner 1 [Member] Partner1 [Member] Name or description of a single external partner 2 that accounts for 10 percent or more of the entity's revenues. Partner 2 [Member] Partner2 [Member] Basis Of Presentation And Significant Accounting Policies [Line Items] Basis Of Presentation And Significant Accounting Policies [Line Items] Allocation of undistributed earnings to participating securities Undistributed Earnings Loss Allocated To Participating Securities Basic Contractual obligation Contractual Obligation Number of external partners that accounts for 10 percent or more of an entity's revenues during the period. Number of major partners Number Of Major Partners Concentration risk, percentage (in hundredths) Concentration Risk Percentage1 Consolidated financial statement detail. Consolidated Financial Statement Detail [Abstract] Schedule Of Cash And Cash Equivalents [Table] Schedule Of Cash And Cash Equivalents [Table] Cash and Cash Equivalents Cash And Cash Equivalents [Axis] Cash and Cash Equivalents Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member] Demand Deposits [Member] Demand Deposits [Member] Cash and Cash Equivalents [Line Items] Cash And Cash Equivalents [Line Items] Money market funds Money Market Funds At Carrying Value Proceeds from sale of property plant and equipment including other receivables. Property Plant And Equipment [Abstract] Schedule Of Property Plant And Equipment [Table] Schedule Of Property Plant And Equipment [Table] Income Statement Location Income Statement Location [Axis] Income Statement Location Income Statement Location [Domain] Other Income (Expense) [Member] Other Nonoperating Income Expense [Member] EX-101.PRE 12 xoma-20180331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 13 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2018	May 07, 2018
Document And Entity Information [Abstract]
Entity Registrant Name	XOMA Corp
Trading Symbol	XOMA
Entity Central Index Key	0000791908
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		8,367,118
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q1
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2018

XML 14 R2.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($)
$ in Thousands

Mar. 31, 2018

Dec. 31, 2017

Current assets:

Cash and cash equivalents

$ 41,968

$ 43,471

^[1]

Trade and other receivables

436

397

^[1]

Prepaid expenses and other current assets

273

327

^[1]

Total current assets

42,677

44,195

^[1]

Property and equipment, net

^[1]

Other assets

559

657

^[1]

Total assets

43,311

44,935

^[1]

Current liabilities:

Accounts payable

1,420

1,679

^[1]

Accrued and other liabilities

1,338

2,675

^[1]

Income taxes payable

1,666

1,637

^[1]

Unearned revenue recognized under units-of-revenue method – current

658

615

^[1]

Contract liabilities

798

^[1]

Accrued interest on long-term debt – current

^[1]

Total current liabilities

5,880

7,422

^[1]

Unearned revenue recognized under units-of-revenue method – non-current

17,019

17,123

^[1]

Long-term debt

14,572

^[1]

Other liabilities – non-current

203

^[1]

Total liabilities

37,674

39,149

^[1]

Commitments and Contingencies (Note 10)

^[1]

Stockholders’ equity:

Convertible preferred stock, $0.05 par value, 1,000,000 shares authorized, 5,003 shares issued and outstanding at March 31, 2018 and December 31, 2017

^[1]

Common stock, $0.0075 par value, 277,333,332 shares authorized, 8,332,118 and 8,249,158 shares issued and outstanding at March 31, 2018 and December 31, 2017, respectively

^[1]

Additional paid-in capital

1,188,440

1,184,783

^[1]

Accumulated deficit

(1,182,865)

(1,179,059)

^[1]

Total stockholders’ equity

5,637

5,786

^[1]

Total liabilities and stockholders’ equity

$ 43,311

$ 44,935

^[1]

[1]	The condensed consolidated balance sheet as of December 31, 2017 has been derived from the audited consolidated financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017.

XML 15 R3.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical) - $ / shares	Mar. 31, 2018	Dec. 31, 2017
Statement Of Financial Position [Abstract]
Convertible preferred stock, par value (in dollars per share)	$ 0.05	$ 0.05
Convertible preferred stock, shares authorized (in shares)	1,000,000	1,000,000
Convertible preferred stock, shares issued (in shares)	5,003	5,003
Convertible preferred stock, shares outstanding (in shares)	5,003	5,003
Common stock, par value (in dollars per share)	$ 0.0075	$ 0.0075
Common stock, shares authorized (in shares)	277,333,332	277,333,332
Common stock, shares issued (in shares)	8,332,118	8,249,158
Common stock, shares outstanding (in shares)	8,332,118	8,249,158

XML 16 R4.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Revenues:
Revenue from contracts with customers	$ 401	$ 150
Revenue recognized under units-of-revenue method	62	110
Total revenues	463	260
Operating expenses:
Research and development	432	3,993
General and administrative	5,168	5,167
Restructuring		2,020
Total operating expenses	5,600	11,180
Loss from operations	(5,137)	(10,920)
Other income (expense):
Interest expense	(170)	(609)
Loss on extinguishment of debt		(515)
Other income, net	1,501	1,329
Net loss and comprehensive loss	(3,806)	(10,715)
Deemed dividend on convertible preferred stock		(5,603)
Net loss and comprehensive loss available to common stockholders, basic and diluted	$ (3,806)	$ (16,318)
Basic and diluted net loss per share available to common stockholders	$ (0.46)	$ (2.37)
Weighted average shares used in computing basic and diluted net loss per share available to common stockholders	8,313	6,887

XML 17 R5.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($)
$ in Thousands

3 Months Ended

Mar. 31, 2018

Mar. 31, 2017

Cash flows used in operating activities:

Net loss

$ (3,806)

$ (10,715)

Adjustments to reconcile net loss to net cash used in operating activities:

Stock-based compensation expense

1,416

1,000

Common stock contribution to 401(k)

506

Depreciation and amortization

147

Amortization of debt issuance costs, debt discount and final payment on debt

286

Loss on extinguishment of debt

515

Unrealized loss on foreign currency exchange

261

Gain on sale of equipment

(1,314)

Other

(21)

Changes in assets and liabilities:

Trade and other receivables

(39)

Prepaid expenses and other current assets

345

Accounts payable and accrued liabilities

(1,593)

(5,281)

Accrued interest on long-term debt

138

(76)

Unearned revenue recognized under units-of-revenue method

(62)

(110)

Income tax payable

Other liabilities

Net cash used in operating activities

(3,839)

(14,348)

Cash flows from investing activities:

Proceeds from sale of property and equipment

813

Net cash provided by investing activities

813

Cash flows from financing activities:

Proceeds from issuance of convertible preferred stock, net of issuance costs

20,072

Proceeds from issuance of common stock, net of issuance costs

2,309

5,380

Proceeds from exercise of options

Principal payments – debt

(16,380)

Payment of final fee related to loan extinguishment

(1,150)

Principal payments – capital lease

(4)

(51)

(3)

Net cash provided by financing activities

2,316

7,871

Effect of exchange rate changes on cash

(33)

Net decrease in cash and cash equivalents

(1,503)

(5,697)

Cash and cash equivalents at the beginning of the period

43,471

^[1]

25,742

Cash and cash equivalents at the end of the period

41,968

20,045

Supplemental Cash Flow Information:

Cash paid for interest

396

Non-cash investing and financing activities:

Prepaid financing cost related to issuance of common stock

$ 100

Other receivable related to sale of equipment

$ 811

[1]	The condensed consolidated balance sheet as of December 31, 2017 has been derived from the audited consolidated financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017.

XML 18 R6.htm IDEA: XBRL DOCUMENT

Description of Business	3 Months Ended
Description of Business	Mar. 31, 2018
Description Of Business [Abstract]
Description of Business	1. Description of Business XOMA Corporation (referred to as “XOMA” or the “Company”), a Delaware corporation, has a long history of discovering and developing innovative therapeutics derived from its unique platform of antibody technologies. Over the Company’s 37-year history, it built an extensive portfolio of fully-funded programs by advancing product candidates into the earlier stages of development and then licensing them to licensees who assumed the responsibilities of later stage development, approval and commercialization. Fully-funded programs are those for which the Company’s partners pay all of the development and commercialization costs. As licensees advance these programs, the Company is eligible for potential milestone and royalty payments. As part of the Company’s royalty aggregator business model, the Company intends to expand its portfolio of fully-funded programs by acquiring potential milestone and royalty revenue streams on additional product candidates. Liquidity and Financial Condition With the exception of the year ended December 31, 2017, the Company has typically incurred significant operating losses and negative cash flows from operations since its inception. As of March 31, 2018, the Company had cash and cash equivalents of $42.0 million. The Company has evaluated and concluded there are no conditions or events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern for a period of one year following the date that these financial statements are issued.

XML 19 R7.htm IDEA: XBRL DOCUMENT

Basis of Presentation and Significant Accounting Policies	3 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies	2. Basis of Presentation and Significant Accounting Policies Basis of Presentation The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions among consolidated entities were eliminated upon consolidation. The unaudited consolidated financial statements were prepared in accordance with generally accepted accounting principles (“GAAP”) in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. As permitted under those rules certain footnotes or other financial information can be condensed or omitted. These financial statements and related disclosures have been prepared with the assumption that users of the interim financial information have read or have access to the audited consolidated financial statements for the preceding fiscal year. Accordingly, these statements should be read in conjunction with the audited consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, filed with the U.S. Securities and Exchange Commission (“SEC”) on March 7, 2018. These financial statements have been prepared on the same basis as the Company’s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments that are necessary for a fair statement of the Company’s consolidated financial information. The interim results of operations are not necessarily indicative of the results that may be expected for the full year. Use of Estimates The preparation of financial statements in conformity with GAAP in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to, those related to revenue recognition, debt amendments, long-lived assets, restructuring liabilities, legal contingencies, and stock-based compensation. The Company bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ significantly from these estimates, such as the Company’s billing under government contracts. Under the Company’s contracts with the National Institute of Allergy and Infectious Diseases (“NIAID”), a part of the National Institutes of Health (“NIH”), the Company billed using NIH’s provisional rates and thus is subject to future audits at the discretion of NIAID’s contracting office. These audits can result in an adjustment to revenue previously reported which potentially could be significant. Revenue Recognition Effective January 1, 2018, the Company adopted Accounting Standards Codification Topic 606, Revenue from Contracts with Customers ("ASC 606") using the modified retrospective transition method and applied the standard only to contracts that are still active or in place at that date. Also, as permitted, the Company applied the practical expedient under ASC 606 which permits the Company to treat all contract modifications that occurred prior to the adoption in aggregate when determining the performance obligations, transaction price and its allocation. Except for the Company’s license agreement with Rezolute, Inc. (formerly AntriaBio, Inc.) (“Rezolute”), the Company did not have any other contracts with customers for which the Company had not completed its performance obligations as of the adoption date January 1, 2018. The license agreement with Rezolute was not considered a contract under ASC 606 as it is not probable that the Company will collect substantially all of the consideration to which it will be entitled in exchange for the goods or services that will be transferred to Rezolute and there was no consideration exchanged upon execution of the arrangement or as of January 1, 2018 (see Note 4). Thus, the Company determined that the adoption of ASC 606 did not have a financial impact on the Company's consolidated financial statements and related disclosures. In addition, the adoption of ASC 606 has no material impact for tax purposes. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation based on relative fair values, when (or as) the performance obligation is satisfied. The Company recognizes revenue from its license and collaboration arrangements and royalties. The terms of the arrangements generally include payment to the Company of one or more of the following: non-refundable, upfront license fees, development, regulatory and commercial milestone payments, and royalties on net sales of licensed products. Licenses of intellectual property: If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, such as transfer of related materials, process and know-how, the Company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. Under the Company’s license agreements, the nature of the combined performance obligation is the granting of licenses to the customers as the other promises are not separately identifiable in the context of the arrangement. Since the Company grants the license to a customer as it exists at the point of transfer, and is not involved in any future development or commercialization of the products related to the license, the nature of the license is a right to use the Company’s intellectual property as transferred. As such, the Company recognizes revenue related to the combined performance obligation upon completion of the delivery of the related materials, process and know-how (i.e., at a point in time). Milestone payments: At the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. ASC 606 suggests two alternatives to use when estimating the amount of variable consideration: the expected value method and the most likely amount method. Under the expected value method, an entity considers the sum of probability-weighted amounts in a range of possible consideration amounts. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. The Company expects to use the most likely amount method for development and regulatory milestone payments. If it is probable that a significant cumulative revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability or achievement of each such milestone and any related constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and earnings in the period of adjustment. Royalties: For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Upfront payments and fees are recorded as deferred revenue upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company’s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one year or less. Sale of Future Revenue Streams The Company has sold its rights to receive certain milestones and royalties on product sales. In the circumstance where the Company has sold its rights to future milestones and royalties under a license agreement and also maintains limited continuing involvement in the arrangement (but not significant continuing involvement in the generation of the cash flows that are due to the purchaser), the Company defers recognition of the proceeds it receives for the sale of milestone or royalty streams and recognizes such unearned revenue as revenue under units-of-revenue method over the life of the underlying license agreement.. Under the units-of-revenue method, amortization for a reporting period is calculated by computing a ratio of the proceeds received from the purchaser to the total payments expected to be made to the purchaser over the term of the agreement, and then applying that ratio to the period’s cash payment. Estimating the total payments expected to be received by the purchaser over the term of such arrangements requires management to use subjective estimates and assumptions. Changes to the Company’s estimate of the payments expected to be made to the purchaser over the term of such arrangements could have a material effect on the amount of revenues recognized in any particular period. Stock-Based Compensation The Company recognizes compensation expense for all stock-based payment awards made to the Company’s employees, consultants and directors that are expected to vest based on estimated fair values. The valuation of stock option awards is determined at the date of grant using the Black-Scholes Option Pricing Model (the “Black-Scholes Model”). The Black-Scholes Model requires inputs such as the expected term of the option, expected volatility and risk-free interest rate. To establish an estimate of expected term, the Company considers the vesting period and contractual period of the award and its historical experience of stock option exercises, post-vesting cancellations and volatility. The estimate of expected volatility is based on the Company’s historical volatility. The risk-free rate is based on the yield available on United States Treasury zero-coupon issues corresponding to the expected term of the award. The Company records forfeitures when they occur. The Company records compensation expense for service-based awards over the vesting period of the award on a straight-line basis. For awards with performance-based conditions, the Company records the expense over the remaining service period when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based condition is probable based on the expected satisfaction of the performance conditions as of the reporting date. The amount of stock-based compensation expense recognized during a period is based on the value of the portion of the awards that are ultimately expected to vest. The valuation of restricted stock units (“RSUs”) is determined at the date of grant using the Company’s closing stock price. Net Loss per Share Available to Common Stockholders Basic net loss per share available to common stockholders is based on the weighted average number of shares of common stock outstanding during the period. Net loss available to common stockholders consists of net loss, as adjusted for the convertible preferred stock deemed dividends related to the beneficial conversion feature on this instrument at issuance. For the three months ended March 31, 2017, the convertible preferred stock had a deemed dividend which represented the accretion of a beneficial conversion feature. As such, the net loss for the three months ended March 31, 2017 was adjusted for the convertible preferred stock deemed dividend related to the beneficial conversion feature on these shares at issuance. During periods of loss, the Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company. Diluted net loss per share available to common stockholders is based on the weighted average number of shares outstanding during the period, adjusted to include the assumed conversion of preferred stock, and the exercise of certain stock options, RSUs, and warrants for common stock. The calculation of diluted loss per share available to common stockholders requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of any outstanding options, RSUs or warrants and the presumed exercise of such securities are dilutive to earnings (loss) per share available to common stockholders for the period. Adjustments to the denominator are required to reflect the related dilutive shares. Concentration of Risk Cash equivalents and receivables are financial instruments which potentially subject the Company to concentrations of credit risk, as well as liquidity risk for certain cash equivalents, such as money market funds. The Company has not encountered any such liquidity issues during 2018. The Company has not experienced any significant credit losses and does not generally require collateral on receivables. For the three months ended March 31, 2018, two partners represented 86% and 13% of total revenues, respectively. For the three months ended March 31, 2017, two partners represented 58% and 42% of total revenues, respectively. As of March 31, 2018, two partners represented 50% of the trade receivables balance, respectively. As of December 31, 2017, one partner represented 95% of the trade receivables balance. Recent Accounting Pronouncements In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-02, Leases (Topic 842). ASU 2016-2 is aimed at making leasing activities more transparent and comparable, and requires substantially all leases be recognized by lessees on their balance sheet as a right-of-use asset and corresponding lease liability, including leases currently accounted for as operating leases. ASU 2016-2 is effective for the Company’s interim and annual reporting periods during the year ending December 31, 2019, and all annual and interim reporting periods thereafter. Early adoption is permitted. The Company is evaluating the impact of the adoption of the standard on its consolidated financial statements.

XML 20 R8.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Financial Statements Detail

3 Months Ended

Mar. 31, 2018

Condensed Consolidated Financial Statements Detail [Abstract]

Condensed Consolidated Financial Statements Detail

3. Condensed Consolidated Financial Statements Detail

Cash and Cash Equivalents

Property and Equipment, net

Accrued and Other Liabilities

Accrued and other liabilities consisted of the following (in thousands):

	March 31,		December 31,
	2018		2017
Accrued payroll and other benefits	$	83	$	141
Accrued restructuring		—		130
Accrued incentive compensation		90		229
Accrued legal and accounting fees		237		431
Deferred rent		754		765
Liability related to sublease		—		800
Other		174		179
Total	$	1,338	$	2,675

Net Loss Per Share Available to Common Stockholders

	Three Months Ended March 31,
	2018			2017
Numerator
Net loss	$	(3,806	)	$	(10,715	)
Less: Deemed dividend on convertible preferred stock		—			(5,603	)
Net loss available to common stockholders, basic and diluted	$	(3,806	)	$	(16,318	)

Denominator
Weighted average shares outstanding used for basic and diluted net loss per share available to common stockholders		8,313			6,887

	Three Months Ended March 31,
	2018		2017
Common stock options and RSUs		1,645		653
Warrants for common stock		17		381
Convertible preferred stock		5,003		2,446
Total		6,665		3,480

XML 21 R9.htm IDEA: XBRL DOCUMENT

Collaborative, Licensing and Other Arrangements	3 Months Ended
Collaborative, Licensing and Other Arrangements	Mar. 31, 2018
Collaborative Licensing And Other Arrangements [Abstract]
Licensing and Other Arrangements	4. Licensing and Other Arrangements Novartis – Gevokizumab and IL-1 Beta On August 24, 2017, the Company and Novartis Pharma AG (“Novartis”) entered into a license agreement (the “XOMA-052 License Agreement”) under which the Company granted to Novartis an exclusive, worldwide, royalty-bearing license to gevokizumab, a novel anti-Interleukin-1 (“IL-1”) beta allosteric monoclonal antibody (the “Antibody”) and related know-how and patents (altogether, the “XOMA IP”). Under the terms of the XOMA-052 License Agreement, Novartis will be solely responsible for the development and commercialization of the Antibody and products containing the Antibody. On August 24, 2017, pursuant to a separate agreement (the “IL-1 Target License Agreement”), the Company granted to Novartis non-exclusive licenses to its intellectual property covering the use of IL-1 beta targeting antibodies in the treatment and prevention of cardiovascular disease and other diseases and conditions, and an option to obtain an exclusive license (the “Exclusivity Option”) to such intellectual property for the treatment and prevention of cardiovascular disease. Under the XOMA-052 License Agreement, the Company received total consideration of $30.0 million for the license and rights granted to Novartis. Of the total consideration, $15.7 million was paid in cash and $14.3 million (equal to €12.0 million) was paid by Novartis Institutes for BioMedical Research, Inc. (“NIBR”), on behalf of the Company, to settle the Company’s outstanding debt with Les Laboratories Servier (“Servier”) (the “Servier Loan”). In addition, NIBR extended the maturity date on the Company’s debt to Novartis. The Company also received $5.0 million cash related to the sale of 539,131 shares of the Company’s common stock, at a purchase price of $9.2742 per share. The fair market value of the common stock issued to Novartis was $4.8 million, based on the closing stock price of $8.93 per share on August 24, 2017, resulting in a $0.2 million premium paid to the Company. Based on the achievement of pre-specified criteria, the Company is eligible to receive up to $438.0 million in development, regulatory and commercial milestones under the XOMA-052 License Agreement. The Company is also eligible to receive royalties on sales of licensed products, which are tiered based on sales levels and range from the high single digits to mid-teens. Under the IL-1 Target License Agreement, the Company received an upfront cash payment of $10.0 million and is eligible to receive low single-digit royalties on canakinumab sales in cardiovascular indications covered by the Company’s patents. Should Novartis exercise the Exclusivity Option, the royalties on canakinumab sales will increase to the mid-single digits. Unless terminated earlier, the XOMA-052 License Agreement and IL-1 Target License Agreement will remain in effect, on a country-by-country and product-by-product basis, until Novartis’ royalty obligations end. The two agreements contain customary termination rights relating to material breach by either party. Novartis also has a unilateral right to terminate the XOMA-052 License Agreement on a product-by-product and country-by-country basis or in its entirety on six months’ prior written notice to the Company. Under the IL-1 Target License Agreement, Novartis has a unilateral right to terminate the agreement on a product-by-product and country-by-country basis or in its entirety upon a prior written notice. The XOMA-052 License Agreement and IL-1 Target License Agreement were accounted for as one arrangement because they were entered into at the same time in contemplation of each other. The Company concluded that there are multiple promised goods and services under the combined arrangement, including the transfer of license to IL-1 beta targeting antibodies, and the transfer of license, know-how, process, materials and inventory related the gevokizumab antibody, which were determined to represent two distinct performance obligations. The Company determined that the Exclusivity Option is not an option with material right because the upfront payments to the Company were not negotiated to provide an incremental discount for the future additional royalties upon exercise of the Exclusivity Option. Therefore, the Company concluded that the Exclusivity Option is not a performance obligation. The additional royalties will be recognized as revenue when, and if, Novartis exercises its option because the Company has no further performance obligations at that point. At the inception of the arrangement, the Company determined that the transaction price under the arrangement was $40.2 million, which consisted of the $25.7 million upfront cash payments, the $14.3 million Servier Loan payoff and the $0.2 million premium on the sale of the common stock. The transaction price was allocated to the two performance obligations based on their standalone selling prices. The Company determined that the nature of the two performance obligations is the right to use the licenses as they exist at the point of transfer, which occurred when the transfer of materials, process and know-how, and filings to regulatory authority were completed. During the year ended December 31, 2017, the Company recognized the entire transaction price of $40.2 million as revenue upon completion of the delivery of the licenses and related materials, process and know-how and filings to regulatory authority. The Company concluded that the development and regulatory milestone payments are solely dependent on Novartis’ performance and achievement of specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the development and regulatory milestones are fully constrained and excluded from the transaction price as of March 31, 2018. Any consideration related to commercial milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the licenses granted to Novartis and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly. As of March 31, 2018, and December 31, 2017, there are no contract assets or contract liabilities related to this arrangement. In addition, the Company did not recognize any revenue related to this arrangement during the three months ended March 31, 2018. None of the costs to obtain or fulfill the contract were capitalized. Novartis International – Anti-TGFβ Antibody On September 30, 2015, the Company and Novartis International Pharmaceutical Ltd. (“Novartis International”) entered into a license agreement (the “License Agreement”) under which the Company granted Novartis International an exclusive, world-wide, royalty-bearing license to the Company’s anti-transforming growth factor beta (TGFβ) antibody program (now “NIS793”). Under the terms of the License Agreement, Novartis International has worldwide rights to NIS793 and is responsible for the development and commercialization of antibodies and products containing antibodies arising from NIS793. Unless terminated earlier, the License Agreement will remain in effect, on a country-by-country and product-by-product basis, until Novartis International’s royalty obligations end. The License Agreement contains customary termination rights relating to material breach by either party. Novartis International also has a unilateral right to terminate the License Agreement on an antibody-by-antibody and country-by-country basis or in its entirety on one hundred eighty days’ notice. The Company concluded that there are multiple promised goods and services under the License Agreement, including the transfer of license, regulatory services and transfer of materials, process and know-how, which were determined to represent one combined performance obligation. The Company recognized the entire upfront payment of $37.0 million as revenue in the consolidated statement of comprehensive loss in 2015 as it had completed its performance obligations as of December 31, 2015. During the three months ended June 30, 2017, Novartis International achieved a clinical development milestone pursuant to the License Agreement and, as a result, the Company earned a $10.0 million milestone payment which was recognized as license fees in the consolidated statement of comprehensive income. As of March 31, 2018, the Company is eligible to receive up to a total of $470.0 million in development, regulatory and commercial milestones. The Company concluded that the development and regulatory milestone payments are solely dependent on Novartis’ performance and achievement of the specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the development and regulatory milestones are fully constrained and excluded from the transaction price as of March 31, 2018. Any consideration related to commercial milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the licenses granted to Novartis and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly. The Company is also eligible to receive royalties on sales of licensed products, which are tiered based on sales levels and range from a mid-single digit percentage rate to up to a low double-digit percentage rate. Novartis International’s obligation to pay royalties with respect to a particular product and country will continue for the longer of the date of expiration of the last valid patent claim covering the product in that country, or ten years from the date of the first commercial sale of the product in that country. As of March 31, 2018, and December 31, 2017, there are no contract assets or contract liabilities related to this arrangement. In addition, the Company did not recognize any revenue related to this arrangement during the three months ended March 31, 2018. None of the costs to obtain or fulfill the contract were capitalized. Rezolute On December 6, 2017, the Company entered into a license agreement with Rezolute pursuant to which the Company granted an exclusive global license to Rezolute to develop and commercialize X358 (now “RZ358”) for all indications. The Company and Rezolute also entered into a common stock purchase agreement pursuant to which Rezolute agreed to issue to the Company, as consideration for receiving the license for RZ358, a certain number of its common stock related to its future financing activities. Under the terms of the license agreement, Rezolute is responsible for all development, regulatory, manufacturing and commercialization activities associated with RZ358 and is required to make certain development, regulatory and commercial milestone payments to the Company of up to $232.0 million in the aggregate based on the achievement of pre-specified criteria. Under the license agreement, the Company is also eligible to receive royalties ranging from the high single digits to the mid-teens based upon annual net sales of any commercial product incorporating RZ358. Rezolute is obligated to take customary steps to advance RZ358, including using diligent efforts to commence the next clinical study for RZ358 by a certain deadline and to meet certain spending requirements on an annual basis for the program until a marketing approval application for RZ358 is accepted by the Food and Drug Administration. Rezolute’s obligation to pay royalties with respect to a particular RZ358 product and country will continue for the longer of the date of expiration of the last valid patent claim covering the product in that country, or twelve years from the date of the first commercial sale of the product in that country. Rezolute has an option through June 1, 2019 to obtain an exclusive license for their choice of one of the Company’s preclinical monoclonal antibody fragments, including X129, in exchange for a $1.0 million upfront option fee and additional clinical, regulatory and commercial milestone payments to the Company of up to $237.0 million in the aggregate based on the achievement of pre-specified criteria as well as royalties ranging from the high single digits to the mid-teens based on annual net sales. Pursuant to the license agreement and common stock purchase agreement, the Company is eligible to receive $6.0 million in cash and $12.0 million of Rezolute’s common stock contingent on the completion of Rezolute’s financing activities. Further, in the event that Rezolute does not complete a financing that raises at least $20.0 million in aggregate gross proceeds (“Qualified Financing”) by March 31, 2019 (the “2019 Closing”), the Company will receive an additional number of shares of Rezolute’s common stock equal to $7.0 million divided by the weighted average of the closing bid and ask prices or the average closing prices of Rezolute’s common stock on the ten-day trading period prior to March 31, 2019. Finally, in the event that Rezolute is unable to complete a Qualified Financing by March 31, 2020, the Company is eligible to receive $15.0 million in cash in order to maintain the license. Under the common stock purchase agreement, Rezolute granted the Company the right and option to sell the greater of (i) 5,000,000 shares of common stock or (ii) one third of the aggregate shares held by the Company upon failure by Rezolute to list its shares of its common stock on the Nasdaq Stock Market or a similar national exchange on or prior to December 31, 2018. In addition, under the terms of the license agreement, the Company is eligible to receive a low single digit royalty on sales of Rezolute’s other products from its current programs. Rezolute’s obligation to pay royalties with respect to a particular Rezolute product and country will continue for the longer of twelve years from the date of the first commercial sale of the product in that country or for so long as Rezolute or its licensee is selling such product in such country, provided that such royalty will terminate upon the termination of the licensee’s obligation to make payments to Rezolute based on sales of such product in such country. The license agreement contains customary termination rights relating to material breach by either party. Rezolute also has a unilateral right to terminate the license agreement in its entirety on ninety days’ notice at any time. The Company has the right to terminate the license agreement if Rezolute challenges the licensed patents. On March 30, 2018, the Company and Rezolute amended the license agreement and common stock purchase agreement. The license agreement was amended to add terms specifying the financial responsibility for certain tasks related to the technology transfer. The common stock purchase agreement was amended as follows: (1) adjusted the total shares due upon the Initial Closing (as defined in the common stock purchase agreement) from $5.0 million in value to 7,000,000 shares; (2) increase the shares due upon a Qualified Financing from $7.0 million in value to $8.5 million in value; and (3) increase the shares due upon the 2019 Closing from $7.0 million in value to $8.5 million in value. All other terms of the license agreement and common stock purchase agreement remain unchanged. Under the license agreement and common stock purchase agreement, no consideration was exchanged upon execution of the arrangement. In consideration for receiving the license for RZ358, Rezolute agreed to issue shares of its common stock and pay cash to the Company upon the occurrence of Rezolute’s financing activities and the amounts to be paid will be based on the timing of those activities. Upon execution of the arrangement, the Company determined that it is not probable that the Company will collect substantially all of the consideration to which it will be entitled in exchange for the goods or services that will be transferred to Rezolute. Therefore, the Company determined that there is no contract on December 6, 2017 under ASC 606. During the three months ended March 31, 2018, Rezolute completed an Interim Financing Closing as defined in the common stock purchase agreement resulting in consideration due to XOMA consisting of 69,252 shares of Rezolute’s common stock and cash of $50,000. In addition, during the three months ended March 31, 2018, the Company completed the delivery of the license and related materials, product data/filing, process and know-how to Rezolute. However, the Company determined that the achievement of the Interim Financing Closing and related consideration as well as the amendment in March 2018 were not substantive to overcome the collectability criterion required to establish a contract under ASC 606. Thus, there is no contract as of March 31, 2018 and no revenue was recognized during the three months ended March 31, 2018 under the arrangement. (See Note 14). NIAID Prior to the sale of the Company’s biodefense business discussed in Note 6, the Company performed services under a $64.8 million multiple-year contract funded with federal funds from NIAID (Contract No. HHSN272200800028C), for development of anti-botulinum antibody product candidates. The contract work was being performed on a cost plus fixed fee basis over a three-year period. The Company recognized revenue under the arrangement as the services were performed on a proportional performance basis. Consistent with the Company’s other contracts with the U.S. government, invoices were provisional until finalized. The Company operated under provisional rates from 2010 through 2014, subject to adjustment based on actual rates upon agreement with the government. In 2014, upon completion of NIAID’s review of hours and external expenses, XOMA agreed to exclude certain hours and external expenses resulting in a $0.4 million receivable and $0.8 million deferred revenue balances. As of December 31, 2017, the Company wrote off the $0.4 million receivable from NIAID as the likelihood of collection is remote. The Company classified $0.8 million as contract liabilities on the consolidated balance sheets as of March 31, 2018 and December 31, 2017, respectively. Sale of Future Revenue Streams On December 21, 2016, the Company entered into two Royalty Interest Acquisition Agreements (together, the “Acquisition Agreements”) with HealthCare Royalty Partners II, L.P. (“HCRP”). Under the first Acquisition Agreement, the Company sold its right to receive milestone payments and royalties on future sales of products subject to a License Agreement, dated August 18, 2005, between XOMA and Wyeth Pharmaceuticals (subsequently acquired by Pfizer, Inc. (“Pfizer”)) for an upfront cash payment of $6.5 million, plus potential additional payments totaling $4.0 million in the event three specified net sales milestones are met in 2017, 2018 and 2019. The 2017 sales milestone was not achieved. The Company remains eligible to receive up to $3.0 million if specified net sales milestones are achieved in 2018 and 2019. Under the second Acquisition Agreement, the Company sold all rights to royalties under an Amended and Restated License Agreement dated October 27, 2006 between XOMA and Dyax Corp. for a cash payment of $11.5 million. The Company classified the proceeds received from HCRP as unearned revenue, to be recognized as revenue under units-of-revenue method over the life of the license agreements because of the Company's limited continuing involvement in the Acquisition Agreements. Such limited continuing involvement is related to the Company’s undertaking to cooperate with HCRP in the event of litigation or a dispute related to the license agreements. Because the transaction was structured as a non-cancellable sale, the Company does not have significant continuing involvement in the generation of the cash flows due to HCRP and there are no guaranteed rates of return to HCRP, the Company recorded the total proceeds of $18.0 million as unearned revenue recognized under units-of-revenue method. The Company allocated the total proceeds between the two Acquisition Agreements based on the relative fair value of expected payments to be made to HCRP under the license agreements. The unearned revenue is being recognized as revenue over the life of the underlying license agreements under the "units-of-revenue" method. Under this method, amortization for a reporting period is calculated by computing a ratio of the allocated proceeds received from HCRP to the payments expected to be made by the licensees to HCRP over the term of the Acquisition Agreements, and then applying that ratio to the period’s cash payment. The Company recognized $0.1 million as revenue recognized under units-of-revenue method under these arrangements during the three months ended March 31, 2018 and 2017. As of March 31, 2018, the current and non-current portion of the remaining unearned revenue recognized under units-of-revenue method was $0.7 million and $17.0 million, respectively. As of December 31, 2017, the Company classified $0.6 million and $17.1 million as current and non-current unearned revenue recognized under units-of-revenue method, respectively.

XML 22 R10.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

3 Months Ended

Mar. 31, 2018

Fair Value Disclosures [Abstract]

Fair Value Measurements

5. Fair Value Measurements

Level 1 – Observable inputs, such as quoted prices in active markets for identical assets or liabilities.

The following tables set forth the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as follows (in thousands):

	Fair Value Measurements at March 31, 2018 Using
	Quoted Prices in Active Markets for Identical Assets		Significant Other Observable Inputs		Significant Unobservable Inputs
	(Level 1)		(Level 2)		(Level 3)		Total
Assets:
Money market funds ⁽¹⁾	$	35,021	$	—	$	—	$	35,021

	Fair Value Measurements at December 31, 2017 Using
	Quoted Prices in Active Markets for Identical Assets		Significant Other Observable Inputs		Significant Unobservable Inputs
	(Level 1)		(Level 2)		(Level 3)		Total
Assets:
Money market funds ⁽¹⁾	$	34,907	$	—	$	—	$	34,907

(1)Included in cash and cash equivalents

	March 31, 2018				December 31, 2017
	Carrying Amount		Fair Value		Carrying Amount		Fair Value
Novartis note	$	14,572	$	13,873	$	14,572	$	14,178

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 23 R11.htm IDEA: XBRL DOCUMENT

Dispositions	3 Months Ended
Dispositions	Mar. 31, 2018
Dispositions [Abstract]
Dispositions	6. Dispositions On November 4, 2015, XOMA and Ology Bioservices entered into an asset purchase agreement under which Ology Bioservices agreed to acquire XOMA’s biodefense business and related assets (including certain contracts with the U.S. government), and to assume certain liabilities of XOMA. As part of the transaction, the parties entered into an intellectual property license agreement (the “Ology Bioservices License Agreement”), under which XOMA agreed to license to Ology Bioservices certain intellectual property rights related to the purchased assets. Under the Ology Bioservices License Agreement, the Company was eligible to receive contingent consideration up to a maximum of $4.5 million in cash and 23,008 shares of common stock of Ology Bioservices, based upon Ology Bioservices achieving certain specified future operational objectives. In addition, the Company is eligible to receive 15% royalties on net sales of any future Ology Bioservices products covered by or involving the related patents or know-how. In February 2017, the Company executed an Amendment and Restatement to both the asset purchase agreement and Ology Bioservices License Agreement primarily to (i) remove the obligation to issue 23,008 shares of Ology Bioservices under the asset purchase agreement, and (ii) revise the payment schedule related to the timing of the $4.5 million cash payments due to the Company under the Ology Bioservices License Agreement. Of the $4.5 million, $3.0 million was contingent upon Ology Bioservices achieving certain specified future operating objectives. In the first quarter of 2017, the Company became entitled to receive $1.6 million under the agreement that will be received in quarterly payments through September 2018. In the third quarter of 2017, Ology Bioservices achieved the specified operating objectives and the Company earned the $3.0 million milestone fee that will be received in monthly payments through July 2018. The Company received $1.0 million and $0.2 million during the three months ended March 31, 2018 and 2017, respectively, which was recognized as other income in the condensed consolidated statements of operations and comprehensive loss.

XML 24 R12.htm IDEA: XBRL DOCUMENT

Restructuring Charges

3 Months Ended

Mar. 31, 2018

Restructuring And Related Activities [Abstract]

Restructuring Charges

7. Restructuring Charges

The following table summarizes the accrued restructuring costs on the condensed consolidated balance sheet as of March 31, 2018 (in thousands):

	Employee Severance
	and Other Benefits
Balance at December 31, 2016	$	3,594
Restructuring charges		3,447
Cash payments		(6,911	)
Balance at December 31, 2017		130
Cash payments		(130	)
Balance at March 31, 2018	$	—

XML 25 R13.htm IDEA: XBRL DOCUMENT

Long-Term Debt

3 Months Ended

Mar. 31, 2018

Debt Disclosure [Abstract]

Long-Term Debt

8. Long-Term Debt

Novartis Note

Servier Loan Agreement

Hercules Term Loan

Interest Expense

	Three Months Ended March 31,
	2018		2017
Novartis note	$	139	$	117
Servier loan		—		177
Hercules loan		—		311
Other		31		4
Total interest expense	$	170	$	609

XML 26 R14.htm IDEA: XBRL DOCUMENT

Common Stock Warrants

3 Months Ended

Mar. 31, 2018

Warrants And Rights Note Disclosure [Abstract]

Common Stock Warrants

9. Common Stock Warrants

As of March 31, 2018 and December 31, 2017, the following common stock warrants were outstanding:

			Exercise Price		March 31,		December 31,
Issuance Date	Expiration Date	Balance Sheet Classification	per Share		2018		2017
February 2015	February 2020	Stockholders' equity	$	66.20		9,063		9,063
February 2016	February 2021	Stockholders' equity	$	15.40		8,249		8,249
						17,312		17,312

XML 27 R15.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies	3 Months Ended
Commitments and Contingencies	Mar. 31, 2018
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	10. Commitments and Contingencies Collaborative Agreements, Royalties and Milestone Payments The Company has committed to make potential future milestone payments to third parties as part of licensing and development programs. Payments under these agreements become due and payable only upon the achievement of certain developmental, regulatory and commercial milestones by the Company’s licensees. Because it is uncertain if and when these milestones will be achieved, such contingencies, aggregating up to $15.5 million (assuming one product per contract meets all milestones events) have not been recorded on the accompanying consolidated balance sheets. The Company is unable to determine precisely when and if payment obligations under the agreements will become due as these obligations are based on milestone events, the achievement of which is subject to a significant number of risks and uncertainties. Lease Agreements The Company leases facilities and office equipment under operating leases expiring on various dates through April 2023. These leases require the Company to pay taxes, insurance, maintenance and minimum lease payments. For each facility lease, the Company has two successive renewal options to extend the lease for five years upon the expiration of the initial lease term. On November 21, 2017, the Company entered into a non-cancellable sublease agreement for a portion of one of its three leased facilities. The term of the sublease agreement commenced on December 26, 2017. Under the term of the sublease agreement, the Company will receive $5.1 million over the term of the sublease, which ends at the same time as the original lease in April 2023. Under the sublease agreement, the Company’s future sublease income will be equal to the amount required to be paid to the Company’s landlord. In addition, the sublease provides for a tenant improvement allowance of $0.8 million to the subtenant, which was funded by the Company in January 2018. Upon execution of the sublease agreement, the Company recognized a loss on the sublease equal to the tenant improvement allowance. Under the sublease agreement, the sub-lessee executed a standby letter of credit naming the Company as the beneficiary amounting to $1.0 million as security under the sublease in the event of uncured default by the sub-lessee. As of March 31, 2018, the Company has not drawn any funds from the letter of credit as there was no default by the sub-lessee. During the three months ended March 31, 2018, the Company recognized $0.4 million of sublease income under this agreement.

XML 28 R16.htm IDEA: XBRL DOCUMENT

Stock-based Compensation

3 Months Ended

Mar. 31, 2018

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock-based Compensation

11. Stock-based Compensation

Stock Options

The fair value of the stock options granted during the three months ended March 31, 2018 and 2017, was estimated based on the following weighted average assumptions:

	Three Months Ended March 31,
	2018			2017
Dividend yield		0	%		0	%
Expected volatility		101	%		100	%
Risk-free interest rate		2.72	%		1.95	%
Expected term	5.6 years			5.6 years

Stock option activity for the three months ended March 31, 2018, was as follows:

	Number of shares			Weighted Average Exercise Price Per Share		Weighted Average Contractual Term (in years)		Aggregate Intrinsic Value (in thousands)
Outstanding at beginning of year		1,622,065		$	24.54
Granted		133,000			26.90
Exercised		(400	)		33.80
Forfeited, expired or cancelled		(101,469	)		54.24
Outstanding at end of period		1,653,196		$	22.91		8.32	$	16,625
Exercisable at end of period		915,442		$	29.09		7.55	$	9,959

As of March 31, 2018, $6.7 million of total unrecognized compensation expense related to stock options is expected to be recognized over a weighted average period of 2.3 years.

Performance-Based Stock Options

Restricted Stock Units

RSU activity for the three months ended March 31, 2018, is summarized below:

				Weighted-
	Number of			Average Grant-
	Shares			Date Fair Value
Unvested balance at January 1, 2018		18,480		$	18.00
Granted		—			—
Vested		(13,360	)		13.08
Forfeited		—			—
Unvested balance at March 31, 2018		5,120		$	30.86

As of March 31, 2018, $24,000 of unrecognized compensation expense related to employee RSUs is expected to be recognized over a weighted average period of 0.6 years.

Stock-based Compensation Expense

The following table shows total stock-based compensation expense for stock options, RSUs and ESPP in the condensed consolidated statements of operations and comprehensive loss (in thousands):

	Three Months Ended March 31,
	2018		2017
Research and development	$	104	$	441
General and administrative		1,312		559
Total stock-based compensation expense	$	1,416	$	1,000

XML 29 R17.htm IDEA: XBRL DOCUMENT

Capital Stock	3 Months Ended
Capital Stock	Mar. 31, 2018
Stockholders Equity Note [Abstract]
Capital Stock	12. Capital Stock Biotechnology Value Fund Financing In February 2017, the Company sold 1,200,000 shares of its common stock and 5,003 shares of Series X convertible preferred stock directly to Biotechnology Value Fund, L.P. and certain of its affiliates (“BVF”) in a registered direct offering, for aggregate net cash proceeds of $24.8 million. BVF purchased the shares of common stock from the Company at a price of $4.03 per share, the closing stock price on the date of purchase. Each share of Series X convertible preferred stock has a stated value of $4,030 per share and is convertible into 1,000 shares of registered common stock based on a conversion price of $4.03 per share of common stock. The total number of shares of common stock issued upon conversion of all issued Series X convertible preferred stock will be 5,003,000 shares. Each share is convertible at the option of the holder at any time, provided that the holder will be prohibited from converting into common stock if, as a result of such conversion, the holder, together with its affiliates, would beneficially own a number of shares above a conversion blocker, which is initially set at 19.99% of the total common stock then issued and outstanding immediately following the conversion of such shares. As of March 31, 2018, BVF owned approximately 18.0% of the Company’s total outstanding shares, and if all of the Series X convertible preferred shares were converted, BVF would own 48.8% of the Company’s total outstanding common shares. As of March 31, 2018, none of the preferred stock has been converted into shares of the Company’s common stock. The designations, preferences, rights and limitations of the convertible preferred shares are set forth in a Certificate of Designation of Preferences, Rights and Limitations of Series X convertible preferred stock filed with the Delaware Secretary of State. Shares of Series X convertible preferred stock will generally have no voting rights, except as required by law and except that the consent of the holders of the outstanding Series X convertible preferred stock will be required to amend the terms of the Series X preferred stock and to approve certain corporate actions. In the event of the Company’s liquidation, dissolution or winding up, holders of Series X convertible preferred stock will participate, on a pro-rata basis, with any distribution of proceeds to holders of common stock. Holders of Series X convertible preferred stock are entitled to receive dividends on shares of Series X convertible preferred stock equal (on an as if converted to common stock basis) to and in the same form as dividends actually paid on the Company’s common stock or other junior securities. The Company evaluated the Series X convertible preferred stock for liability or equity classification under the applicable accounting guidance, and determined that equity treatment was appropriate because the Series X convertible preferred stock did not meet the definition of the liability instruments defined thereunder for convertible instruments. Specifically, the Series X convertible preferred shares are not mandatorily redeemable and do not embody an obligation to buy back the shares outside of the Company’s control in a manner that could require the transfer of assets. Additionally, the Company determined that the Series X convertible preferred stock would be recorded as permanent equity, not temporary equity, based on the relevant guidance given that they are not redeemable for cash or other assets (i) on a fixed or determinable date, (ii) at the option of the holder, and (iii) upon the occurrence of an event that is not solely within control of the Company. The Company has also evaluated the embedded conversion and redemption features within the Series X convertible preferred stock in accordance with the accounting guidance for derivatives. Based on this assessment, the Company determined that the conversion option is clearly and closely related to the equity host, and thus, bifurcation is not required. The contingent redemption feature was determined to not be clearly and closely related to the equity-like host; however, it met the criteria as a scope exception for derivative accounting. Therefore, the contingent redemption feature was also not bifurcated from the Series X convertible preferred stock. The fair value of the common stock into which the Series X convertible preferred stock is convertible exceeded the allocated purchase price of the Series X convertible preferred stock by $5.6 million on the date of issuance, as such the Company recorded a deemed dividend. The Company recognized the resulting beneficial conversion feature as a deemed dividend equal to the number of shares of Series X convertible preferred stock sold on February 16, 2017 multiplied by the difference between the fair value of the common stock and the Series X convertible preferred stock effective conversion price per share on that date. The dividend was reflected as a one-time, non-cash, deemed dividend to the holders of Series X convertible preferred stock on the date of issuance, which is the date the stock first became convertible. ATM Agreement On November 12, 2015, the Company entered into an At Market Issuance Sales Agreement (the “2015 ATM Agreement”) with Cowen and Company, LLC (“Cowen”), under which the Company may offer and sell from time to time at its sole discretion shares of its common stock through Cowen as its sales agent, in an aggregate amount not to exceed $75 million. Cowen may sell the shares by any method permitted by law deemed to be an “at the market” offering as defined in Rule 415 of the Securities Act, including without limitation sales made directly on The NASDAQ Global Market, and also may sell the shares in privately negotiated transactions, subject to the Company’s prior approval. The Company will pay Cowen a commission equal to 3% of the gross proceeds of the sales price of all shares sold through it as sales agent under the 2015 ATM Agreement. For the three months ended March 31, 2018, the Company sold a total of 67,658 shares of common stock under the 2015 ATM Agreement for aggregate gross proceeds of $2.4 million. Total offering costs of $0.1 million were offset against the proceeds upon the sale of common stock. For the three months ended March 31, 2017, the Company sold a total of 110,252 shares of common stock under the 2015 ATM Agreement for aggregate gross proceeds of $0.6 million. Total offering costs of $0.2 million were offset against the proceeds upon sale of common stock. The shares subject to 2015 ATM Agreement were registered on the shelf registration statement on Form S-3 that expired in February 2018. Common Stock Purchase Agreement In August 2017, in connection with the XOMA-052 License Agreement, the Company and Novartis entered into a Common Stock Purchase Agreement under which Novartis purchased 539,131 shares of the Company’s common stock, at a price per share of $9.2742 for the aggregate purchase price of $5.0 million in cash. The fair market value of the common stock issued to Novartis AG was $4.8 million, based on the closing stock price of $8.93 per share on the effective date of the Common Stock Purchase Agreement, or August 24, 2017. The excess of the purchase price over the fair market value of the common stock represents a premium of $0.2 million which was accounted for as additional consideration to the license agreements (See Note 4 for further discussion). The shares issued to Novartis are unregistered securities and the Company agreed to use commercially reasonable efforts to make and keep public information available and timely file all reports and other documents with the SEC as required of the Company under the Securities Exchange Act of 1934, as amended. Under the Common Stock Purchase Agreement, upon a request by Novartis, the Company will use commercially reasonable efforts to register the shares for resale under the Securities Act on a registration statement on Form S-3, to be filed within 60 days of the written request, and will use commercially reasonable efforts to keep such registration statement continuously effective under the Securities Act until the date all of the shares of common stock covered by such registration statement have been sold or can be sold publicly without restriction or limitation under Rule 144.

XML 30 R18.htm IDEA: XBRL DOCUMENT

Income Taxes	3 Months Ended
Income Taxes	Mar. 31, 2018
Income Tax Disclosure [Abstract]
Income Taxes	13. Income Taxes No provision was made for federal income tax, since the Company has incurred net operating losses during the three months ended March 31, 2018 and 2017, respectively. As of March 31, 2018 and December 31, 2017, the Company had a total of $4.5 million of net unrecognized tax benefits, none of which would affect the effective tax rate upon realization. The Company does not expect its unrecognized tax benefits to change significantly over the next twelve months. In accordance with SAB 118, the effects of the Tax Cuts and Jobs Act of 2017 (the “Tax Act”) may be adjusted within a one-year measurement period from the enactment date for items that were previously reported as provisional, or where a provisional estimate could not be made. The income tax provision for the three months ended March 31, 2018 did not reflect any adjustment to the previously assessed Tax Act enactment effect. The Company will continue to assess forthcoming guidance and accounting interpretations on the effects of the Tax Act and expects to complete its analysis within the measurement period in accordance with the SEC guidance.

XML 31 R19.htm IDEA: XBRL DOCUMENT

Subsequent Events	3 Months Ended
Subsequent Events	Mar. 31, 2018
Subsequent Events [Abstract]
Subsequent Events	14. Subsequent Events Rezolute On April 2, 2018, Rezolute completed a closing on a convertible note financing for gross proceeds of $4.0 million, which triggered the Initial Closing defined under the amended common stock purchase agreement between the Company and Rezolute (see Note 4). As such, pursuant to the terms of the amended common stock purchase agreement with Rezolute, the Company received 8,023,758 shares of Rezolute’s common stock and cash of $0.5 million. In addition, in April 2018, the Company received from Rezolute the 69,252 shares of common stock and cash of $50,000 in connection with the Interim Financing Closing that occurred during the three months ended March 31, 2018 (see Note 4). Sublease On April 14, 2018, the Company entered into a non-cancellable sublease agreement for a portion of one of its three leased facilities. The term of the sublease agreement commenced on May 1, 2018. Under the term of the sublease agreement, the Company will receive $1.1 million over the term of the sublease, which ends at the same time as the original lease in April 2023. In addition, the sublease provides for a tenant improvement allowance of $65,000 to the subtenant. Silicon Valley Bank Loan Agreement On May 7, 2018 (the “Effective Date”), the Company executed a Loan and Security Agreement (the “Loan Agreement”) with Silicon Valley Bank (“SVB”). Under the Loan Agreement, upon the Company’s request, SVB may make advances (each, a “Term Loan Advance”) available to the Company up to $20.0 million (the “Term Loan”), subject to additional funding at the bank’s discretion. The Company may borrow advances under the Term Loan from the Effective Date until the earlier of March 31, 2019 (which will be extended to March 31, 2020, if the Company receives $20.0 million in gross cash proceeds from milestone/licensing payments by March 31, 2019) or an event of default (the “Draw Period”). The interest rate will be calculated at a rate equal to the greater of (i) 4.75%, and (ii) 0.25% plus the prime rate as reported from time to time in The Wall Street Journal. Payments under the Loan Agreement are interest only until the first anniversary of the funding date of each Term Loan Advance. The interest-only period will be followed by equal monthly payments of principal and interest over 24 months. Each Term Loan Advance will mature at the earlier of (i) the 23 months following the applicable term loan amortization date for each such Term Loan Advance (ii) March 1, 2023, or (iii) 30 days prior to the earliest maturity of any portion of the Company’s loan with Novartis (the “Loan Maturity Date”). After repayment, no Term Loan Advance (or any portion thereof) may be reborrowed. The entire principal balance, including a final payment equal to 8.5% of the principal, will be due and payable on the Loan Maturity Date. If the Company prepays the Term Loan Advance prior to the Loan Maturity Date, it will pay SVB a prepayment premium, based on a prepayment fee equal to 3.00% of the amount prepaid, if the prepayment occurs on or before the first anniversary of the Effective Date, 2.00% of the amount prepaid, if the prepayment occurs after the first anniversary of the Effective Date but prior to the second anniversary of the Effective Date, and 1.00% of the amount prepaid if the prepayment occurs after the second anniversary of the Effective Date. Upon the occurrence of an event of default, a default interest rate of an additional 4% may be applied to the outstanding payments due to SVB, and SVB may declare all outstanding obligations immediately due and payable and take such other actions as set forth in the Loan Agreement. Under the Loan Agreement, the Company may be obligated to pay a fee equal to 1% of the unused portion of the Term Loan upon the earlier of (i) the termination of the Loan Agreement, or (ii) the Draw Period. The Company’s obligations under the Loan Agreement are secured by a security interest in substantially all of its assets, other than its intellectual property. The Loan Agreement includes customary affirmative and restrictive covenants, but does not include any financial maintenance covenants, and also includes standard events of default, including payment defaults. In connection with the Loan Agreement, the Company issued a warrant to SVB which is exercisable in whole or in part for up to an aggregate of 6,332 shares of common stock with an exercise price of $23.69 per share (the “Warrant”). The Warrant may be exercised on a cashless basis and is exercisable for a term beginning on the date of issuance and ending on the earlier to occur of 10 years from the date of issuance or the consummation of certain acquisitions of the Company as set forth in the Warrant. The number of shares for which the Warrant is exercisable and the associated exercise price are subject to certain proportional adjustments as set forth in the Warrant.

XML 32 R20.htm IDEA: XBRL DOCUMENT

Basis of Presentation and Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Liquidity and Financial Condition	Liquidity and Financial Condition With the exception of the year ended December 31, 2017, the Company has typically incurred significant operating losses and negative cash flows from operations since its inception. As of March 31, 2018, the Company had cash and cash equivalents of $42.0 million. The Company has evaluated and concluded there are no conditions or events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern for a period of one year following the date that these financial statements are issued.
Basis of Presentation	Basis of Presentation The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions among consolidated entities were eliminated upon consolidation. The unaudited consolidated financial statements were prepared in accordance with generally accepted accounting principles (“GAAP”) in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. As permitted under those rules certain footnotes or other financial information can be condensed or omitted. These financial statements and related disclosures have been prepared with the assumption that users of the interim financial information have read or have access to the audited consolidated financial statements for the preceding fiscal year. Accordingly, these statements should be read in conjunction with the audited consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, filed with the U.S. Securities and Exchange Commission (“SEC”) on March 7, 2018. These financial statements have been prepared on the same basis as the Company’s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments that are necessary for a fair statement of the Company’s consolidated financial information. The interim results of operations are not necessarily indicative of the results that may be expected for the full year.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to, those related to revenue recognition, debt amendments, long-lived assets, restructuring liabilities, legal contingencies, and stock-based compensation. The Company bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ significantly from these estimates, such as the Company’s billing under government contracts. Under the Company’s contracts with the National Institute of Allergy and Infectious Diseases (“NIAID”), a part of the National Institutes of Health (“NIH”), the Company billed using NIH’s provisional rates and thus is subject to future audits at the discretion of NIAID’s contracting office. These audits can result in an adjustment to revenue previously reported which potentially could be significant.
Revenue Recognition	Revenue Recognition Effective January 1, 2018, the Company adopted Accounting Standards Codification Topic 606, Revenue from Contracts with Customers ("ASC 606") using the modified retrospective transition method and applied the standard only to contracts that are still active or in place at that date. Also, as permitted, the Company applied the practical expedient under ASC 606 which permits the Company to treat all contract modifications that occurred prior to the adoption in aggregate when determining the performance obligations, transaction price and its allocation. Except for the Company’s license agreement with Rezolute, Inc. (formerly AntriaBio, Inc.) (“Rezolute”), the Company did not have any other contracts with customers for which the Company had not completed its performance obligations as of the adoption date January 1, 2018. The license agreement with Rezolute was not considered a contract under ASC 606 as it is not probable that the Company will collect substantially all of the consideration to which it will be entitled in exchange for the goods or services that will be transferred to Rezolute and there was no consideration exchanged upon execution of the arrangement or as of January 1, 2018 (see Note 4). Thus, the Company determined that the adoption of ASC 606 did not have a financial impact on the Company's consolidated financial statements and related disclosures. In addition, the adoption of ASC 606 has no material impact for tax purposes. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation based on relative fair values, when (or as) the performance obligation is satisfied. The Company recognizes revenue from its license and collaboration arrangements and royalties. The terms of the arrangements generally include payment to the Company of one or more of the following: non-refundable, upfront license fees, development, regulatory and commercial milestone payments, and royalties on net sales of licensed products. Licenses of intellectual property: If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, such as transfer of related materials, process and know-how, the Company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. Under the Company’s license agreements, the nature of the combined performance obligation is the granting of licenses to the customers as the other promises are not separately identifiable in the context of the arrangement. Since the Company grants the license to a customer as it exists at the point of transfer, and is not involved in any future development or commercialization of the products related to the license, the nature of the license is a right to use the Company’s intellectual property as transferred. As such, the Company recognizes revenue related to the combined performance obligation upon completion of the delivery of the related materials, process and know-how (i.e., at a point in time). Milestone payments: At the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. ASC 606 suggests two alternatives to use when estimating the amount of variable consideration: the expected value method and the most likely amount method. Under the expected value method, an entity considers the sum of probability-weighted amounts in a range of possible consideration amounts. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. The Company expects to use the most likely amount method for development and regulatory milestone payments. If it is probable that a significant cumulative revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability or achievement of each such milestone and any related constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and earnings in the period of adjustment. Royalties: For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Upfront payments and fees are recorded as deferred revenue upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company’s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one year or less.
Sale of Future Revenue Streams	Sale of Future Revenue Streams The Company has sold its rights to receive certain milestones and royalties on product sales. In the circumstance where the Company has sold its rights to future milestones and royalties under a license agreement and also maintains limited continuing involvement in the arrangement (but not significant continuing involvement in the generation of the cash flows that are due to the purchaser), the Company defers recognition of the proceeds it receives for the sale of milestone or royalty streams and recognizes such unearned revenue as revenue under units-of-revenue method over the life of the underlying license agreement.. Under the units-of-revenue method, amortization for a reporting period is calculated by computing a ratio of the proceeds received from the purchaser to the total payments expected to be made to the purchaser over the term of the agreement, and then applying that ratio to the period’s cash payment. Estimating the total payments expected to be received by the purchaser over the term of such arrangements requires management to use subjective estimates and assumptions. Changes to the Company’s estimate of the payments expected to be made to the purchaser over the term of such arrangements could have a material effect on the amount of revenues recognized in any particular period.
Stock-Based Compensation	Stock-Based Compensation The Company recognizes compensation expense for all stock-based payment awards made to the Company’s employees, consultants and directors that are expected to vest based on estimated fair values. The valuation of stock option awards is determined at the date of grant using the Black-Scholes Option Pricing Model (the “Black-Scholes Model”). The Black-Scholes Model requires inputs such as the expected term of the option, expected volatility and risk-free interest rate. To establish an estimate of expected term, the Company considers the vesting period and contractual period of the award and its historical experience of stock option exercises, post-vesting cancellations and volatility. The estimate of expected volatility is based on the Company’s historical volatility. The risk-free rate is based on the yield available on United States Treasury zero-coupon issues corresponding to the expected term of the award. The Company records forfeitures when they occur. The Company records compensation expense for service-based awards over the vesting period of the award on a straight-line basis. For awards with performance-based conditions, the Company records the expense over the remaining service period when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based condition is probable based on the expected satisfaction of the performance conditions as of the reporting date. The amount of stock-based compensation expense recognized during a period is based on the value of the portion of the awards that are ultimately expected to vest. The valuation of restricted stock units (“RSUs”) is determined at the date of grant using the Company’s closing stock price.
Net Loss per Share Available to Common Stockholders	Net Loss per Share Available to Common Stockholders Basic net loss per share available to common stockholders is based on the weighted average number of shares of common stock outstanding during the period. Net loss available to common stockholders consists of net loss, as adjusted for the convertible preferred stock deemed dividends related to the beneficial conversion feature on this instrument at issuance. For the three months ended March 31, 2017, the convertible preferred stock had a deemed dividend which represented the accretion of a beneficial conversion feature. As such, the net loss for the three months ended March 31, 2017 was adjusted for the convertible preferred stock deemed dividend related to the beneficial conversion feature on these shares at issuance. During periods of loss, the Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company. Diluted net loss per share available to common stockholders is based on the weighted average number of shares outstanding during the period, adjusted to include the assumed conversion of preferred stock, and the exercise of certain stock options, RSUs, and warrants for common stock. The calculation of diluted loss per share available to common stockholders requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of any outstanding options, RSUs or warrants and the presumed exercise of such securities are dilutive to earnings (loss) per share available to common stockholders for the period. Adjustments to the denominator are required to reflect the related dilutive shares.
Concentration of Risk	Concentration of Risk Cash equivalents and receivables are financial instruments which potentially subject the Company to concentrations of credit risk, as well as liquidity risk for certain cash equivalents, such as money market funds. The Company has not encountered any such liquidity issues during 2018. The Company has not experienced any significant credit losses and does not generally require collateral on receivables. For the three months ended March 31, 2018, two partners represented 86% and 13% of total revenues, respectively. For the three months ended March 31, 2017, two partners represented 58% and 42% of total revenues, respectively. As of March 31, 2018, two partners represented 50% of the trade receivables balance, respectively. As of December 31, 2017, one partner represented 95% of the trade receivables balance.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-02, Leases (Topic 842). ASU 2016-2 is aimed at making leasing activities more transparent and comparable, and requires substantially all leases be recognized by lessees on their balance sheet as a right-of-use asset and corresponding lease liability, including leases currently accounted for as operating leases. ASU 2016-2 is effective for the Company’s interim and annual reporting periods during the year ending December 31, 2019, and all annual and interim reporting periods thereafter. Early adoption is permitted. The Company is evaluating the impact of the adoption of the standard on its consolidated financial statements.
Fair Value Measurements	The Company records its financial assets and liabilities at fair value. The carrying amounts of certain of the Company’s financial instruments, including cash and cash equivalents, trade receivables and accounts payable, approximate their fair value due to their short maturities. Fair value is defined as the exchange price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting guidance for fair value establishes a framework for measuring fair value and a fair value hierarchy that prioritizes the inputs used in valuation techniques. The accounting standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value, which are the following: Level 1 – Observable inputs, such as quoted prices in active markets for identical assets or liabilities. Level 2 – Observable inputs, either directly or indirectly, other than quoted prices in active markets for identical assets or liabilities, such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities; therefore, requiring an entity to develop its own valuation techniques and assumptions.

XML 33 R21.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Financial Statements Detail (Tables)

3 Months Ended

Mar. 31, 2018

Condensed Consolidated Financial Statements Detail [Abstract]

Accrued and Other Liabilities

Accrued and other liabilities consisted of the following (in thousands):

	March 31,		December 31,
	2018		2017
Accrued payroll and other benefits	$	83	$	141
Accrued restructuring		—		130
Accrued incentive compensation		90		229
Accrued legal and accounting fees		237		431
Deferred rent		754		765
Liability related to sublease		—		800
Other		174		179
Total	$	1,338	$	2,675

Reconciliation of Numerator and Denominator Used in Calculation of Basic and Diluted Net Loss per Share Available to Common Stockholders

	Three Months Ended March 31,
	2018			2017
Numerator
Net loss	$	(3,806	)	$	(10,715	)
Less: Deemed dividend on convertible preferred stock		—			(5,603	)
Net loss available to common stockholders, basic and diluted	$	(3,806	)	$	(16,318	)

Denominator
Weighted average shares outstanding used for basic and diluted net loss per share available to common stockholders		8,313			6,887

Outstanding Securities Considered Anti-Dilutive

	Three Months Ended March 31,
	2018		2017
Common stock options and RSUs		1,645		653
Warrants for common stock		17		381
Convertible preferred stock		5,003		2,446
Total		6,665		3,480

XML 34 R22.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Tables)

3 Months Ended

Mar. 31, 2018

Fair Value Disclosures [Abstract]

Financial Assets and Liabilities Carried at Fair Value on Recurring Basis

The following tables set forth the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as follows (in thousands):

	Fair Value Measurements at March 31, 2018 Using
	Quoted Prices in Active Markets for Identical Assets		Significant Other Observable Inputs		Significant Unobservable Inputs
	(Level 1)		(Level 2)		(Level 3)		Total
Assets:
Money market funds ⁽¹⁾	$	35,021	$	—	$	—	$	35,021

	Fair Value Measurements at December 31, 2017 Using
	Quoted Prices in Active Markets for Identical Assets		Significant Other Observable Inputs		Significant Unobservable Inputs
	(Level 1)		(Level 2)		(Level 3)		Total
Assets:
Money market funds ⁽¹⁾	$	34,907	$	—	$	—	$	34,907

(1)Included in cash and cash equivalents

Outstanding Long Term Debt Carrying Amount and Estimated Fair Value

The carrying amount and the estimated fair value of the Company’s outstanding long-term debt at March 31, 2018, and December 31, 2017, are as follows (in thousands):

	March 31, 2018				December 31, 2017
	Carrying Amount		Fair Value		Carrying Amount		Fair Value
Novartis note	$	14,572	$	13,873	$	14,572	$	14,178

XML 35 R23.htm IDEA: XBRL DOCUMENT

Restructuring Charges (Tables)

3 Months Ended

Mar. 31, 2018

Restructuring And Related Activities [Abstract]

Components of Accrued Restructuring Costs

The following table summarizes the accrued restructuring costs on the condensed consolidated balance sheet as of March 31, 2018 (in thousands):

	Employee Severance
	and Other Benefits
Balance at December 31, 2016	$	3,594
Restructuring charges		3,447
Cash payments		(6,911	)
Balance at December 31, 2017		130
Cash payments		(130	)
Balance at March 31, 2018	$	—

XML 36 R24.htm IDEA: XBRL DOCUMENT

Long-Term Debt (Tables)

3 Months Ended

Mar. 31, 2018

Debt Disclosure [Abstract]

Interest Expense and Amortization of Debt Issuance Costs

	Three Months Ended March 31,
	2018		2017
Novartis note	$	139	$	117
Servier loan		—		177
Hercules loan		—		311
Other		31		4
Total interest expense	$	170	$	609

XML 37 R25.htm IDEA: XBRL DOCUMENT

Common Stock Warrants (Tables)

3 Months Ended

Mar. 31, 2018

Warrants And Rights Note Disclosure [Abstract]

Summary of Common Stock Warrants Outstanding

As of March 31, 2018 and December 31, 2017, the following common stock warrants were outstanding:

			Exercise Price		March 31,		December 31,
Issuance Date	Expiration Date	Balance Sheet Classification	per Share		2018		2017
February 2015	February 2020	Stockholders' equity	$	66.20		9,063		9,063
February 2016	February 2021	Stockholders' equity	$	15.40		8,249		8,249
						17,312		17,312

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

XML 38 R26.htm IDEA: XBRL DOCUMENT

Stock-based Compensation (Tables)

3 Months Ended

Mar. 31, 2018

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Weighted Average Assumptions

The fair value of the stock options granted during the three months ended March 31, 2018 and 2017, was estimated based on the following weighted average assumptions:

	Three Months Ended March 31,
	2018			2017
Dividend yield		0	%		0	%
Expected volatility		101	%		100	%
Risk-free interest rate		2.72	%		1.95	%
Expected term	5.6 years			5.6 years

Stock Option Activity

Stock option activity for the three months ended March 31, 2018, was as follows:

	Number of shares			Weighted Average Exercise Price Per Share		Weighted Average Contractual Term (in years)		Aggregate Intrinsic Value (in thousands)
Outstanding at beginning of year		1,622,065		$	24.54
Granted		133,000			26.90
Exercised		(400	)		33.80
Forfeited, expired or cancelled		(101,469	)		54.24
Outstanding at end of period		1,653,196		$	22.91		8.32	$	16,625
Exercisable at end of period		915,442		$	29.09		7.55	$	9,959

RSU Activity

RSU activity for the three months ended March 31, 2018, is summarized below:

				Weighted-
	Number of			Average Grant-
	Shares			Date Fair Value
Unvested balance at January 1, 2018		18,480		$	18.00
Granted		—			—
Vested		(13,360	)		13.08
Forfeited		—			—
Unvested balance at March 31, 2018		5,120		$	30.86

Stock-based Compensation Expense

The following table shows total stock-based compensation expense for stock options, RSUs and ESPP in the condensed consolidated statements of operations and comprehensive loss (in thousands):

	Three Months Ended March 31,
	2018		2017
Research and development	$	104	$	441
General and administrative		1,312		559
Total stock-based compensation expense	$	1,416	$	1,000

XML 39 R27.htm IDEA: XBRL DOCUMENT

Description of Business - Additional Information (Details) - USD ($)
$ in Thousands

Mar. 31, 2018

Dec. 31, 2017

Mar. 31, 2017

Dec. 31, 2016

Description Of Business [Abstract]

Cash and cash equivalents

$ 41,968

$ 43,471

^[1]

$ 20,045

$ 25,742

[1]	The condensed consolidated balance sheet as of December 31, 2017 has been derived from the audited consolidated financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017.

XML 40 R28.htm IDEA: XBRL DOCUMENT

Basis of Presentation and Significant Accounting Policies - Additional Information (Details)	3 Months Ended		12 Months Ended
	Mar. 31, 2018 USD ($) Customer	Mar. 31, 2017 USD ($) Customer	Dec. 31, 2017 Customer
Basis Of Presentation And Significant Accounting Policies [Line Items]
Allocation of undistributed earnings to participating securities \| $	$ 0	$ 0
Contractual obligation \| $	$ 0	$ 0
Customer Concentration Risk [Member] \| Trade Receivables [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Number of major partners \| Customer	2		1
Customer Concentration Risk [Member] \| Trade Receivables [Member] \| Partner 1 [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Concentration risk, percentage (in hundredths)	50.00%		95.00%
Customer Concentration Risk [Member] \| Revenues [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Number of major partners \| Customer	2	2
Customer Concentration Risk [Member] \| Revenues [Member] \| Partner 1 [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Concentration risk, percentage (in hundredths)	86.00%	58.00%
Customer Concentration Risk [Member] \| Revenues [Member] \| Partner 2 [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Concentration risk, percentage (in hundredths)	13.00%	42.00%

XML 41 R29.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Financial Statements Detail - Additional Information 1 (Details) - USD ($)
$ in Thousands

Mar. 31, 2018

Dec. 31, 2017

Mar. 31, 2017

Dec. 31, 2016

Cash and Cash Equivalents [Line Items]

Cash and cash equivalents

$ 41,968

$ 43,471

^[1]

$ 20,045

$ 25,742

Money market funds

35,000

8,600

Demand Deposits [Member]

Cash and Cash Equivalents [Line Items]

Cash and cash equivalents

$ 7,000

$ 34,900

[1]	The condensed consolidated balance sheet as of December 31, 2017 has been derived from the audited consolidated financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017.

XML 42 R30.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Financial Statements Detail - Additional Information 2 (Details) $ in Millions	3 Months Ended
	Mar. 31, 2017 USD ($)
Property, Plant and Equipment [Line Items]
Total proceeds from sale of equipment	$ 1.6
Carrying value of equipment sold	0.3
Other Income (Expense) [Member]
Property, Plant and Equipment [Line Items]
Gain on sale of equipment	$ 1.3

XML 43 R31.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Financial Statements Detail - Accrued and Other Liabilities (Details) - USD ($)
$ in Thousands

Mar. 31, 2018

Dec. 31, 2017

Accrued and other liabilities [Abstract]

Accrued payroll and other benefits

$ 83

$ 141

Accrued restructuring

130

Accrued incentive compensation

229

Accrued legal and accounting fees

237

431

Deferred rent

754

765

Liability related to sublease

800

Other

174

179

Total

$ 1,338

$ 2,675

^[1]

[1]	The condensed consolidated balance sheet as of December 31, 2017 has been derived from the audited consolidated financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017.

XML 44 R32.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Financial Statements Detail - Reconciliation of Numerator and Denominator Used in Calculation of Basic and Diluted Net Loss per Share Available to Common Stockholders (Details) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Numerator
Net loss	$ (3,806)	$ (10,715)
Less: Deemed dividend on convertible preferred stock		(5,603)
Net loss and comprehensive loss available to common stockholders, basic and diluted	$ (3,806)	$ (16,318)
Denominator
Weighted average shares outstanding used for basic and diluted net loss per share available to common stockholders	8,313	6,887

XML 45 R33.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Financial Statements Detail - Outstanding Securities Considered Anti-Dilutive (Details) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	6,665	3,480
Common Stock Options and RSUs [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	1,645	653
Warrants for Common Stock [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	17	381
Convertible Preferred Stock [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	5,003	2,446

XML 46 R34.htm IDEA: XBRL DOCUMENT

Licensing and Other Arrangements - Novartis - Additional Information (Details) $ / shares in Units, € in Millions				3 Months Ended		12 Months Ended
	Aug. 24, 2017 USD ($) Agreement Obligation $ / shares shares	Aug. 24, 2017 EUR (€) Agreement Obligation shares	Sep. 30, 2015	Mar. 31, 2018 USD ($)	Jun. 30, 2017 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2015 USD ($)
Novartis Pharma AG [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront payment received	$ 25,700,000
Common stock aggregate fair value	4,800,000
Common stock premium	$ 200,000
Number of license agreements \| Agreement	2	2
Number of performance obligations \| Obligation	2	2
License agreement transaction price	$ 40,200,000
Contract liabilities				$ 0		$ 0
Contract assets				0		0
Revenue recognize				0
Capitalized contract costs				0
Novartis Pharma AG [Member] \| Licenses and Related Materials, Process and Know-How and Filings to Regulatory Authority [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Recognized the entire transaction price as revenue upon completion of delivery						40,200,000
Novartis Pharma AG [Member] \| Common Stock [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Cash received from sale of shares	$ 5,000,000
Number of shares sold \| shares	539,131	539,131
Sale of stock price per share \| $ / shares	$ 9.2742
Common stock closing price \| $ / shares	$ 8.93
Novartis Pharma AG [Member] \| Les Laboratories Servier [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Repayments of debt	$ 14,300,000	€ 12.0
Novartis Pharma AG [Member] \| XOMA-052 License Agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
License agreement consideration received	30,000,000
Upfront payment received	15,700,000
Eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones	$ 438,000,000
Agreement termination prior written notice period	6 months	6 months
Novartis Pharma AG [Member] \| IL-1 Target License Agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront payment received	$ 10,000,000
Novartis International [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Cash received from sale of shares	$ 5,000,000
Number of shares sold \| shares	539,131	539,131
Common stock aggregate fair value	$ 4,800,000
Common stock closing price \| $ / shares	$ 8.93
Common stock premium	$ 200,000
Novartis International [Member] \| License Agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones				470,000,000
Contract liabilities				0		0
Contract assets				0		$ 0
Revenue recognize				0
Capitalized contract costs				$ 0
Agreement termination notice period			180 days
Upfront payment recognized as revenue							$ 37,000,000
Milestone received under the collaboration agreement					$ 10,000,000

XML 47 R35.htm IDEA: XBRL DOCUMENT

Licensing and Other Arrangements - Rezolute - Additional Information (Details) - USD ($)					3 Months Ended		18 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Mar. 30, 2018	Dec. 06, 2017	Mar. 31, 2018	Mar. 31, 2017	Jun. 01, 2019
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Proceeds from issuance of common stock					$ 2,309,000	$ 5,380,000
Contract revenue					$ 401,000	$ 150,000
Rezolute [Member] \| Initial Closing [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Common stock value receivable			$ 5,000,000
Rezolute [Member] \| Qualified Financing [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Common stock value receivable			7,000,000
Rezolute [Member] \| 2019 Closing [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Common stock value receivable			$ 7,000,000
Rezolute [Member] \| License Agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Future milestone payments, maximum				$ 232,000,000
Eligible to receive in cash				6,000,000
Eligible to receive common stock, financing activities				$ 12,000,000
Number of shares of common stock held for future issuance				5,000,000
Common stock purchase agreement description					Under the common stock purchase agreement, Rezolute granted the Company the right and option to sell the greater of (i) 5,000,000 shares of common stock or (ii) one third of the aggregate shares held by the Company upon failure by Rezolute to list its shares of its common stock on the Nasdaq Stock Market or a similar national exchange on or prior to December 31, 2018.
Percentage of aggregate shares held for future issuance				33.33%
Agreement termination notice period				90 days
Rezolute [Member] \| License Agreement [Member] \| Forecast [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Future milestone payments, maximum							$ 237,000,000
Upfront option fee							$ 1,000,000
Gross proceeds from qualified financing		$ 20,000,000
Additional common stock receive for qualified financing		$ 7,000,000
Common stock, trading period		10 days
Eligible to receive, in order to maintain license agreement	$ 15,000,000
Rezolute [Member] \| Amended Common Stock Purchase Agreement [Member] \| Initial Closing [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Common stock shares receivable			7,000,000
Rezolute [Member] \| Amended Common Stock Purchase Agreement [Member] \| Qualified Financing [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Common stock value receivable			$ 8,500,000
Rezolute [Member] \| Amended Common Stock Purchase Agreement [Member] \| 2019 Closing [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Common stock value receivable			$ 8,500,000
Rezolute [Member] \| Common Stock Purchase Agreement [Member] \| Interim Financing Closing
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Issuance of common stock, shares					69,252
Proceeds from issuance of common stock					$ 50,000
Contract revenue					$ 0

XML 48 R36.htm IDEA: XBRL DOCUMENT

Licensing and Other Arrangements - NIAID - Additional Information (Details) - USD ($)
$ in Thousands

1 Months Ended

12 Months Ended

Sep. 30, 2008

Dec. 31, 2017

Mar. 31, 2018

Dec. 31, 2014

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Unearned revenue recognized under units-of-revenue method – non-current

$ 17,123

^[1]

$ 17,019

National Institute of Allergy and Infectious Diseases "NIAID" [Member]

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Contract liabilities

800

$ 800

National Institute of Allergy and Infectious Diseases "NIAID" [Member] | Arrangement with Governmental Agency 2 [Member]

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Total contract amount awarded

$ 64,800

Contracts revenue wrote off

$ 400

National Institute of Allergy and Infectious Diseases "NIAID" [Member] | Arrangement with Governmental Agency 3 [Member]

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Contractual term

3 years

Accounts receivable

$ 400

Unearned revenue recognized under units-of-revenue method – non-current

$ 800

[1]	The condensed consolidated balance sheet as of December 31, 2017 has been derived from the audited consolidated financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017.

XML 49 R37.htm IDEA: XBRL DOCUMENT

Licensing and Other Arrangements - Sale of Future Revenue Streams - Additional Information (Details)
$ in Thousands

3 Months Ended

Dec. 21, 2016

USD ($)

Mar. 31, 2018

USD ($)

Agreement

Dec. 31, 2017

USD ($)

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Unearned revenue recognized under units-of-revenue method – current

$ 658

$ 615

^[1]

Unearned revenue recognized under units-of-revenue method – non-current

$ 17,019

17,123

^[1]

HCRP [Member]

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Number of royalty Interest acquisition agreements | Agreement

Unearned revenue recognized under units-of-revenue method

$ 18,000

Revenue recognized under units-of-revenue method

100

Unearned revenue recognized under units-of-revenue method – current

700

600

Unearned revenue recognized under units-of-revenue method – non-current

17,000

$ 17,100

HCRP [Member] | First Acquisition Agreement [Member]

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Upfront cash payment received

$ 6,500

Eligible potential additional payments receivable upon achievement of specified net sales milestones in future years

4,000

$ 3,000

HCRP [Member] | Second Acquisition Agreement [Member]

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Upfront cash payment received

$ 11,500

[1]	The condensed consolidated balance sheet as of December 31, 2017 has been derived from the audited consolidated financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017.

XML 50 R38.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value on Recurring Basis (Details) - Recurring [Member] - Money Market Funds [Member] - USD ($)
$ in Thousands

Mar. 31, 2018

Dec. 31, 2017

Assets:

Money market funds

^[1]

$ 35,021

$ 34,907

Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]

Assets:

Money market funds

^[1]

$ 35,021

$ 34,907

[1]	Included in cash and cash equivalents

XML 51 R39.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Outstanding Long Term Debt Carrying Amount and Estimated Fair Value (Details) - Novartis Note [Member] - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Carrying Amount [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt	$ 14,572	$ 14,572
Fair Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt	$ 13,873	$ 14,178

XML 52 R40.htm IDEA: XBRL DOCUMENT

Dispositions - Additional Information (Details) - USD ($)		1 Months Ended	3 Months Ended
	Nov. 04, 2015	Feb. 28, 2017	Mar. 31, 2018	Sep. 30, 2017	Mar. 31, 2017
Asset Purchase Agreement and Ology Bioservices License Agreement [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Cash payments from Ology Bioservices		$ 4,500,000
Number of shares removed from obligation to issue of common stock		23,008
Contingent upon achieving certain specified future operating objectives		$ 3,000,000
Amount entitled to receive					$ 1,600,000
Milestone payment earned				$ 3,000,000
Amount received from sale of discontinued operation			$ 1,000,000		$ 200,000
Biodefense Business [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Sales of business, number of common stock shares eligible to receive	23,008
Royalties receivable percentage on net sales	15.00%
Biodefense Business [Member] \| Maximum [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Cash payments from Ology Bioservices	$ 4,500,000

XML 53 R41.htm IDEA: XBRL DOCUMENT

Restructuring Charges - Additional Information (Details) - Employee		3 Months Ended
	Dec. 19, 2016	Mar. 31, 2018
2016 Restructuring [Member]
Restructuring Cost And Reserve [Line Items]
Number of employees terminated	57
2017 Restructuring [Member]
Restructuring Cost And Reserve [Line Items]
Number of employees terminated		5

XML 54 R42.htm IDEA: XBRL DOCUMENT

Restructuring Charges - Components of Accrued Restructuring Costs (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Restructuring Cost And Reserve [Line Items]
Balance at period start	$ 130
Restructuring charges		$ 2,020
Balance at period end			$ 130
Employee Severance and Other Benefits [Member]
Restructuring Cost And Reserve [Line Items]
Balance at period start	130	$ 3,594	3,594
Restructuring charges			3,447
Cash payments	$ (130)		(6,911)
Balance at period end			$ 130

XML 55 R43.htm IDEA: XBRL DOCUMENT

Long-Term Debt - Novartis Note - Additional Information (Details) - USD ($)			1 Months Ended
	Sep. 22, 2017	Sep. 30, 2015	May 31, 2005	Mar. 31, 2018	Dec. 31, 2017
Novartis Note [Member]
Debt Instrument [Line Items]
Maturity date			Jun. 30, 2015
Research and development expenses funded through loan facility, maximum			75.00%
Maximum borrowing capacity under loan agreement			$ 50,000,000
Interest rate at period end				3.81%
Outstanding principal balance				$ 14,600,000	$ 14,600,000
Novartis Note [Member] \| Six-month LIBOR [Member]
Debt Instrument [Line Items]
Basis spread on variable rate			2.00%
Secured Note Amendment [Member]
Debt Instrument [Line Items]
Maturity date	Sep. 30, 2022	Sep. 30, 2020
Reduction in outstanding principal amount		$ 7,300,000

XML 56 R44.htm IDEA: XBRL DOCUMENT

Long-Term Debt - Servier Loan Agreement - Additional Information (Details) $ in Thousands		1 Months Ended	3 Months Ended
	Aug. 25, 2017 USD ($) € / $	Dec. 31, 2010 EUR (€)	Sep. 30, 2017 USD ($)	Mar. 31, 2017 USD ($)
Debt Instrument [Line Items]
Loss on extinguishment of debt				$ 515
Servier Loan [Member]
Debt Instrument [Line Items]
Date of agreement		Dec. 30, 2010
Maximum borrowing capacity under loan agreement \| €		€ 15,000,000
Payment of debt through cash by NIBR	$ 14,300
Euro to US Dollar exchange rates \| € / $	1.1932
Loss on extinguishment of debt			$ 100

XML 57 R45.htm IDEA: XBRL DOCUMENT

Long-Term Debt - Hercules Term Loan - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands			3 Months Ended
	Mar. 21, 2017	Feb. 27, 2015	Mar. 31, 2018	Mar. 31, 2017
Debt Instrument [Line Items]
Loss on extinguishment of debt				$ 515
Hercules Term Loan [Member]
Debt Instrument [Line Items]
Variable rate basis			The Hercules Term Loan had a variable interest rate that was the greater of either (i) 9.40% plus the prime rate as reported from time to time in The Wall Street Journal minus 7.25%, or (ii) 9.40%.
Prepayment charge not required to pay	1.00%
Loss on extinguishment of debt				$ 500
Aggregate number of unregistered shares of common stock called by warrants (in shares)		9,063
Exercise price of warrants (in dollars per share)		$ 66.20
Exercisable period of warrants		5 years
Warrants expiration period		2020-02
Minimum [Member] \| Hercules Term Loan [Member]
Debt Instrument [Line Items]
Percentage bearing variable rate		9.40%
Prime Rate [Member] \| Hercules Term Loan [Member]
Debt Instrument [Line Items]
Basis spread, addition		9.40%
Basis spread, subtraction		7.25%

XML 58 R46.htm IDEA: XBRL DOCUMENT

Long-Term Debt - Interest Expense and Amortization of Debt Issuance Costs (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Interest expense and amortization of debt issuance costs [Abstract]
Interest expense	$ 170	$ 609
Novartis Note [Member]
Interest expense and amortization of debt issuance costs [Abstract]
Interest expense	139	117
Servier Loan [Member]
Interest expense and amortization of debt issuance costs [Abstract]
Interest expense		177
Hercules Loan [Member]
Interest expense and amortization of debt issuance costs [Abstract]
Interest expense		311
Other [Member]
Interest expense and amortization of debt issuance costs [Abstract]
Interest expense	$ 31	$ 4

XML 59 R47.htm IDEA: XBRL DOCUMENT

Common Stock Warrants - Summary of Common Stock Warrants Outstanding (Details) - $ / shares	3 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Class Of Warrant Or Right [Line Items]
Warrant outstanding (in shares)	17,312	17,312
Five Year Warrants Issued in February 2015 [Member] \| Stockholders' Equity [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2015-02
Expiration Date	2020-02
Exercise price of warrants (in dollars per share)	$ 66.20
Warrant outstanding (in shares)	9,063	9,063
Five Year Warrants Issued in February 2016 [Member] \| Stockholders' Equity [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2016-02
Expiration Date	2021-02
Exercise price of warrants (in dollars per share)	$ 15.40
Warrant outstanding (in shares)	8,249	8,249

XML 60 R48.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Additional Information (Details)			3 Months Ended
	Mar. 31, 2018 USD ($) RenewalOption	Nov. 21, 2017 USD ($) Facility	Mar. 31, 2018 USD ($) RenewalOption
Commitments And Contingencies [Line Items]
Estimate of milestone payments	$ 15,500,000		$ 15,500,000
Operating leases, expiry date			2023-04
Operating leases, number of successive renewal options \| RenewalOption	2		2
Operating leases, extended lease term			5 years
Operating leases, number of portions of leased facilities \| Facility		1
Operating leases, number of leased facilities \| Facility		3
Operating leases, sublease commencement date		Dec. 26, 2017
Operating leases sublease income receivable		$ 5,100,000
Operating leases sublease expiry date		2023-04
Sublease tenant improvement allowance		$ 800,000
Sublease income			$ 400,000
Standby Letter of Credit [Member]
Commitments And Contingencies [Line Items]
Letter of credit amount		$ 1,000,000
Funds drawn from letter of credit	$ 0

XML 61 R49.htm IDEA: XBRL DOCUMENT

Stock-based Compensation - Additional Information (Details) - USD ($)	1 Months Ended	3 Months Ended
	Dec. 31, 2017	Mar. 31, 2018	Mar. 31, 2017
Additional disclosures [Abstract]
Stock-based compensation expense		$ 1,416,000	$ 1,000,000
Stock Options [Member]
Additional disclosures [Abstract]
Minimum age required for employees to qualify for immediate vesting of RSUs		55 years
Threshold years required for retirement age		70 years
Unrecognized compensation expense related to stock options		$ 6,700,000
Weighted average period of unrecognized compensation expense expected to be recognized		2 years 3 months 18 days
Options outstanding	1,622,065	1,653,196
Options granted		133,000
Performance Shares [Member]
Additional disclosures [Abstract]
Unrecognized compensation expense related to stock options		$ 400,000
Options outstanding		82,500
Number of options subject to achievement of corporate goals		41,250
Stock-based compensation expense		$ 56,000
Grant date fair value		$ 400,000
Restricted Stock Units (RSUs) [Member]
Additional disclosures [Abstract]
Minimum age required for employees to qualify for immediate vesting of RSUs		55 years
Threshold years required for retirement age		70 years
Weighted average period of unrecognized compensation expense expected to be recognized		7 months 6 days
Unrecognized compensation expense related to employee RSUs		$ 24,000
Non Executive Employee [Member] \| Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period		3 years
Non Executive Employee [Member] \| Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period		4 years
Non Executive Employee [Member] \| Restricted Stock Units (RSUs) [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period		3 years
Directors [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period		1 year
Directors [Member] \| Restricted Stock Units (RSUs) [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period		1 year
Executives [Member] \| Performance Shares [Member]
Additional disclosures [Abstract]
Options granted	130,000
Stock options cancelled		50,000
Executives [Member] \| Service-Based Stock Options [Member]
Additional disclosures [Abstract]
Options granted		80,000
2015 ESPP [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage related to employees to purchase shares at the lower fair market value at offering period		85.00%

XML 62 R50.htm IDEA: XBRL DOCUMENT

Stock-based Compensation - Weighted Average Assumptions (Details) - Stock Options [Member]	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Stock-based awards weighted average assumptions [Abstract]
Dividend yield	0.00%	0.00%
Expected volatility	101.00%	100.00%
Risk-free interest rate	2.72%	1.95%
Expected term	5 years 7 months 6 days	5 years 7 months 6 days

XML 63 R51.htm IDEA: XBRL DOCUMENT

Stock-based Compensation - Stock Option Activity (Details) - Stock Options [Member] $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2018 USD ($) $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares, Outstanding at January 1, 2018 \| shares	1,622,065
Number of shares, Granted \| shares	133,000
Number of shares, Exercised \| shares	(400)
Number of shares, Forfeited, expired or cancelled \| shares	(101,469)
Number of shares, Outstanding at March 31, 2018 \| shares	1,653,196
Number of shares, Exercisable at March 31, 2018 \| shares	915,442
Weighted Average Exercise Price Per Share, Outstanding at January 1, 2018 \| $ / shares	$ 24.54
Weighted Average Exercise Price Per Share, Granted \| $ / shares	26.90
Weighted Average Exercise Price Per Share, Exercised \| $ / shares	33.80
Weighted Average Exercise Price Per Share, Forfeited, expired or cancelled \| $ / shares	54.24
Weighted Average Exercise Price Per Share, Outstanding at March 31, 2018 \| $ / shares	22.91
Weighted Average Exercise Price Per Share, Exercisable at March 31, 2018 \| $ / shares	$ 29.09
Weighted Average Contractual Term (in years), Outstanding at March 31, 2018	8 years 3 months 25 days
Weighted Average Contractual Term (in years), Exercisable at March 31, 2018	7 years 6 months 18 days
Aggregate Intrinsic Value, Outstanding at March 31, 2018 \| $	$ 16,625
Aggregate Intrinsic Value, Exercisable at March 31, 2018 \| $	$ 9,959

XML 64 R52.htm IDEA: XBRL DOCUMENT

Stock-based Compensation - RSU Activity (Details) - Restricted Stock Units (RSUs) [Member]	3 Months Ended
	Mar. 31, 2018 $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares, Unvested balance at January 1, 2018 \| shares	18,480
Number of Shares, Vested \| shares	(13,360)
Number of Shares, Unvested balance at March 31, 2018 \| shares	5,120
Weighted-Average Grant-Date Fair Value, Unvested balance at January 1, 2018 \| $ / shares	$ 18.00
Weighted-Average Grant-Date Fair Value, Vested \| $ / shares	13.08
Weighted-Average Grant-Date Fair Value, Unvested balance at March 31, 2018 \| $ / shares	$ 30.86

XML 65 R53.htm IDEA: XBRL DOCUMENT

Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 1,416	$ 1,000
Research and Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	104	441
General and Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 1,312	$ 559

XML 66 R54.htm IDEA: XBRL DOCUMENT

Capital Stock - Biotechnology Value Fund Financing - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended	3 Months Ended
	Feb. 28, 2017	Mar. 31, 2018	Dec. 31, 2017
Class Of Warrant Or Right [Line Items]
Cash proceeds from issuance of common stock and convertible preferred stock	$ 24.8
Preferred stock, stated value		$ 0.05	$ 0.05
Ownership percentage on outstanding shares		18.00%
Convertible Preferred Stock (as Converted) [Member]
Class Of Warrant Or Right [Line Items]
Sale of shares	5,003
Preferred stock, stated value	$ 4,030
Conversion of preferred stock into registered common stock	1,000
Preferred stock conversion price per share	$ 4.03
Total number of shares of common stock issued upon conversion	5,003,000
Percentage of convertible preferred stock conversion blocker provision	19.99%
Convertible preferred stock voting rights description		Shares of Series X convertible preferred stock will generally have no voting rights, except as required by law and except that the consent of the holders of the outstanding Series X convertible preferred stock will be required to amend the terms of the Series X preferred stock and to approve certain corporate actions.
Ownership percentage on outstanding shares upon conversion		48.80%
Preferred shares converted		0
Fair value of common stock amount exceeded purchase price of convertible preferred stock	$ 5.6
Common Stock [Member]
Class Of Warrant Or Right [Line Items]
Sale of shares	1,200,000
Common stock share price	$ 4.03

XML 67 R55.htm IDEA: XBRL DOCUMENT

Capital Stock - ATM Agreements - Additional Information (Details) - USD ($)	1 Months Ended	3 Months Ended
	Feb. 28, 2017	Mar. 31, 2018	Mar. 31, 2017	Nov. 12, 2015
Class Of Warrant Or Right [Line Items]
Proceeds from issuance of common stock		$ 2,309,000	$ 5,380,000
Common Stock [Member]
Class Of Warrant Or Right [Line Items]
Sale of shares	1,200,000
2015 ATM Agreement [Member]
Class Of Warrant Or Right [Line Items]
Sales commission paid per transaction (in hundredths)		3.00%
Maximum amount of shares can be issued				$ 75,000,000
Proceeds from issuance of common stock		$ 2,400,000	600,000
Offering costs offset against proceeds upon sale of common stock		$ 100,000	$ 200,000
Agreement expired date		2018-02
2015 ATM Agreement [Member] \| Common Stock [Member]
Class Of Warrant Or Right [Line Items]
Sale of shares		67,658	110,252

XML 68 R56.htm IDEA: XBRL DOCUMENT

Capital Stock - Common Stock Purchase Agreement - Additional Information (Details) - Novartis [Member] $ / shares in Units, $ in Millions	Aug. 24, 2017 USD ($) $ / shares shares
Class Of Warrant Or Right [Line Items]
Number of common stock agreed to issue and sell \| shares	539,131
Common stock sale price \| $ / shares	$ 9.2742
Aggregate purchase price of common stock agreed to issue and sell	$ 5.0
Common stock aggregate fair value	$ 4.8
Common stock closing price \| $ / shares	$ 8.93
Common stock purchase agreement date	Aug. 24, 2017
Common stock premium	$ 0.2

XML 69 R57.htm IDEA: XBRL DOCUMENT

Income Taxes - Additional Information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Provision for federal income tax	$ 0	$ 0
Unrecognized tax benefits that would impact effective tax rate	4,500,000		$ 4,500,000
Provision for income tax reflect any adjustment to previously assessed tax act enactment effect	$ 0

XML 70 R58.htm IDEA: XBRL DOCUMENT

Subsequent Events - Additional Information (Details)					1 Months Ended	3 Months Ended
Subsequent Events - Additional Information (Details)	May 07, 2018 USD ($) $ / shares shares	Apr. 14, 2018 USD ($) Facility	Apr. 02, 2018 USD ($) shares	Nov. 21, 2017 USD ($) Facility	Apr. 30, 2018 USD ($) shares	Mar. 31, 2018 USD ($)	Mar. 31, 2017 USD ($)
Subsequent Event [Line Items]
Proceeds from issuance of common stock						$ 2,309,000	$ 5,380,000
Operating leases, number of portions of leased facilities \| Facility				1
Operating leases, number of leased facilities \| Facility				3
Operating leases, sublease commencement date				Dec. 26, 2017
Operating leases sublease income receivable				$ 5,100,000
Operating leases sublease expiry date				2023-04
Sublease tenant improvement allowance				$ 800,000
Subsequent Events [Member]
Subsequent Event [Line Items]
Operating leases, number of portions of leased facilities \| Facility		1
Operating leases, number of leased facilities \| Facility		3
Operating leases, sublease commencement date		May 01, 2018
Operating leases sublease income receivable		$ 1,100,000
Operating leases sublease expiry date		2023-04
Sublease tenant improvement allowance		$ 65,000
Loan and Security Agreement [Member] \| Subsequent Events [Member] \| Silicon Valley Bank [Member] \| Warrants for Common Stock [Member]
Subsequent Event [Line Items]
Aggregate number of shares of common stock called by warrants \| shares	6,332
Exercise price of per share \| $ / shares	$ 23.69
Exercisable period of warrants	10 years
Loan and Security Agreement [Member] \| Subsequent Events [Member] \| Term Loan [Member] \| Silicon Valley Bank [Member]
Subsequent Event [Line Items]
Maximum borrowing capacity under loan agreement	$ 20,000,000
Gross cash proceeds received from milestone and licensing payments	$ 20,000,000
Earlier effecitve date of term loan	Mar. 31, 2019
Effective date of term loan extended	Mar. 31, 2020
Basis spread on variable rate	4.75%
Variable rate basis	The interest-only period will be followed by equal monthly payments of principal and interest over 24 months. Each Term Loan Advance will mature at the earlier of (i) the 23 months following the applicable term loan amortization date for each such Term Loan Advance (ii) March 1, 2023, or (iii) 30 days prior to the earliest maturity of any portion of the Company’s loan with Novartis (the “Loan Maturity Date”). After repayment, no Term Loan Advance (or any portion thereof) may be reborrowed.
Period of monthly payments of principal and interest	24 months
Repayment of term loan	$ 0
Loan borrowed	$ 0
Percentage of final payment of Loan	8.50%
Percentage of prepayment fee	3.00%
Additional interest rate of outstanding payments due	4.00%
Percentage of unused portion of term loan	1.00%
Loan and Security Agreement [Member] \| Subsequent Events [Member] \| Term Loan [Member] \| Silicon Valley Bank [Member] \| First Anniversary [Member]
Subsequent Event [Line Items]
Percentage of amount prepaid	2.00%
Loan and Security Agreement [Member] \| Subsequent Events [Member] \| Term Loan [Member] \| Silicon Valley Bank [Member] \| Second Anniversary [Member]
Subsequent Event [Line Items]
Percentage of amount prepaid	1.00%
Loan and Security Agreement [Member] \| Subsequent Events [Member] \| Term Loan [Member] \| Prime Rate [Member] \| Silicon Valley Bank [Member]
Subsequent Event [Line Items]
Basis spread on variable rate	0.25%
Loan and Security Agreement [Member] \| Subsequent Events [Member] \| Novartis [Member] \| Silicon Valley Bank [Member]
Subsequent Event [Line Items]
Days of interest, period	30 days
Earliest maturity of loan	30 days
Maturity date	Mar. 01, 2023
Rezolute [Member] \| Amended Common Stock Purchase Agreement [Member] \| Subsequent Events [Member]
Subsequent Event [Line Items]
Gross proceeds from convertible note finaning			$ 4,000,000
Issuance of common stock, shares \| shares			8,023,758		69,252
Proceeds from issuance of common stock			$ 500,000		$ 50,000

EXCEL 71 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 72 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 73 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 75 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 171 298 1 true 75 0 false 12 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.xoma.com/20180331/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) Sheet http://www.xoma.com/20180331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) Statements 2 false false R3.htm 100020 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical) Sheet http://www.xoma.com/20180331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical) Statements 3 false false R4.htm 100030 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited) Sheet http://www.xoma.com/20180331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited) Statements 4 false false R5.htm 100040 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) Sheet http://www.xoma.com/20180331/taxonomy/role/StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) Statements 5 false false R6.htm 100050 - Disclosure - Description of Business Sheet http://www.xoma.com/20180331/taxonomy/role/DisclosureDescriptionOfBusiness Description of Business Notes 6 false false R7.htm 100060 - Disclosure - Basis of Presentation and Significant Accounting Policies Sheet http://www.xoma.com/20180331/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies Basis of Presentation and Significant Accounting Policies Notes 7 false false R8.htm 100070 - Disclosure - Condensed Consolidated Financial Statements Detail Sheet http://www.xoma.com/20180331/taxonomy/role/DisclosureCondensedConsolidatedFinancialStatementsDetail Condensed Consolidated Financial Statements Detail Notes 8 false false R9.htm 100080 - Disclosure - Collaborative, Licensing and Other Arrangements Sheet http://www.xoma.com/20180331/taxonomy/role/DisclosureCollaborativeLicensingAndOtherArrangements Collaborative, Licensing and Other Arrangements Notes 9 false false R10.htm 100090 - Disclosure - Fair Value Measurements Sheet http://www.xoma.com/20180331/taxonomy/role/DisclosureFairValueMeasurements Fair Value Measurements Notes 10 false false R11.htm 100100 - Disclosure - Dispositions Sheet http://www.xoma.com/20180331/taxonomy/role/DisclosureDispositions Dispositions Notes 11 false false R12.htm 100110 - Disclosure - Restructuring Charges Sheet http://www.xoma.com/20180331/taxonomy/role/DisclosureRestructuringCharges Restructuring Charges Notes 12 false false R13.htm 100120 - Disclosure - Long-Term Debt Sheet http://www.xoma.com/20180331/taxonomy/role/DisclosureLongTermDebt Long-Term Debt Notes 13 false false R14.htm 100130 - Disclosure - Common Stock Warrants Sheet http://www.xoma.com/20180331/taxonomy/role/DisclosureCommonStockWarrants Common Stock Warrants Notes 14 false false R15.htm 100140 - Disclosure - Commitments and Contingencies Sheet http://www.xoma.com/20180331/taxonomy/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 15 false false R16.htm 100150 - Disclosure - Stock-based Compensation Sheet http://www.xoma.com/20180331/taxonomy/role/DisclosureStockBasedCompensation Stock-based Compensation Notes 16 false false R17.htm 100160 - Disclosure - Capital Stock Sheet http://www.xoma.com/20180331/taxonomy/role/DisclosureCapitalStock Capital Stock Notes 17 false false R18.htm 100170 - Disclosure - Income Taxes Sheet http://www.xoma.com/20180331/taxonomy/role/DisclosureIncomeTaxes Income Taxes Notes 18 false false R19.htm 100180 - Disclosure - Subsequent Events Sheet http://www.xoma.com/20180331/taxonomy/role/DisclosureSubsequentEvents Subsequent Events Notes 19 false false R20.htm 100190 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies) Sheet http://www.xoma.com/20180331/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies Basis of Presentation and Significant Accounting Policies (Policies) Policies http://www.xoma.com/20180331/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies 20 false false R21.htm 100200 - Disclosure - Condensed Consolidated Financial Statements Detail (Tables) Sheet http://www.xoma.com/20180331/taxonomy/role/DisclosureCondensedConsolidatedFinancialStatementsDetailTables Condensed Consolidated Financial Statements Detail (Tables) Tables http://www.xoma.com/20180331/taxonomy/role/DisclosureCondensedConsolidatedFinancialStatementsDetail 21 false false R22.htm 100210 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.xoma.com/20180331/taxonomy/role/DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.xoma.com/20180331/taxonomy/role/DisclosureFairValueMeasurements 22 false false R23.htm 100220 - Disclosure - Restructuring Charges (Tables) Sheet http://www.xoma.com/20180331/taxonomy/role/DisclosureRestructuringChargesTables Restructuring Charges (Tables) Tables http://www.xoma.com/20180331/taxonomy/role/DisclosureRestructuringCharges 23 false false R24.htm 100230 - Disclosure - Long-Term Debt (Tables) Sheet http://www.xoma.com/20180331/taxonomy/role/DisclosureLongTermDebtTables Long-Term Debt (Tables) Tables http://www.xoma.com/20180331/taxonomy/role/DisclosureLongTermDebt 24 false false R25.htm 100240 - Disclosure - Common Stock Warrants (Tables) Sheet http://www.xoma.com/20180331/taxonomy/role/DisclosureCommonStockWarrantsTables Common Stock Warrants (Tables) Tables http://www.xoma.com/20180331/taxonomy/role/DisclosureCommonStockWarrants 25 false false R26.htm 100250 - Disclosure - Stock-based Compensation (Tables) Sheet http://www.xoma.com/20180331/taxonomy/role/DisclosureStockBasedCompensationTables Stock-based Compensation (Tables) Tables http://www.xoma.com/20180331/taxonomy/role/DisclosureStockBasedCompensation 26 false false R27.htm 100260 - Disclosure - Description of Business - Additional Information (Details) Sheet http://www.xoma.com/20180331/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails Description of Business - Additional Information (Details) Details 27 false false R28.htm 100270 - Disclosure - Basis of Presentation and Significant Accounting Policies - Additional Information (Details) Sheet http://www.xoma.com/20180331/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails Basis of Presentation and Significant Accounting Policies - Additional Information (Details) Details 28 false false R29.htm 100280 - Disclosure - Condensed Consolidated Financial Statements Detail - Additional Information 1 (Details) Sheet http://www.xoma.com/20180331/taxonomy/role/DisclosureCondensedConsolidatedFinancialStatementsDetailAdditionalInformation1Details Condensed Consolidated Financial Statements Detail - Additional Information 1 (Details) Details 29 false false R30.htm 100290 - Disclosure - Condensed Consolidated Financial Statements Detail - Additional Information 2 (Details) Sheet http://www.xoma.com/20180331/taxonomy/role/DisclosureCondensedConsolidatedFinancialStatementsDetailAdditionalInformation2Details Condensed Consolidated Financial Statements Detail - Additional Information 2 (Details) Details 30 false false R31.htm 100300 - Disclosure - Condensed Consolidated Financial Statements Detail - Accrued and Other Liabilities (Details) Sheet http://www.xoma.com/20180331/taxonomy/role/DisclosureCondensedConsolidatedFinancialStatementsDetailAccruedAndOtherLiabilitiesDetails Condensed Consolidated Financial Statements Detail - Accrued and Other Liabilities (Details) Details 31 false false R32.htm 100310 - Disclosure - Condensed Consolidated Financial Statements Detail - Reconciliation of Numerator and Denominator Used in Calculation of Basic and Diluted Net Loss per Share Available to Common Stockholders (Details) Sheet http://www.xoma.com/20180331/taxonomy/role/DisclosureCondensedConsolidatedFinancialStatementsDetailReconciliationOfNumeratorAndDenominatorUsedInCalculationOfBasicAndDilutedNetLossPerShareAvailableToCommonStockholdersDetails Condensed Consolidated Financial Statements Detail - Reconciliation of Numerator and Denominator Used in Calculation of Basic and Diluted Net Loss per Share Available to Common Stockholders (Details) Details 32 false false R33.htm 100320 - Disclosure - Condensed Consolidated Financial Statements Detail - Outstanding Securities Considered Anti-Dilutive (Details) Sheet http://www.xoma.com/20180331/taxonomy/role/DisclosureCondensedConsolidatedFinancialStatementsDetailOutstandingSecuritiesConsideredAntiDilutiveDetails Condensed Consolidated Financial Statements Detail - Outstanding Securities Considered Anti-Dilutive (Details) Details 33 false false R34.htm 100330 - Disclosure - Licensing and Other Arrangements - Novartis - Additional Information (Details) Sheet http://www.xoma.com/20180331/taxonomy/role/DisclosureLicensingAndOtherArrangementsNovartisAdditionalInformationDetails Licensing and Other Arrangements - Novartis - Additional Information (Details) Details 34 false false R35.htm 100340 - Disclosure - Licensing and Other Arrangements - Rezolute - Additional Information (Details) Sheet http://www.xoma.com/20180331/taxonomy/role/DisclosureLicensingAndOtherArrangementsRezoluteAdditionalInformationDetails Licensing and Other Arrangements - Rezolute - Additional Information (Details) Details 35 false false R36.htm 100350 - Disclosure - Licensing and Other Arrangements - NIAID - Additional Information (Details) Sheet http://www.xoma.com/20180331/taxonomy/role/DisclosureLicensingAndOtherArrangementsNIAIDAdditionalInformationDetails Licensing and Other Arrangements - NIAID - Additional Information (Details) Details 36 false false R37.htm 100360 - Disclosure - Licensing and Other Arrangements - Sale of Future Revenue Streams - Additional Information (Details) Sheet http://www.xoma.com/20180331/taxonomy/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsAdditionalInformationDetails Licensing and Other Arrangements - Sale of Future Revenue Streams - Additional Information (Details) Details 37 false false R38.htm 100370 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value on Recurring Basis (Details) Sheet http://www.xoma.com/20180331/taxonomy/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value on Recurring Basis (Details) Details 38 false false R39.htm 100380 - Disclosure - Fair Value Measurements - Outstanding Long Term Debt Carrying Amount and Estimated Fair Value (Details) Sheet http://www.xoma.com/20180331/taxonomy/role/DisclosureFairValueMeasurementsOutstandingLongTermDebtCarryingAmountAndEstimatedFairValueDetails Fair Value Measurements - Outstanding Long Term Debt Carrying Amount and Estimated Fair Value (Details) Details 39 false false R40.htm 100390 - Disclosure - Dispositions - Additional Information (Details) Sheet http://www.xoma.com/20180331/taxonomy/role/DisclosureDispositionsAdditionalInformationDetails Dispositions - Additional Information (Details) Details 40 false false R41.htm 100400 - Disclosure - Restructuring Charges - Additional Information (Details) Sheet http://www.xoma.com/20180331/taxonomy/role/DisclosureRestructuringChargesAdditionalInformationDetails Restructuring Charges - Additional Information (Details) Details 41 false false R42.htm 100410 - Disclosure - Restructuring Charges - Components of Accrued Restructuring Costs (Details) Sheet http://www.xoma.com/20180331/taxonomy/role/DisclosureRestructuringChargesComponentsOfAccruedRestructuringCostsDetails Restructuring Charges - Components of Accrued Restructuring Costs (Details) Details 42 false false R43.htm 100420 - Disclosure - Long-Term Debt - Novartis Note - Additional Information (Details) Sheet http://www.xoma.com/20180331/taxonomy/role/DisclosureLongTermDebtNovartisNoteAdditionalInformationDetails Long-Term Debt - Novartis Note - Additional Information (Details) Details 43 false false R44.htm 100430 - Disclosure - Long-Term Debt - Servier Loan Agreement - Additional Information (Details) Sheet http://www.xoma.com/20180331/taxonomy/role/DisclosureLongTermDebtServierLoanAgreementAdditionalInformationDetails Long-Term Debt - Servier Loan Agreement - Additional Information (Details) Details 44 false false R45.htm 100440 - Disclosure - Long-Term Debt - Hercules Term Loan - Additional Information (Details) Sheet http://www.xoma.com/20180331/taxonomy/role/DisclosureLongTermDebtHerculesTermLoanAdditionalInformationDetails Long-Term Debt - Hercules Term Loan - Additional Information (Details) Details 45 false false R46.htm 100450 - Disclosure - Long-Term Debt - Interest Expense and Amortization of Debt Issuance Costs (Details) Sheet http://www.xoma.com/20180331/taxonomy/role/DisclosureLongTermDebtInterestExpenseAndAmortizationOfDebtIssuanceCostsDetails Long-Term Debt - Interest Expense and Amortization of Debt Issuance Costs (Details) Details 46 false false R47.htm 100460 - Disclosure - Common Stock Warrants - Summary of Common Stock Warrants Outstanding (Details) Sheet http://www.xoma.com/20180331/taxonomy/role/DisclosureCommonStockWarrantsSummaryOfCommonStockWarrantsOutstandingDetails Common Stock Warrants - Summary of Common Stock Warrants Outstanding (Details) Details 47 false false R48.htm 100470 - Disclosure - Commitments and Contingencies - Additional Information (Details) Sheet http://www.xoma.com/20180331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails Commitments and Contingencies - Additional Information (Details) Details 48 false false R49.htm 100480 - Disclosure - Stock-based Compensation - Additional Information (Details) Sheet http://www.xoma.com/20180331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails Stock-based Compensation - Additional Information (Details) Details 49 false false R50.htm 100490 - Disclosure - Stock-based Compensation - Weighted Average Assumptions (Details) Sheet http://www.xoma.com/20180331/taxonomy/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsDetails Stock-based Compensation - Weighted Average Assumptions (Details) Details 50 false false R51.htm 100500 - Disclosure - Stock-based Compensation - Stock Option Activity (Details) Sheet http://www.xoma.com/20180331/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails Stock-based Compensation - Stock Option Activity (Details) Details 51 false false R52.htm 100510 - Disclosure - Stock-based Compensation - RSU Activity (Details) Sheet http://www.xoma.com/20180331/taxonomy/role/DisclosureStockBasedCompensationRSUActivityDetails Stock-based Compensation - RSU Activity (Details) Details 52 false false R53.htm 100520 - Disclosure - Stock-based Compensation - Stock-based Compensation Expense (Details) Sheet http://www.xoma.com/20180331/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails Stock-based Compensation - Stock-based Compensation Expense (Details) Details 53 false false R54.htm 100530 - Disclosure - Capital Stock - Biotechnology Value Fund Financing - Additional Information (Details) Sheet http://www.xoma.com/20180331/taxonomy/role/DisclosureCapitalStockBiotechnologyValueFundFinancingAdditionalInformationDetails Capital Stock - Biotechnology Value Fund Financing - Additional Information (Details) Details 54 false false R55.htm 100540 - Disclosure - Capital Stock - ATM Agreements - Additional Information (Details) Sheet http://www.xoma.com/20180331/taxonomy/role/DisclosureCapitalStockATMAgreementsAdditionalInformationDetails Capital Stock - ATM Agreements - Additional Information (Details) Details 55 false false R56.htm 100550 - Disclosure - Capital Stock - Common Stock Purchase Agreement - Additional Information (Details) Sheet http://www.xoma.com/20180331/taxonomy/role/DisclosureCapitalStockCommonStockPurchaseAgreementAdditionalInformationDetails Capital Stock - Common Stock Purchase Agreement - Additional Information (Details) Details 56 false false R57.htm 100560 - Disclosure - Income Taxes - Additional Information (Details) Sheet http://www.xoma.com/20180331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails Income Taxes - Additional Information (Details) Details 57 false false R58.htm 100570 - Disclosure - Subsequent Events - Additional Information (Details) Sheet http://www.xoma.com/20180331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails Subsequent Events - Additional Information (Details) Details 58 false false All Reports Book All Reports xoma-20180331.xml xoma-20180331.xsd xoma-20180331_cal.xml xoma-20180331_def.xml xoma-20180331_lab.xml xoma-20180331_pre.xml http://fasb.org/us-gaap/2017-01-31 http://xbrl.sec.gov/dei/2014-01-31 true true ZIP 77 0001564590-18-012453-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-18-012453-xbrl.zip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
C^QCU?NV5R->OM^^ KQ]7JD"O'WQ](R M!T67L,)AF9JJK+!DT<_4I.16>A5R5)/P'2C(K%C\PV3JAS/&$#T1YB-0E<9C M%KUC 1MY,<]IB /CAODU2[ZHN.H=QBZ#[>>MMTSNP^K>46NZUZ0IQK89Q/!% MK?>QMDSN _8*ZD;WFO@'U??C.ZU6'_ZO+3_4G_Q;W#U_5*>\_BG^_\I.>?38 M?HEK:%JM VA*JCW6Q?S#CCQ[Z+,;8!6].N!S&+AA0,>?AW;PV_5HQ+ O$#SU M^=.[ZQLCS&M-6\1RML5?"<]&KQR(JU +O;*G>CNZ?""?*^ZW+CH7\D/]=ZDJ M$:^PRAW70+0N3CL7JVL@MK[]M!FYSX#V7)2_K8GA3Q0<3J M]5#$3U>??XM;52SZ'-I!1JE66Q8;M0Z:9'-KVZD4MI!FJV/HUO9S:FN2UE"T MD@RV]BN#9ZWS3C_]8"A6U1*>GW;Z%2RA>&P_,F@HND9UG2#4OF3PD(KEZB.# M>ZI]6T#:O[/(27S&O[-HDJ?O86TG+*1O^0*/:\-@ 9$7GF'R@L(9IE:G,?N/(]:F_Q>3ENBTH0GD6>X6GKUNJ78UBPK?D\ MK.H3$[=V%G5! OA9T/;)$\#U(JTR3,^2MO.+.R[B4JG\1R^P \<+[@[VK,!" M^I:N[[CL[D(2/Q,1?GH2[T^*KWR;\^O1/VT\61]?1S?>W5B_W.^>_;_,CN3/ M_!/G"7/%]7*X 9'/@VI] C][]M#S8?DT?F;4X]#Y;1SZ+HLX]K6.9X>J'Q;B M+;V"KPKF=M2E<1[[RO%8@/]GJK\V86YY:YSA[O6Y>PYUAKUKQ]Z[TMW/EJF/ M167O^":A.FGB9\NK1Z. Z\>LN]&K!W%$P^C5/5[^5!^]^HQY]1CUZC:9E;BC M_01U+.NMKTT%(-M;7ZL^"RUDEW"I*R\?3S&RO0CE<\CY%?4DOV.!XV'S\J]V MG$3L>I1]G;MB[A9HX0YGGUD< Z_#8Q%S%5L_'7H?J66J+SNK;UNV\-V*^=;$ M8&=$1Y>]=3"^>]VI7\Q>=.G8QY-G+[ M8^Z.>JTQXT=OA&T9TU9,:/Y4@U=\ M[U#S:OJ:Y]M15EOU,TUFK3@2HCHB>[$/G M,'BH;%*ZRK0N9-$Z#_EX26V9,'>WDF'"O3/ADUVDM,>N[Z7LI;;DO8@Y<1@] M,ZY*]^1SRWNF!+Y\L",7&]KKA,U9_>LIWMUTJ#3.K4^['7#1"@V9#[)^IE9D MWE\%S09D/H1,Z;ZIN]N\^28JV(CDGO?E2HGVC46C,)J(:Q/MB/'G0;(%RWKN M!'L&;LX34:[.3LXB$E<)<-*X\GHT\AP6Y]LSES-7NX'18]+ 56-Q;-SD8MI(_1HH9%CU6+UHP]Z385 MSXFEF/X(O)C?W/XPJ?)]I,H7L.E2&AEFK<2L)O%N6'-_K'EP?&;(_4AR'T1T M6P'ELP-??8M8B,61=*A/G@&**Y8)_[2-3\W5GAZ$M8=(]O0B07=Q&C'WN'&LR4+D_NPI4L\)E& M+!NJ8,,B&[#((=J.XV33PXJ]#9O6+LBORFC]=KM=^QO3]VPI<]=]M-NG[ MO9RCU@T'*I=780(/1%.8=I9K(J&N3?B$/P>4LK3];V,[FM@.2V+/L?W/L:L3 M_[S351]Z=2=^V;(+]T546?@3W/G-A-;8L1Z"9B)%B^77L?IAZ4SMV4$Q#[H3&XLP7@;8]3B)$)@RP]IOU?YBU-VPY+8LZW(D;Q.*A?=<[>X: M]T4\K<[XEG/U;O5Z_[3U%-<*/R\A'QAI-])^&-)>M/T@[RLOHD[5@K']U=2" M?/\?=N390Y_= ,YR+0LBX [\TF@1HT76G++(4UJSA3Q7&=7UM*I+[28,8K.*+KM*KI':9TJ9?OR M\LSZZ"NCI@Y$-50\?9!CL.>G)W:[;W5\XF_<%:,'#E$//)&_X#+OS0<"Y(;= M40N7(,;Z0](@'TF#M%HGEGSGAHWFNR$43X'^Z_K+I7451M-?7B\:/9O[>V2[ M7G!W.YL,0U^?M+W^I&*^W(C%15X!TB/;_Q2X[.=_LYD^86>]"75-L'#\;/JK M)(K@MX\>=VP?+QG_($BD0]!=#X)3U?=PV?A%!'ST?!9=P0]W891;?F^]R6\G MR/^1=<.F8837VEHHIW8PT[&1FVR.%%E9J>BB?9W$:.:0>#I@_56 H6JW7.9X M !+_]>33UX\G5A)XXO$?_^8T^,E?S[N#LW8[3ZTE(&3@O@\="E8RW'Z$;[@. MXV ]Y.$G <>"L1=-+N+&N>G/UIO^?]IEDVMCST^/ED&?\7R]&=NMT__)SXD# M9M-0I3&!XMLYXE^L-\\(.(")B7)#SB](K'9>"-MK*CO]@/3"\<7T::FWS;'/ M'OX'+=R][9-QBZ_ H,V \\"R)#F05JI"A$23@--N3@ \'O8Z[;,?M^]/_MIK M7PS.X>U?7J\%S2,7L$*UBJ:W%1?0[9VU'[N &^8P>'#H,_Z5Q5)UZ@"OU,1K M8+P[R(%;.O>:X*W0U>O@LWMQMBYXWR(VM3U7MGD#U%_'8Q9==LVX.V J0/ KT%6I]+3QWSAX'^D(@5RK_-7BU,SC+@[D)0"MLPUK2#OJJ M7Q6@;U$(?FX\P]O28\ H:@-J8PJ,K,.WTJ941]A9OT#4Q1!L!&MGA35:!Y?G M1=FI"JO&F5_#P)DC>&>+]JG?O\A!63KWFN!MT?H,^F?K@B=^U>'9JG'IMMLE M\K$*A"T:D%[OHELFH@40' HM+9UX5PB]:@ M/3B[J RA.(OG.%'"7&4H/GOV$!,3'BO1P)TMFH1VMRO\Q6I0; KQ%FT&V+#^ MVA!K=,#'1?_;[_;/4F"W:$#:@\&@R CE *P/9W>+QJ,]Z)YM N=[V3;OAMVS M("F1JNX6C<>@GP]MRB=?%\!MFH]V?VT KT+,*#GQ/[UX?)7P&-"=SBT*H6 &4QP&_1;OT>."I@0;C\4*+T%UAL]82L#RTY7/GX5NJ4;LK4U)K M.&7GYWE[NDJ++H=LA75:B\B]3FU&UC840IE;V5&;1W/KG]6('CI].N"N,((K87(C4 L M.B?E8*[Q_M!MAM'=:Z!O^_6_OGR^Q:UW^U34.C@PW^N-X#Y;"VZ) MXUW"G6\=7*LU:':8NV9BV8+EW7 MD\W@; \"MRM[ZL6VK[VD0[E%4]-NGY_W>GD/=J:!X#_19M M&D!_=M$J)(37A9[(,0Y]ET5R+09)_;/SP5J0::X# M5GPMA7.+L=)\,GL5()N#O<7(:3X!OA[8>7O[S8ZN(ZJ NPRUC6$>UB&J JZ3.)Q&'E_,%<'?UT+N:@N M"5D^QS[+0=@4W'5MXI.!^XGS) _JNA9P$:@@E=WE<(JY-X%Q73NW>QC+R^<& MZYJXS0&=*Y[; -IUS=X.H-7;75;08NL:P&I:K'76+_7KJRFQ-9>PKC%\XB4L MT6IGCS6%"M[.V5D7_^F4@KQ@SBFVLVV9M7. D,IM5\R]-H#; M,F3GG=Y%N_]H ,L5V=FV;-AJ-%919$M!W98I6XW0):"*S3DN-QMT\-:KK:[H ML[<*-:2%^:M#M\I@Y:\7J9ASZ+NQ"5AFNC9#?;FV\DBQ)03_I>>GS]>K**[+Q()^8 M4O.NAF:5,=H$ ?@SS8''H@41XD3)Q$8O"NP M@'=Y(5Q54+B1$+8Z12F*J6)VO-\N))Q+@%@'RHM5Y8*;8/*TW;KH+$#E M(C!5[9-$-99-Z&"N=S"T@^QVX+[W[K'K@POL>[7HW2Q"J0Z7MIC<(B_O;<_'(M/OH1:P MRPVK=S;W''0R/;R!2 ^^+G9BU%)6>1RU4'A V9;]!MGV]ML8J!U<:X M2JLN6=7&EK2S*OU[VFKV!IE0K8!IXP5L;&97+Z#3[)YMN(!_,N]N#-]>@AS: M=^QK@GU KD?THI8!6[*N]1I!+&:W+(G8SH>/FX&X[66NJO:O*E5JF8/S\[.M M+U/1F^Y!0T^+;M34E['RY-HF/DBO7:C9* 5C75!W$7'.;0@O U7:K!&6\%!: MTQLFU!#1MP-,MV.%W_5(4WD?P^B61?>> RYC=.7;WH3K"]I%>"KCE6V NIM% M[\2KT.WN5E:=G2.81@ !,0'F32;8+^:/.=;J= M;0:S_LOUZ*,7 *$PX1-R*I=^[W%QP%1?P$Z2P(5:LZIPY5<#3 6J.Q!'>)S9 M]\@&+>+@&!A"HH/T(XB8[>?W6-LK&XULY*=U!OEPUN.W]NH1I8Y>&N8_.Q<%OG4K+M57U*-M/.Y;'Y'!P;@+N+ M^/RTW]\$7O@)6 BS.N*_GP*M,8L.\RX"]FXQT;0$E@W!WDDTW^UN#V[9GT4= M@BOMTZ(O:!=[JJ?]50NJ N6V5[J+3=?3;J__!$LM=%E @RJ.L9<>T&JOZKZR M&5';_8M59*T"Y[;7N@MGX+3?.6\_P5H+IZ5S/73:J_J_;!:?=8OGM5?#]+A5 M["1!?S;8^BH*QX;U)>S"'3@MG(%:"= CX-^)?Z#J3;:V@/G.'))X^E)VX39T M5KD-"R%;M212\>F^X0(%MHM4P%Q7ALJ0S>UJ8']"<*PQ3^^^F_W@B(?TQ4L( M'^Y%UP(ZUYK =_+',,BM\X/(]#MY=K7TGGD>[U^V=[VSQ,(C#F,L_ M1N&D)+C2^ZYI*UW9N6>3E9ZWYQK 506M$D$_!?=@*-8AZ*K>/UM9YN.@74Q- M/1FVPO;*+T&:U/JU"JXDU :RVNI(CMNW5;88V,2#=0HG#2H@>L8!M;3[D MDJC=0MG0(Q9 /U_3;4'\PT\6.1[/Y;I6-1_:<-MAL8HH@Z=8[S:U9]2@X7JD M-SW1H=[)#L2@B/=%D&CY^ \0.8[P^X^,X3'N[^%GAM6].K [*>Y6U=U+H5B- M6'GH_#/Z(==#W[N;5Z^[\!5Z*_&\ +"MK&@7'D"_O9TE?9.OW3 ZC?X]! \7 MFXWAICW8%-PG6;4_M[I5TB;9O+Q(;PAE)1<@3>]7=@%6=5[:T(ZTY^J-'@'N MKI:^"Y?@[+S0'7V;2_\P&C$GOAY]^.F,\888O)7[.L#A5RUU)]Y"7N6O!]RV M%K8++Z*8QW[,RLJ;XXO+"8K1K+ZN73@7IV#Y\BM;![KMK&L7[L=I?U!HHK_M M=2V\6J'=6^&B#-9IG-L_ZW4JK&.;=T.T>RN+&=;2"(5MA T6D&4\/=W=[NW" M]>A>%/.OV=R:JRJW/G*;YZG]7A7HK.Z!M4F++4?JQNLY6_;>9_^_%;U[O_WW?QVS__ MZ4_XU]3B\@/?8O6G]Y>T((#E]H)JY-T/P!]\ZH1]&;_[+3N)0_,B]/]B;-KY* M?X[LB>?/WGSW)HQ;7]F#=0,H"^2C"-:;((P WV(BO/V+C^ +^#9@XJE[._)L MF-V2#Y[@TMI-ZSWC3N11M&F%(^M=PKV <6[ADE]/\:&JJ\>U#K*E:\AXS.HD MEB34CUBP3H)>L]_[BT!!>H=:*)C&>JD2-U8<6C8@PIY,W_[7>:?3HF?3/]MO MK3"R@&GU)^357-I#KQJ6#4CV[0?L!>%D$S6L,8QN6SZ$/M;8XS%>$P84<+%0 MYY[A(3++#ER0)#IU2$?)@R"\IU-P.&]D3UD2>PZ'1R+XSK5&43BQO)BCO/T. MRG\*$H18P6$!%=XP=&=6S)QQ 2Y T^T:5W#3+2( N3ML[?@: M,+8U3#P_AM$L0"?>YP>PX+UDH]#W0IQGE/C^['24 *)=:QJ%=Y$]X=9P9MGN MO=!:^*V;.+'E8%&H"T(.@AH LA$,F,ZGZR%C&\_P(3ZR4Y>$#W@JL'S/P6 M(L7\"U88$]9-_=10S"=1A_J'3()'297X %5'#@G;82+.&_YH;JKGU>JN]JJNT_@U+P M7.S/AKB27@3@ X(;@9MMZOQY=5L+*T"(P#2,T#8_'9::/OR"U!TCSH.P05Q< MVFTW+'1L\HR,RCN>33T'1!C9FGHCNQ8')'DC^!:D.#T8!CH>3^(1V@,4$M2: M6)=FC?SP@0N]'69N"X@/B#0*!GZ8"LUS28KK"YY%5R"=%T%RQ:BD/O #RUQQ M?/E%K]-LHZ"@>#*D"Y:1[=PP&8*J&X9)3&N5-P2@:G!$ MN,TLLI!W(>(0X6%10!K,ML0]J[@HE'TB&R@0P*:T"1;*M9A9J,91RNY:&>_3)^G[:>F=.>\R[WWBT0:.;BI,%L2JC/@V8P=9?@/P?0OQVEK& MOP/3OO,+0<1Z"9S-_%1279U#4EV=ID4(1H+K*"9.U9!L95BV%)JWZLJNPH^V M4$QD>\ZF&%L//^7(.19]CHH,]1+Z1*2X.)#>)4U6*O:>T&Q"3\FJN(*/8RG7 M!+Q)5/#A0X#:'=076%" 7V&2W#>T)^)'/6.&HO\U*Q:';Z8A$*%99"A T/N MZ -J5W#0)@ J_I!,R==3CZ:J.@GL!%1OI172F%-,%TB5C*!%+KF*#VC][D1[ M#9^ !A.#2C\3G2EX68XWQ5+BEUIT\[?+RV]Z:*-T/?;I@0&HU1PG!4UH\28: M<%Z E,R$]D'98&PWCFTS"$^@^S]BP(+7V-)CEQ%$.."WMEM(H!MVAQV(<8S; MTW\)_Y1%$R\FO-&FHG##HP1A!WN!/8P!HC .0H0-0 O1G"T #%2(-=1Y"9\7 MPQ,-%MH1]#U%OH+B-[#W8"PX6%4P]$,& 4M*BW3=%*((YX/,5,(Q*)!.+U4:ZAKIXD9242$,HR,KM"?Q"-@S=Z@6$M@6A*_%10W$,9DZD@P\K MAGA?Q/D1&_D,8D ,P&T743_1/%FJ5P+@?,K(B.7!*^CC4UHF>T'(+OG&#$70 MCF;20QW97I0!M2R$7K @3>*% 5!* 31+X@N+I04-PC^/4S@\"DM<<(LHW)#S MJW<)[(D]0^F%0!Q0@7-+<<$(7&J )XV+]^0\_>"$G@^PC E9L&/RFX0HVBH( M7N O(8_BB!B?D:)$5Z#<_$<8=*+QR\0-[=+$_@TX+44Q*M7, BHQHOU7R:>H MS=$KF:3NF4U'3QJ6GQ7_-M)4#P[(9,NHQB*#W+2NT?L R18Q):FFPQI8D;RNN0,\)R%5B1:&@H$KXNEFB!J@MQR-6RG&KYW1H"^\W*R7)A_CX>W%9Z$Q0 M!NL!X2SQ$O\#* 7.8N9RC:80Z MW_?8O4",\!9X&%"AO/+9P.?R(B>9B)MG9/Y2TW,BI4JY;/Q%F I45\!6B*?_ M).Z=U/V43Z 1Y=:CA21E&@<1W!IF-1T.9$5?!G6G/443!4L2V1E:)@^3R"'7 M'PA$)D% B(K4]8![(ST!!(/0N\)Q2I'>@# "%K/$T TQ0P. "^S$CR!NB!B2MGE%I3#&YG_$9"1 M*;]?CH,1@J Z156!Y@OH8@]:]1X1Z<\R329X.$U=PT^.\I\UICD.DZO._-QD MZO%HK*ZH,D*?[/_:X-""PUB:S;7=D,)R+:-UBVU4[,CE\)!+_$*(^PX^KF,- M6H,&X1!G5KB;)V\._:2>KO*Z0EW9*MT@' %?>7ER>7N%DYR\DI*)P$X(#H;& M-HY"- QB=Q)Q(:@Z$;V$R=Y/I[XG-^6X7(IPLF7*5T"1:F.@-7KG8DA**N". M)AJG6#R$'C.F83A88%M+!100J4T[)>%6ML[U4&R%EI6K4U)*0^4T- 778!Q$ MS*# E1AP;,WDA8[<#)B"\8S2H!SI256H098>4<'!IITF_^7[H2*/_@78U4F^^S#[(#40 )&+"\2':W[ _0NS,TP - M[C2MEP@%BX! E]B?Q'[GA>*75SEEKMY:K-%=CP)ZF:N +X0Y+5@I)^6\TEU4 MVM_ 4=#%\1FU.(KY(F0A0TBSE&*>]@0*0B=\I!7XL!Y@-#%UNL]A9SR0YR ; MG2PT1O@"F*LA>3IJ*R)=S8-';.13&*KMB_BY76$UH9!T8"6!%B\6[V/TAGE$ M7Z1(F$I3*-K?A:%+62\N.\<(.-2[0F>EU0[IZ067@!#32-SE>PG1,;Z M+AHX7OBSB'LC28D"WJV7G('' -;0ZKU"(B2%76LE%"2Y$GC.\Y8> M/\,X3JQ2#*D43$.^..9>G=-K@@"DF\F-A5"-!=[0X8LT8(@N]D]KFD0 !X[V M?8QNB]*&0E=1(D_7,D4!:K#*A&1>J$^>'B9, M8($H1@UB2W"D);DU<@JTZ#D*C%9$M0")?S#DT[?9IQ^Z9.3I&ZE6[SSUFD@9 MDI%)!4@41,ZH3/'VPWEDE'(*+<=19Z'EPC3O((1B1 N'#DL M1&,E0H6!WMS4FWIMA^>]? \SR2R+8.?EZ1Q7^4PA^D /J)D]H)Y2J57 MSQZ0GY:J)R0 H/T4T2[*?/(^G)1DM()Y"UAJ_>9E4[R:FC88NYIU@_>434MW M0Q2]2Y=XF0756;%%PPIE397V(\]9)$ID5.9C***%^:)?)<82"L,SY(J7:1Y6G,"\&"8=#L2K%P MCTA]+[? :05IZA!3)=!2;T 4W7G"F0'*,E31\YX@U_:&*5;%ZG&QQ4%IV#9P>]&S=( -Q0 #^(4ZA%#3L@5=D9BZQB+;//5E5H) MH2I\;.37A;P6,'#2;5]6CXII7%5)R#?A>:5F'Z/:UJ M+>/7E=XJ3;*($T=4G%M4;FJUI*/T+V UA5A,MUPJ'LN^0,U)-C7$N@'Z?0C2 M-?*TMH99 (;U5,*1B&GALBL?6N5 #OP7A MP^DX?,CC#>)"G["&&?IT,TC8)7HPH+JZ+-R=#(F@"Y1VK'N?RJA5>5'7]E9( M1>\@&Q2=QN@4A5Y &5W\=E5R?2Y9("/7]9;B26\@L@.9;M:(E*<_SV7BRB6, MY+^CY#\G<%)9T$FBEA2_"B/.R:SLK=4FQ#6.%%#6%K$D&^'OL)$I\F]P41<0+)M4*/RTR,%]R'_KVLAH(I MY/Z 7G9/P72QZEX"K%2]OLFG@5?& 9IPVU:$2E?)ZWJJSLXI!ZIZ0OE'@VX./)MDAJ T*?)FHT2\7K5G.>^8["=7^;\C,K& M\E(P>!J@("W(E=D%.W< PTDFB0P1,YT(N@P<>>N!]E[1 M,-!VC?#%B";O.RWB^N$#+&&@IS5SL$^FV@V6NF![ MR$-J&*C(@9>*(PBCJ+_ ?41?9A#206@,F>]T90PW%Z\+;R7(N[0BFU!N34)B M'16A4]H9E#EBAC-1W2 &IE*./.^4F#*;$B:IV[S(H=?*2=+L"6XD9G&^U*0L M<%,=BGLO[/<$&4_LU1-P=+ZD:&)/,]4H?0(EP.1)"C2KV+K MX@$D=<:GR5151(G02T M ;$X8)MMEV2)$<'&*QU1Z9^+0[< "6;I4UE6HB"S*T(9 THH.;]"XC.X>"BC MN6SK5!T&Q:TXJCK.=%?Z51838L80:YG$#FSZ_=,ZJ_7)$_Z0>8R4IVC?C[&" M'K&1>6320E&;X@BR)],XU=INP@3K8:F<+!&5K]J^R"[,;R51R"?C-*EBE 4K MV15"+5EJ#'@^#PGZ4?I84]FNMY!^+*XP/=83I=TI,L8L/1.M8KW"I@;"E)Z? MM/V\U7-#)@)5F1Q1OK=69R :!N@>SDBU J' #4B* CO2?%+IHI7M!*UW(Z] M.O2EQZO%;+[J $ VARHZB#NU$F04ORB?DUHPK]1/"Z<3:L@N*3$B9]#G6"4" M#B#5.:B:A85R[H8[;/J*CM3!=3/%(,T29CLL!F7_)]Y+O"#LM:J98.( 5-7@A15 M$J#CJ9D:;=-1H!D;#?'3<'2JOI819JC:G/C>*,W/T2O^3-39%XC3U&/J!:,V M,(S-+JP2QWZ*(01J6J$GL#8.A9-+W)(4\%8ELM/*:!($H:?EQ$FI*^WJ$@*)($Z/#1:=L MFM85E5!P:\F&FWH[YZDT/%,':0Y?'+8 M4;0BR9C'X3_0<1]J'&OIG6./)399D"O23SZIHV!"*?M^[HB4\FNQ)9?+O5Q$Q@,@J2?M) MH%JRI%3"F-_M5H=9I(S29IE6E/_.MV&MM\XXQ(A:=!*WOD4>Q0E?J%CK)3ZG ME7#G7Z%G]&IN 67)0YD^\@(P:CQWM"E#A69O0EEAE:7,0\Q!^:HM4>3QWTY' M8)/$<5?$8$1E_M]#Q" $7QYUN,EIJ=Q,>1\EG^J65Q$HVRS[W%!@1%MN:1Z+ M5- #E>3*"OORC'9L!UWQ4(.#"PG=-"I]'U5FQ[HZQ;8+5V/AAROD-$I:/ I19 $4SF=[D<5!4D?,BZEO@HJN9R(?=%2GY^<0LU"OR>A::C6I M*5+S6V#U'$]3^I<2SP#[J8_%%#(/3\E(,1(5AFAYM_2 J6H -9_WP]<4[1'* M%)B(88R#X*A:0PD645KS97*%CJA2\SGUW$:DOOW3M+Z4'>)-TS2%<>QE"\MM M*^6D).5ID1^467?E)FDI2JU+5G8.)0L-Q,&E[SDW9]$AWA29FOOCBM/!MA9C MY. 46U8*+IQ4.YPAJ)L:++!GI'?\V9SM.BZYRQEA.H;M"5J3?J<8,'_LZ?8' MSW?#6<=(EY[:]4/Z7,0QUZ1DQ69.%6*!-?'5BR:(*=-$T6Q@^ MBEK'Z"/!$N(QERV# MFF2IBRK1D Y&U3<:"7+HH(U,A0R%2A1E0KV.4XJ -;:D7#HBA@[&AUGMQ$M$ MTZMU$1V:Y,:^%+O0R60!E)*&_SSR3>D1WY(6)FG#%4UMBXWO#,/"LP F MQ,T@P#29_@>&O1UPQTLUI<:?A)Z16JG8PCBKA0/) !TOM0$>OBA4D(WE<7T6 MT,Z].*^OBJ*R&67Z0NI:T0W@6+B@%%UI7DNB2]]2%/33.EFG!0O9N2Y5V$$G MQF)&I1V!SEO5_2SLAO(09MWR=T(H3];S[%; M-&'_7$S8ZU28<$&C[H5CM_ZRXD1'R8F-[%RERW*R.[1]<81?AZG*^/F=.[F( MDF:9HM",UJ$OH^RXZ$7_+]8J0$O/F1Z##<*;;@K]JJ,P@,^.W"0[FMS+I\#Z MR(81-0?!B[1$#)!=3U#: .E=B'E,/1WS\?+V72$=@XW=RU__,:6\C/[^Y>V/ MW.L(RFFK4[FGTF?9,$UT8SKO=5[E) J/,OP0@W;H1) W$4DBV<$.NW"(6FUU M3: X_$IHE)WHY,%5/&=%APV%X9:^\WP+&='80VXYJ]3A<$:%5DP4P@"FO4C) M(OB C,6BYS[5MV#) QTOQ+9Y*P6)['[!'\W+0^V-@F*>OQI'6CRKLF7GK/@@))]:DI-"N2?VN-LD1K ME%6-:U;>9/"8FPKR=QYJI-+Z*6M:^SYMFE-ZT<&*"QVW=]'!0=W1TFUF MA7%7:1OR*YWHF6:\S;H5O6?@,OM/>M7!GC!TI6XXH0_:98-'X[J7.YB+;WZ1 MZ5?FBNNT)J*AR#3DGKP6YJS9JN(BYDLV4\LF[Y,1U=US@1E-T.UG]\Z(?<4) MI@BSZ[C$:7 [L"Y:EFO/>''W1)47-1<[IH]8?[?7O+ J+..\.=C.*K;%J56N M%BPR:T;*1_C:!Z4QOJ4'J;&3O[H\LH%9W6-1&>\S#ZCB!D=6/Z.:+>JENRR] M(E0=J?$"T;-E)-K',$I]CVQ']5@F)T[41:HR5Q2I=B92*J6L=VU67E V'U5@ MXS[&BU:SF[U:O*FB4): KK9UATDE,6GZ9G8#07%AZOX ]/+0L<4#1B_E7ORK MAM@2\ *MW4/I_3.Y"P#T;OW2E8_86-ZBB)F5I]WMW9,X JFB1!X.ITM?K<]9 M+^[MI ,T]5@0VSH+J8X8P79ZD_*<%4..RSK@O21>#1,.;_)7;[:%KZ)UT8]: M5C0GTF.GS[&HIT%IC'X]P]#:(MEB>G?4VRM*?\F4'\]P3P)BT[4*L0 MIY1BG'+V1GUX"R;9C<=OSEOR9E91@58 WZS8N!#EE*EI4TD'^FL.0% M&[]8+:YYGM[!49X"]>E3[-8$^:#P=XM[PN_YGDY1K48](!H$#7#?.=DK&;K- M\TXI'335),1]M6:J2)GY5&]E4CV"+N119?$2N%9U%8U6\P)(\C#V8G:*RA@7 M_!#9TUU*RWYH8M14O1%?%R75;P[.CT))J23*H>@IHZ;44E_K;NT3>[@Y=U:Z M\PK7%/=:XD%]Y^J(7:^G(HBP'88>AV)EA"N\C%ZYAIW/VQ+A#D8MI,AXP\>N MOFI-C;HH+^$B&^6EE-=9+63(N,@U<9'WF 3>^^;%U)Y%H>]KFQBR,3W?LXSL M.3F\#YK4QL8OPWTO,R2(UU(K\K1*;6_T>E%;,G6:O?.MT4ES *C,=&OV?V^$ M.^_6E7+["&B,OEO?UCP_F3@(8ACC+-8[7HZ0G' M3FTI9.+*6I'#Q)7U(L8>C'Q>WNZVZ4L8$;68GL0Y!FT+C:U[&8S\,CDQ)@,8S(,.4PT^+;3N:@K M94PT:+;PZA -^NQ.-N2SLX:.>"%Q7=,HQKH?:P;6D,,$A#GKWMWT?(C9QCLR M03';>+4BAC$B-2+'<8>(O>ZF59YFP_ 0D2S8;@Y3=ZKFZ[P;'A=\R@F'#3) M7D,.$P[&;\_ZO;I2QH2#M2*'L1G&9AARF.@/;,:@7U?*F.C/;!#NDR;J\H"9 M?CDU3X9T!45=4R;&LIN\KB&'B0;-6;]:TJ/> F-LA[$=AAPF*GQ[WC*'"&M MAKKO"=:R8_\^"$6WS>TYCU*S=M>U%IHZ9("K-+DV>JXN),OW*7T\S9Z?S] ^ MV_?NHQY45M6 1L*,E3IJ@A@K]8Q(UMLRS9ZCE=KW@4@MC#5&ZJ V09>%NVZ( M&X-6I[EMX]7N-L]J2*OO86S[>\X1+?$E=D:.0Y6;.F2W5S;:7D;$(W,V-FV: M_E2[JD](RV?HA#2ZW4VO)=RN\BP-EA;UA5OW<#5V[[54YOJ8?;KV 9TI4^YWOU2%OY/PF-O-%O-Q#FL M_*7(L0M!K3HQ3G,^+0I3;\'$^GVCQ(EO_LM.XG!M.7H$7;ZRV/H<W.2KSTFGU0@H_!Q);S M#6-FC4+?#Q] S"V/6[85,2<,',_WJ'VO%8ZL&!X*D@F+[#B,K)0B^OD>DF#APF'@?BK-^M3KYHT">*M)5"Z5).\2YWYZTGK MQ'*8C]=#.X#Z]&^I<>EOJV#O=[8WFTUVROH=40WMG\? M1XQ97^#W,;<^ $RN]<6.G+&HQ6\/6F^[[48]Q,QMA1W0TYF=?*,_IM(W$Y(F47JUI M953>P5$65%ZU/KE&Y3U_CWNA4$DG_,D)LON\LLJ(UK9LE2S3<]SDK$U8LQCW M%Q('P"Q.M7L_K%N.Q\ !PP_ M]T:3K[)2IK85G\81V!_NCT8SU;?@69CW8[7>+[N-\]:@ML0Y&OEX55L2&/-@ MV-^8AV,U#^U6XZR][\,L1D"6V8>CJ^ ;-,_[-2319\;Y&^L]8Q.&YR3N/0#, MM<+ HI9L9.U8P@QDX]%WH9.[4R!NXW!JUN/32@,5&[C8O-1N?C-SI7 M-@)HS/<3J&V"R62_]YG<,U52AY$>-\519GNUUG0PVZO&P!@#8PS,\S,P[4&C M6_%,N[$PAQ.(/H,#GX=K>,^[PU.>8NQ = K'GS;UH-'Q8%C\8#. !: M&+-CS(XAEC$[1T!!8W9,!+JGED/OLS[KM14/XPD8U61H<>S'>PZ 0$98ZD,+ M8S2,'!A:&*-1>P(98:E)'>RR\Z%'=8GG/VDTYEKV/8OL.R9OW;+").:Q'2#> MQ 5<,-AVKMO:8*P5K5\]7-"M5G/[HUJM4YR_W]ZT M=GK..Y"FM=,!$%I*P79CT#-7\.R=# <@2,;B&(MCB&4LSJ.KD_K[KIXU M]F9+46@AZGD&71WV=X;'CN#1F-,9';U69I/PTYS6/?SDM%%2AT"+XSZMN_?, ML1&20Q 28RR,'!A:'+NQZ)ZW:TL9(R6/B?N>HJ'#45W%>?7(2[UW2I]Z%0/6 M58CVGL@R-Z4>$KW,3:FKB-AOM#:^*'77AUJ/_:+4V@B8L5 U(XBQ4,^%7L9" MK:RD;?1Z^[Z.TUBH ]SO-(T,U7G1,+;]?6YXFK9-!Y-,7?^$A^GK5&N"5BR; M,HV?EI16-0:#38MYMWZ8I\Z-GXY9 HV-JQE!C(T[&H(:&_?X;>1&[[Q5#Q5: M;QM73P%\!LT--YCX8MF\^N)_>9WPTSO;GKZY!*[#@ZBV_]$+[,#Q;/]3@%2@ MSGOO/>[X(4\B]AWF?.>'SF]__?.?+.N7GT#<-Y\]AP6<70;N%3:9 R:EER[O M(L8F !Q/7[(\]]>3C_\&A=+N]T^P*2"NX8:-?CVYPF];9Q?MB];YO[%'1JO= M:HL/W6[[Y*\(MH3ZSW]:$W>]:KC33V@_IDOD(WBZU[0$-D$%T)'@:^R-:%UB MM?:=0.;Z'(1K'DR+RKA7D'#1MG 57K0%>C',YFR*J?7P\C6$KV./6Z*7UWFG MW7YK_8W=A[]Y?R03>TBX^O3YM&V]8[&]3135N8'H=6!=)G>P$JO3:UC86J%! M/3.OPLG4#F:$E!1SW\8VO&E=_LUZJ9#8::6(3;]JOWUE4:,)YEI>$(>6;?E" MOBU;";3U$F?11OG7]9?+TU:_(YF76:GLY\9- (V1!=;)&>?@O,.S"# ?S):" M:P>B&2CW[EG#>@@CWP4["!^C<&;[\>QTR E("4*.GCY+F.(!L =A/?,%^U& M/^&*?);\!L1MYQ" 3),#<@@,9-D^J#MXQ7.L21B$H/Q ,])0P]"=S:W_4OZ0 M&PBQ'S'?QI7]!F;X=!P^T)=3&_N^#Y_NP-@L\0.;/ # ^Q9:LZ$#@&1 '^D#5CQ0;5T%2!/]H:9US.(X32*>P),621)G MX*$!]9>($BFQ[[!N%B^7IL9*$0)P3U,94G+"\1$/R 7"S7R?.7$"G U$G+(H MG@$1[UFD2)C W$!R HG$(B:XA&TBZF)K7^JJ"RP9,3M.>6<: 3,%BFD<.W(] M (MCY^+(CA$)LNIAU0%%''Y M03[AP<*N:82<@,)H/ %55(X))17KK^MX.#Y32,MTD,ZG$7,8D P9%=R'M"UT MJEY>=%O-E@7P^_B%HD%J@5"EX@)X&<,WK6NAGTK&;E@OVOWF63KR@\U!#WMH MXX"*?$Q#OVCWFMWTD9?L=V0(F$!R37?0>PLQ=0K>JVR4X2P3NT\!4#9.8B9. MU[WSPB_,]1P8ZH8!?T3.N '/.,V\'?[T[B8OW0#!D(UM?Z2TKD1A@_B6Q3$V MNLZ^3AVCL[?YJ[A<-HQ!^\=CZS- ]%FXYV&$DGO+HGL/"*@#(K_+"4I1KM1[ MGT,[R%NH3R"9,I( VP-K BD%8X>M6'$,B":P(?C,EABA&"UB4]J&S6G]:+5[*0( X4V M\9*)8&.),(F2X]%C[W1$V\[8 R5/*A\0# @ZY5/F>",/GG& ?<% VGFM!M1C M@ U/-I^7K&DE4_SK1:][KG$HD$!SM) X=]C./XQF!:<+WV! [0!6GU10M'D9 M01<:Q:0,+N%"HP9 ?@3I(&&02C;SZ!K254>V@J!98#S#_R10F Q*1Q$_MF:+7B[9N M01"T!=3QP1T7$)X2A'FT.'9@0[1 P:58+%F*G+T';@:]+OIWD>/$R!(LTBK2 M[V]:M^,P\;70C/U$BG.AS^>=%H&#%="1?^\%3D2>E11DQ'>.",UCD>@? 2"% M4YSD!60,P/+ZGHJT%DM1EDE8Q)("U: VT0^%_V>C$?B.9+!M8(,DB".(3F>G M\J,>).'7\B/=C DB!L]XOE4,PX%?5* +'B^017(9F%(AYO%#F 41:>QE.4 [ M0"G,JE:.0B!=)C*+Y-N':(E1C4%(" P#,@YLRSQRQ2%"B4'U9X$X:A&P?+"X M)/#0L$;P&@U);*8PO JOA)X2/ BE-X3:783#\D1 MA;-Y2PP/RDMMXK$8""&"_TW0*9O2H:MPXJ%AO0M#5YA3CBZVD[/\X!D,O0"- M7P9X0US=XZJ(7> 57LCL.7+J\@B^H2[A*7N]D>:N&@@G@ 3/*^TA8/4"#(G1 M@4D=;QCK+I>=%;D@Y5$0AETF!$BXP1$#1XLC+5"U020-0(+,@&-+NQ !>KN9 M(LQC6!])HKC$C%J4$HFU= )%1:DF%'*M<4+J8DCO@A>TB5@&#AFP.Q!+%7, MFNXA\,2)R"#CNS ^K(FX,(UJ1PE$0RP-F!"$U,:3[*=^@8P@YM=$>!!W)^4] MI7FF6X:1!6@66"Z%3Z43P9D*[P+0#BZ*%25'(.)Y&+- <)4W:LS[.9STG"2" MCG %/>K<( 0$1<(DE3.!$$OXUS0$*3T:E7@IR FLQ:9Z5C:G%N(5XD&SV4XL M0D"TE)FBT16C"$JU@%&),&57.'*\G/Y%1\^OE'GG7("5S[+HN01\,!R-4G54 M&JC**$T%]<7(NJGM>::?OI>N&->&B7Y'3Q:@]EG$;WH\#D$^I5AL'VT)9P D M*%4:N()V"FP2?0G_LCD]<<]:ZG0H44G3N3875HO]!'(H2T420<-+C:[(%CI. M0L=[443G='ZJUU-=3[3(+ #^-?)PJ5PH[2QV3>)Q2+D=THIX;9L/"P=W]7V2 M)I1GX(1;(AWT'J*PR1"F[;;+MJXTO8)?"Y^HA(88\.GLJ6LATJ$2$$U.7 @& M(5:;J;\S3&H;-BLP40411Z.0ECL[<]M*&J[2#$=F8M$QDGM4+ILR6C&*7%F$ MI,L,;13D,S=9UH9R]BO$THN5.02"#\4]@F-*_7&@%(SCX#:.DTSH\D7,HD@V MP_]&H(Z$3<0!2,C01Y06'N#TT+&3AI^GIE^M>LZ,5\&9P-4HP>LC41L#O81[ M",_/WZ,X+SHV97V^8$):">%YT[H41-2R\EHVM3PY]3+S05,'X569AY#J'#6D MS#T1NI0>*_4-\7&T &Z($5<0PY*EODZEMWP36;M+.+&_ MI @ICTQ1DN2P)*;MT<^QVRPM3LJ_]KA2I<=5*"U82$FQTNG*:J5%VP14L)12 M %^ZB\*'>&R-0#I!:"F/\S+'=Z^RTB1P7@#8B?42/%5]W5\_W9Y=="O5$RW+ MAN;7C7%Z6IJETLQH@&DRM?FR<:V15F2RJ-)(?R3R:(.4K+F H%0GKM@:>-)\ M?SEG$QLL3?_/ REQPG>Q!5!@]G4V!,KW 8*47Q%#MEY.MN96 -JW,4@MZ@#2 M;%A;,,M%"4>8,=]VZKE$(ZS,.^=VMM,QR2-?)^-0(6&,/) FQY=E,II!5GSALXYGJ@1P4P,_U%O8MHA8F.LY*:M9D[[QV@=<1B(-<>V MFR5)B*T79CE),1==V/[Q5&>\7^H%_]\$R"]=C[.%EDJF!EQ4V3Z8#O0W=!ND M92*TBLUR#08,VK!(_XG"FKR_ \:$8K5"(<)'N6V[:.QQ2/ M0@0GIL18QQ/E?"5U.H*!,;;R4+NE]>@A+#!*-Y0DW[*?4R^K9*?G;$Y%P)XZ M] /.A^U-\J6)D5)CN@T)8+ M^1;G?G-'SNY\<(M]/9V;C@:?I<%ZUF%,8]O^;<:9/T\$J&@?DU9\/A0Z2!Z)1*(5=-H6_>,T-HA3^A MU%,:P$OM#H\C^NPB#1-D!#E0 ]Y0X.Z"L"_E^?@,]6@60T>4.PI!0@IGV?[? M$R\2-)S8O[&4[.OF#1:670("Y,F:3K>3STU0^=H=8.0.O:3AVL=Z]#V1$@3' M:SO5:+S338EXX<&86![6H,,Q$FY1_AT$> @Q8''FG(OT0HJPS,^#*&=*S3=@ M0J)),\<2TC&6S@61)MTKX#&;$B2V>T]I!"FU632;T.:*"[[/':*0C8"K!/ $ M"[Y#E6W VUF*C<>).\NT .XQV!I#V"X\*%(6R"T,5JE^Y)CRH"A:$/@!+5Y M0$@1^P+*)U<;7V*#Q99'\(B?IUB1BTG Z=27ZE2#"0GI8"UE=GKG8QB* /-] ME-Q9ER[$V1X&GB*5G)K;K40= H@ZQAX/S+]G6P\_,I:D/:3L;/M#7UH_8/Y'I&3.;BLO)I-?'VU-_9=M4?FG:@ND];'=O0824: M[&CBSV^%C81Y+U21?HF?5BEI_V*09P/M0+MN'X'LI:HK!X+0-WJT%YW" MAD3&\7<1;K311B)S>:Z6Y'^ "06S?U3#Y]N^S/(!],525.82]NQ"&+ M!01A[$ 7_\SOS4Z@KR9(VH7@A2[LKH='3%*#)3@7@Q10[I@M4T&^/#0^](0] ML[D\.DY)#=(+\@7UI/JU"FB20<"XG+I@\$ RW"P1+,^M >!YO#:) +X_6\H7 M'FX_VY+/-=XH(6.1=)U6-:%I]TNDAA(AY &B]^J)4Y6:].H.XDK135>3IN,U ML.*TJI_:H*0-3O H ?UXAXU'!+^\]%Y9>"--"_^G<4^>&A$\!P^B[8C'7I2> MS,CD0[XY9G[QH++P-D>VYV/ !;_IX:R/)PM0RV^VMRU?[=NZ;LO MH@L"F4KN :K!W4EW9%-3&E+N*>668G*N/)-U+$8DET5,*D>"%?C?U@[ 6_H! M^%EN)Z#BQP#X@@\6Q+$RA?G6_>5TXS-)N[R3OQ9RIO"_R 2Q*G0 M^1$)')6IB\"D+ M6V&HC9QQ $B_FZ75?@*856EI'30;DSL^6"G^QGK9?@5P(@M(A(@")>F0N(FF M"3\%8"[A-^FJ6R]M["=9RA;*G MWL*R?X.4CL%%H]/OK)67(L6%,HY%PGTRAX6BEW7*58K=2Q1R1/UGZ8'])>?U M*42!R,Y^+<[H+SC$GQ.'OX & M\9+UF$G5QST1$7=QL-9;\@2I&%NZ9S*=3^6JV68LXW@!@H>IX4R0"T+[?9SP M1KG(EU7(TO*",.O[DB]F7XUQ DIMU[=3Q:A1:*/ZL%5J@U M$N=6/UU^>D]8P@?2"Q^V<.7$H("R?K,S=]O%4V^QJ*0ANJ+JE'J_B]I#;HN5:ZSPU_]!JHU?^C,IT4WHIV=.GFJ6A*+L80 M@62^ADTX@ I^,L!BX)+F-T(UY,Z8LGL/Y!-^&X=)Q.5I"2JLQ@3]E X3-(3# MD(4 \JA F@%8\FY)Z^%>*C(B_"#/F38K6YHXH:22RZJ8:&C[2'FNSC:MZ!_T M$(64UY6]J19,J\F@K1)3OX&W,<;Z#]I?(;LJ3Q] !O&A:28X]N@UL1_##8$D1++88NY%;".2M@C=H73K@'7+RUK/CC=QZN?!6 MDO(7->)V)4I MG3J_8) H<9(VS5"KO:ZRXW7HF.MG7V2M:;K=D>YNZ2JZ["2T$&+9=!TC&;#< M_0:V:7C @U5"><)L_YP!4@L]+P#9Z->#E\[H')?M2']]"!@; 6]%)7<%B!]T M=,F"X25-L0=9?J\AS/LT1+N)B5*M1$';"D*)!K7]HC=?8J0V[-&ESXJ(LAK% MPJF\"8OEX>DQ8K$>;26"'.U!ZVW.^<[8F#.\UZ0R'V-^*&NHH34&%=XGO*RR MY+1E0&>"W9+#RH([KYTX)$U!%&@-YKGS_.AH]FL6 MV'JY(2S*C-*N].1.H"I#&YX$\B2X]& :,EE9WC%5D#4)0'V=AJ-3]36(SAA= MD?LT?SQB"[/P/.VE6HR"IB%_B_O0$T_F(7"/7#AE]Z%_G^X4XDOE.KYIW>)V M[ZHAYC:"RKQQ6FN,_>OO1'6/])ZE[4#\Y10-G4>,U:XU,2?$;5/,HA5FFT=) MTWJG]9?5CX:B]N!QENZ"%33B+X36&OC &A820JE>CX[.YP]!+L7K' M I:OSR7Y&N'NELK+"0D"@/@_8@!T(%Z9[YS9J2V#<4N M6R +'(Y>Z%[OE]_)"E?0F M%8PLG)AVCK.JA2%>+>-F2$P6;[C(:'ANU9Z*A\OELU0":1I_IO=UTH0Q ^*D MB,&3%(7*/L#TXJL&[FU R/M'MDUCSQVRIK/0MH]%,;)J'2.]1%2[6\1GZ7Y& M2I=E^DK*3XK3%,L:93SYHU6IAP@ BL7=:MI2I'9R3CN5P%7R^3*7V"LV5M.%2EE$B@@M91E5,B MW:&P*)P8.GZQJ9B*%LXMK3>SJ S6MH*+<62E"#L?^0[F1L]18M%R-U[5XM W M?[_MFA?4BEMMU:6X'T'S_ ,53W;_;?E=M@-SE^V\Z]1O6HA BS!H?6$VXD^( MTS:]QUKXBO,N[)SW*.RR:'V?%=;($^8H%WJ:"#1B9O9D_A84$NE+M?>-^2F9 M@5N2]E>M^CC(?:UZ>ZD(2N8 M,558B27WB%.J*59WFJF&8W:*Y)DESA11L;<_RWF&REN1E[B)^E,/,!MSU5]] MDG$S15CRI@2!&6K9F'@N)?70@&O82#?A$)EXV&C"*!^/CXE!J5@G>X$PKG\! M 6B$!F4FT$%UTX#+/V1EG1> '\"Q3;RK"GED70&69'F_)VH_0 -6-+*/7$ _ M=R)O*& KFU+ST- *RIX?6 9"TS9$5Q=U@EID;NBJHB@K<\ !AICV3S._Y%;@ MT8XDR'YIB/5-[!D2F]9#9P0)\1ITNMH.P77# M=&<5IF5AK^N!QL(D7RANCA-_-52!'2BZ;=!B/<*J4QD+AIH;0KTKFH')R@0Y M+KPLEB)54/J,)NU8-VJCA@5M$$4A>6(B@-$>DGH7ZS<$D+G"*9+Q1!;!IU&. M84UGIE4KCZ^;=4[%5#]H,8CHZCD?5 EGQ-K;$P_++ MA,-X_-5"L[RT^&11G%.U$9 ,M^@S8&M]>"Y\?C-14M& 6+2*/OHTKE\'%(L M]L0:WA%K_7KR7Q_IGW02"8;0.[A,]<4-<1.$]7WMR^^(*?&5@*$'?YW_Y:U< MK,(M;3U;XD'A^8*/"XO3P*U.%5TQXM]Y,N$7A3[.Z# M.NUF]W'$T=2:8,[E%5P;DHM(0!&0J]T[>0+2J:_>92@6U.P/ MFN>=Y>3,[6L^ 2D7E&Q4IN(5$K-7B=O=J[=J?9S8B)Z"Y5 MC<8>TNK^1Z12OJE42H5(]5FL^Y*20UEUE.@)PK,O8)!CP<6G-'5W20'V 3@] MCQ)KXQ7MV<(NI-X3D>$1EO68S&BO9^QHY>K_+.FC]T)JI2,//\>Y'T(7%6;'*,SC%&6C/(WR-,KS<1K=F#]OBPW-#D =&FVW^]SSU<>/K8]7.Z2G3$<_99IY'V?811'\ MFPVE:N=46&B=GC"?O ^R/-I)V#UE:K=G:HBUF%CM2AG_:O321(^:(V_-PS $ M--+V+(BUPY#*F*@#%1I#N+7,U19KLHRKN&]R&CD\4,(90U8/.A@!.E#"&4/V MK,AIY/! "6<,63WH8 3H0 EG#-FS(J>1P]UM5L+*G_J4C!LFV$ZYT]SV*9EV MMWE6<@FW6K ,D1Z\BV:5[4EDRYO=#'4^KY;8=V^XU6IUU;^ADQ MJZ-:-#:KQL0Y&&&J#^WJ;+]*ZH-K9L#J0\?TZIV.$<+#)%X=%*BQ;C4FCA$L M8]V,=:LM18T0UEV!&NM68^(ETGNQ\G3 M$;=P+QX^F*O8E]->P9*'D:?O=Z)=(3; Y_!K<_?LLUYQ+:[64R9TG4MJZK#W M=@D(]8\N*%VH?(V]K).][#WV9L/CM9?'H/C-/;(UB!?K:>SJFSROG\TSL60= M2=>N8OM,LF;?M\-N]?+E/?;', 1>N.U;?PM77UJ9K>*#W'PT6\6'1*VZ!.QF MJ_BY7")K-@2?CXH\.LK411T^A_V^>NC#O=\1J^_N&'U8 WUH,%XG/7?X^S3U MT'-[O\[UL!+[M99.HP^/5Q_V5XC/D:J[.MS0:O*ZS_I25DSU/O?>$[6_E'6! M07K"7.U!M@1Y"LK4:4_9D&Z](,M=RM4&O<=$ZJTM)U'S5VD(M>"2B51ME:"Q5C8ES M0):J/M2KK]7*;U_6TVS5AX[UN6-N20N^_=NQFA&L#FK3V+0:$\?8M&=FTSHK MM**Q:76V:;6,S6I&L#JH36/3:DR.R-9JNY.(<5_=+4P735G:D+:-%;3HM>LP\V,3=MLP=> M37WLE-R8Q <**Z0%=#/,^-KE$I\"QT]8#DV'UMVX(H/[/?$ TG#ZPT7 M87"KE*MPW6V%B7&:SK2H!WN%B04UZT.[]TD$&LB*QPS^%S%V.H%'Q]:415[H M6BQ GVQ(V>L+I<\;^##$;,>\%]!*%31B$7<&K+X@;' HN8<%CPN/G0:5AC) MSUW+ID.X5L2F8837?-FQ-<*K+>_I:LLPL&SXS4DB FMH_!, MS)QQX/V> '82#H.XG@N@Q)8SMH,[9CGA!'4CO!72BU?X=S!+HY.SM]QB'!6$ MQ\?PV#2RG=AS6',SJK M\]T'$UN_WK=+VU8RUK4^GVVR9:[S38D"T#EKC M,FDF:ILVJ$8XL5*B/^MR6B!V!]OQH>YKO_P_,HAO%>30B:_(>1B\:O7A 7J7)BAR( MLC->HM&&ST<;HI=HU<$Y-/KO.5UA(1/%S[&F_&L(7\<>QPJW387F*9JC/4_L MU[\95A7C8XY?[)=&%]7R\,=Z]*+=:_3/.G4EGA&P0]*&QA 9.=D[L6ILB+9' MI6=HA[J-\[-N76EGY.N0E*&Q0T9.]DXL8X<.DFRUCX>.1'P.0-<9,V/,S-Z) M9_H& M-WQIO_>]QQT_Y$G$^'>8_)T?.K_]]<]_LJQ??L(T;^#G:<@][._ LT?3)RW/ M_?7DX[]!7-O]LQ-L"( KN&&C7T^N\-O6V47[HG7^;SQ-V6JWVN)#M]L^^2O" M)<'Z\Y_6/$]?TIRE#'/Z;NUCNCP\@HL&34M'84:6=5I9#*9%M88(J$7?BOEV M&K3LZ\#Z&MZ+[@H].F[6;UC_NOYR28T7KOWP;F:]\T+.HGO/ ?"HAH*ZSL0A M]IN@?B36-(FLZ3"4M?]3U[Z/G @!C."*@FM8EMZ9V%*N>%H1M M['@2!@W9CB.B%XJXP?8:OL^<.+%]:QJ%4YAD!E,XM*@,52]Q$+7V3NOM/+H^ MRW"FDXXF< S/$9]"'_/@=O CCG8@F4* MCY4PK3/VV+W.:7S*'&_D8>N3) 9U:R'J"%) 9#C\#Z 4E@,X^@22 G8ZXQF% M :\< >W^7ZPHG-F^X,2 >L%PVQ<+P1?EA/-0 OWA M3\#C](JH4QN;PG!\X#?P$$['X0-U\4$54G*]CC)?= -/VHIJ,UUY@&U_@(H? MV3!*[&@FV]#HI&0_F9.09@JL2^!UEX0;.?$&NR7%0MB!R+!:H946*L]RW3LG M3$!K#S (J\=A7WJO@*X3H#H-'@X!\[+?4PA\QA,V+Q+SDR2I-"^"3NC.EQY- M=^]QIOB+T),I_4H3FA)8E5/8TL-V&%QE,:3!60TK2NY^=H M6"^ZS58Z(^H=3<<\6MYQ87EI1P!&7L1CZW=@%[ +N/)YGADRQP;S T!XL2^0 MI53 BW9SD *L424E/C5W>H '8!3U%K6#DS,"5Z1(C<=1F-R-K5LVC86Q1__N M_V?O39_;-I+&X>^IRO^ \CJ_LJLHAI[9P88D. AZL"0Z*W46B1QS'1/WU>^TG3BQZ/EE:X"B9"-GPIH M5($A[P^5TX<;A^K.$C+@7Z /H#QG+,3J75%GM:H]_2L+YFH[7XW7Y?<"((N7 MX:*>=]J]_(O10@;%"L$&J"?F=QH,->-L_!4P5NCZQ 8%,I')\)> M;[!XD#S"\26LX=R-\,2.2+2A/4UDDG,(HLMV6$S@-CP9H-K#(5ME M.&QC#4B[09L8R)YB$!D$B?-P]$52[CENCU2A#?;$Z1/8$R0Q3C=*#(L,BI.V M4P*LGQ7VP^NO8G2:2!96WX.M.G;@W M5,U@=0"O(WB[1UQ!<@^356)'/#\DOG!\XHCI+(CF0DD68*-!E?HQSF+B-E(F MCP@8L QXR#6I!Z K1#%LY+\"._ =2<, U^?F=$Z\1C_'RU#F!;@905P0?S3@ M@^Q?-O$C1E^L>(P\2FN[ )MB^8U1%/$0R-:$)%NH\Q_8F:BK_5?($^EZ7IR) MT<)9\:(DS8_8"DEQY09N""=]N#T MR4:08#P9UC_=@.K'>LK?285X'HB[,3-&:E>"]<)K;+^Z? MTNA?YR5G5F<+OHZWCFPT56UX,6R==;MV\#];&\#6AIR7[!"P!15KH@/V:MWL M%[!XJDE#>-@>((O#!!M:\76L11W[%=BO8!>BV*]@'T[VP%)ES\)^X8L]"QL] M"[OK#>Q7:*1?89T.,8HRK/OKM9L@KPQG0[D:TXX$I(GFGAE[=Y+I*'UG)/+GK9I5>LDW7S8WM)"O M-"B MP)X>$-NW^-RE_TZY@\^O47C]5<33M^(JK6S1<_9$+7KVJD//:=M!P!TAY!P$ MG=%3Z?Z]>39MVEB]G\*SO5W!<+=-Y^,0?RN-0WS8_=K6C^5#"#HY-LWI'*_J MV>V2\0QD6N:8&LO_?. M'JD'FR?$/ZSHGK6SI MHWJ-347L^8#^_\KV@;(IC6Q!YU-CR2!P81WR5S<&+%Q+8"U $")JQ'?/.Q& M^ORX8S1B@[V[U[#%:V!UV)LH]/R9&S@NS?;&1D?82S5)=2^B7^MR/JX.;\^N'-IR_.+,@2I_>#B0WQ'VQS"NOJMT^[/RS;:]B34V.J M#&2-+P13'E"&A0@7;I\#2-O.^4CW/<*^<+A"7^\$6S$1Z &$VSPI7=VY"GNU MYJU$C346+\N[Y'E1%HRPEQYH-D4WQBA+D]25[9L60=MRJ!&NR*C5:*D[8PO; M#041]GQ278Q6HM 9^41+E=@O=^J;NB-J05ALS &B=MR@8C_(LH'HC8:(96)Q M;N'ZG):OYBMAF#_9#RL.]<)!+GH,XWISV!(=8G--0E4L:%'M':7('K:Y^A0: M#27['=T^&C0- '^<,P1$@62T"%HZ5,M-D$L0E^0?ZDZZR$)!!2)KX_C:%J\Y=_ .+"%G//6=Z]#X'*^!\C^ M$'KM4C-7-V_FJAZU<.061<2E.GWR,GUS2528'9M++:2_I;+Q)'XY=5$E3.<. M]OW2#*_8QC+H<7V+W_8ZLE^K"'S=H$T^.X2G1C&BE>BB. +VD@5RI7FCT)9JURG"HW6,K 2RHJ7H*/,D:WA^TN[G\@@(?T(< MQ0U+\E:V$<7')QE*3/ED.)%ESMA4JN_U6JH7H6R\'BH&GA,^TNA1Y[A7T;UX M@I)+M>VVG.D3BO:D)8TFUTVEUK MC?JA&QL6LGT%'E"+>]X=%/V1)8O#K_-FFZC#H'&'C2F!J5RENO\N\'QYR*A( M<&5CQ61GBM[-!J[)'+S$SLX ;=2J#+.F.79A?D+A='96J)&PK$A4(JR>Z^.Q)\49Y>T-'66@2FD1JIOZP\%K ML#4-11SQBP!:[O9/?$CARFPE)!_5'7:D.PMOP*^_:FL,R=!0P-4@#*UK+\WY M6#M\ E9^+6ZBO_W_9E/WBJ@<%8PL(2,:3I7OJ3;9MU$DXI MTPRTQQF8X+G43PJQ7T46B%U2@G63]O)T!&-407D406[-Z7[UE1H!GNPUDS$( M RM&8SP(=8'2=9Y= ^J=WK&6I*0@)2*5DP,6 :-'H5R1P8H;'E&[;0D.?2F* MT4()ELP$# )T4X3:5C"EM9:1IOO%( J!1 &/'R&_1&QZ$W0.2>*!>[KM[EF_ M)\U_]% 3TW@FS"0H-8HWZ^ M2(0RY08O:<@/]1Z'8Z??0%K#EM(W 1_Z7Q;I4 0$/%QUHWYU!%!_4 WK?T0, @4>0&$&/ U-T:X^ MF>-R3K1WJ*07E29F*=T(12,1$E#4@J)DP-*;A!&-)_EG'-W"3Q?N#'&MW#>+ MFE0%$@QQ+/G1\C7.Q$65C38G_?:F*U=.*E&.T$5&7WVJ""RP)5>-61$^&:0X MN>>L/>C\(-W5RM\]56R3J!N9'ZIWQ ;P)Y2%OIPJ@HO_ [VEEVF,+>'_%64Q MNLU RL'33MJ]XQ]:..&)1O;0>]IE*76>%!!'!1)5K&)\D.EL7891&:'7<#:, M< H^T%3^0.5!28+3%("=XI(!"/@V\/0WG2&.^5S.Z*$X[GEP2OCDDM3NW!"]"-;SH$00;1-=T?3.^A M;+A#1\JK_/'P2L<+@/5) M#[JO5CT!54C$B6%LXY*1)=]AODA"FO&2FOS;7%(0$ MG>&94=\\[ PU-:(P]RL4$WN4OQC3LN3CMARH\P ); M(Y!D[%&+TLH/L?@]KV$(2V5\=R*&)YAT-3A0\.]! MLR/N9GG?1A&/CZ/>=G*_J4T@NOTS:U''32SMP06+&18S]2.+Q(JZ[LSG) M8L:R7LDU.&\.V,C4)0Q!*6F]%H<+"W\;8<_IA_[?0_;[\OLR19<-%N(W]_T8VII M$K6PU& Z8%PT76KT:Q^@SE1B?=#/RN*N6EHY89\B.W*NK2KLLI5H:O==\6#4 M?<)7.4'H_C@[1'7!#N['8U%MI2X63Y8AA,73H>"+Q=,F) [L8'XLG?8LMKG. MP&W4=.BO46J.3U/]YFKV$*U1*1J%G#UPIO+H[D:5RO#H[G5)51T[^*;=([N; MS$=9L%F&$!9L+-A8L&U [K!3=SN"O1!L=K)1T\K^D7IEYU>97;2WATE5W^[- M+:#S:0@KUZQ6\]./67)T[;JS5[]&X37.1G@KKM*O\-(W0>3]_"WG9.S[EGG]$_L+-CI=KKRCWZ_^^P77)5:U/??K:3QZG[G@^W@9O:UND]' M^WN9!=6C/*SHUF\B8$!20?;OO^,,UZ);?FE4 MQLI1$(_6-%_N8>D<+0+8ND[ZW4ZMK?17JPJ#]J,E2'+3_.WQT&F?/FJ>ZG;- M!,\!=DV =O>D??RX><$,;S[==4&[-VCW:DAZ-\#;/.Y]]K@'W$Z(V])1N=L^ MK3[PAK9Y$,V0W^FA=)]Q*)VMU,"=DFU!! W[J1WP3RIW;>%)O?:P&3SIHVT3 MDY@OV\:RNC1DM %X,9V.4A[30[C[HR;]O MW9T'5#QL=C*)F'M49AP:ANQ7"I1/EBE*6?HS7PZT9IJR%4?VTY3T!#-)T>[> MN ')J,N)$*ES$;A)XH]]CXC,$OHZNQ^!L;?YZ;S-3%2TNQE849<3.)%64! ; M3;5 ?>-,^2?B6U9CPQ;V)1W3S+YH=SQ;V4I:>5*+AA6I6OW-S(DT)ZJ[/;GE M=?WV>8P+[\8Y$]>CXJ4?V6%*@4S-IE%W- M3:6-7MVEVTP;]H&^[#)N%&E0+=@$U L1)__/G47):T?\)_/3N:VX:FC:L>45 M\ES]7C...B4'_3WQ=("5[<.VO9*?VZ%;A(O'3A]GV+.@.0AD=4LQ%98XB^T6 M6IUAWUKDL<2Q!A?-C,>PF&'JV-*P.=ZFK1>+&1N1QV+&DI*.;>LW#KT?I1DE M&UH1>KYO@OG>H\2R])@M2C(.'2-FN,R.J4!,)'81R>8:BT-'R$/'S;BJX@#) MQ-JTLKT+H#TP7CH;RUGNCIO#LRV[Q^W!KD$S)J1&*036E,,P0K;Q>Z[+.V<" ML@5?W:VKEIHJH4Y;O<&N(PM80C6$P/;!A7#X%A&+I4/!5V?K$C862W5S/19+ M^U;;MB92QY/CZHANKU8?&!_UX:,Z3,<880IA?*R)T3%"ZB20BJ"\1/DQ!RK]($'D:^3PC=LDJ.IY*O M24,Y:?6[/3MX* LY6TEP'YP0AV]BL61K#$*W+,QCR<:2[?[(L9,"S3CACZD+ MX,JO&ODW.\"D!((?-F]9 @>ALW[-:C4__?@-[GUU$4VG44@5#'^X,0 D?>LG M7A E62R^P@K>!/#++]]_YS@_9O.Z!8_G<*ZDO-P= 'OAE,D0L\72<6] MCC_Z^=G[/X&TN\/N,\>#R^&G+V+\\[,+_+9S? M_8++5:O]_KN5]/]7EJ3^>+[ 0;; =3LJ4K$].H?;I9&=^8%]R'\3MLQ0.JX MX<@I ;7 W[8PP!T/9XM,<6 O#"ZB('"!Y;BI?R.<\^M8" )&"YX_=X,4H$!P M^>@'(DGA6YLSBZ#IVITD[![N3 91B>)9(A./F^'*N!*Q+.*-,T$/@ MO<@)G2@,YDXVBT*\PW&]B0]/IT?#>ST1IZX?FF]T@Y83B^LL<-,HGM.C<+\X M_!FVE^\+WC>G)RK R"FLI[WNR>M$;4<(6/4;X;D9+-1/'1^7KM_HC^G1MQ,1 MJJT8C[[U@P#VHU<[:CE)YDV(@>6DV8*]P^:O7?P*-HCP?=X];A_C@P(<7O7" M39)LBK\2'N)HE'D 4( =/BAVX<-4""3[H+0Q>"/ \R6@&@@BC%)8"2PR!O"" M7!XY.20]N7-\ 3R0M"X7#\65&O:3X+ ? (%Y? @&A!=8[DBD(H8%XN($SM8& M3!% $#( ('5TG.@*B(EF!1G(-U&OX%7@/U$P->\$K0&6EL@=%.=3[K95=3I MPP"HPY*3[.HO >""-;M. H1-PXO@HC"C699P;>PG?TM&D>,8#WG[T9B$12ST M5P%@-5AG(QEC@$!(G+'K^8&?2XUH#"=%4$VFY&?R_$9 A9)PU6T"9\Y)4G7P M55&6.$A->)#C*+N>..>SV ^P%+I/% 4 5[?&^' XVP8SPH,*Q..D[C=D%'X( M:A&29 NX-9Q+$1)]XOJ ^OQI-I7/RGEUVWD?Q8X 2))4'Z"9BYN@4]&,TETL!" J( WX8WR+0!99XP7SX4;)P5O%L7 O P0",R(WC>D8?8 M1"4&N&J"QI)K"D8"MPL2.M:01:X'__@I'2ZAT#(RCJ[DV0AOC8F*YY)4A#<3 M/\W'^O:&<4Z]_4'E_Q,I!&@@\(,^/V]U%8XK?2VR!C(]NB>P!? ]6?@)J MF5HJO3=) ;Q7R-Y H25)[@%J0%L+75*=S 6K8W0%/ ZXNH_[ERBE"U']:G=R ML,+%";PE1MZ9+2_.5SSO1ND:H#5D>"9&8NQF0:I!7BRZ[9PG>.%'-P;D]"5S M.%UFR*BPC6+W%K6H.2$0T!A'4\6 %W8IMP0'^)9N7??ZMUFL 2+9!ACOZ21! MDH-UKUN6@6@X>8."HL=+=*,A!4I7CKX'Y/F+MO@ _?0%RS_=WH.QFT>B[,TH M+O@T1EB!S4#B[XL(4)&^B)(TH0%_;Y _:_NGTKW18_=&A7NCVW;(O70D]7X3 MQCN>J6K7AA4:Z=*Y7E)1K]''ECC(5,& 0?8'>AEJ$,4W"8)+:V\MY\OE[_#_ M'CGJU&^DU2+/D)\5:-U;-QYIZTPKL#,07:0"CD#<>6!.P[.D0HQ_B>DLB.9" M*\KT2%B^#X(,EI,HU.6:))IOM %\6XHL/$:3$40?/(\X(W(^9%; /ES)7<>N M'X/*&_\M4O1@9T*+IBHY6]JEDD2H@N,]]&+@P$KZ@MR9+W->>.D[M2>U]L\9 M,$7D;I\!$LX+_;I>Y_6[R\^?\X_=UR]QS4J>)09D4(_7S]"O2I CD)+C%C\2 M% IY>7K\@]XJ/%%R_ P#/7#P"\"I(/8-GX$> SUK<$+MRQ M^LI=+>33?;*0Y7'X)(]R8\SC,@ 2C%RC'N1%P(DA[@ ]*K4>% @[N.,IB M91>B*KO (T)I,])/.4]99!03$9#&6MQ[.XD4TYO3K;%(X6:I05X+YP4H/7Z( M;*5$>D20P'3!+4DZ\B1AE 2R9+I!<*BYQK&*/ MC^>"LNV\?=43T5QR%,@@Z\_/.J XB@"'4GJP M]/RS"M#29Q7ZE:,>\T"OBM)Z&#Z9)>*5_N.U(R.YIQVSG70]C4:')^V^'?U@ M-D=/"R![,*'+9/*^^W3'?([FRJBT%RI MF
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end